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Abstract 
Arrhythmogenic right ventricular cardiomyopathy / dysplasia (ARVC/D) is a cause of 
ventricular arrhythmia and heart failure in adults. Fifty percent of subjects with 
ARVC/D carry pathogenic variants in the genes encoding desmosomal proteins. 
ARVC/D is associated with changes in cardiac desmosomal ultrastructure and the 
cellular distribution of desmosomal proteins in cardiomyocytes. These changes may 
be part of a common pathway of pathogenesis for the disease.  
Induced pluripotent stem cell derived cardiomyocytes (iPSC-CMs) carrying ARVC/D 
associated variants have been reported to recapitulate features of the disease. Five 
iPSC-CM models of ARVC/D have been reported, all of which carry mutations in the 
gene encoding the desmosomal protein plakophilin 2. 
In this study iPSC-CMs were generated from the peripheral blood mononuclear cells 
of a control subject and three subjects with ARVC/D. The ARVC/D iPSC-CMs carried 
pathogenic variants three different desmosomal genes: plakophilin 2 (PKP2), 
desmoglein 2 (DSG2), and desmoplakin (DSP) that have not been studied previously 
using cellular or animal models. 
No differences were found in either the cellular distribution of desmosomal proteins 
or the ultrastructure of desmosomes when ARVC/D and control iPSC-CMs were 
compared. It was concluded that iPSC-CMs are not as robust a platform for 
modelling ARVC/D as had been previously reported.  
The expression of desmosomal genes in iPSCs were at levels similar to those seen 
in iPSC-CMs. The differentiation of iPSCs to iPSC-CMs was associated with a 
decrease in the expression of genes encoding desmosomal cadherins and an 
increase in those encoding arm-repeat proteins. There was also evidence of 
desmosomal protein expression and the presence of desmosomes in iPSC cultures. 
It is suggested that intercellular adhesion junctions containing desmosomal proteins 
have a role in the maintenance of pluripotency in iPSCs in vitro and changes in 
desmosomal gene and protein expression are important in defining the cardiac 
differentiation of iPSCs.  
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1 Chapter 1. Introduction  
Arrhythmogenic right ventricular cardiomyopathy / dysplasia (ARVC/D) is an adult 
onset cardiomyopathy presenting with ventricular arrhythmias and heart failure 
(Pilichou et al., 2016) (Corrado et al., 2017). Mutations in genes encoding 
desmosomal proteins are identified in approximately 50% of probands (Ackerman et 
al., 2011). Studies of the myocardium of ARVC/D patients have found abnormalities 
in desmosomal ultrastructure, desmosomal protein localisation and the expression of 
desmosomal and non-desmosomal genes (Pilichou et al., 2016). These changes will 
be referred to collectively as desmosomal dysfunction in this manuscript and have 
been hypothesised to be part of a common pathway in the pathogenesis of ARVC/D 
(van Tintelen et al., 2007).  
Animal and cellular models have been used to study the pathogenesis of ARVC/D 
(Table 19, Table 20). Patient specific induced pluripotent stem cell derived 
cardiomyocytes (iPSC-CMs) are one type of cellular model that has been used for 
this purpose. iPSC-CMs carrying ARVC/D associated desmosomal mutations 
manifest similar abnormalities in desmosomal structure and function that have been 
observed in the myocardium of subjects with the disease (Caspi et al., 2013) (Ma et 
al., 2012) (Kim et al., 2013) (Basso, 2006) (Asimaki et al., 2009). These studies have 
modelled five different mutations, all of which affected that same gene, plakophilin 2 
(PKP2). The aim of this study is to generate patient specific iPSC-CM models of 
ARVC/D caused by mutations that have not been modelled previously, particularly 
those in genes other than PKP2. 
The first part of the chapter will discuss the generation of induced pluripotent stem 
cells (iPSCs) and of iPSC-CMs. The second part of the chapter will discuss the 
desmosome, and desmosomal proteins. The third part of the chapter will discuss the 
clinical features of ARVC/D and their recapitulation in animal and cellular models. 
The chapter will conclude with an outline of the aims of this study and the hypotheses 
to be investigated. 
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1.1 Overview of induced pluripotent stem cells and iPSC derived 
cardiomyocytes 
1.1.1 Pluripotency in vivo 
In the embryo the first cells that may be considered pluripotent are the 
embryoblastsa that constitute the inner cell mass (ICM) of the blastocyst (Figure 1) 
(Hanna et al., 2010). Pluripotent cells have the ability to give rise to any cell type (and 
therefore any tissue) of the mature organism, including gametes, thereby allowing the 
reproduction of their genetic code to subsequent generations. Pluripotency is 
distinguished from totipotency in that pluripotent cells are unable to give rise to the 
trophectoderm. In vivo, cells of the embryo, from the point of the fertilised ovum to 
the late morula stage are considered totipotent. At the onset of blastulation, cells of 
the morula undergo specification to either pluripotent cells of the ICM, or non-
pluripotent cells of the trophectoderm (Figure 1) 
The process by which pluripotent cells develop into the multiple cell types found in 
mature tissues is called differentiation. Each transition from a progenitor to a more 
differentiated cell type defines and limits the cellular identities or fates at which a cell 
may ultimately arrive in vivo. 
 
                                            
a Embryoblasts are also referred to as epiblasts, and are defined in distinction from hypoblasts that form the trophectoderm. 
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Figure 1 Summary of the early stages of embryonic development. 
Cells fulfilling the definition of toti-, pluri-, and multi-potent are indicated.  
Multi-potent cells differentiate to mature cell type via multiple intermediate progenitor cell types (not shown). 
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1.1.1 Pluripotency in vitro 
Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSC) are types of 
pluripotent cell lines that can be maintained in culture. ESCs and iPSCs will be 
referred to collectively as pluripotent stem cells (PSCs) in this work. Embryonic stem 
cell lines are derived from the embryoblasts of the inner cell mass (ICM) (Thomson et 
al., 1998). Induced pluripotent stem cells (iPSC) are pluripotent lines that are 
generated from non-pluripotent cell types (Takahashi et al., 2007).  
Pluripotent cells in vitro have a number of characteristics. They avoid senescence 
and are therefore theoretically capable of undergoing mitosis indefinitely (Singh et al., 
2016).  They have a characteristic pattern of gene and protein expression, including 
a number of pluripotency markers, which are expressed at high levels when the cells 
are in maintenance culture and whose expression levels decrease during 
differentiation. A large number of such markers have been described (see Zhao et 
al., 2012 for a review). Details of the pluripotency markers assessed in this study are 
discussed in Chapter 4. Gene expression is regulated by epigenetic mechanisms 
such as DNA methylation and histone modification (Chen and Riggs, 2011) 
(Kouzarides, 2007). Despite similarities in the expression of pluripotency markers 
between ICM embryoblasts and PSCs there are differences in epigenetic marker 
patterns in the two cell types. ICM embryoblasts have a globally hypomethylated 
genome, whereas the genome of ESCs and iPSCs is highly methylated (Santos et 
al., 2002) (Meissner et al., 2008). This has been interpreted to indicate that 
widespread genomic de-methylation is not a necessary condition for pluripotency and 
is consistent with the idea that pluripotency is mediated by the expression of a key 
pluripotency associated genes.  
The ultimate test of pluripotency for cells in vitro is their ability to recapitulate the 
cells of the ICM by giving rise to all cells within a mature organism. This can be 
demonstrated by a successful tetraploid complementation assay followed by 
evidence of the production of gametes in the resulting organism (thereby 
demonstrating germ-line transmission to subsequent generations) (Nagy et al., 1990) 
(Nagy et al., 1993) (Boland et al., 2009) (Okita et al., 2007) (Zhao et al., 2009). The 
differentiation potential of human pluripotent cell lines cannot be tested in this way for 
ethical and practical reasons. The challenge of defining and demonstrating 
pluripotency in human cell pluripotent cell lines is discussed in more details in 
Chapter 4.  
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1.1.2 Cellular reprogramming and blood derived iPSCs 
iPSCs are generated from differentiated cell types by a process called 
reprogramming (Jaenisch and Young, 2008). Reprogramming involves changing the 
epigenetic profile of mature cells such that the resulting gene expression patterns 
resemble those of pluripotent cells (Reik et al., 2001) (Papp and Plath, 2013).  
Cellular reprogramming may be achieved by the overexpression of four pluripotency 
associated genes: KLF4, OCT3/4, SOX2 and MYC (Takahashi et al., 2007). A vector 
based on Sendai virus may be used to introduce and drive expression of these genes 
(Fusaki et al., 2009) (Nishimura et al., 2011). Sendai virus is an enveloped single 
negative strand ribonucleic acid (RNA) non-integrating member of the 
Paramyxoviridae family (Li et al., 2000). The infectivity of the Sendai virus is 
dependent on the presence of F protein within the viral envelope that mediates its 
fusion with a host cell’s plasma membrane. The envelope of a Sendai vector contains 
F protein but the gene encoding the protein is absent from the genome it transmits to 
the cell it invades (Inoue et al., 2003). F deficient Sendai vectors are therefore 
capable of transferring genetic material into cells, and will lead to the production of 
virus-like particles which are released into the extracellular space, but these particles 
are incapable of fusing with other cells due to the lack of F-protein in their envelopes. 
This characteristic, in combination with the non-integrating nature of the vector 
contribute to the eventual elimination of the vector within cells over successive 
passages (Fusaki et al., 2009). This technology has been developed into a widely 
used commercial reprogramming system (Life Technologies, 2013).  
Regardless of the method of transfection the epigenetic changes induced by 
transgenes trigger the upregulation of endogenous pluripotency factors that 
perpetuate the pluripotent state after the decline of transgene expression. 
Nucleated peripheral blood cells are an attractive target for the generation of patient 
specific iPSCs for several reasons. Peripheral blood sampling is a low risk and 
common procedure in clinical practice and is therefore more likely to be acceptable to 
potential donors than more invasive and infrequently performed procedures such as 
skin biopsy (from which fibroblasts are obtained for reprogramming). A typical 10ml 
blood sample contains >10x106 nucleated cells, of which 60±20% may typically be 
isolated by techniques such as density gradient centrifugation (Amersham 
Biosciences, 2001). Since most reprogramming protocols involve the transduction of 
between 0.1 to 0.5 x106 cells, blood samples represent an abundant source of cells 
for reprogramming.  
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Peripheral blood contains a mixture of different types of nucleated cells (Table 1) 
iPSCs have been generated from several PBMC types with varying degrees of 
efficiency (Table 2). Different cell types are characterised morphologically and by the 
cluster of differentiation (CD) molecules expressed at their plasma membranes .  
 
PBMC type Surface markers Reference ranges 
(x106/ml) 
Lymphocytes 
Mature T-cell CD3+ 
1.1 - 3.4 
0.67 – 2.89 
Mature B-cell CD19+ 0.08 – 0.78 
NK T-cells  CD3-, CD16+, CD56+ 0.07 – 0.99 
Monocytes CD14+ 0.16 - 0.62 
Multi-potent progenitor cells 
(HPCs) 
CD34+ 0.0006 – 0.0049 
 
Table 1 Reference ranges for the concentrations of mononuclear cells found 
in the peripheral blood of healthy Caucasian adults and their characteristic 
surface markers. 
(Bain, 1996) (Reichert et al., 1991) (Sekhsaria et al., 1996) 
The expansion of a target cell type during pre-transduction culture appears to be an 
important factor in determining its susceptibility to reprogramming (Egli et al., 2008). 
The protocols used to generate iPSCs from PBMCs have sought to optimise 
reprogramming efficiency by identifying cytokines and growth factors that promote 
proliferation of the target cell type in pre-transduction culture. Summaries of the pre-
transduction culture conditions used in these protocols are given in the appendix 
(Table 61 to Table 63). 
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Paper Target cell type. Vector MOI Efficiency 
(Seki et al., 2012) T-cells Sendai 20 0.1-0.2% 
(Brown et al., 2010) Gamma-
retrovirus  
NA 0.01% 
(Merling et al., 2013) Non-T-
cells 
Purified CD34+ 
cells 
Sendai 6 >0.024% * 
(Mack et al., 2011) Purified CD34+ 
cells 
Episome NA 0.0007-0.07% ∞ 
(Lin Ye et al., 2013) Un-purified, but 
high proportion of 
myelo-erythroid 
progenitors 
Sendai 10 0.02-0.27% * 
(Chou et al., 2011) Episome NA 0.0007%  
(Su et al., 2013) Mixed PBMCs 
 
Lentivirus 4 0.2% 
(Kunisato et al., 2011) Gamma-
retrovirus  
NA 0.004-0.006% 
(Loh et al., 2010) Lentivirus  5 0.0008-0.001% 
(Ohmine et al., 2011) PBMCs purified 
according to 
adhesion to 
culture plates 
Lentivirus  
5 0.002-0.01% 
Table 2. Reports of reprogramming PBMCs to iPSCs and the vectors used. 
Efficiency is defined as the number of colonies with a stem cell like morphology per 
input cell with the exception of the studies indicated by * which assessed TRA-1-81 
positive colonies and the study indicate by ∞ which assessed TRA-1-60 positive 
colonies per input cell. 
1.1.3 The maintenance of human PSCs in vitro 
Culture conditions stimulate the expansion of iPSCs and ESCs in vitro whilst 
maintaining their pluripotency through a combination of soluble factors within the 
culture medium and insoluble factors of the culture surface to which they are 
attached (Xu et al., 2001). Pluripotency culture systems for human PSC can be 
divided into two groups: (1) those employing co-culture with another cell type – 
referred to as a feeder layer and (2) feeder-free conditions without such cells. Mouse 
embryonic fibroblasts (MEFs) are widely used as a feeder layer (Thomson et al., 
1998) (Reubinoff et al., 2000). MEFs are thought to support pluripotency by the 
excretion of factors into the culture medium. Feeder-free culture systems were 
developed to improve the consistency of culture conditions and to avoid the potential 
for feeder cells to contaminate PSC samples used in subsequent applications (Xu et 
al., 2001). One such culture system involves mTeSR1 medium (StemCell 
Technologies) with cells adherent to cultureware coated in Matrigel (Corning) a 
(Ludwig et al., 2006).  
                                            
a Matrigel is a solution of solubilized basement membrane proteins including laminin, collagen IV, and heparin sulphate 
proteoglycans derived from cultures of Engelbreth-Holm-Swarm mouse sarcoma (Kleinman et al., 1982). It also contains TGF-β, 
epidermal growth factor, fibroblast growth factor and tissue plasminogen activator (Kleinman et al., 1986).  
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1.1.4 PSC-CM generation 
Cardiac differentiation involves a transition of cell identity from pluripotency to 
cardiomyocytes via a series of intermediate cell types, each of which is associated 
with a characteristic pattern of gene and protein expression (Figure 2) (Cao et al., 
2008) (Beqqali et al., 2006) (Germanguz et al., 2011) (He et al., 2003).  
The differentiation of pluripotent cells in vitro can be triggered by the withdrawal of 
factors known to maintain pluripotency, combined with exposure to growth factors 
that encourage differentiation to specific lineages. Differentiation triggered by the 
withdrawal (or failure) of pluripotency maintenance conditions is referred to as 
spontaneous differentiation. This may be achieved by both changing the 
compositions of culture medium and by the culture of cells in suspension, thereby 
detaching them from their supportive protein matrix and encouraging the formation of 
clusters of cells called embryoid bodies (EBs). Cardiomyocytes may be generated by 
spontaneous differentiation of PSCs, but the efficiency of this technique is low with 
<1% of the output cells expressing cardiac troponin proteins (Kehat et al., 2001) 
(Boheler et al., 2002) (Xu et al., 2002). 
Differentiation in which the culture conditions are manipulated with the intention of 
differentiating cells to a specific fate is referred to as directed differentiation. Directed 
differentiation protocols have taken advantage of an increasing knowledge of 
temporal interplay of signalling pathways that mediate cardiac differentiation. In 
directed cardiac differentiation protocols, mesodermal specification is promoted by 
the upregulation of one or more of the canonical Wnt, BMP or Activin pathways 
(Ueno et al., 2007) (Paige et al., 2010) (Zhang et al., 2008) (Kitamura et al., 2007) 
(Kubo et al., 2004) (Gadue et al., 2006). Cardiac mesodermal specification is 
promoted by upregulation of BMP, Activin and FGF signalling and downregulation of 
canonical Wnt signalling (Kattman et al., 2011) (Yang et al., 2008) (Yang et al., 2008). 
The development of cardiac progenitors from cardiac mesoderm is promoted by 
upregulation of FGF signalling and downregulation of Wnt, Activin and BMP 
signalling (Kattman et al., 2011) (Zhang et al., 2008). Other factors that have been 
found to influence cardiac differentiation and maturation include: ascorbic acid, 
insulin, p38 MAP kinase inhibition and VEGF and hypoxic culture conditions (Cao et 
al., 2012) (Freund et al., 2008) (Lei Ye et al., 2013) (Burridge et al., 2011) (Graichen 
et al., 2008). 
Directed cardiac differentiation protocols can be divided into two broad categories, 
those involving the formation of EBs and those involving cells grown in a monolayer. 
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Tables summarising and comparing selected protocols are provided in the appendix 
(Table 64 and Table 65). The efficiencies of these protocols have been reported to 
be >70%, though in some cases achieving this requires modification of the protocol 
to account for the characteristics of the hPSC line (Burridge et al., 2011).  
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Figure 2 Pathway of differentiation from pluripotent cell to cardiomyocytes. 
The genes and proteins listed are a selection of those cited in publications describing cardiac differentiation markers. Genes and 
proteins whose expression is limited to cardiomyocytes are indicated (*) 
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1.1.5 PSC-CM maturation 
Features that have been used as evidence of successful cardiac differentiation are 
listed in Figure 2. The presence of spontaneous contractions within differentiated 
culture indicates that there are cells containing the myofibrils necessary for both 
repetitive contraction and the fluctuating calcium transients needed to mediate them. 
The presence of spontaneous contractions increases the probability that these 
cultures contain cardiomyocytes. Striated myofibrils may be identified by 
immunofluorescence microscopy and transmission electron microscopy (TEM). The 
ultrastructural features of striated myofibrils are summarised in Figure 3.  
 
Figure 3 Ultrastructural features of the cardiac sarcomere. 
A simplified illustration of the molecular organisation of a cardiac sarcomere and its 
ultrastructural features. Myofibrils are traversed at regular intervals along their 
length by electron dense Zwischenscheibes (Z-lines), mid way between Z lines are 
the less dense Mittelscheibes (M-lines). M-lines sit in the middle of regions of lower 
electron density called Heller (H) zones. Z-lines also sit in the middle of regions of 
lower electron density called isotropic (I) bands. The regions between adjacent I-
bands are called A-bands. This appearance is produced by two groups of partially 
overlapping fibres. Thin filaments consisting mainly of actin are anchored at the Z-
lines. Thick filaments consisting mainly of myosin are anchored at the M-lines. A-
bands correspond to the whole region of a sarcomere in which thick filaments are 
present. I-bands correspond to regions in which there are thin filaments alone 
(without overlapping thick filaments). H-zones correspond to regions in which there 
are thick filaments alone (without overlapping thin filaments) (Sonnenblick, 1968). 
 
Other cell types also express of the genes and proteins expressed by 
cardiomyocytes e.g. skeletal myocytes. For this reason, cardio-specific markers such 
as the cardiac isoforms of troponins T and I are typically used to assess the 
efficiency of cardiac differentiation protocols (Figure 2). 
PSC-CMs are similar to fetal cardiomyocytes in terms of gene expression, protein 
expression, ultrastructure, electrophysiology and cellular metabolism (Table 3). The 
characteristics of PSC-CMs change during maintenance culture (Lundy et al., 2013). 
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Several reports have described using these changes to generate an index of 
cardiomyocyte maturity (Table 4). These indices have several potential uses 
including: (1) providing a tool for assessing techniques to accelerate maturation and 
(2) allowing investigators to assess and control for cardiomyocyte maturity when 
comparing PSC-CM populations e.g. in disease modelling studies. 
A range of strategies have been reported to augment the maturation of PSC-CMs. 
Media additives found to influence maturation include ascorbic acid and tri-
iodothyronine (Cao et al., 2012) (Yang et al., 2014). Other investigators have 
reported that maturation can be facilitated by manipulating mechanical aspects of the 
culture environment such as the matrix to which they adhere to cultureware, culture 
in micro-patterned cultureware or on biological scaffolds to which loading conditions 
can be controlled (Salick et al., 2014) (Ruan et al., 2016) (Guyette et al., 2016) (Fong 
et al., 2016) (Chun et al., 2015).   Regulation of the rate of contraction by pacing has 
also been found to influence maturation (Lieu et al., 2013) (Ruan et al., 2016). 
1.1.6 PSC-CMs and disease modelling 
Prior to the development of PSC-CMs the techniques for studying cardiomyocytes in 
vitro were limited to fetal and neonatal rodent myocytes or the immortalised mouse 
cardiomyocytes line (HL-1) (Claycomb et al., 1998). When studying human cardiac 
disease, human PSC-CMs have an obvious attraction of being derived from the 
same species. The development of patient specific hiPSCs presented the opportunity 
to develop disease models without the need for genetic modification of cell lines and 
to develop models where the causative mutations were unknown. hPSC-CMs have 
been used to study a range of inherited human cardiac diseases and have been 
reported to successfully recapitulate aspects of their phenotypes (Sallam et al., 2014). 
Many of the diseases studied have an onset of clinical features in adulthood and 
consequently the issue of iPSC-CM maturity is important in interpreting the findings 
of these studies. For example iPSC-CMs express both fetal and adult isoforms of 
cardiac troponin I (cTnI) (Bedada et al., 2014). When using these cells to model 
hypertrophic cardiomyopathy due to mutations in TNNI3 the expression of the fetal 
isoform of cTnI (encoded by TNNI1) must be taken into account. 
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Characteristics hPSC-CMs and fetal cardiomyocytes Adult ventricular cardiomyocytes 
Morphology Small, circular 
Abundant cytoplasm 
Large rectangular 
Scant cytoplasm, abundant contractile apparatus 
Contractile 
apparatus 
Protein 
expression 
Myosin light chains Majority of cells “double positive” for MLC-2V and MLC-2A Majority of cells contain only MLC-2V 
Myosin heavy 
chains 
β-MHC more abundant than α-MHC No change 
Ultrastructure Myofibrils Sparse and disorganised Abundant and organised into sarcomeres 
I, H and M bands Absence initially  
May develop with prolonged culture.  
Present 
T-tubules Absent Present 
Mitochondria and metabolism Energy source High glucose, low fatty acid metabolism Low glucose, high fatty acid metabolism 
Ultrastructure Low number and low density of mitochondrial cristae. Higher number and high density of cristae. 
Electro-
physiology 
AP morphology 
and component 
currents 
Spontaneous 
contraction 
Spontaneous depolarisation, 
Large If (funny current) associated with spontaneous phase 4 
depolarisation  
Absent or infrequent spontaneous depolarisations 
Reduced or absent If (funny current)  
Depolarisation 
(phase 0) 
Slow upstroke (5-50 V/S) 
Low amplitude 70-90mV 
Rapid upstroke (150 – 300V/s)  
High amplitude (110 – 120 mV) 
Repolarisation 
(phase 4) 
Elevated diastolic resting potential (approx. -40mV) 
Weak “rapid delayed rectifier current” (Ikr, Kv11.1)  
Absent Ik1 (inward rectifier, Kir2.1, Kir2.2) 
Low diastolic resting potential (approx. -85mV) 
Strong “rapid delayed rectifier current “ (Ikr, Kv11.1) 
Presence of an inward rectifier (Ik1, Kir2.1, Kir2.2) 
Table 3 Features of hPSC-CM maturation 
Adapted from Mummery et al. (Mummery et al., 2012) 
 
Modality Details Reference 
Gene expression  Whole transcriptome data of PSC-CMs compared with gene expression of 
cardiomyocytes in in vivo from subjects of varying ages. 
(Uosaki et al., 2015)  
(van den Berg et al., 2015)  
(Uosaki and Taguchi, 2016) 
Ratio of ventricular myosin light chain (encoded by MYL2) relative to atrial myosin light 
chain (encoded by MYL2) is indicative chamber specification of PSC-CMs and therefore 
maturation 
(Bedada et al., 2016)  
(Kamakura et al., 2013) 
Immunofluorescence microscopy Automated digital image analysis to assess the organisation of myofibrils within PSC-
CMs, greater degrees of parallel orientation indicated greater maturity. 
(Pasqualini et al., 2015) 
Western blotting The ratio of fetal troponin I (ssTnI) (encoded by TNNI1) to cardiac troponin I (cTnI) 
(encoded by TNNI3) 
(Bedada et al., 2014) 
TEM I-bands, H-zones and M-lines appear in a characteristic temporal pattern during 
maturation over 12 months. 
(Kamakura et al., 2013) 
Table 4 Techniques proposed for the quantification of PSC-CM maturity. 
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1.2 Overview of the desmosome 
The term desmosome is reported to have been coined in the 1920s to refer to 
nodular bodies at points of cell to cell contact observed by light microscopy that were 
hypothesised to mediate intercellular adhesion (Holthöfer et al., 2007) a.  
From the 1950s onwards the junctions mediating intercellular interactions were 
studied by electron microscopy. Junctions were observed to consist of protein dense 
regions of adjacent sections of plasma membranes separated by a region of extra-
cellular space. In cardiac tissue three main types of junction were differentiated on 
morphological grounds: desmosomes, adherens junctions and gap junctions (Muir, 
1965). Desmosomes were distinguished from other junction types by the laminated 
appearance of their protein dense regions, which were referred to as desmosomal 
plaques (Table 5). 
The following discussion will first summarise desmosomal ultrastructure, then 
outline the three major types of proteins from which desmosomes are assembled 
(desmosomal cadherins, arm-repeat proteins b and plakins) and finally discuss the 
aspects of desmosomal function which are relevant to ARVC/D.  
 Type of intercellular junction 
Desmosome Adherens junction Gap junction 
Membrane associated 
plaques and their 
appearance 
Yes, laminated Yes, non-laminated No 
Association with 
cytoskeletal filaments 
Intermediate 
filaments 
Thin filaments of 
myofibrils 
No 
Midline within the 
intermembranous gap 
Yes No No 
Size of 
intermembranous gap 
Approx. 20-30nm Approx. 20nm <2nm 
Table 5 Comparison to the ultrastructural features of different adhesion 
junction, adapted from Muir 1965  
(Muir, 1965) 
 
1.2.1 Desmosomal ultrastructure 
Desmosomal plaques in mammals have been reported to range from 0.1µm to 
>2µm in diameter, with variations between tissue types and species (Holthöfer et al., 
2007). When studied in cross section, by transmission electron microscopy (TEM) 
desmosomal plaques may be divided into five regions (Figure 4) (Figure 5) (Holthöfer 
                                            
a These structures were first observed in the late 1800’s in the spinous layer of epidermis (Schultze, 1864) (Bizzozero, 1864) 
(Schrön, 1863). 
b Also referred to a armadillo proteins. 
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et al., 2007): (1) an extracellular domain between adjacent plasma membranes, 
containing fibrillar proteins oriented perpendicular to the membranes, with a more 
dense linear structure parallel to and midway between them referred to as the dense 
midline, (2) a section of the plasma membrane containing the transmembrane 
domains of desmosomal plaque proteins, (3) a cytoplasmic region adjacent to the 
plasma membrane containing a high density of protein referred to as the outer dense 
plaque (ODP), (4) a cytoplasmic region adjacent to the ODP with a slightly lower 
density of proteins referred to as the inner dense plaque (IDP) and (5) intermediate 
filaments (IF) passing through or adjacent to the IDP.  
 
 
 
Figure 4 Schematic illustration of desmosomal ultrastructure 
Desmosomes are typically found where plasma membranes of two cells are 
adjacent (Panel A). A schematic representation of the three dimensional structure of 
a desmosome is presented in Panel B, illustrating the laminated plaques. The 
boxed region in panel B is shown in detail in panel C. This type of cross sectional 
view may be seen in TEM images of desmosomes and the key feature in such an 
image are illustrated in Panel C.  
 
The appearance of a desmosome when imaged by transmission electron 
microscopy (TEM) depends on the fixation and staining technique employed (Figure 
5) (Figure 6). Sample preparation involves labelling proteins with heavy metal ions. 
Heavy metal ions absorb electrons from a TEM imaging beam and therefore regions 
of higher protein density absorb a greater proportion of the TEM beam. The extent to 
which a region absorbs electrons is commonly referred to as its electron density.  
The typical appearance of a desmosome fixed with osmium tetroxide (OsO4) and 
stained with aqueous uranyl acetate and alkaline lead citrate is presented in Figure 5. 
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 Some investigators have reported that the cytoplasmic side of the ODP is more 
dense than that adjacent to the plasma membrane (Figure 6, panels A, C) (Kelly, 
1966) (North et al., 1999). Investigators using cryo-electron microscopy have 
reported that within this less dense ODP region there is a sub-region of higher 
density which they attributed to the localisation of plakophilin molecules (Figure 6, 
Panel D) (Al-Amoudi et al., 2011). The IDP has been reported to be separated from 
the ODP in a similar manner by a region of lower protein density. 
 
 
 
Figure 5 Representative TEM image of typical desmosome ultrastructure. 
Panel A presents a TEM image of a desmosome from a sample of HaCaT cells 
(passage 72), taken at 130,000x magnification. Panel B presents the same image 
as panel A with shading to indicate the regions occupied by the intermediate 
filaments (green), inner dense plaque (yellow) and outer dense plaque (red). Panel 
C shows a selected region of panel A with annotations to indicate the regions 
occupied by intermediate filaments (IF), inner dense plaque (IDP), outer dense 
plaque (ODP), intracellular surface of the plasma membrane (PM(i)), extracellular 
surface of the plasma membrane (PM(e)), midline (Mid). The scale bars represent 
100nm in panels A and B, and 50nm in panel C.
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Figure 6 Schematic illustrations of the ultrastructural features of desmosomes reported by different authors and using 
different methods of sample preparation. 
Panel A illustrates the findings of Kelly in samples that were fixed with OsO4, embedded in resin and stained with aqueous uranyl 
acetate and alkaline lead citrate solutions(Kelly, 1966). The ODP was reported to contain an electron lucent region separating its more 
electron dense cytoplasmic region from the plasma membrane (Kelly, 1966). Panel B and C illustrate the findings of North et al(North et 
al., 1999). Panel B shows the findings in samples that were fixed with 2% formaldehyde / 2% glutaraldehyde, then OsO4, then 
embedded in resin and stained with aqueous uranyl acetate and alkaline lead citrate solutions. Although the electro-lucent region 
reported by Kelly was not apparent the investigator did identify a region of lower protein density at this location using negative staining 
(Panel C). Panel D shows the findings of Al-Amoudi et al. in samples prepared using cryo-electron tomography (Al-Amoudi et al., 2011). 
Two regions of increased density distinct from the plasma membrane were identified within the ODP region and term the plakoglobin 
and plakophilin layers. 
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Many investigators have reported typical ranges for the dimensions of desmosomal 
components. Only a small number of these publications describe data sets from 
which these ranges were derived (Table 6) and few studies provide a detailed 
description of the locations within a desmosome between which these width 
parameters are measured e.g. several publications report typical values for the 
desmosomal gap (Table 6) but do not indicate whether these measurements are 
made between the inner leaflet, outer leaflet, or the electro-lucent line separating 
them. As a result it is difficult to know whether differences in the dimensions of 
desmosomes in these studies results from biological variation or differing 
methodology. 
 
Publication Sample 
size (n) 
Intermemb
rane width 
(nm) 
ODP width (nm) Less dense 
region within IDP 
(nm) 
Tono-
filaments 
(North et al., 1999) Not 
specified 
20-50 Entire region: 
15-20nm from 
plasma membrane 
<10nm region 
separating ODP 
and IDP 15-20nm  
- 
(McNutt, 1970) Not 
specified 
25-35 - - - 
(Karrer, 1960) Not 
specified 
22 Dense region: 
16nm  
- - 
(Kelly, 1966) Not 
specified 
 Dense region: 
15-20 
 40-70nm 
from plasma 
membrane 
(Garrod et al., 2005) 50 23.9±0.5nm - - - 
 
Table 6 Publications providing typical values for desmosomal width 
parameters 
 
1.2.2 Desmosomal cadherins 
The desmosomal cadherins are type 1 trans-membrane proteins belonging to the 
cadherin superfamily. They have been divided into two groups: desmocollins and 
desmogleins on the basis of structural differences at their C-termini (outlined below) 
(Figure 7).  
At the time of this study, three genes had been identified in humans encoding 
desmocollins and four encoding desmogleins. Each desmocollin gene may be 
transcribed into two isoforms referred to as a or b, with the a isoform being the longer 
of the two. To date only one transcript has been identified from each of the DSG1, 
DSG2 and DSG3 genes. Two transcript variants of DSG4 have been described, the 
shorter (variant 1) lacks a sequence in the intracellular anchor domain encoded by 
exon 14 (Whittock and Bower, 2003).  
The structure of desmosomal cadherins are summarised in Figure 7. All 
desmosomal cadherins contain a similar extra-cellular component consisting of four 
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extra-cellular calcium-binding domains (ECB). Each ECB consists of a seven 
stranded β-barrel, adjacent domains are connected by flexible linker regions within 
which calcium ions can be accommodated (Overduin et al., 1995) (Shapiro et al., 
1995) (Boggon et al., 2002). Both the desmogleins and the desmocollin a isoforms 
contain a 72 amino acids long intracellular cadherin sequence (ICS) at its C-terminus. 
Desmogleins contain three additional domains at their C terminus that are not 
present in desmocollins, namely: a proline rich linker (PRL), a repeat unit domain 
(RUD) and a terminal domain. The RUD consist of a variable number repeating 29 
amino acid motif desmogleins 1, 2, 3 and 4 contain 5, 6, 2, and 3 repeating units 
respectively (Garrod and Chidgey, 2008). 
 
 
Figure 7 Schematic of the structure of desmosomal cadherins.  
Non-folded pre-pro-proteins are represented with the regions responsible for 
different functions labelled. Annotations indicate: the precursor sequence (P), extra-
cellular calcium binding sequence (ECB), extra-cellular anchor (EA), 
transmembrane sequence (TM), intracellular anchor (IA), intracellular cadherin-like 
sequence (ICS), proline-rich linker (PRL), repeat unit domain (RUD) and carboxy-
terminal domain (T). 
 
The ECB1 domain has been identified as the principle site of binding between 
desmosomal cadherins from adjacent cells, this binding has been referred to as 
trans-dimerisation (Boggon et al., 2002). All desmosomal cadherins contain a 
tryptophan residue at position two in the ECB1 domain that is essential for trans-
dimerisation. During trans-dimerization the hydrophobic tryptophan residues are 
associated with hydrophobic pockets in the ECB1 domains of the opposing 
molecules (Boggon et al., 2002). Desmosomal cadherins can also interact in cis with 
each other through their ECB domains, producing parallel oriented clusters of 
cadherins described as “adhesion zippers” (Brieher et al., 1996) (Garrod et al., 2005). 
The ECB domains are separated by linker regions containing calcium binding 
domains which are thought to regulate cadherin shape and thence then changes in 
desmosomal structure and adhesion associated with calcium dependent and 
independent binding (Troyanovsky et al., 1999) (Garrod et al., 2005). 
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The intracellular cadherin-like sequence (ICS) mediates binding of desmosomal 
cadherins with JUP (Troyanovsky et al., 1994b) (Troyanovsky et al., 1994a) (Roh and 
Stanley, 1995). The intracellular anchor (IA) sequence is thought to mediate the 
binding of desmosomal cadherins with plakophilins and desmoplakin (Bonné et al., 
2003) (Chen, 2002). 
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 Arm repeat protein DSP 
JUP PKP1 PKP2 PKP3 
Desmosomal 
cadherin 
DSC1 a (Witcher et al., 1996) 
(Smith and Fuchs, 1998) 
(Smith and Fuchs, 1998) (Chen, 2002)  (Bonné et al., 2003) (Troyanovsky et al., 1994b) 
b - - - - - 
DSC2 a (Bornslaeger et al., 2001) - (Chen, 2002) (Bonné et al., 2003)  
b - - - - - 
DSC3 a - - - (Bonné et al., 2003)  
b - - - (Bonné et al., 2003) - 
DSG1 (Mathur et al., 1994) 
(Witcher et al., 1996) 
(Chitaev et al., 1998) 
(Smith and Fuchs, 1998) 
(Bornslaeger et al., 2001) 
(Smith and Fuchs, 1998) 
(Hatzfeld et al., 2000) 
(Chen, 2002) (Bonné et al., 2003) (Bornslaeger et al., 2001) 
DSG2 - - (Chen, 2002) (Bonné et al., 2003)  
DSG3 (Roh and Stanley, 1995) - - (Bonné et al., 2003)  
DSG4 - - - -  
DSP (Kowalczyk et al., 1997), 
(Smith and Fuchs, 1998) 
(Bornslaeger et al., 2001) 
(Smith and Fuchs, 1998), 
(Kowalczyk et al., 1999) 
(Hatzfeld et al., 2000), 
(Bornslaeger et al., 2001) 
(Chen, 2002) (Bonné et al., 2003) - 
 
Table 7 Summary of the molecular interactions reported between the intracellular regions of desmosomal plaque proteins. 
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1.2.3 Desmosomal arm-repeat proteins 
Plakoglobin and the plakophilins are members of the armadillo (or arm-repeat) 
group of proteins (Figure 8) (Hatzfeld et al., 2003). Three major desmosomal 
plakophilins have been identified named PKP 1 to 3. 
 
 
Figure 8 Classification of arm-repeat proteins  
Adapted from (Hatzfeld, 2007). 
 
The structure of arm-repeat proteins is summarised in Figure 9. Arm-repeat proteins 
have a central domain in containing repeats of a 45 amino acid long arm-repeat 
sequence bracketed at either end by head and tail domains (Hatzfeld, 2007). Each 
central domain repeat forms a cluster of three α-helices, these repeat units are then 
packed to form a superhelix. Plakoglobin contains 12 arm repeats whilst members of 
the plakophilin group contain nine arm repeats with an sequence between the 5th and 
6th repeats that introduces a bend in the domain (Choi and Weis, 2005). Although 
splice variants of the plakoglobin gene exist they are thought to encode the same full-
length protein. Each plakophilin gene may be transcribed as two isoforms referred to 
as a and b; the b isoform is longer of the two.  
Interactions between desmosomal arm-repeat proteins and other desmosomal 
components are summarised in Table 7.  
Plakoglobin binds to the ICS domain of desmogleins and desmocollin a isoforms via 
the first three units of its arm-repeat domain (Chitaev et al., 1998) (Chitaev et al., 
1996). The site of within the plakoglobin molecule which interacts with desmoplakin 
has yet to be characterised (Holthöfer et al., 2007). Plakoglobin can also bind to 
proteins in the canonical Wnt signalling pathway (see 1.2.7). Binding to TCF/LEF 
transcription factors is mediated via a domain at its C-terminus (Simcha et al., 1998). 
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Plakophilins bind to the plakin domain of DSP via their N-terminus / head domain 
(Kowalczyk et al., 1999). There is also evidence that the N-terminus / head domain of 
plakophilins interacts with desmogleins (Hatzfeld et al., 2000). The functions of the C-
terminus tail of plakophilins are less well characterised, but have been implicated in 
the localisation of plakophilins to the plasma membrane (Sobolik-Delmaire et al., 
2006). 
 
 
Figure 9 Structure of desmosomal arm repeat proteins. 
Arm-repeat domains are numbered. For the plakophilins the sequence which 
introduced a bend in the arm-repeat domain (L) is indicated as are the additional 
sequences which render the b isoforms longer than the a isoforms (*).  
1.2.4 Desmoplakin 
Desmoplakin is thought to be obligatory component of mature desmosomes. It links 
the desmosomal plaques to intermediate filaments (IF). In epithelial cells the main IF 
protein is keratin, in cardiomyocytes it is desmin (Garrod and Chidgey, 2008). The 
structure of desmoplakin is summarised in Figure 10. Desmoplakin is a member of 
the plakin family of proteins that are defined by containing plakin domains.  The 
plakin domain of desmoplakin consists of a pair of spectrin repeats, linked by an Src-
homology 3 domain (Jefferson et al., 2007). Each repeat is organised into a cluster of 
three α-helices (Jefferson et al., 2007). The plakin domain is located at the N-
terminus of desmoplakin. The C-terminus of desmoplakin contains a series of three 
plakin repeat domains (PRD) (designated A, B and C) and a glycine-serine-arginine 
rich domain. The plakin domain and PRD are separated by central rod domain, 
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organised into a coiled-coil α-helix. Desmoplakin exists in two isoforms, DSP I and 
DSP II, which differ in the length of their rod domain, the later of these being the 
shorter. 
Desmoplakin binds to plakoglobin and plakophilins via its N-terminus plakin domain 
(Kowalczyk et al., 1997) (Kowalczyk et al., 1999). Within the desmosome, 
desmoplakin molecules are thought to form homo-dimers through their rod domains 
(Green et al., 1990). Intermediate filaments bind to the C-terminus plakin repeat 
domains (PRDs) located at the carboxy terminus of desmoplakin (Stappenbeck and 
Green, 1992) (Fontao et al., 2003). 
 
 
Figure 10 Desmoplakin structure. 
Spectrin repeat (SR), Src-homology 3 linker region (L), glycine-serine-arginine rich 
domain (GSR). 
1.2.5 The composition and organization of proteins within the cardiac 
desmosome and their correlation with ultrastructural features. 
The repertoire of desmosomal proteins expressed in the heart is more limited than 
in other desmosome bearing tissues such as the skin. The major desmosomal 
cadherins are DSC2 and DSG2, with both isoforms of DSC2 being expressed (De 
Bortoli et al., 2010). The major arm-repeat proteins are JUP and PKP2, with only the 
shorter PKP2a isoform being expressed at a protein level (Gandjbakhch et al., 2011). 
The shorter isoform of desmoplakin (DSPI) has been reported to be absent from 
cardiac tissue (Angst et al., 1990). The longer isoform of desmoplakin DSP II has 
been identified in all desmosome-bearing tissues, and is therefore thought to be the 
only isoform present in the heart.  
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A model of the molecular organisation of proteins within cardiac desmosomal 
plaques (based on the organisation of epithelial desmosomes) is presented in Figure 
11.  
The intermembrane gap is bridged by the extra-cellular domains of desmosomal 
cadherins that link at their terminal ECB1 domains. The overlap of these proteins is 
thought to be responsible for the dense midline seen in some desmosomes a. 
Desmocollins and desmogleins are capable of forming heterophilic and homophilic 
trans-dimers (Chitaev and Troyanovsky, 1997) (Marcozzi et al., 1998) (Runswick et 
al., 2001) (Syed et al., 2002). There is evidence that the majority of trans-
dimerization in desmosomes is homophilic and isoform specific (Nie et al., 2011). 
The cytoplasmic domains of desmosomal cadherins interact with desmoplakin via 
arm repeat proteins (PKP2 and JUP). The concentration of proteins mediating these 
interactions is responsible for the ODP seen by TEM. The homodimers of DSP then 
extend from the cytoplasmic surface of the ODP to interact with the intermediate 
filaments composed of desmin in the region corresponding to the IDP.  
Adhesion junctions with a typical desmosomal morphology have been identified in 
the heart (Muir, 1965) however it has not yet been demonstrated the these junctions 
have the same molecular organisation as the epidermal desmosomes described by 
North et al. . Desmosomal proteins have also been demonstrated to participate in 
cardiac adhesion junctions other than those with a typical desmosomal morphology 
(see below) the molecular architecture of these junctions has also not been fully 
characterised (Borrmann et al., 2006) (Franke et al., 2006) (Pieperhoff and Franke, 
2007).  
                                            
a Associated with a calcium independent binding state (Garrod et al., 2005). 
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Figure 11 A proposed organisation of desmosomal proteins within a cardiac 
desmosome and their correlation with features seen by TEM. 
This model assumes that the organisation of cardiac desmosomes is similar to that 
described by North et al. in epidermal desmosomes. It shows a possible molecular 
architecture for cardiac desmosomes using the more limited repertoire of 
desmosomal proteins described in the reports outlined in 1.2.5 . 
 
1.2.6 Desmosomal proteins and intercellular adhesion 
Desmosomes provide a mechanism by which the cytoskeleton of adjacent cells may 
be linked. They are abundant in tissues exposed to high levels of mechanical stress 
e.g. the epidermis. In circumstances where desmosomal adhesion is disrupted then 
tissue damage is more readily induced (Delva et al., 2009). For these reasons the 
maintenance of tissue integrity is regarded as a major function of desmosomes. 
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In adult mammalian hearts desmosomes have been reported to constitute between 
8-15% of the adhesion junctions (Forbes and Sperelakis, 1985).  Immunoelectron 
and immunofluorescence microscopy data has suggested that desmoplakin, 
plakoglobin, PKP2, DSC2 and DSG2 are components of long adhesion junctions 
found at the intercalated discs which lack the typical ultrastructural characteristics of 
desmosomes (Franke et al., 2006) (Borrmann et al., 2006). These investigators have 
proposed that during cardiac development desmosomes and adherens junctions 
become concentrated and coalesce at the intercalated discs to form junctions 
referred to as area composita (Pieperhoff and Franke, 2007). At the level of 
molecular architecture, these area composita may be composed of a mosaic of 
regions arranged as desmosomal and fascia adherens plaques. Alternatively they 
may have an entirely novel molecular architecture composed of desmosomal and 
fascia adherens proteins. In support of the later possibility plakoglobin has been 
shown to be interchangeable with β-catenin in binding to α-catenin and the 
cytoplasmic domain of E-cadherin (the major transmembrane cadherin in adherens 
junctions) (Cowin et al., 1986) (Chitaev et al., 1996). Plakoglobin has a lower binding 
affinity for E-cadherin than desmosomal cadherins and this is thought to account for 
its lower abundance at adhesion junctions than at desmosomes in tissue with these 
distinct junction types (Chitaev et al., 1996).  
In addition to the role of desmosomal proteins in facilitating the mechanical 
connections between cells they have been shown to regulate the localisation of 
structures mediating their electrical activity. Abnormalities in desmosomal protein 
abundance and function have been associated with reduction in the abundance of 
gap junctions, gap junction proteins and the voltage gated sodium channel Nav1.5 at 
the intercalated discs with (Kaplan et al., 2004) (Tandri et al., 2008) (Gehmlich et al., 
2011) (Swope et al., 2012) (Noorman et al., 2013) (Sato et al., 2011). The 
mechanisms responsible for the this have yet to be fully elucidated but there is 
evidence that DSP can regulate gap junction localisation via the regulation of 
microtubules (Patel et al., 2014).  
1.2.7 Desmosomal proteins and intracellular signalling pathways 
In addition to their roles in desmosomal adhesion, plakoglobin and the plakophilins 
have roles in intracellular signalling pathways. Non-membrane bound, cytoplasmic 
and nuclear pools of plakoglobin and the plakophilins have been reported in many 
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cell types (Heid et al., 1994)  (Mertens et al., 1996) (Bonné et al., 1999) (Schmidt et 
al., 1997). 
Plakoglobin has structural and functional similarities to β-catenin, which in addition 
to its role as a component of adhesion junctions is a key regulator of canonical Wnt 
signalling (Figure 12). β-catenin and plakoglobin are capable of binding to TCF/LEF 
transcription factorsa and modifying the activity of these molecules (Simcha et al., 
1998) (Miravet, 2001) (Maeda et al., 2004). Despite the similarities between 
plakoglobin and β-catenin, they have different binding sites to TCF/LEF transcription 
factors and differing effects on gene transcription. TCF4 binds to the first 50 amino 
acids in plakoglobin, and to residues 51-80 in β-catenin (Miravet, 2001). Plakoglobin 
binding to TCF4 inhibits gene transcription, whereas binding to β-catenin increases 
transcriptional activity (Miravet, 2001). β-catenin and plakoglobin can bind to LEF1, 
but plakoglobin does so with much lower efficiency and results in a lesser degree of 
transcription factor activation (Simcha et al., 1998). 
The abundance of cytoplasmic and nuclear β-catenin and plakoglobin is regulated 
by a cytoplasmic multi-protein complex of adenomatosis polyposis coli (APC), axin, 
glycogen synthase kinase 3β (GSK), casein kinase 1α (CK1α) and protein 
phosphatase 2A (PP2A). After binding to this complex, β-catenin and plakoglobin are 
phosphorylated by GSK b leading to their degradation by ubiquitin dependent 
proteolysis (Kodama et al., 1999) (Ben-Ze’ev and Geiger, 1998). 
Experimentally induced changes in plakoglobin abundance have been shown to 
influence canonical Wnt signalling. Homozygous knock-out of plakoglobin results in 
an increase in β-catenin binding to TCF4 (which normally binds preferentially to 
plakoglobin), resulting in increased transcriptional activation of Wnt signalling targets 
(J. Li et al., 2011).c 
Over expression of plakoglobin causes the displacement of β-catenin from adhesion 
junctions (Salomon et al., 1997), the inhibition of β-catenin degradation by the 
destruction complex (Miller and Moon, 1997) and the accumulation of both β-catenin 
and plakoglobin within the nucleus (Simcha et al., 1998). Since plakoglobin and β-
catenin bind to different site on TCF/LEF transcription factors, the net effect on Wnt 
                                            
a The N-terminus of TCF/LEF transcription factor binds to the arm-repeat region of β-catenin. The C-terminus of β-catenin then 
interacts with TCF/LEF to increase its activity. 
b The N-terminus serine residue (S28) is a critical site of phosphorylation in this process. 
c Knock-out models lacking plakoglobin develop normally during the earliest stages of development, then develop lethal 
cardiac and epidermal abnormalities (Haegel et al., 1995) (Bierkamp et al., 1996) (Ruiz et al., 1996).  
 
 
 
  
 
29 
signalling is not simply determined by their relative concentrations as might occur if 
there was competition for the same site. 
 It has also been suggested that over-expression of plakoglobin may increase Wnt 
signalling independently of its effects on β-catenin by binding to inhibitors of TCF/LEF 
transcription (Merriam et al., 1997).  
 
 
Figure 12 Canonical Wnt signalling 
In the absence of activation (A) a destruction complex of adenomatosis polyposis 
coli (APC), axin, glycogen synthase kinase 3β (GSK), casein kinase 1α (CK1α) and 
protein phosphatase 2A (PP2A) bind to and phosphorylates serine residues in β-
catenin (β-Ctn). Phosphoserine residues in the N-terminus are recognised by 
ubiquitin ligase β-TrCP, which catalyses ubiquitination and thereby directing it to 
degradation. (B) Binding of a Wnt ligand to the transmembrane receptors frizzled 
(Frz) and lipoprotein receptor related protein 5/6 (LRP) triggers the binding of axin 
and dishevelled (Dsh) to their cytoplasmic domains. Dsh inhibits GSK resulting in a 
reduction in activity of the destruction complex. Β-catenin levels increase in both the 
cytoplasm and nucleus. Nuclear β-catenin binds to TCF/LEF transcription factors 
that then change the expression of downstream targets of Wnt signalling. In some 
cases binding of β-catenin results in transcription factor binding to enhancer sites 
and promotion of gene expression. In other cases binding of β-catenin releases 
constitutive inhibition of gene expression by transcription factors (Akiyama, 2000). 
 
Several mechanisms by which PKP2 may influence gene expression have been 
reported. It may have a role in regulating ribosomal an tRNA through binding to RNA 
polymerase III within the nucleus (Mertens et al., 2001). It can interact directly with β-
catenin-TCF/LEF Wnt activation (Chen, 2002).  It may also influence Wnt signalling 
via phosphorylated protein kinase C α (pPKCα) and the Hippo pathway. 
Phosphorylated protein kinase C α (pPKCα) associates with the plasma membrane 
and adhesion junctions through its interaction with PKP2. Reduced membrane 
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localisation of pPKCα leads to a reduction in neurofibromin 2 (NF2) phosphorylation, 
a subsequent increase in Hippo pathway activity and thence the inhibition of Wnt 
signalling (Heallen et al., 2011) (Bass-Zubek et al., 2009) (S. N. Chen et al., 2013). 
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1.3 Overview of arrythmogenic right ventricular cardiomyopathy / dysplasia 
1.3.1 Clinical features 
The diagnosis ARVC/D is made using criteria that collate aspects of clinical 
presentation with the results diagnostic tests (Table 8) (Table 9) (Marcus et al., 2010). 
Cases of ARVC/D most commonly present between the ages of 20 and 50 with 
symptoms of ventricular arrhythmias and may go on to develop heart failure due 
ventricular dysfunction. The clinical features of ARVC/D in published case series’ are 
summarised in Table 10.  
ARVC/D has a prevalence of between 1:000 to 1:5000 (Thiene et al., 2007) 
(Gemayel et al., 2001) (Rampazzo et al., 1994) (Peters et al., 2004). The risk of 
sudden cardiac death (SCD) in ARVC/D is between 0.08 and 4.5% per year (Corrado 
et al., 2017).  
The therapeutic options in ARVC/D are limited to: (1) the control of arrhythmias with 
drugs and catheter ablation, (2) the prevention of sudden death my implantation of a 
implantable cardioverter-defibrillator and (3) cardiac transplant in severe cases 
(Corrado et al., 2017) (Pilichou et al., 2016).  
ARVC/D is familial in 20-30% of cases and it follows an autosomal dominant pattern 
of inheritance in most familial cases (Hulot, 2004) (Dalal, 2005) (Quarta et al., 2011a). 
The first ARVC/D associated mutation to be identified was in the gene encoding the 
desmosomal plaque protein plakoglobin (JUP). Subsequent investigators identified 
ARVC/D associated mutations in four other genes encoding desmosomal plaque 
proteins (Table 11). Overall, mutations in desmosomal genes are identified in around 
50% of ARVC/D probands (Table 12) (Ackerman et al., 2011). This led to 
suggestions that desmosomal dysfunction was central to the pathogenesis of 
ARVC/D (van Tintelen et al., 2007). Fewer studies are available to estimate the 
prevalence of non-desmosomal mutations in ARVC/D populations but were found in 
only 5% of a recent series of 502 cases (Bhonsale et al., 2017). In some cases the 
function of these proteins has been linked to the pathogenic mechanisms proposed 
for desmosomal mutations, others are thought to have different modes of 
pathogenesis and produce a phenocopy of ARVC/D (Corrado et al., 2017). 
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Category of clinical feature Test modality Major criteria Minor criteria 
I 
Global or regional 
dysfunction and structural 
alterations 
Echocardiography 
• Regional RV akinesia, dyskinesia or aneurysm 
• and ≥1 of the following (measured at end diastole) 
o RVOT diameter measured in PLAX: 
− ≥32mm 
− ≥19mm/m2 if corrected for BSA 
o RVOT diameter measured in PSAX: 
− ≥36mm 
− ≥21mm/m2 if corrected for  
− 
o Fractional area change ≤33% 
• Regional RV akinesia, dyskinesia 
• and ≥1 of the following (measured at end diastole) 
o RVOT diameter measured in PLAX: 
− ≥29 to <32mm 
− ≥16 to <19mm/m2 if corrected for BSA 
o RVOT diameter measured in PSAX: 
− ≥32 to <36mm 
− ≥18 to <21mm/m2 if corrected for BSA 
o Fractional area change >33% to ≤40% 
Cardiac MRI 
• Regional RV akinesia, dyskinesia or dyssynchronous RV 
contraction 
• and ≥1 of the following: 
o Ratio of RV end-diastolic volume to BSA 
− ≥110ml/m2 (male) 
− ≥100ml/m2 (female) 
o RV ejection fraction ≤40% 
• Regional RV akinesia, dyskinesia or dyssynchronous RV 
contraction 
• and ≥1 of the following: 
o Ratio of RV end-diastolic volume to BSA 
− ≥100 to <110ml/m2 (male) 
− ≥90 to <100ml/m2 (female) 
o RV ejection fraction >40% to ≤45% 
RV Angiography Regional RV akinesia, dyskinesia or aneurysm  
II Tissue characterization Endomyocardial Biopsy 
• Residual myocytes: 
o <60% by morphometric analysis 
o <50% if estimated 
• and fibrous replacement of the RV free wall myocardium 
in ≥1 sample (with or without fatty replacement of tissue) 
• Residual myocytes 
o 60% to 75% by morphometric analysis 
o 50% to 65% if estimated 
• and fibrous replacement of the RV free wall myocardium in 
>1 sample (with or without fatty replacement of tissue) 
III Repolarisation abnormalities ECG 
• Inverted T waves: 
o in the absence of complete RBBB, 
− in V1, V2, and V3 or beyond.  
(in individuals >14 years of age) 
• Inverted T waves: 
o In the absence of complete RBBB 
− in V1 and V2  
− in V4, V5, or V6 
o In the presence of complete RBBB 
− in V1, V2, V3, and V4 
(in individuals >14 years of age) 
Table 8 Diagnostic criteria for ARVC/D 
(continued overleaf) (Marcus et al., 2010) 
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(continued from previous page) 
IV Depolarization/conduction abnormalities 
ECG 
• Epsilon wave  
(a reproducible low-amplitude signals between end of 
QRS complex to onset of the T wave in V1 to V3) 
• Terminal activation duration of QRS ≥55 ms  
(measured from the nadir of the S wave to the end of the 
QRS, including R’ in V1, V2 or V3, in the absence of 
complete RBBB) 
SAECG 
 • ≥1 of the following: 
o Filtered QRS duration ≥114 ms 
o Duration of terminal QRS <40 µV,  ≥38 ms 
o Root-mean-square voltage of terminal 40 ms ≤20 mV 
(in the absence of a QRS duration of ≥110 ms on the 
standard ECG) 
V Arrhythmias ECG 
• Nonsustained or sustained ventricular tachycardia of left 
bundle-branch morphology: 
o with a superior axis (negative or indeterminate QRS in 
leads II, III, and aVF and positive in lead aVL) 
• Nonsustained or sustained ventricular tachycardia of left 
bundle-branch block morphology: 
o with an inferior axis (positive QRS in leads II, III and aVF 
and negative in lead aVL) 
o or of unknown axis 
Ambulatory ECG  • 500 ventricular extra-systoles per 24 hours 
VI Family history 
Family history 
• First degree relative: 
o With a diagnosis ARVC/D based on the current 
diagnostic criteria. 
o With a diagnosis of ARVC/D based on the pathological 
diagnostic standard (from tissue obtained at autopsy or 
surgery) 
• First degree relative: 
o With a diagnosis of ARVC/D but in whom it is not 
possible or practical to determine whether the family 
member meets current diagnostic criteria. 
o Suffering premature sudden death (<35 years of age) 
due to suspected ARVC/D . 
• Second degree relative: 
o With a diagnosis ARVC/D based on the current 
diagnostic criteria. 
o With a diagnosis of ARVC/D based on the pathological 
diagnostic standard (from tissue obtained at autopsy or 
surgery). 
Genetic testing • Identification of a pathogenic ARVC/D mutation in the patient under evaluation. * 
 
RV = right ventricle, RVOT = right ventricular outflow tract, PLAX = parasternal long axis, PSAX = parasternal short axis, BSA = body 
surface area, ECG = electrocardiogram, SAECG = signal averaged electrocardiogram, RBBB = right bundle branch block. 
* A pathogenic mutation is a DNA alteration associated with ARVC/D that alters or is expected to alter the encoded protein, is 
unobserved or rare in a large non-ARVC/D control population, and either alters or is predicted to alter the structure or function of the 
protein or has demonstrated linkage to the disease phenotype in a conclusive pedigree.
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Diagnostic category Number of criteria  Diagnostic points 
Definite • Major criteria in ≥2 different categories 
• Major criterion, and ≥2 minor criteria, all in different 
categories 
• Minor criteria in ≥4 different categories 
≥4 
Borderline • Major criterion and minor criterion in different categories 
• Minor criteria in 3 different categories 
3 
Possible • 1 Major criterion. 
• Minor criteria in 2 different categories 
2 
Table 9 Diagnostic categories of ARVC/D 
The latest diagnostic schema for ARVC/D classifies the clinical features of the disease a major or minor criteria (as described in 
Table 8). These criteria are then grouped into 6 categories. An individual is given two “diagnostic points” for each category in 
which ≥1 major criterion have been identified and one “diagnostic point” for each category in which no major but ≥1 minor criterion 
have been identified. The individual is then given a diagnostic category based on the total number of diagnostic points given 
(Marcus et al., 2010). 
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Publication (Peters et al., 2004) (Hulot, 2004) 
(Dalal, 
2005) 
(Cho et al., 
2007) 
(Sen-Chowdhry 
et al., 2007) 
(Marcus et al., 
2009) 
(Watkins et al., 
2009)  
(Pinamonti 
et al., 2011) 
(Quarta et 
al., 2011a) 
(Cox et al., 
2011) 
Country Germany France US  Korea UK US  South Africa Italy  UK Netherlands 
Size of population studied 80 130 69 37 200 108 50 96 46 147 
Diagnostic criteria used to define cases 1994 1994 1994 1994 1994  1994 1994 1994 2010 2010 
Diagnostic categorization of study population 100% definite 100% definite 100% definite 
100% 
definite 100% definite 
68% definite, 
26% borderline, 
6% unaffected  
100% definite 100% definite 100% definite 100% definite 
Gender (% Male) 56% 77% 52% 51% 49% 57% 66% 68% 58.7% 75% 
Age (years) 
Presentation NR 
Mean: 32±14 
Range 10 to 
73 
Mean: 
30±12 
Mean: 
41±15 
37±16 
Range 12-76 
(at unspecified 
time point) 
Mean: 36±15 Mean: 33±14 NR NR Mean: 37±14 
Diagnosis Mean: 45.6 Range: 22-91 NR NR NR 
Mean: 38±13 
Range 12 to 63 NR Mean 34±15 38±13 NR 
Symptoms  
Time point Unspecified Unspecified Presentation Presentation Unspecified Presentation Presentation Presentation Presentation Presentation 
Palpitations 60% 67% 36% 30% 42% 56% 72% 41% 
46% 
NR Dizziness or pre-syncope NR NR 12% 30% 29% 27% 42% NR Syncope 30% 32% 30% 12% 21% 32% 15% 1% 
Cardiac arrest 1% 13% 1.5% 3% NR 1% 4% 3% 8% 
Chest pain 80% 27% 3% 8% 13.5% 14% 36% 4% 
NR Symptoms of right heart failure 4% 17% 4% NR NR 5% 12% 17% 
Asymptomatic NR 6% 22% 27% 42.5% NR 2% 27 54% 
Ventricular 
arrhythmia 
Non-sustained VT 20% 79% 77% 16% 20.5% NR 82% 23% 22% NR Sustained VT 19% 1% 35% 82% 34% 41% 81% VF NR 6% NR 5% NR NR 11% 8% 
Ventricular 
dysfunction 
RV dysfunction  Global 100% 54% 82% NR NR NR 88% 100% 26% 76% Regional 48% NR 92% 
LV dysfunction 
LV dilation 
NR 
NR 
NR 
14% 40% 
NR NR 
14% 
28% NR Reduced LVEF 10% 5% 18% 26% 
LV WMAs: NR 41% 33% 45% 
Prognosis 
Duration of 
follow-up 
(years) 
Mean 2.4  8.1±7.8 NR 2.3±2.2 
NR NR 
NR 10.7±7.7 NR 12±9 
Median NR 6 6 (IQR: 2 to 13) 1.4 4.6 10 NR NR 
Annual 
mortality 
SCD 0.3%  0.7% 0.5% 
0 NR NR 
1.9% 0.6% 
NR 
0.2% 
Death due 
to heart 
failure 
NR 1.3% 0.3% 0.9% 0.6% 0.1% 
All cause NR 2.3% NR NR 2.8% 1.9% 3.0%  0.3% 
Age of death (years) NR NR NR NR NR NR Mean: 36.9±14.7 NR NR NR 
Table 10. Symptoms, clinical features and prognosis of clinical defined ARVC/D for published cohorts. 
NR = not reported, WMA = ventricular wall motion abnormalities, LVEF = left ventricular ejection fraction, SCD = sudden cardiac death . RV 
dysfunction is defined as any abnormalities on echo, MRI or RV angiography constituting a major or minor criteria for the diagnosis of ARVC/D.  
Unless otherwise stated, LV dysfunction is defined as any degree of regional or global LV dysfunction identified by echo or MRI. 
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Type of protein 
encoded  
Gene Localisation (and function) of protein Reports describing autosomal 
dominant inheritance of ARVC/D 
due to mutations in this gene 
Reports describing autosomal 
dominant recessive of ARVC/D due to 
mutations in this gene 
Desmosomal DSC2 Desmocollin 2 Desmosomal plaques (intercellular adhesion) (Syrris et al., 2006),  
(Heuser et al., 2006) 
(Simpson et al., 2009) 
DSG2 Desmoglein 2 Desmosomal plaques (intercellular adhesion) (Pilichou, 2006) (Torsten B Rasmussen et al., 2013) 
JUP Plakoglobin Desmosomal plaques, Adherens junction 
(intercellular adhesion) 
(Asimaki et al., 2007) (McKoy et al., 2000) 
PKP2 Plakophilin 2 Desmosomal plaque protein 
 
(Gerull et al., 2004) (Awad et al., 2006) 
DSP Desmoplakin Desmosomal plaque protein (Rampazzo et al., 2002) (Alcalai et al., 2003) 
CTNNA3 * αT-catenin Desmosomal plaque and adherens junction 
protein 
(van Hengel et al., 2013) - 
p0072 / PKP4 * Plakophilin 4 Desmosomal plaques (intercellular adhesion) (Gandjbakhch et al., 2013)  
PERP * p53 effector related to 
PMP22 
Desmosomal plaques (intercellular adhesion) (Gandjbakhch et al., 2013)  
Non-desmosomal TMEM43 Transmembrane 
protein 43 
Nuclear envelope (unknown), Intercalated 
discs (unknown), Sarcolemma (unknown) 
(Merner et al., 2008) - 
RYR2 Ryanodine receptor 2 Sarcoplasmic reticum (Receptor for calcium 
triggered calcium release from sarcoplasmic 
reticulum in cardiomyocytes) 
(Tiso et al., 2001) - 
TGFB3 Transforming growth 
factor beta 3 
Cytokine (cellular adhesion and extra-cellular 
matrix formation) 
(Beffagna et al., 2005) - 
LMNA Lamin A/C Nuclear envelope  (Quarta et al., 2011b) - 
TTN Titin Sarcomeric protein connects the Z discs to 
the M line of a sarcomere 
(Taylor et al., 2011) - 
DES Desmin Intermediate filament of the cytoskeleton  (van Tintelen et al., 2009), 
(Klauke et al., 2010) 
- 
PLN Phospholamban Sarcoplasmic reticulum (regulates SERCA2 / 
Calcium ATPase pump) 
(van der Zwaag et al., 2012) - 
CDH2 N-cadherin Transmembrane protein in adherens junctions (Mayosi et al., 2017) - 
Table 11. ARVC/D associated genes, their functions and reports of inheritance patterns associated with mutations in these 
genes. 
* Pathogenicity not well established, rare variants identified in one to two cases. 
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 Un-selected probands Desmosomal mutation negative probands 
Publication (den 
Haan et 
al., 2009) 
(Bauce 
et al., 
2010) 
(Fressart 
et al., 
2010) 
(Klauke 
et al., 
2010) 
(Cox et 
al., 
2011) 
(Xu et 
al., 
2010) 
(Quarta 
et al., 
2011a) 
(Quarta 
et al., 
2011b) 
(Groeneweg 
et al., 2013) 
(Baskin 
et al., 
2013) 
(Lorenzon 
et al., 
2013) 
Summary 
 / Range 
(Taylor et 
al., 2011) 
(Haywood 
et al., 
2013) 
(Gandjbakhch 
et al., 2013) 
(van 
Hengel et 
al., 2013) 
Total number of probands 
✝  
82 42 135 12 149 195 44 108 142 195 91 12   -   
195 
38 143 64 74 
Number of 
probands 
with ≥1 
ARVC/D 
associated 
mutation 
(per gene) 
DSC2 0 (0%) 2 (5%) 2 (2%) 1 (8%) 4 (3%) 4 (2%) 3 (8%) 9 
(12%) 
3 (2%) 2 (1%) NR 0   -  12% Negative Negative Negative Negative 
DSG2 7 (9%) 5 
(12%) 
14 
(10%) 
2 
(16%) 
5 (3%) 10 
(5%) 
13 
(33%) 
22 
(30%) 
6 (4%) 2 (1%) NR 1   -  33%  Negative Negative Negative 
JUP 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (1%) 0 (0%) 0 (0%) 0 (0%) NT NR 0    -   1% NT Negative Negative Negative 
PKP2 37 (45%) 9 
(21%) 
42 
(31%) 
4 
(33%) 
78 
(52%) 
38 
(19%) 
13 
(33%) 
25 
(34%) 
74 (52%) 20 
(10%) 
NR 10  -  
52% 
Negative Negative Negative Negative 
DSP 1 (1%) 7 
(12%) 
6 (5%) 0 (0%) 2 (1%) 10 
(5%) 
10 
(26%) 
17 
(23%) 
1 (1%) 4 (2%) NR 0   -  26%  Negative Negative Negative 
≥1 
desmosomal 
gene (any) 
43 (52%) 23 
(55%) 
62 
(46%) 
8 
(67%) 
87 
(58%) 
52 
(27%) 
32 
(73%) 
61 
(56%) 
102 (71%) 28 
(14%) 
NR 14  -  
73% 
Negative Negative Negative Negative 
TMEM43 NT NT NT NT NT NT NT NT NT 6 (3%)* NR 3% NT 1 (1%) NT NT 
RYR2 NT NT NT NT NT NT NT NT NT NT NR Unknown NT NT NT NT 
TGFB3 NT 2 (5%) NT NT NT NT NT NT NT NT NR 5% NT NT NT NT 
LMNA NT NT NT NT NT NT NT 4 (4%) NT NT NR 4% NT NT NT NT 
TTN NT NT NT NT NT NT NT NT NT NT NR Unknown 7 (18%) NT NT NT 
DES NT NT NT 1 (8%) NT 0 (0%) NT NT NT NT 2 (2%) 0   -   8% NT NT NT NT 
PLN NT NT NT NT NT NT NT NT 19 (13%)* NT NT 13% NT NT 0 (0%) NT 
CTNNA3 NT NT NT NT NT NT NT NT NT NT NT Unknown NT NT 0 (0%) 2 (2%) 
PERP NT NT NT NT NT NT NT NT NT NT NT Unknown NT NT 1 (1%) NT 
PKP4 NT NT NT NT NT NT NT NT NT NT NT Unknown NT NT 1 (1%) NT 
Homozygous 0 (0%) 0 (0%) 1 (1%) 0 (0%) 1 (1%) 0 (0%) NR NR NR 0 (0%) 0 (0%) 0   -   1% NT NR 0 (0%) 0 (0%) 
Compound heterozygous 3 (4%) 1 (2%) 2 (2%) 0 (0%) 0 (0%) 7 (4%) NR NR NR 0 (0%) 0 (0%) 0   -   4% NT  0 (0%) 0 (0%) 
Double heterozygous 3 (4%) 2 (5%) 2 (2%) 0 (0%) 2 (1%) 14 
(7%) 
NR NR NR 0 (0%) 1 (1%) NR NT  1 (1%) NT 
Table 12. Prevalence of ARVC/D associated mutations in published cases series 
NT= not tested, NR = not reported, NA = not applicable  
✝ All probands included have a definite diagnosis of ARVC/D by the 1995 or 2010 criteria. 
* Only 1 proven pathogenic non-desmosomal
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1.3.2 The pathogenesis of ARVC/D 
Our understanding of the pathogenesis of ARVC/D has developed through (1) an 
examination of its pathological features in myocardial tissue (2) the identification of 
pathogenic genetic variants associated with the disease and (3) the use of animal 
and cellular models with which the mechanisms of pathogenesis can be examined. 
When compared with myocardium from healthy controls, the myocardium of 
ARVC/D subjects has been reported to have: (1) an increase in the proportion of 
fibroblasts and extra-cellular matrix relative to cardiomyocytes, (2) infiltration of fatty 
tissue between myocardial fibres, (3) evidence of cardiomyocyte death, including by 
apoptosis, (4) cardiomyocyte steatosis and (5) the presence of inflammatory 
infiltrates (Marcus et al., 1982) (Thiene et al., 1988) (Fontaliran et al., 1991) (Basso 
et al., 1996) (Burke et al., 1998) (Tabib, 2003) (Basso and Thiene, 2005) (Basso et 
al., 2008) (Young et al., 2009) (Lobo et al., 1992) (Fornes et al., 1998) (Corrado et al., 
1997) (Chimenti et al., 2004).  
At the time of writing, more than 400 pathogenic variants, spread across 13 different 
genes have been reported to be associated with ARVC/D. Of 412 variants in a large 
online database, 364 (88%) were in the five main desmosomal genes (van der 
Zwaag et al., 2018). The number and type of pathogenic variants in these major 
desmosomal genes are summarised in Table 13. The locations of pathogenic 
mutations with respect to the domains of the transcribed desmosomal proteins are 
summarised in Table 14. The majority (63% in the ARVD/C Genetic Variants 
Database) of pathogenic desmosomal mutations are radical i.e. they are nonsense 
mutations (23%), frameshift insertions or deletions (26%) or splice site mutations 
(14%). Such mutations may be predicted to generate transcripts which are either not 
translated or generate a truncated peptide. By contrast missense are predicted to be 
translated to mutant proteins containing a single amino acid change and be 
pathogenic by modifying their binding properties. For each desmosomal protein some 
domains are more common sites for pathogenic variants than others (e.g. the ECB 
for DSC2 and DSG2; the arm-repeat domain for PKP2 and JUP; the spectrin repeat 
domains for DSP). Despite these patterns ARVC/D may result from a variant 
affecting almost any domain of the desmosomal proteins (see Table 14 and Table 
15). 
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Pathogenic variants DSC2 DSG2 PKP2 JUP DSP 
Total (364) 42 50 171 15 86 
Missense 23 (55%) 29 (58%) 38 (22%) 10 (67%) 33 (38%) 
Radical Total 19 (45%) 21 (42%) 133 (78%) 5 (33%) 53 (62%) 
Nonsense 4 (10%) 6 (12%) 39 (23%) 1 (7%) (34%) 
Insertion / deletion, 
in-frame or 
frameshift 
9 (21%) 9 (18%) 67 (39%) 3 (20%) 19 (22%) 
Splice site 6 (14%) 6 (12%) 27 (16%) 1 (7%) 5 (6%) 
Table 13 Pathogenic mutations listed in the ARVD/C Genetic Variants 
Database. 
The ARVD/C Genetic Variants Database is maintained by the University Medical 
Centre Groningen Department of Genetic, Cardiogenetics Research Group and is a 
open access resource which collates published data on ARVC/D associated 
variants (van der Zwaag et al., 2018). 
 
 
Gene Total Most frequently affected domains 
(≥30% variants) 
Less frequently affected domains 
(<30% variants) 
DSC2 42 Extracellular cadherin binding domain 29 (69%) 
Intracellular cadherin 
sequence 4 (10%) 
Propeptide 8 (19%) 
Other 1 (2%) 
DSG2 50 Extracellular cadherin binding domain 28 (56%) 
Extracellular anchor  4 (8%) 
Intracellular anchor 1 (2%) 
Intracellular cadherin 
sequence 4 (8%) 
Repeat unit domain 5 (10%) 
Propeptide 4 (8%) 
Other 4 (8%) 
PKP2 171 Arm-repeat domain 116 (68%) C-terminus 1 (<1%) N-terminus 52 (30%) Other 2 (2%) 
JUP 15 Arm-repeat domain 8 (53%) C-terminus 2 (14%) N-terminus 5 (33%) 
DSP 86 Spectrin repeat domain 36 (42%) 
C-terminus 2 (2%) 
Plakin repeat domain 17 (20%) 
Central rod domain 23 (27%) 
Other 8 (9%) 
Table 14 Protein domains associated with of pathogenic variants of all types 
in the major desmosomal genes 
This table summarises the same dataset presented in Table 13 and originates from 
the ARVD/C Genetic Variants Database (van der Zwaag et al., 2018). 
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Gene Total Most frequently affected domains Less frequently affected domains 
DSC2 23 Extracellular cadherin binding domain 16 (70%) 
Intracellular cadherin 
sequence 2 (9%) 
Propeptide 4 (17%) 
Other 1 (4%) 
DSG2 29 Extracellular cadherin binding domain 16 (55%) 
Extracellular anchor  2 (7%) 
Intracellular anchor 0 
Intracellular cadherin 
sequence 3 (10%) 
Repeat unit domain 2 (7%) 
Propeptide 4 
Other 2 (7%) 
PKP2 38 Arm-repeat domain 29 (76%) C-terminus 0 N-terminus 9 (24%) Other 0 
JUP 10 Arm-repeat domain 7 (70%) C-terminus 1 (10%) N-terminus 2 (20%) 
DSP 33 Spectrin repeat domain 15 (45%) 
C-terminus 2 (6%) 
Plakin repeat domain 7 (21%) 
Central rod domain 7 (21%) 
Other 2 (6%) 
Table 15 Protein domains associated with of pathogenic missense variants in 
the major desmosomal genes 
This table summarises the same dataset presented in Table 13 and originates from 
the ARVD/C Genetic Variants Database (van der Zwaag et al., 2018). 
 
Several studies have studied the effects of ARVC/D variants on other desmosomal 
plaque proteins by immunoblotting (to assess overall tissue content) and 
immunofluorescence microscopy (to assess cellular distribution) in either myocardial 
tissue or cellular or animal models. These studies are summarised in Table 18, Table 
19 and Table 20. 
Instead, investigations have focussed on identifying common pathways by which 
these diverse variants induce the same clinical phenotype. To this end studies have 
examined: (1) on inter-cellular adhesion (by examination of desmosomal 
ultrastructure and the mechanical properties of tissue expressing mutant proteins) 
and (2) on the intracellular signalling pathways (both in the myocardium of ARVC/D 
subjects and in disease models).  
Studies of desmosomal ultrastructure support the idea that ARVC/D is associated 
with changes in desmosomal organisation, irrespective of the details of associated 
mutations. Abnormal ultrastructural features have been reported in cardiac tissue 
from subjects with ARVC/D since the 1980s (Table 21). A reduction in the abundance 
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of desmosomes and increase in desmosomal gap width in ARVC/D subjects has 
been one of the most consistently reported features of these reports.  
The most methodologically robust of these studies was from Basso et al. (Basso, 
2006). They examined myocardium obtained by endomyocardial biopsy and 
compared 21 cases of ARVC/D (of which 10 were carriers of a pathogenic variant in 
DSP, PKP2 or DGS2), 10 cases of idiopathic dilated cardiomyopathy (IDCM) and 10 
samples from donor transplant hearts. They conducted morphometric analysis of the 
major intercalated disc (ICD) structures i.e. desmosomes, adherens junctions and 
gap junctions. When compared to controls, ARVC/D samples had a smaller number 
of desmosomes per unit length of ICD but an overall increase in the amount of 
desmosomal plaque at the ICDs due to an increase in desmosomal length. In 
addition the average intermembrane gap width of desmosomes was greater in 
ARVC/D compared with controls. The IDCM cases had trends in these parameters in 
the same directions as the ARVC/D cases but the differences between them and 
controls did not reach statistical significance. Similarly the difference between 
ARVC/D and IDCM cases in these parameters did not reach statistical significance. 
Overall this study supports the proposal that changes in cardiomyocytes 
desmosomal ultrastructure are a feature of ARVC/D irrespective of genotype but that 
they are also present in other forms of cardiomyopathy. 
Desmosomal ultrastructure has been assessed in animal models of reduced or 
deficient DSC2, JUP, PKP2 and DSP, and those of over-expression of mutant DSG2 
and DSP (Table 19). Whilst all of these studies describe some form of abnormality at 
the intercalated discs (ICDs) there was no single characteristic that was reported 
consistently. Abnormalities included: a complete disruption of the ICD including 
desmosomes, a loss of the desmosomal midline, a reduction in the abundance of 
desmosomes and desmosomal pallor. None of these studies performed quantitative 
analysis of desmosomal ultrastructure. 
The only cellular models of ARVC/D in which desmosomal ultrastructure was 
assessed have been iPSC-CMs described by Caspi et al. Both Caspi et al. and 
Basso et al. reported desmosomal pallor and Caspi et al. reported the presence of 
blurred and asymmetrical desmosomes in ARVC/D lines but not in control iPSC-CMs. 
Caspi et al. also performed quantitative analysis of desmosomal width and reported 
the same increase in the width of the desmosomal gap as had been described 
studies of desmosomes in the myocardium of ARVC/D cases (Table 16). Caspi et al. 
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reported an increase in desmosomal widths relative to a control iPSC-CM, but did not 
study desmosomal length or abundance.  
 
 Caspi et al Basso et al Lahtinen et al iPSC-CM Cardiac tissue Cardiac tissue 
Subjects 
Control vs ARVC/D 1 vs 1 10 vs 21 10 vs 3 
Gap width (nm) 
Control vs ARVC/D 
24±1 vs 32±2  
33% greater 
p<0.05 
22±3 vs 29±9 
32% greater 
p=0.004 
22±3 vs 32±18 
45% greater 
p not given 
Total desmosomal width (nm) 
Control vs ARVC/D 
101±5 vs 171±12 
69% greater 
p<0.001 
- - 
Length (nm) 
Control vs ARVC/D - 
160±80 vs 310±80 
94% greater 
p<0.001 
- 
Abundance  
(desmosomes per 10µm) 
Control vs ARVC/D 
- 
5.6±2 vs 3.3±1 
41% less 
p=0.01 
5.5±3 vs 3.1±0.4 
45% less 
p not given 
 
Table 16 Comparison of the results of studies of ARVC/D in which quantitative 
assessments of desmosomal morphology were performed.  
Measurements presented are the mean±SEM for a given study group 
 
The changes in molecular structure and organisation associated with these changes 
in desmosomal morphology are produced has not been elucidated. In the discussion 
of their findings, Basso et al. 2006 propose only that the increase in desmosomal gap 
width could be due “abnormal expression of transmembrane proteins” and that the 
pallor of plaques could be due to an “abnormal composition” of desmosomal plaque 
proteins. In other tissues desmosomal gap width has been demonstrated to be a 
dynamic feature. Conformational changes in desmosomal cadherins may be 
triggered by intracellular regulators acting via protein kinase C α (PKCα) to 
phosphorylate the intracellular component of the desmosomal plaque (Wallis et al., 
2000) (Garrod et al., 2005). It is unlikely that the differences reported in ARVC/D 
represent occur by this mechanism. The mean difference in desmosomal gap 
induced by PKCα was reported to be 9% (24±0.5 nm vs 22±0.5 nm) (Garrod et al., 
2005), much smaller than the 32-45% differences reported in studies of ARVC/D. 
Evidence of the dynamic nature of desmosome morphology does make the idea that 
mutations affecting proteins constituting the desmosome affect the structure of 
extracellular domains of desmosomal cadherins more plausible.  
The effects of ARVC/D an mutation on the mechanical properties of a cellular model 
of ARVC/D have been studied by Huang et al. . They generating a desmosome 
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producing cell line (HEK cells) which stably expressed a mutant JUP protein 
associated with ARVC/D which lacked its N-terminal domain (Huang et al., 2008).  
Intercellular adhesion (assessed by both drag-deform and dispase fragmentation 
assays) was reduced compared with controls. These techniques have not been used 
to study other ARVC/D associated mutations to date.    
The role of desmosomal proteins (particularly JUP and PKP2) in intracellular 
signalling was outlined in 1.2.7. The suggestion that changes to these pathways had 
a role in ARVC/D pathogenesis arose from the following observations. Firstly that the 
plakoglobin signal at the intercalated discs of myocardial samples appeared to be 
reduced in ARVC/D subjects regardless of the gene in which an ARVC/D associated 
variant was located. Secondly that there was evidence of changes in these pathways 
in animal and cellular models of ARVC/D, the effects of which were known to 
regulate the processes of fibrosis, adogenesis and apoptosis that were noted in 
pathological studies of the disease. These observations are discussed in more detail 
below. 
Studies using immunofluorescence and immunohistochemistry to assess the 
abundance and localisation of desmosomal proteins in ARVC/D myocardium are 
summarised in Table 17. Plakoglobin signal intensity has been described as reduced 
in 75-91% of patients across cohorts of between 17 and 34 cases (Table 18). A 
reduction in the intensity of plakoglobin signal at the intercalated discs was noted a 
ARVC/D subjects with and without ARVC/D associated mutations and appeared to 
be independent of the gene in which mutations were located (Table 18).  
The loss of plakoglobin from intercalated discs has also been reported in animal and 
cellular models of ARVC/D, summarised in Table 19 and Table 20. In particular a 
mouse model of DSP deficiency has been shown to produce an increase in the 
cytoplasmic and nuclear abundance of plakoglobin associated with a downregulation 
of canonical Wnt signalling (Garcia-Gras, 2006) (Lombardi et al., 2011). DSP 
deficiency also disturbs upstream regulators of the Hippo signalling pathway (protein 
kinase C-α and neurofibromin-2), the resultant activation of the Hippo pathway also 
down-regulates canonical Wnt signalling (S. N. Chen et al., 2013) (Heallen et al., 
2011). Downregulation of Wnt signalling is associated with adipogenesis, fibrosis and 
apoptosis and is therefore an appealing candidate for a part of a common-pathway of 
ARVC/D pathogenesis (Ross, 2000) (Longo, 2002) (Pećina-Slaus, 2010) (Rao and 
Kuhl, 2010). Downregulation of Wnt signalling has also been reported in iPSC-CM 
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models of ARVC/D caused by PKP2 mutations. In both iPSC-CM models PKP2 
expression was reduced by the mutation. A similar reduction in PKP2 expression in 
HL-1 cells has been shown to suppress Wnt signalling via upregulation of the Hippo 
pathway (S. N. Chen et al., 2013). 
Additional evidence for the role of Wnt signalling suppression in ARVC/D has come 
from studies demonstrating that GSK3β inhibitors (which increase Wnt signalling) can 
rescue animal and cellular models of ARVC/D caused by variants in JUP, DSG2 and 
PKP2 from the disease phenotype (Asimaki et al., 2014) (Chelko et al., 2016) 
(Hariharan et al., 2014). The work of Chelko et al. is of particular they studied human 
myocardium of ARVC/D patients with a range of and desmosomal mutations and 
those with no identified mutations and found that GSK3β was localised to the 
intercalated discs in ARVC/D patients but to the nucleus in both controls and patients 
with other forms of cardiomyopathy (Chelko et al., 2016). This is consistent with the 
idea that changes in Wnt signalling are part of a common pathway of disease 
pathogenesis and that they are specific to ARVC/D. 
The downregulation of Wnt signal has not been reported universally in ARVC/D or 
ARVC/D models. Down-stream targets of Wnt have been reported to be up regulated 
in a whole transcriptome analysis of ARVC/D myocardium and in a mouse model of 
ARVC/D caused by DSG2 deficiency (Kant et al., 2016).  
In addition the theory that the downregulation of Wnt signalling in ARVC/D is 
mediated by nuclear redistribution of plakoglobin from the plasma membrane has 
been challenged by studies which found no reduction in plakoglobin signal in 
ARVC/D myocardium (Tavora et al., 2013) (Vite et al., 2013) (Kant et al., 2016). The 
origin of these apparent conflicting findings was investigated by Kant et al. who 
conducted a rigorous and well controlled quantitative analysis of 
immunofluorescence intensity from four anti-plakoglobin antibodies targeting different 
epitopes, including the antibody (15F11) used in all the studies reporting a reduced 
plakoglobin signal (Kant et al., 2016).  This study indicated that plakoglobin was not 
reduced in abundance at the intercalated discs and that the reduced signal detected 
with 15F11 labelling was due to epitope masking possibly due to changes in the 
organisation of proteins within the desmosomal plaques (Kant et al., 2016). This idea 
is consistent with the hypothesis from TEM studies that ARVC/D is associated with 
organisational changes in the desmosomal plaques. 
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In summary, electron and immunofluorescence microscopy studies suggest that 
changes in desmosomal structure are a common feature of the disease and there is 
good evidence that ARVC/D is mediated by the suppression of Wnt signalling. 
However the molecular mechanisms by which ARVC/D associated mutations lead to 
these changes has yet to be clearly elucidated.
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c 
Publication Mutation 
Protein assessed by immunohistology 
Number 
of cases 
Cases in which 
signal of ≥1 
desmosomal 
protein is 
reduced 
DSC2 DSG2 JUP PKP2 DSP β-Catenin 
α-
Catenin TMEM43 DES N-Cad Cx43 Nav1.5 
(Ermakov et al., 2014) Various NA NA !" / # NA NA NA NA NA NA NA NA NA 5 3/5 (60%) 
(Vite et al., 2013) DSG2 !" !" / 
# !" !" NA !" NA NA NA !" NA NA 7 3/7 (42%) 
(Tavora et al., 2013) Unknown NA NA !" !" !" NA NA NA NA !" !" NA 23 0/23 (0%) 
(T B Rasmussen et al., 2013) DSP NA NA NA NA !" / 
# NA NA NA NA NA NA NA 3 2/3 (66%) 
(Torsten B Rasmussen et al., 
2013) DSG2 NA !" !" NA !" NA NA NA NA !" !" NA 9 0/9 (0%) 
(Noorman et al., 2013) Various NA NA !" / # !" / # NA NA NA NA NA !" 
!" 
/ # 
!" / 
# 19 
14/19 (74%) 
(JUP) 
(Kwon et al., 2013) Unknown NA NA !" / # NA NA NA NA NA NA !" !" NA 17 13/17 (76%) 
(van der Zwaag et al., 2012) PLN NA NA !" / # NA NA NA NA NA NA !" NA NA 7 5/7 (71%) 
(Munkholm et al., 2012) Various NA NA !" / # NA NA NA NA NA NA NA NA NA 34 29/34 (85%) 
(Kirchner et al., 2012) PKP2 NA NA !" / # NA NA NA NA NA NA !" NA NA 2 1/2 (50%) 
(Gehmlich et al., 2012) DSG2 NA NA # NA NA NA NA NA NA !" NA NA 1 1/1 (100%) 
(Gehmlich et al., 2011) DSC2, DSG2 NA NA # NA NA NA NA NA NA !" !" NA 1  
(Quarta et al., 2011b) LMNA NA NA !" $ NA NA NA NA NA NA NA NA NA 1 1/1 (100%) 
(Lahtinen et al., 2011) DSG2 NA # # # # NA NA NA NA !" !" NA 1 1/1 (100%) 
(Christensen et al., 2011) TMEM43 NA NA # !" NA NA NA # NA NA !" NA 2 2/2 (100%) 
(Otten et al., 2010) DES NA NA !" # # NA NA NA !"  (Abn) !" !" NA 2 2/2 (100%) 
(Katja Gehmlich et al., 2010) DSG2 NA NA # # # NA NA NA NA !" # NA 1 1/1 (100%) 
(Fidler et al., 2009) PKP2 NA NA NA !" !" NA NA NA NA !" # NA 1 0/1(0%) 
(Asimaki et al., 2009) Various NA NA # # # NA NA NA NA !" # NA 22 21/22 (95%) 
(Lahtinen et al., 2008) PKP2 NA NA NA !" NA NA NA NA NA NA NA NA 1 0/1 (0%) 
(Kaplan et al., 2004) JUP !" * NA # !" !" !" !" NA NA !" # NA 4 4/4 (100%) 
 
Table 17. Summary of studies describing the desmosomal immunohistology of cardiac tissue from cases of ARVC 
!" = Protein abundance unchanged, # = Protein abundance reduced,  NA = Not assessed, * DSC2/3 ,  $ a reduced number for 
ICDs were detected by plakoglobin IHC, the intensity of the signal was not described as reduced. 
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Results of 
genetic 
screening 
Type of 
protein 
encoded 
Gene Publications 
Proportion of cases in 
which a reduction in 
JUP identified 
ARVC/D 
associated 
mutation 
identified 
Desmosomal 
DSC2 (Munkholm et al., 2012) (3 cases)* 3/3 (100%) 
25/28 
(89%) 
DSG2 
(Asimaki et al., 2009) (2 cases) 
(Munkholm et al., 2012) (1 case)* 
(Lahtinen et al., 2011) (1 case) 
4/4 (100%) 
JUP (Asimaki et al., 2009) (1 case) (Munkholm et al., 2012) (1 case)* 2/2 (100%) 
PKP2 
(Asimaki et al., 2009) (2 cases) 
(Munkholm et al., 2012) (3 cases)* 
(Noorman et al., 2013) (11 cases) 
13/16 
(81%) 
DSP (Asimaki et al., 2009) (3 cases) 3/3 (100%) 
Non-
desmosomal 
TMEM43 (Christensen et al., 2011) (2 cases) 2/2 (100%) 
18/22 
(81%) 
RYR2 -  
TGF -  
LMNA (Quarta et al., 2011b) (1 case) 1/1 (100%) 
TTN -  
DES (Otten et al., 2010) (2 cases) 2/2 (100%) 
PLN (Noorman et al., 2013) (2 cases) (van der Zwaag et al., 2012) (7 cases) 7/9 (78%) 
No ARVC/D associated mutation identified (Asimaki et al., 2009) (3 cases) (Noorman et al., 2013) (5 cases) 6/8 (75%) 
Table 18 Studies assessing plakoglobin expression by immunohistology in 
genotyped cases of ,ARVC/D. 
Studies were selected on the basis of similar staining protocol, in particular the 
choice of anti-JUP dilution. * The series reported by Munkholm et at 2012 consisted 
of 6 cases with ARVC/D associated mutations, they reported 3 case to be digenic 
carriers but did not describe which mutations were co-existent.  
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Gene Publication Animal 
Model Abnormalities 
Over 
expression 
of wild type 
protein 
Knock-out / 
knock-
down 
Mutated 
gene 
expression 
Mutation, 
Protein modification 
Gross histology 
and clinical 
findings 
Localisation 
and content 
of 
desmosoma
l proteins. 
Desmosomal 
ultrastructure 
Adipo-
genesis 
and 
Fibrosis 
Wnt 
signalling Apoptosis Details 
DSC2 (Heuser et al., 2006) 
Zebra-
fish  
●  Knock-down DSC2 ✔ NA ✔ NA NA NA 
• Cardiomegaly 
• Bradycardia 
• Reduced myocardial contractility 
• Loss of midline / desmoglia at cardiac desmosomes (TEM)  
 ● 
c.631-2A>G 
Splice acceptor site 
mutation 
p. M211fsX221 
Expressed in context of 
knock down DSC2 
✔ NA NA NA NA NA • Reported as not rescuing cardiac phenotype, details not given. 
DSG2 
(Krusche et 
al., 2011) Mouse   ● 
Homozygous 
knock-out exons 4-6 
(EC1/EC2) (no human 
analog) 
✔ NA NA ✔ NA NA 
• Cardiomegaly 
• Reduced myocardial contractility 
• Cardiac fibrosis (TC) 
(Pilichou et 
al., 2009) Mouse   ● 
c.797A>G 
p.N266S 
Overexpression 
✔ ✗ ✗ ✔ NA ✔ 
• Cardiomegaly, myocardial thinning., electrical conduction 
delay 
• No change in desmosomal protein localisation. (IM) 
• No change in desmosomal appearance or gap wdth (TEM) 
• Fibrosis (TC), no marked increase in adipogenesis 
• Increased apoptosis (TUNEL), and necrosis 
JUP 
(Swope et 
al., 2012) Mouse  ●  
Cardiac restricted, 
inducible homozygous 
JUP and CTNNB1 
knock-out. 
✔ ✔ ✔ ✔ NA ✔ 
• Cardiomegaly, and thickening of ventricular walls 
• Reduced PKP2, DSG2, DSP, N-cad, Cx43 localisation to 
membrane (IM). 
• Reduced total, PKP2, DSP, DSG2, N-cad. (WB) 
• Complete loss of normal ICD architecture (TEM). 
• Fibrosis (TC), but no adiposis (ORO) 
• Increased apoptosis (TUNEL) 
(Lombardi et 
al., 2011) Mouse 
●   Overexpression. ✔ ✔ NA NA NA NA 
• Cardiomegaly 
• Overexpressed WT protein at membrane, and in cytoplasm 
and nucleus (WB, IM) 
  ● 
c.2157_2158delTG, 
p.G680fsX690 
expressed on 
background of 
heterozygous JUP 
knock-out.  
✔ ✔ NA NA NA NA 
• Cardiomegaly 
• Reduced mutant JUP at the membrane, accumulation in 
nucleus and cytoplasm (WB, IM) 
(D. Li et al., 
2011) Mouse  ●  
Cardiac restricted, 
inducible homozygous 
JUP knock-out. 
✔ ✔ ✔ ✔ / ✗ ✔ ✔ 
• Cardiomegaly, thinning of ventricular walls 
• Reduced PKP2, DSG2, DSP, Cx43 localisation to membrane 
(IM). 
• Reduced total, PKP2, no change in DSP or DSG2. (WB) 
• Number and length of desmosomes reduced. Number and 
length of fascia adherens increased  
• Fibrosis (TC), but no adiposis (ORO) 
• Increase in β-catenin and  unphosphorylated β-catenin. 
Upregulation of  gene targets of canonical Wnt signalling. 
• Increased apoptosis (TUNEL) 
(Bierkamp et 
al., 1996) Mouse  ●  Homozygous knock-out ✔ NA ✔ NA NA NA 
• Embryonic lethality, myocardial wall thinning. 
• Desmosomes, pale, reduced density, reduced number (TEM). 
 
Table 19. Animal models of desmosomal gene abnormalities and ARVC/D associated desmosomal mutations 
✔  = Abnormality found on testing,  ✗ = No abnormality found on testing,  NA = Not assessed  
TF = TOPFlash assay, IM = immunofluorescence microscopy, WB = Western immunoblot, FC = Flow cytometry, PC = single cell patch clamping, ORO = oil red O staining and light microscopy, TEM = transmission electron microscopy, TUNEL = terminal 
deoxynucleotidyl transferase dUTP nick end labelling, qPCR = quantitative reverse transcriptase polymerase chain reaction. (continued below) 
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 (Table 16 continued) 
Gene Publication Animal 
Model Abnormalities 
Over 
expression 
of wild type 
protein 
Knock-
out / 
knock-
down 
Mutated 
gene 
expression 
Mutation, 
Protein modification 
Gross 
histology 
and clinical 
findings 
Localisation 
and content of 
desmosomal 
proteins. 
Desmosomal 
ultrastructure 
Adipo-
genesis 
and 
Fibrosis 
Wnt 
signalling Apoptosis Details 
PKP2 (Grossmann et al., 2004) Mouse - ● - 
Homozygous knock-
out ✔ ✔ ✔ NA NA ✗ 
• Embryonic lethality, myocardial wall thinning. 
• Loss of co-localisation of DSP with PKP2, JUP, DSG2, N-Cad (IM). 
• Reduction in DSG2 signal (IM) (WB) 
• Redistribution of JUP and DSP to cytoplasm (IM) (WB) 
• Desmosomes indistinct. (TEM) 
• No increase in apoptosis (TUNEL) 
DSP 
(Gomes et 
al., 2012) Mouse  ●  
Heterozygous cardiac 
restricted knockout ✔ ✔ NA ✔ NA NA 
• Higher incidence of inducible VT 
• No change in INa (PC) or SCN5A expression (qPCR) 
• Cytoplasmic localisation of Cx43. (IM) 
• Reduction in JUP and DSP signal (IM) 
• Fibrofatty infiltration. (TC) (ORO) 
(Yang, 2006) Mouse 
●   Cardiac restricted, overexpression. ✗ ✗ ✔ ✗ NA ✗ 
• Normal cardiac morphology and function 
• Increase electron density of fascia adherens (TEM) 
  ● 
c.8501G>A 
p. R2834H 
Cardiac restricted, 
overexpression. 
✔ ✔ / ✗ ✔ ✔ NA ✔ 
• Cardiomegaly and impaired ventricular function. 
• Reduced colocalisation of DES with DSP, no change in 
colocalisation of JUP, PKP2, Cx43.with DSP (IM) 
• Redistribution of JUP, PKP2 and Cx43 from cytoskeleton to 
cytoplasm. (WB) 
• Widening intercellular gap throughout ID length (TEM) 
• Spontaneous adipogenesis (ORO), and fibrosis (TC) 
• Increased apoptosis (TUNEL) 
  ● 
c.88G>A 
p.V30M 
Cardiac restricted, 
overexpression. 
✔ NA NA NA NA NA • Embryonic lethality • Myocardial thinning 
  ● 
c.269A>G 
p.Q90R 
Cardiac restricted, 
overexpression. 
✔ NA NA NA NA NA • Embryonic lethality • Myocardial thinning 
(Garcia-Gras, 
2006) Mouse 
 ●  Homozygous, cardiac restricted knock-out ✔ NA NA ✔ ✔ ✗ 
• High rate of embryonic lethality 
• Cardiomegaly, myocardial thinning 
• Fibrosis (TC) and adiposis (ORO) 
• Reduced expression of canonical Wnt signalling target genes, 
suggesting suppression of signalling (qPCR) 
 ●  
Heterozygous, cardiac 
restricted knock-out ✔ ✔ NA ✔ ✔ ✗ 
• Cardiomegaly 
• Increased nuclear JUP (WB), no change in cytosolic content. 
• Fibrosis (TC) and adiposis (ORO), upregulation of proadipogenic 
gene expression (qPCR). 
• Reduced expression of canonical Wnt signalling target genes, 
suggesting suppression of signalling (qPCR) 
• No increase in apoptosis (TUNEL) 
(Gallicano et 
al., 2001) Mouse   ● 
Homozygous knock-
out ✔ ✔ NA NA NA NA 
• Embryonic lethality 
• Myocardial thinning 
• Reduction in DSG2 signal, no change in PG, (IH) 
✔  = Abnormality found on testing,  ✗ = No abnormality found on testing,  NA = Not assessed 
TF = TOPFlash assay, IM = immunofluorescence microscopy, IH = immunohistochemistry, WB = Western immunoblot, FC = Flow cytometry, PC = single cell patch clamping, ORO = oil red O staining and light microscopy, TC = Trichrome staining for fibrosis e.g. 
Masson’s, TEM = transmission electron microscopy, TUNEL = terminal deoxynucleotidyl transferase dUTP nick end labelling, qPCR = quantitative reverse transcriptase polymerase chain reaction
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Gene Publication Cell type 
Over 
expression 
of wild type 
protein 
Knock-out / 
Knock-down 
Mutated 
gene 
expression 
Mutation, 
Protein modification 
Abnormalities 
Details 
Localisation 
and content of 
desmosomal 
proteins. 
Desmosomal 
ultrastructure 
Adipo-genesis 
and 
Fibrosis 
Wnt 
signalling Apoptosis 
DSC2 
(K. Gehmlich 
et al., 2010) 
HL-1 
and 
NRVM 
  ● c.2687_2688insGA, p.A897fsX900 ✔ NA NA NA NA 
• Mutant protein localisation to cell border (IM) 
• Some accumulation of mutant protein in golgi apparatus (IM) 
  ● c.607 C>T p.R203C ✔ NA NA NA NA 
• Failure of mutant protein to localise to cell border (IM) 
• Accumulation of mutant protein in cytoplasmic vesicles (IM) 
  ● c.824 C>T p.T275M ✔ NA NA NA NA 
• Mutant protein localised to cell border, (IM) 
• Accumulation of mutant protein in cytoplasmic vesicles and golgi apparatus. 
(IM) 
(Beffagna et 
al., 2007) 
HL-1 
and 
NRVM 
  ● 
c.304G>A 
p.E102K ✔ NA NA NA NA 
• Mutant protein localised to cell border (IM) 
• Accumulation of mutant protein in cytoplasm. (IM) 
  ● 
c.1034T>C 
p.E134T ✔ NA NA NA NA 
• Reduced localisation of mutant protein to cell border, (IM) 
• Accumulation of mutant protein in cytoplasm. (IM) 
DSG2 No published cardiac cellular models  
JUP (Lombardi et al., 2011) mCPC 
●    NA NA ✔ ✔ NA 
• Spontaneous adipogenesis (ORO) 
• Suppressed canonical Wnt signalling. (qPCR) 
• Upregulated non-canonical Wnt signalling (qPCR) 
 ●   NA NA ✔ ✔ NA • Resistant to adipogenesis despite proadipogenic culture.(ORO) • Upregulation of canonical Wnt signalling. (qPCR) 
  ● 
Mutant transgene  
c.2157_2158delTG, 
p.G680fsX690 
expressed on 
background of 
heterozygous JUP 
knock-out. 
NA NA ✔ ✔ NA 
• Spontaneous adipogenesis  (ORO) 
• Suppressed canonical Wnt signalling. (qPCR) 
• Upregulated non-canonical Wnt signalling (qPCR) 
PKP2 
(Caspi et al., 
2013) iPSC-CM 
  ● c.972insT/N p.A324fsX335 ✔ ✔ ✔ NR NR 
• Reduced total PKP2, JUP, Cx43 signal (IM). 
• Pale, indistinct, dissymmetrical desmosomes, increased desmosomal gap 
width, Increased total external desmosomal width (TEM) 
• Spontaneous adipogenesis (TEM) 
  ● 
c.148_151delACAG/
N 
p.T50SfsX110 
✔ NR ✔ ✔ ✔ 
• Reduced PKP2, JUP, Cx 43 signal (IM). (localisation not assessed) 
• Spontaneous adipogenesis and accelerated adipogenesis with 
proadipogenic medium (TEM) 
• Suppressed canonical Wnt signalling (IM) 
• Increase apoptosis (TUNEL) 
(Kim et al., 
2013) iPSC-CM 
  ● 
c.2484C>T 
Cryptic splicing exon 
12: r.2483_2489del 
 frameshift.mutation 
✔ NR ✔ ✔ ✔ 
• Nuclear localisation of JUP (IM) 
• Accelerated adipogenesis ith proadipogenic medium (ORO), upregulation 
of proadipogenic gene expression (qPCR) 
• Suppressed canonical Wnt signalling (IM) (TF) 
• Increase apoptosis with proadipogenic culture (TUNEL) 
  ● c.2013delC R672fsX683 ✔ NR ✔ ✔ ✔ 
• Nuclear localisation of JUP (IM) 
• Accelerated adipogenesis ith proadipogenic medium (ORO), upregulation 
of proadipogenic gen expression (qPCR) 
• Suppressed canonical Wnt signalling (IM) 
• Increase apoptosis with proadipogenic culture (TUNEL) 
(Ma et al., 
2012) iPSC-CM   ● 
c.1841T>C 
p.L614P ✔ ✔ ✔ NA NA 
• Reduced total PKP2, JUP, no change in DSP, Cx43, N-cad signal (IM). 
• Desmosomes “less dense” unquantified (TEM) 
• Greater spontaneous adipogenesis (ORO) 
Table 20 Cellular models of desmosomal gene abnormalities and ARVC/D associated desmosomal mutations 
✔  = Abnormality found on testing,  ✗ = No abnormality found on testing,  NA = Not assessed 
NRVM= neonatal rat ventricular myocytes, mCPC = mouse cardiac progenitor cells, iPSC-CM = induced pluripotent stem cell derived cardiomyocytes, TF = TOPFlash assay, IM = immunofluorescence microscopy, WB = Western immunoblot, FC = Flow cytometry, PC = 
single cell patch clamping, ORO = oil red O staining and light microscopy, TEM = transmission electron microscopy, TUNEL = terminal deoxynucleotidyl transferase dUTP nick end labelling, qPCR = quantitative reverse transcriptase polymerase chain reaction. (continued 
below) 
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 (Table 17 continued) 
Gene Publication Cell type 
Over 
expression 
of wild type 
protein 
Knock-out / 
Knock-down 
Mutated 
gene 
expression 
Mutation, 
Protein 
modification 
Abnormalities 
Details 
Localisation 
and content of 
desmosomal 
proteins. 
Desmosomal 
ultrastructure 
Adipo-genesis 
and 
Fibrosis 
Wnt 
signalling Apoptosis 
PKP2 
(cont’) 
(Kirchner et 
al., 2012) HL-1   ● 
c.2386T>C 
p.C796R ✔ NA NA NA NA 
• Reduced mutant PKP2 protein content (WB) 
• Accumulation of mutant protein in cytoplasm and nucleus (IM) 
• No effect on JUP distribution (IM) 
(Fidler et al., 
2009) HL-1  ●   NA NA NA NA NA • Possible reduction in Cx43 content  
(Joshi-
Mukherjee et 
al., 2008) 
NRVM 
  ● c.235C>T p.R79X ✔ NA NA NA NA 
• Reduced localisation of mutant to membrane, increase cytoplasmic signal 
(IM) (WB) 
• No change in DSP localisation and signal (IM) (WB) 
• Reduced Cx43 signal (IM) (WB) 
  ● c.534_535insCT p.C179fsX190 ✔ NA NA NA NA 
• Reduced localisation of mutant to membrane, increase cytoplasmic signal 
(IM) (WB) 
• No change in DSP or Cx43 localisation. 
DSP 
(Zhang et al., 
2013) HL-1  ●   NA NA NA NA NA 
• Redistribution of Cx43 to cytoplasm, reduction in total content, reduced rate 
of intercellular dye transfer. (IM) (WB) (FC) 
• Redistribution of Nav1.5 to cytoplasm, reduction in total content, changes in 
cellular action potential  (IM) (WB) (FC) (PC) 
(Garcia-Gras, 
2006) HL-1  ●   ✔ NA ✔ ✔ ✗ 
• Redistribution of JUP from cytoplasmic to nuclear distribution.(IM) (WB)  
• No change in β-catenin content by 2-fold reduction in canonical Wnt 
signalling activity (TF). 
• Accelerated adipogenesis in proadipogenic medium (ORO), upregulation of 
proadipogenic gene expression. (qPCR) 
• Upregulation of profibrotic gene expression (qPCR) 
• No change in apoptosis (TUNEL) 
✔  = Abnormality found on testing,  ✗ = No abnormality found on testing,  NA = Not assessed 
NRVM= neonatal rat ventricular myocytes, mCPC = mouse cardiac progenitor cells, iPSC-CM = induced pluripotent stem cell derived cardiomyocytes, TF = TOPFlash assay, IM = immunofluorescence microscopy, WB = Western immunoblot, FC = Flow cytometry, PC = 
single cell patch clamping, ORO = oil red O staining and light microscopy, TEM = transmission electron microscopy, TUNEL = terminal deoxynucleotidyl transferase dUTP nick end labelling, qPCR = quantitative reverse transcriptase polymerase chain reaction. 
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 Guiraudon et al. 
1989 
Roncall et al. 
1989 
Kaplan et al. 
2004 
Lahtinen et al. 
2008 
Pilichou et al. 
2006 
Basso et al. 2006 
Sample Source EMB EMB EMB EMB EMB EMB 
Handling Not reported Fixed from fresh Frozen before 
fixative 
Recovered from 
paraffin 
Fixed from fresh Fixed from fresh 
Desmosomes Abundance Reduced - - Reduced Reduced* Reduced* 
Length Reduced - - (Reduced §)   (Reduced §)   Increased* 
Electron density - Reduced - - (Reduced ¶) (Reduced ¶) 
Plaque width - Reduced - - - - 
Gap width - - - - Increased* Increased* 
General appearance - Hazy or ill-
defined 
- - - - 
Adherens junctions Abundance Reduced - - - - - 
Length - - - - - - 
Electron density Reduced Reduced - - - - 
Plaque width - Reduced - - - - 
Gap width - - - Increased - No change 
Gap junctions General appearance - No change - - - - 
Abundance - - Reduced* - - No change 
Length - - Reduced* - - No change 
ICD General appearance - - - Vacuolated - - 
Tortuosity / 
convolutions 
Reduced Reduced - - Measured but 
not reported* 
No change 
Myofibrils General appearance - No change - - - No change 
T-tubules General appearance - Contain fibrillar 
material 
- - - No change 
Lipid droplets Abundance - No change - - - Increased 
Data from non-ARVC/D control myocardium 
provided for comparison 
No No Yes Yes Yes Yes 
Table 21 Summary of ultrastructural features of ARVC/D myocardium.	
* quantitative analysis 
§ small abnormally located desmosomes noted, length of desmosomes at the intercalated discs not described 
¶ Pallor of the “internal plaques” reported, thought to refer to the IDPs
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1.4 Hypotheses, aims and objectives 
The main aim of this project was to determine whether patient specific iPSC-CMs 
carrying ARVC/D associated genetic variants showed abnormalities in desmosomal 
protein expression, localisation and ultrastructure.  
More specifically this project aimed to generate patient specific iPSC-CM disease 
models of genetic variants that had not previously been investigated using this 
technique, including those in genes other than PKP2.  
The main hypotheses investigated in this project were that patient specific iPSC-
CMs from subjects with ARVC/D caused by desmosomal mutations differ from 
control iPSC-CMs in that: 
• Mutation specific disturbances in the abundance of desmosomal gene transcripts 
and the abundance and cellular localisation of desmosomal proteins will be seen 
in ARVC/D iPSC-CMs. 
• All ARVC/D iPSC-CMs will have a reduction in the intensity of 
immunofluorescence signal of plakoglobin at their intercellular junctions relative to 
control iPSC-CMs. 
• ARVC/D iPSC-CMs have desmosomes with abnormal ultrastructural 
characteristics such as asymmetry and indistinct plaque morphology, and such 
features are absent in control iPSC-CMs. 
• The desmosomes of ARVC/D iPSC-CMs have an increase in the width of their 
intermembrane gap and in the width of their desmosomal plaques relative to 
control iPSC-CMs. 
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2 Chapter 2 Methods 
2.1 Recruitment of study participants and the origin of cells lines and 
tissues. 
2.1.1 Recruitment of subjects from which peripheral blood samples were 
collected 
Control blood derived iPSCs were generated from healthy volunteers that were 
recruited via the “Collection of blood, plasma and urine samples from healthy 
volunteers“ programme based at the Newcastle University, Northern Institute of 
Cancer Research (ethics committee reference 00216). 
iPSCs derived from subjects with ARVC/D were generated from participants in the 
Arrhythmogenic Cardiomyopathy Induced Pluripotent Stem-cell Study (ACIS), (NHS 
research ethics committee reference 14/EM/1147). 
2.1.2 Recruitment of subjects from which myocardial samples were collected 
Sample of right atrial appendage were collected from subjects recruited via “The 
isolation and characterisation of cell lines, including adult human stem cells, from 
tissue discarded following cardiothoracic surgery” study (NHS research ethics 
committee reference 10/H0908/56) 
2.1.3 Control fibroblasts and fibroblast derived iPSCs 
Some experiments included the human dermal fibroblasts (HDFs), AD3-C1 iPSCs 
and iPSC-CMs. HDFs purchase from Lonza (Product CC-2511, LOT0000264781) 
and originated from a 31 year old female who was not known to have a history or 
family history of hereditary cardiac disease or sudden cardiac death. AD3-C1 was 
generated as from these HDFs under ethical approvals secured by the Lonza. The 
line was generated outside the present study but using the same Sendai based 
reprogramming system and was kindly donated by Prof Lyle Armstrong.  
2.1.4 Immortalised human keratinocytes 
Some experiments included an immortalised human keratinocyte line (HaCaT) as a 
control. This is a commercially available cell line (ThermoFisher) that was kindly 
donated by Dr Mustafa Al-Musawi (Newcastle University). 
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2.1.5 Human embryonic stem cells 
Some experiments used commercially obtained H9 (WA09) human embryonic stem 
cells (WiCell Research Institute) (NIHhESC-10-0062) as controls. 
2.2 The collection and processing of samples of right atrial appendage 
Sample of right atrial appendage (RAA) were collected from subjects undergoing 
routine cardiac surgery performed by Dr Andrew Owens. It was standard clinical 
practice in this surgery to excise and discard a portion of the RAA to allow the subject 
to receive cardiopulmonary bypass. This was performed as follows, after accessing 
the heart via a sternotomy under general anaesthesia, a purse string suture was 
placed around the base of the RAA. An incision was then made into the RAA through 
which a cannula was passed into the right atrium. The suture was tightened to allow 
haemostasis and the remainder of the RAA proximal to the suture was excised and 
discarded. As part of the study protocol (see above) an investigator was present in 
the operating theatre at the time of the surgery and collected the RAA immediately 
after excision. The tissue was then divided into samples to be used for RNA 
extraction or TEM analysis and handled as described in 2.13.2 and 2.20.2.  
2.3 The collection and processing of blood samples 
2.3.1 Blood sampling 
A tourniquet was applied to the upper arm of subjects, a site selected for 
venepuncture, the skin over the was swabbed with an alcohol and 10-30ml of blood 
drawn into sterile blood collection tubes pre-treated with ethylenediaminetetraacetic 
acid (EDTA) to achieve a concentration of 5mM in the final sample. Samples were 
kept at room temperature and processed within 6 hours of collection.  
2.3.2 Density gradient centrifugation 
The mononuclear cell fraction of whole blood was isolated by density gradient 
centrifugation by a standard technique (GE Healthcare Life Sciences, 2005). Blood 
samples of 10-30ml volume were diluted 1:1 with Dulbecco’s phosphate buffered 
saline (DPBS), layered over Ficoll-Paque Premium 1.077g/ml (GE) and centrifuged 
for at 400 g, 20oC for 40min, beginning with a slow acceleration and no break applied 
to the deceleration. The buffy coat at the interface between ficoll and plasma was 
collected with a Pasteur pipette, diluted in 50ml of DPBS and centrifuged at 400 g, 
20oC for 10 minutes. The supernatant was discarded, the pellet resuspended in 
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DPBS and centrifuged again at 200g, 20oC for 10 minutes. The supernatant was 
discarded, the pellet resuspended in DPBS and centrifuged again at 200g, 20oC for 
10 minutes. The supernatant was discarded, the pellet resuspended in culture 
medium, flow buffer or sort buffer as appropriate. The total population of viable 
mononuclear cells obtained estimated using a haemocytomer and trypan blue as 
described below. 
2.3.3 Estimation of the concentration of cells within a single cell suspension 
using a haemocytometer 
Single cell suspensions were prepared in a known volume such that their 
concentration was in the range of 0.2 to 2.0 x106 cells/ml. Sample were gently 
triturated to ensure uniform suspension. A 10µl sample was removed, diluted 1:1 with 
trypan blue 0.05% and incubated at room temperature for 2 minutes. Samples were 
loaded into a Neubauer haemocytometer and visualised using Nikon TS100 inverted 
microscope. The average number of viable cells across four 1mm2 (1x10-4ml) 
counting areas was calculated, from which the concentration of cells in the original 
suspension could be estimated. 
2.3.4 FACS sorting of CD3+ cells 
In some experiments CD3+ cells were purified from PBMCs by FACS. 1x108 freshly 
isolated PBMCs were suspended at in 100µl of sterile sort buffer (DPBS, 0.2% fetal 
bovine serum (FBS), 2mM EDTA) and incubated with anti-CD3-V500 (BD) in the dark 
at 4oC for 30minutes before being washed in flow buffer, centrifuged at 400g for 5 
minutes, the supernatant aspirated, then resuspended in 500µl of flow buffer. DAPI 
was added at 0.25mg/ml immediately prior to analysis. Samples were process using 
a BD FACSFusion sorter. Live singlet cells expressing CD3 were sorted into PBMC 
base medium. Purified samples were centrifuged, resuspended in culture medium 
without cytokines and the concentrations of cells estimated as described above cells 
ready for pre-transduction culture. 
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2.4 Cellular reprogramming 
The process of reprogramming is summarised in Figure 13.  
Figure 13 Generation of iPSCs from nucleated peripheral blood cells. 
 
2.4.1 Pre-transduction culture 
PBMCs were cultured in either T-cell expansion medium (TCEM) or non-T-cell 
expansion medium (NTCEM). The base PBMC media for both media consisted of 
Stemline II medium (Sigma) with 1% penicillin/streptomycin.  
TCEM consisted of base media supplemented with IL2 100ng/ml (R&D). In addition, 
beads coated with anti-CD3 and anti-CD28 (Life technologies) with a bead to cell 
ratio of 1:1 were included in TCEM on the first day of pre-transduction culture. 
NTCEM consisted of base medium supplemented with SCF 100ng/ml, FLT3L 
100ng/ml, TPO 100ng/ml, IL6 100ng/ml and IL3 100ng/ml (all from R&D).  
All blood cells were seeded at a density of 1.0 x106 cells/ml and 1.0 x106 cells/well 
in a 24 well ultra low attachment plates (Costar). Cultures were incubated at 37oC in 
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a humidified atmosphere with 5% CO2 (referred to hereafter as standard conditions). 
Each day the cultures were removed from the incubator taking care not to disturb the 
cells at the bottom of the well. The upper 50% of the medium was aspirated from 
each well, and replaced with an equal volume of fresh expansion medium (TCEM or 
NTCEM as appropriate). 
2.4.2 Transduction 
After 4 days of pre-transduction culture the total population of cultured cells was 
estimated using a haemocytometer and between 30 and 100 x103 cells collected for 
transduction. The cell suspension was centrifuged and resuspended in fresh pre-
transduction culture media to which hexadimethrine bromide (Sigma) 4 µg/ml and 
Cytotune 2.0 reprogramming vectors (Life Technologies) were then added. The final 
volumes of cell suspension and regents were calculated to ensure that the final 
volume of the cell suspension was 300µl, which was then transferred to a single well 
of a ultra-low attachment 96 well plate (Costar) and incubated overnight in standard 
conditions. 
Cytotune 2.0 consists of 3 types of vector: a polycistronic vector encoding SOX2, 
OCT4 and KLF4, a vector encoding MYC and a vector encoding KLF4. 
Transductions were performed with a multiplicity of infection (MOI) of 5, 5 and 3 for 
each vector respectively.  
2.4.3 Post transduction culture  
On day 1 after transduction the cells were collected and centrifuged at 200g, 20oC 
for 10 minutes, the supernatant aspirated, and the cells resuspended in 1ml of fresh 
expansion medium and re-plated in a 24 well ultra low attachment plates (Costar).  
On day 3 after transduction cells were collected, centrifuged at 200g, 20oC for 10 
minutes, the supernatant aspirated, resuspended in base medium alone (without 
cytokines) and the total viable cell count was estimated using a haemocytometer. 
The cells were transferred to pre-prepared plates containing inactivated MEFs. 
Transduced cells we plated at a density ranging from 500 to 5000 cells per cm2 
cultured area.  
On days 4 and 6 the upper 50% of the medium was removed from each well, and 
replaced with fresh base PBMC medium. From day 7 the upper 50% of the medium 
was removed from each well (as previously described), and replaced with 
conditioned PSC medium (see 2.5.2 for composition) daily until the appearance of 
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adherent colonies. Thereafter the whole volume of medium was changed daily. 
Cultures were observed for the appearance of colonies with an “embryonic stem cell 
like” morphology i.e. small cells with a high nuclear to cytoplasmic ratio. Whole 
colonies were transferred manually to fresh MEF feeders for further expansion.  
2.5 Clonal expansion and maintenance culture of iPSCs on MEF feeder 
layers 
2.5.1 Preparation of plates containing a MEF feeder layer  
Pregnant Swiss MF1 mice containing 12.5 to 14 day embryos were sacrificed by a 
method compliant with university regulations. Following abdominal dissection the 
uterine horns were identified, dissected and placed in a petri dish containing DPBS, 
10% FBS and 1% pen/strep (all from Life Technologies). The embryos were released 
from the amniotic sacs and the limbs, heads, tails and visible organs removed using 
fine dissection scissors and forceps. The remaining torsos were transferred to a petri 
dish containing 1% trypsin/EDTA (Life Technologies) in a sterile tissue culture hood. 
The tissues were minced for 1 minute with fine scissors, incubated for 5 minutes at 
37oC and triturated with a 1ml pipette to facilitate dissociation. Twice the volume of 
fibroblast medium (Dulbecco’s modified Eagle medium (DMEM) - high glucose, 10% 
FBS, 1% pen/strep, 1% Glutamax, 1% Minimal essential medium non-essential 
amino acids (NEAA) (all from Life Technologies)) was added to inactivate the trypsin. 
The cell suspension was triturated through a 19G needle 1-2 times then centrifuged 
at 300g for 5 minutes, the supernatant aspirated and the pellet resuspended in 
fibroblast medium. Cell suspension was plated in T75cm2 tissue culture flasks in a 
total volume of 10mls with approximately 3 embryos per flask. The cells were 
incubated in standard conditions. The medium was replaced with fresh fibroblast 
medium daily until they were 90% confluent, where upon they were either cryo-
preserved or passaged for further expansion.  
MEFs were passaged by aspirating the spent medium, washing the flask with DPBS, 
incubating 0.05% trypsin/EDTA for 5 minutes at 37oC and inactivating the trypsin by 
adding double the volume of fibroblast medium. The cell suspension was collected, 
centrifuged at 800g for 5 minutes, the supernatant aspirated, the cells resuspended 
in fibroblast medium and transferred to new flask with a split ratio of 1:3.  
Tissue culture plates of the format intended for pluripotent cell culture were treated 
with the addition of 0.1% gelatin (Sigma) sufficient to cover the culture surface 
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followed by incubation at room temperature for 2 hours. Gelatin was aspirated from 
the plates immediately before use. Confluent flasks of MEFs between passages 3 
and 5 were inactivated by irradiation (67.2Gy). A single cell suspension was prepared 
using 0.05% trypsin/EDTA as described above for passaging and transferred to the 
gelatin coated wells to provide a density of 15-20 x103 cells per cm2 of culture area. 
Plates were incubated in standard conditions for a minimum of 1 and a maximum of 4 
days. On the day of use the fibroblast medium was aspirated, the plate washed with 
DPBS, sufficient conditioned pluripotent cell medium added to cover the well and the 
plate incubated until needed. 
2.5.2 Preparation of MEF conditioned pluripotent cell culture medium. 
Suspensions of inactivated MEFs were prepared as described above and plated in 
a tissue culture flask at a density of 56x103 cells/cm2. The following day the flask was 
washed with DPBS, replaced with 0.4ml/cm2 growth area of stem cell medium and 
incubated. Stem cell medium consists of Knock-out DMEM (KO-DMEM), 20% 
knockout serum replacement (KSR), 1% pen/step, 1% NEAA, 1% Glutamax-I, 
10ng/ml basic fibroblast growth factor (bFGF) (all from Life Technologies). The 
medium was collected and replaced every 24hrs for 10 days. During the period of 
collection, medium was stored at 4oC. At the end of the collection period medium was 
passed through a 0.2µm filter, aliquoted, frozen and stored at -20oC until use of for 
up to 3 months. On the day of use the medium was supplemented with 1% insulin-
transferrin-selenium (ITS-G) (Life Technologies) and a further 10µg/ml bFGF. 
2.5.3 Clonal expansion on inactivated MEF feeder layers 
Pluripotent cells were cultured in standard conditions on with inactivated MEFs and 
conditioned pluripotent cell medium. The medium was changed daily and the size 
and morphology of the colonies observed to determine the optimal timing of 
passaging. In preparation for passaging differentiated areas were released from the 
colony with a 19-gauge needle or a 10µl pipette tip, the differentiated fragments 
aspirated and fresh conditioned PSC medium added to the well. Conditioned PSC 
medium was added to new MEF plates as described earlier.  
Very early passage iPSCs (p1-4) were passaged manually. Colonies were cut into 
fragments with a needle or 10µl pipette tip, the fragments released manually from the 
culture surface, collected in a 1ml pipette and transferring them to new MEF feeder 
plates.  
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Clones that had expanded to fill a well of a 12 well plate or more were passaged 
enzymatically. After cleaning, the medium was aspirated, the culture washed with 
DPBS and then incubated with 1mg/ml collagenase IV (Gibco) in KO-DMEM for 4-7 
minutes in standard conditions until the edges of colonies appear the be lifting from 
the culture surface. The collagenase solution was then aspirated and replaced with 
conditioned PSC medium. Colony fragments were released from the culture surface 
by the hydraulic action of medium gently expelled from a P1000 pipette. If necessary, 
fragments were gently triturated with a serological pipette to reduce their size. The 
suspension of colony fragments was then transferred to a new MEF feeder plate 
(prepared as described above). Split ratios (in terms of growth area) ranged from 1:1 
to 1:6 depending on the growth characteristics of the cells. Cells were passaged 
every 4-7 days. Clones that were slow growing or showing high levels of 
differentiation in repeated passages were discarded.  
2.6 Clonal expansion and maintenance culture in feeder-free conditions 
2.6.1 Preparation of Matrigel coated cultureware 
Tissue culture plates coated with hES qualified Matrigel (Corning) were prepared as 
per the manufacturers instructions. The manufacturer provides a recommended 
volume of Matrigel necessary to coat a culture area of 215-235cm2 – referred to as 
an aliquot. Aliquots of Matrigel were thawed on ice, diluted with 25ml of ice-cold 
DMEM/F12 1:1 (Life Technologies) per aliquot and plated onto pre-chilled 
cultureware at a density of approximately 0.12ml/cm2 of growth area i.e. 1ml per well 
of a 6 well plate. Plates could be stored for up to 1 week at 4ºC, in all cases were 
incubated at room temperature for 1 hour before use and the Matrigel solution 
aspirated from the plate immediately before use. 
2.6.2 Transfer of pluripotent cells from culture on MEF feeder layers to 
feeder-free conditions 
For each clone, colonies, co-cultured with of inactivated MEFs, in a single well were 
selected for an attempted adaptation to feeder-free conditions. Cultures were 
passaged using the same techniques as for enzymatic except that care was taken 
not to disrupt the colonies into fragments. Where possible whole colonies including 
surrounding inactivated MEFs were lifted from the culture surface. The suspension of 
colonies was then collected using a serological pipette (being careful to avoid 
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disruption to the colonies) and transferred to a single well of a Matrigel coated plate. 
After 24 hours and daily thereafter the medium was changed to mTeSR1 and 
cultures were cleaned and passaged as described in 2.6.1. 
2.6.3 Culture and passaging of pluripotent cells in feeder-free conditions 
Pluripotent cells adapted to growth on Matrigel with mTeSR1 medium (StemCell 
Technologies) were incubated in standard conditions with daily medium changes. 
Cultures were passaged when they reached 80% confluence or showing signs of 
differentiation or reached 4 days since the previous passage. Differentiated areas 
were removed with a 10µl pipette tip immediately before passaging. Pluripotent cells 
were released from adherent culture using Versene (Lonza), which is a solution 
containing calcium and magnesium ion chelating agents including 0.05% EDTA. The 
plates were washed with DPBS, incubated with Versene for 4-8 minutes at room 
temperature, the Versene was aspirated and a suspension of aggregated colony 
fragments produced by flushing the well will mTESR1 using a 1ml pipette. The 
suspension was distributed to Matrigel coated plate in a ratio from 1:2 to 1:6. 
2.7 Spontaneous differentiation of iPSCs 
2.7.1 Embryoid body differentiation 
Pluripotent cells were cultured in feeder-free conditions such that they formed large 
(2-3mm diameter) colonies at 3-5 days after passaging. Cultured cells were washed 
in DPBS and then incubated with Dispase-Collagenase medium (DMEM-F12, 
0.5mg/ml Dispase, 1mg/ml Collagenase IV (both from Gibco)) for 30-60 minutes at 
37oC, until the colonies were released completely by tapping the plate. Fragments 
were collected with a serological pipette, allowed to settle in a centrifuge tube, 
resuspended in mTeSR1, transferred to an ultra-low attachment plates and incubated 
in standard conditions. On day 1, 3, and 5, 50% of the medium was removed and 
replaced with spontaneous differentiation medium (DMEM-F12 with 20% FBS). On 
day 7 EBs were transferred to plates coated with 0.2% gelatin and cultured for a 
further 7 days (14 days total), when they were prepared for immunofluorescence 
microscopy for markers of differentiation to the three germ layers.  
2.7.2 Teratoma assay 
Teratoma assay was performed at Newcastle University as part of an existing 
project (In vivo behaviour of progenitor cells, Home Office Project licence 6004508) 
 
 
  
 
63 
in accordance with the UK CCCR Guidelines for the Welfare of Animals in 
Experimental Neoplasia (Workman et al., 1998) (Workman et al., 2010).  
iPSCs were cultured in feeder-free conditions to approximately 70% confluence, the 
medium was aspirated, the culture washed with DPBS and incubated with Versene 
for 7 minutes at 20oC. The Versene was aspirated and the colonies detached from 
the plate by washing with cell buffer (DPBS with 2% FBS). The cell suspension was 
centrifuged at 200g, for 3 minutes at 20oC, the supernatant aspirated and the pellet 
resuspended in sufficient cell buffer to give an approximate concentration of 5 x106 
cells/ml. The cell suspension was chilled to 4ºC and mixed with an equal volume of 
Matrigel that had been thawed from frozen and held at 4ºC to avoid gelling. 
Subcutaneous injections of the iPSC-Matrigel suspension were performed on 8 
week old male ICRF-Foxn1nu mice (Harlan Laboratories) according to an existing 
departmental protocol. Each animal received a single 200µl injection of 0.5 x106 cells 
to a flank. Each clone was tested in two mice. 
From 3 weeks after the injections mice were examined weekly for the appearance of 
tumours. Tumours were harvested when one of 3 end-points were reached, either a 
tumour reached 1cm3, the animal showed signs of distress or 3 months had elapsed 
since injection. Mice were euthanased using CO2 chamber and checked for the 
absence of vital signs. The skin over each tumour was incised with a scalpel and the 
tumour dissected, severing any vascular connection. Tumours were fixed in 4% 
formaldehyde at 4ºC for 12-16 hours then washed with dH2O 3 times. Tumours were 
then incubated in graded solution of ethanol (70%, 80%, 90%, 95%) for 2 hours each 
and then stored in 95% ethanol until ready for further processing. 
Samples were processed an under-went either Masson’s Trichrome staining, 
Weigherts haematoxylin staining or Mayer’s haematoxylin and eosin staining as per 
an established protocol. 
2.8 Directed cardiac differentiation of iPSCs after embryoid body formation 
Three different methods of embryoid bodies (EB) formation were studied. All 
techniques used pluripotent cells cultured in feeder-free conditions to a point 
estimated to be 24hrs before the time at which they would normally be passaged. 
2.8.1 Enzymatic EB formation 
In some experiments EBs were formed enzymatically. Cultured cells were washed 
in DPBS and then incubated with Dispase-Collagenase medium for 5-20 minutes at 
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37oC, until the edges of colonies started to detach. mTeSR1 was added and colonies 
were dispersed into large aggregates mechanically by a serological pipette and 
gentle trituration. Fragments were plated in ultra-low attachment plates in mTeSR1 
and incubated in standard conditions for a further 24hrs before starting directed 
cardiac differentiation. 
2.8.2 Aggrewell EB formation 
Aggrewell 400Ex plates (StemCell Technologies) were prepared as per the 
manufacturers instructions to ensure all wells we prefilled with mTeSR1-RI (mTeSR1, 
10µM Y27632 (Chemdea)). Cultured pluripotent cells were washed with DPBS and 
then incubated with Accutase (Life Technologies) for 7-9 minutes at 37oC until the 
cells were visibly detached from the plate. mTeSR1-RI was then added to each plate 
and the suspension gently triturated with a 5ml serological pipette to produce a single 
cells suspension. Cells were centrifuged at 200g, for 5 minutes, at 20oC, the 
supernatant aspirated and the pellet resuspended in mTeSR1-RI. The density of cells 
in suspension was estimated using a haemocytometer and the appropriate number of 
cells transferred to each well of the Aggrewell plate necessary to generate EBs of 
300 cells each. The plate was then centrifuged at 100g, for 3 minutes, 20oC and 
incubated in standard conditions. After 24hours the EBs were loosened from the 
wells into suspension by gentle pipetting with a 1ml pipette and collection with a 5ml 
serological pipette and transferred to an ultra-low attachment plates. EBs were 
incubate in mTeSR1 for a further 24 hours before starting directed cardiac 
differentiation.  
2.8.3 Directed cardiac differentiation 
The first day of exposure to the cardiac differentiation medium was referred to as 
day 0 of the protocol. On day 0 EBs were collected in a serological pipette and 
allowed to settle in a centrifuge tube for 10 minutes. The supernatant was aspirated 
and the EBs resuspended in embryoid body cardiac induction medium (ECIM) 
consisting of StemPro34, 1% Pen/Strep, 1% GlutaMax (all from Life Technologies), 
1mM ascorbic acid and 0.4mM monothioglycerol (both from Sigma)  .On day 0 this 
was supplemented with 1ng/ml BMP4 (R&D). On day 1 the medium was changed, 
using the same method, to ECIM supplemented with 10ng/ml BMP4, 6ng/ml Activin A 
(R&D) and 5ng/ml bFGF. On day 3 the medium was changed, using the same 
method, to ECIM supplemented with 150ng/ml Dickkopf related protein 1 (DKK1) 
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(R&D). On day 5 the medium was changed, using the same method, to ECIM 
supplemented with 10ng/ml vascular endothelial growth factor (VEGF) (R&D), 2µg/ml 
SB431542 (Tocris) and 118ng/ml dorsomorphin (DSM) (R&D). On day 7 the medium 
was changed, using the same method, to ECIM supplemented with 150ng/ml DKK1, 
10ng/ml VEGF. EBs were then plated at a density of approximately 5 EBs/cm2 on 
tissue culture plates coated with 0.1% gelatin. On day 10 and every 3 days thereafter 
the medium was replaced with ECIM supplemented with 10ng/ml VEGF and 5ng/ml 
bFGF EBs were observed daily for evidence of attachment and spontaneous 
contraction.  
2.9 Directed cardiac differentiation of iPSCs as a monolayer 
iPSCs were differentiated to iPSC-CMs using a modified version of an published 
protocol and is summarised in Figure 14 (Lian et al., 2013a). iPSCs were cultured as 
described in 2.6 with the exception that were adapted to culture on growth factor 
reduced (GFR) rather than hESC qualified Matrigel. The manufacturer provides an 
estimate of the protein content of each batch of GFR Matrigel. Matrigel plates were 
prepared as described in 2.6.1 with the exception that the dilution of Matrigel was 
performed to achieve a protein content of 0.13mg/ml in the solution used to coat 
cultureware giving 15µg of Matrigel per cm2 of culture area. 
iPSCs were passaged into 12 well plates at a density such that they reached 
confluence 3-4 days after passaging. The differentiation protocol was initiated when 
the cultures were estimated visually to be between 80-100% confluent. On day 0 of 
differentiation, mTeSR1 was replaced with monolayer cardiac induction medium 
(MCIM) (RPMI 1640, 2% B27 without insulin (both from Life Technologies)) 
supplemented with CHIR99021 trihydrochloride (Tocris) at either 6, 9 or 12µM 
concentrations depending on the cell line and passage. On day 1 the medium was 
changed to MCIM alone. On day 3 the medium was changed to a mixture of fresh 
MCIM and the medium from the culture in a 1:1 ratio, this was supplemented with 
5µM IWP2 (Tocris). On day 5 the medium was changes to MCIM alone. On day 7 the 
medium was changed to monolayer cardiac maintenance medium (MCMM) (RPMI 
1640 with 2% B27 (both from Life Technologies)). Thereafter the medium was 
replaced with fresh MCMM medium every 2-3 days until cultures were collected for 
analysis, with the exception of those cultures that underwent metabolic purification 
(see below).  
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Figure 14 Monolayer directed cardiac differentiation protocol.  
(*) Metabolic purification was not performed in all experiments. 
 
2.10 Purification of iPSC-CMs following directed differentiation 
2.10.1 Purification based on SIRPA expression 
See 2.16.3. 
2.10.2 Metabolic purification 
In monolayer cardiac differentiation experiments that underwent metabolic 
purification the medium was changed to metabolic purification medium consisting of 
monolayer cardiac purification medium (MCP) medium (RPMI 1640 without glucose 
supplemented with 2% B27). During the initial testing of this protocol this change 
occurred on day 12 of differentiation, in subsequent experiments it was on day 9. 
Purification medium was the changed every other day. During the initial testing of the 
protocol the medium was changed back to cardiomyocytes MCMM after 7 days, in 
subsequent experiments this occurred after 5 days. The day after change back to 
MCMM cultures were either analysed by flow cytometry or replated. Culture were 
replated by changing the medium to maintenance medium supplemented with 10µM 
Y27632 and incubated for 2 hours in standard conditions. The cultures were then 
washed with DPBS and incubated 0.25% trypsin/EDTA in standard conditions for 5-
20minutes until the fragments detached from the culture surface. Fragments were 
gently triturated to produce clusters of cells and equal volume of RPMI-20 (RPMI 
1640 with 20% FBC) added to inactivate the trypsin. The cell suspension was 
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centrifuged at 200g for 4 minutes at 20ºC, the supernatant aspirated and the pellet 
resuspended in RPMI-20 supplemented with 10µM Y27632. The concentration of 
cells in suspension was estimated using a haemocytometer and the cells were 
transferred to Matrigel coated cultureware (prepared as described earlier) at a 
density of 0.125 – 0.25 x106 cells per cm2 and incubated overnight in standard 
conditions. The follow day the medium was changed to maintenance medium and 
changed every 2-3 days thereafter. 
2.11 Culture of immortalized keratinocytes 
Immortalised keratinocytes (HaCaT) were cultured on tissue culture plastic-ware 
coated in MEF medium (Advanced DMEM (Life Technologies), 10% FBS, 1% 
Glutamax). The medium was changes every 48 hours. When cultures reached 90-
100% confluence they were washed with DPBS and incubated with 0.05% 
trypsin/EDTA, at 37oC for 5-20 minutes until they were released from the culture 
surface gentle agitation. An equal volume of MEF medium was added to the 
suspension which was then collected, centrifuged at 200g for 4 minutes, 20oC. The 
supernatant was aspirated and the pellet resuspended with MEF medium. The cell 
suspension was then passaged to fresh culture vessels with a split ratio of 1:4. 
Cultures typically reached confluence 2-5 days after passaging depending on the 
starting density. 
2.12 Cryopreservation of culture cells 
Cells in feeder-free culture conditions were collected for cryopreservation once the 
cultures had reached 60-80% confluence. This typically occurred 3-4 days after 
passaging. 
Cells were collected from adherent culture in feeder-free conditions as follows. 
Culture medium was aspirated and the adherent culture washed with DPBS. 
Adherent cultures were then incubated with Accutase, approximately 150ul per cm2 
of culture area, for 3 minutes at 37oC. Cultures were then gently agitated and 
observed under the microscope to determine whether cells had begun to detach from 
the culture surface. If not then they were incubated further until this occurred. Once 
detachment of the cells from the culture surface had been observed, all cells were 
detached from the culture surface by gentle flushing with mTeSR1-RI using a P1000 
pipette. The total volume of mTeSR1-RI added was at least equal to that of the 
Accutase to terminate its activity. The cell suspension was collected with a 
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serological pipette, transferred to a 15ml centrifuge tube and centrifuged at 200g for 
3 minutes, at room temperature. The supernatant was then aspirated leaving a cell 
pellet. The cell pellet was then resuspended in freezing medium, that had been pre-
chilled to 4oC. The volume of freezing medium used to re-suspend the cells was 
determined by the area of the culture surface from which they were collected. Cells 
from each square centimetre of culture surface were resuspended in 50-100ul of 
freezing medium i.e. cells from a single well of a 6 well plate, having a culture area of 
9cm2, were resuspended in 0.5 – 1ml of freezing medium. The cell suspension was 
then transferred to cryotubes within an isopropanol filled freezing container (Mr 
Frosty, Nalgene) that had been pre-chilled to 4oC. 0.5 to 1ml of suspension was 
placed in each cryotube. Freezing containers were then transferred to a -80 freezer 
for at least 24 hours. Samples were then stored at either -80oC or in liquid nitrogen (-
180oC). 
2.12.1 Cryopreservation of cells following directed cardiac differentiation 
Cells were incubated with maintenance medium supplemented with 10µM Y27632 
for 2 hours. The medium was then aspirated, the cells were washed with DPBS and 
then incubated with cardiac dissociation medium for 15-30 minutes until the cells 
detached from the culture surface with gentle agitation and hydraulic action by 
flushing with a P1000 pipette.  If possible the size of fragments was reduced to small 
clusters by trituration with a serological pipette. An equal volume of RPMI-20 was 
added, the suspension transferred to a 15ml centrifuge tube and centrifuged at 200g 
for 3 minutes, at room temperature. The supernatant was then aspirated leaving a 
cell pellet. The cell pellet was then resuspended in freezing medium, that had been 
pre-chilled to 4oC. The cell suspension was then transferred to cryotubes and frozen 
as described for pluripotent cells. 
2.12.2 Cryopreservation of MEFs and immortalised keratinocytes 
Culture medium was aspirated and the adherent culture washed with DPBS. 
Adherent cultures were then incubated with 0.05% trypsin/EDTA for 3-5 minutes in 
the case of MEFs and 5-20 minutes in the case of HaCaT cells, at 37oC, until they 
were released from the culture surface gentle agitation. An equal volume of MEF 
medium was added to the suspension which was then collected, centrifuged at 200g 
for 4 minutes, 20oC. The supernatant was aspirated and the pellet resuspended in 
freezing medium – without Y27632 at a concentration of 2-10 x106 cells per ml. The 
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cell suspension was then transferred to cryotubes and frozen as described for 
pluripotent cells. 
 
 Component Concentration / molarity 
Freezing medium FBS 80% (v/v) 
DMSO 20% (v/v) 
Y27632 10uM 
PSC medium KO-DMEM - 
KSR 20% 
Glutamax 1% 
Pen/Strep 1% 
NEAA 1% 
bFGF 10ng/ml 
Conditioned PSC medium PSC medium (co-cultured with 
inactivated MEFs, filtered) 
- 
ITS 1% 
bFGF 10ng/ml 
MEF medium Advanced DMEM  
FBS 10% 
Glutamax 1% 
Pen/Strep 1% 
mTeSR1-RI mTeSR1  
Y27632 10µM 
Collagenase IV medium KO-DMEM  
Collagenase IV 1mg/ml 
Dispase-Collagenase 
medium 
DMEM:F12  
Dispase 0.5mg/ml 
Collagenase IV 1mg/ml 
Embryoid body cardiac 
induction medium (ECIM) 
 
StemPro34 - 
Glutamax 1% 
Pen/Strep 1% 
L-ascorbic acid 1mM 
1-thioglycerol 0.4mM 
Pen/Strep 1% 
Monolayer cardiac induction  
medium (MCIM) 
RPMI 1640  
B27 supplement minus insulin 2% 
Pen/Strep 1% 
Monolayer cardiac 
maintenance medium 
(MCMM) 
RPMI 1640  
B27 supplement 2% 
Pen/Strep 1% 
Monolayer cardiac 
purification medium (MCPM) 
RPMI 1640 without glucose  
B27 supplement 2% 
Pen/Strep 1% 
Flow cytometry cell buffer DPBS  
PBS 2% 
RPMI-20 RPMI 1640  
FBS 20% 
Cardiomyocyte dissociation 
medium 
Cell dissociation buffer 50% 
Trypsin/EDTA 0.25% 50% 
Table 22 Composition of major culture media and reagents 
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2.13 Collection of samples for molecular analysis 
2.13.1 Collection of a cell pellet from adherent cultures of iPSCs for DNA and 
RNA extraction. 
All samples were obtained from cells grown in feeder-free conditions. Samples of 
iPSCs were collected for assessment of transgene expression from passage 10 
onwards. If transgene expression was identified in the initial samples further samples 
were taken every 2-4 passages until it became absent or the clone was abandoned. 
Assessments of pluripotency gene expression were collected at passage numbers 
greater than that at which transgene expression was first undetectable. 
Cells were collected from adherent cultures in feeder-free conditions as follows. 
Culture medium was aspirated and the adherent culture washed with DPBS. 
Adherent cultures were then incubated with Accutase, approximately 150ul per cm2 
of culture area, for 5 minutes at 37oC. Cultures were then gently agitated and 
observed under the microscope to determine whether cells had begun to detach from 
the culture surface. If not then they were incubated further until this occurred. Once 
detachment was observed, all cells were detached from the culture surface by gentle 
flushing with DPBS using a P1000 pipette. The total volume of DPBS added was at 
least equal to that of the Accutase to terminate its activity. The cell suspension was 
collected with a serological pipette, transferred to a 15ml centrifuge tube and 
centrifuged at 400g for 4 minutes, at room temperature. The supernatant was then 
aspirated leaving a cell pellet. If not processed immediately cell pellets were stored at 
-80oC for a maximum of 1 week.  
2.13.2 Collection of human right atrial appendage tissue samples for RNA 
extraction. 
Immediately following excision during surgery myocardial tissue was finely minced 
and placed in RNAlater (Sigma) and stored at 4oC for a maximum of 7 days until 
RNA extraction was performed. 
2.13.3 Collection of samples from contracting cultures for RNA extraction 
Single cell suspensions were prepared from contracting cultures as described in 
2.16.2. These samples were then divided into two aliquots. One aliquot was analysed 
by flow cytometry to assess the proportion of iPSC-CMs within the sample. The 
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second aliquot was centrifuged at 400g for 4 minutes, at room temperature. The 
supernatant was then aspirated leaving a cell pellet. If not processed immediately cell 
pellets were stored at -80oC for a maximum of 1 week. 
2.14 Genomic DNA analysis 
2.14.1 Extraction of genomic DNA from PBMCs and cultured cells. 
Genomic DNA was extracted from pelleted cells using the QIAamp DNA Micro kit 
(QIAGEN) as per the manufacturers protocol for the “isolation of genomic DNA from 
small volumes of blood”.  
The yield of dsDNA from each extraction estimated by photo-absorbance 
spectrometry using the Qubit BR assay (Life Technologies) as per the manufacturers 
instruction. The Qubit assay utilises a dsDNA binding dye to aid the accuracy of 
quantification. 
The levels of contamination with proteins and salts were assessed by photo-
absorbance spectrometry using a Nanodrop 2000 (Thermo). Samples with 260:280 
ratios >1.8 were considered to have minimal levels of proteins contamination and 
those with 260:230 ratios >1.8 considered to have minimal levels of salt 
contamination. Samples with either ratio below these levels were discarded. 
2.14.2 SNP array analysis 
Genomic DNA was assessed for evidence of copy number variations (CNV) using a 
SNP microarray. The HumanCytoSNP-12v2.1 kit (Illumina) was used and 
experiments were conducted using the protocols recommended by the manufacturer 
(Illumina, 2009). The HumanCytoSNP-12v2.1 array contains probes for 299,140 
SNPs at loci throughout the genome (Illumina, 2016). Each position on the array 
tests a single SNP by hybridisation of genomic DNA to probes specific to the SNP 
locus. Each SNP is bi-allelic and each position on the array contains a two probes 
(one specific to each allele) distinguished by conjugation to either dinitrophenol or 
biotin, referred to as the red and green fluorophores respectively. Fluorescence 
output is quantified with an imaging system, and the resulting data consist of paired 
data sets of red and green signal intensity for each location in the array. 
Fluorescence data were then processed using Beeline 2.0 and Genomestudio 
2011.1 software (Illumina) to determine the genotype of each sample tested. The two 
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parameters used to describe genotype are B allele frequency (BAF) and Log R ratio 
(Peiffer et al., 2006).  
BAF values are derived from the ratio of green and red signal intensities after polar 
normalisation and comparison to values from reference data sets from normal 
subjects (Peiffer et al., 2006). Homozygosity at a locus (with or without the presence 
of a CNV) would result in signal that is either exclusively red or exclusively green this 
would be represented by a BAF of 0 or 1 respectively. Heterozygosity and balanced 
duplications  (where there are an equal number or copies of each allele) would be 
represented by a BAF of 0.5. CNVs resulting in an unequal number of copies of each 
allele would be represented by a BAF of approximately 0.33 or 0.66, depending on 
which allele was more abundant. 
Log R ratio values are derived from the total fluorescence intensity for each array 
position (i.e. the sum of intensities in the red and green data sets) after polar 
normalization and comparison to values from reference data sets from normal 
subjects. In the absence of CNV the log R ratio of a SNP should approximate 0 
(Peiffer et al., 2006). A hemizygous deletion (loss of a one of the two alleles) reduces 
the log R ration to approximately -0.5. A duplication (giving three copies of an allele) 
increases the log R ratio to approximately 0.4. A triplication (giving four copies of the 
allele) increases the log R ratio to approximately 0.5. 
Assessment of the BAF and Log R ratio values of multiple loci within a genomic 
region allow the identification and characterisation of CNVs.  
The quality of data sets where assessed before looking for evidence of CNVs by 
consideration of the median log R deviation and the median call rate. Both 
parameters are calculated by arranging all autosomal SNPs in ascending genomic 
order, dividing them into non-overlapping bins of 1000 SNPs per bin. The call rate 
and standard deviation of Log R ratios are calculated for each bin, followed by the 
median of these value across all bins (“BlueFuse Multi v4.3 Software Guide,” 2016). 
Data sets with either or both a median call rate of <0.95 and a median Log R 
deviation >0.23 were rejected. 
Data sets that passed the quality control assessment were analysed with BlueFuse 
Multi v4.4 software (Illumina). BlueFuse Multi contains an algorithm which identifies 
CNVs on the basis of regional changes in BAF and Log R ratios and classifies CNVs 
as “benign?”, “unknown?” or “pathogenic?” by cross referencing them with the 
locations of normal and pathogenic CNVs that have been reported previously in large 
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online databases (Table 23). Log R ratio and BAF charts were also examined by the 
author in the BlueFuse Multi interface to identify CNVs not detected by the BlueFuse 
algorithm. 
Possible abnormalities were then assessed manually by the author with help from 
Dr Simon Zwolinski. Possible CNV were firstly accepted as genuine or rejected as 
artefact by manual inspection of the Log R ratio and BAF charts and by comparison 
to reference data run on the same array. In the case of CNVs in iPSC lines 
interpretation was aided by comparison to the originating PBMC sample.  
CNVs that were accepted as genuine were then assessed using the UCSC Genome 
Browser which allow the identification of case reports describing the clinical 
phenotypes associated with CNVs. 
 
Classification Definition 
Benign? Region must be fully covered by either: 
• significant CNVs from the DGV database 
• benign CNVs from the ISCA database 
and not overlapping a known disease region, 
and not overlapping an ISCA pathogenic CNV region 
Unknown? Regions not meeting the criteria for benign? or 
pathogenic? 
Pathogenic? Less than 80% of the region is covered by a DGV 
region of the same type, and the region must be either: 
• ≥1Mb in size 
• overlapping a known disease region 
• fully covered by an ISCA pathogenic region of the 
same type. 
 Table 23 Definitions of CNV type used by BlueFuse Multi algorithm 
The Database of Genomic Variants (DGV) collates reports of cytogenetic variants 
found in healthy subjects from affiliated laboratories (MacDonald et al., 2014). The 
International Standards for Cytogenomic Arrays (ISCA) consortium database 
collates cytogenetic abnormalities reported by affiliated laboratories (Kaminsky et 
al., 2011). An ISCA review committee may categorise a variant as pathogenic after 
consideration of clinical data from the submitting laboratory, previous submission to 
the NCBI/ISCA database and data from the UCSC and OMIM databases (Illumina, 
2017). 
 
An assessment of the genetic identity of an iPSC line relative to the PBMCs used in 
the reprogramming experiment from which it was derived can be made using the 
~300,000 SNP genotypes characterised by the microarray. Genotype information is 
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expressed as the fluorescence intensity at a location on the array. Samples with the 
same genotype should have a similar fluorescence of a given fluorochrome at the 
comparable positions on the array. If the red fluorescence of all positions on the array 
for two genetically similar samples are plotted against each other the data points 
would be expected to cluster around a single line described by x=y. If genetically 
dissimilar samples are plotted against each other the data would be expected to 
cluster around five lines reflecting the possible genotype mismatches (including 
option of a failed call in one of the samples).  Pearson’s correlation co-efficient (r) 
may be used to describe this relationship, with values close to 1 implying a similar 
genetic identity and values closer to 0.5 implying differing identities. 
2.14.3 Mutation sequencing 
PCR reactions were prepared with Immomix Red (Bioline) master-mix. Target 
regions were amplified by PCR using the primers listed in Table 25. Each 20µl PCR 
reactions contained 3mM MgCl2, 1µM primers and 0.25ng/ul DNA. The concentration 
of other components within the reaction such as the heat activated taq polymerase is 
proprietary information. Reactions were run on Eppendorf Mastercycler gradient 
thermocycler. Details of the thermocycler program are given in Table 24.  
Name of stage Details of stage 
Taq activation 95oC, 10mins 
Cycle Denaturing 95oC, 1min 
Annealing 60oC , 1min 
Extension 72oC, 2min 
Number of cycles 35 
Final extension 72oC, 10min 
Holding 4oC, indefinite 
 Table 24 Thermocycler program for amplification of genomic DNA prior to 
sequencing 
 
The products of the amplification reaction were purified using the QIAquick PCR 
purification kit (QIAGEN) using the manufacturers recommended protocol. Sanger 
sequencing of a single strand of the purified cDNA was performed according to the 
protocol of a commercial provider (GATC Biotech Ltd). 
Reported sequences were compared to genomic DNA using an online platform 
(BLAST) to confirm amplification of the region of interest (“Basic Local Alignment 
Search Tool (BLAST),” n.d.). 
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Target Fw/Rv Sequence* Size of 
product 
from 
target 
(bp) 
DSP c.3195C>G Fw gtagcgcgacggccagtGATCGAAGTTTTGGAAGAGGAGC 223 
Rv cagggcgcagcgatgacTTTTGCTTAGCCGACTTCCC 
PKP2 c.2146-1G>C Fw gtagcgcgacggccagtTCGTGAAATCAAATACAATAGCACT 217 
 Rv cagggcgcagcgatgacAGATTCCGGGACAGATTCCT 
DSG2 c.691-5T>A Fw gtagcgcgacggccagtGGACTAAAACCAGAAAGCCAGATG 148 
 Rv cagggcgcagcgatgacGCCATCTCTTGCTTCTACTGTC 
DSC2 
c.2686_2687dupGA 
Fw gtagcgcgacggccagtATGAAGGAAGAGGATCGGTGG 197 
Rv cagggcgcagcgatgacCCACTGGCTTTCAGAGACTTATTA 
 Table 25 Primers used for the amplification of genomic DNA prior to 
sequencing. 
*Primers directed to target a genomic sequence consist of a “tag” sequence (shown 
in lowercase) followed by sequence designed to target  
 
 
Target Sequence 
Amplicon forward strand GTAGCGCGACGGCCAGT 
Amplicon reverse strand CAGGGCGCAGCGATGAC 
 Table 26 Primers used to initiate Sanger sequencing reaction 
 
2.14.4 TCR re-arrangement assay 
Re-arrangements of TRG and TRB may be detected by multiplex PCR. Standards 
for the design of assays used in clinical practice have been established (Sandberg et 
al., 2005). A commercial multiplex PCR kit meeting these standards was used in this 
work (IdentiClone TCRB + TCRG T-cell clonality assay, Invivoscribe) and performed 
according to the manufacturers protocol by Northgene Ltd, Newcastle upon Tyne. 
The PCR reactions in this assay employed multiple primers targeted to conserved 
variable (V) joining (J) and diversity (D) regions of two T-cell receptor genes (TRB or 
TRG). A PCR product will only be generated from genes that have undergone 
rearrangement. These primers will amplify the region when V(D)J recombination has 
occurred. Reverse primers are labelled with either 6-carboxyfluorescien (6FAM) or 
hexachlorofluorescein (HEX) fluorophores allowing detection using the ABI 
fluorescence detection platform. Reactions yielding a PCR product with a size within 
one of the pre-specified ranges is considered positive (Table 27). 
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Reaction Expected size of 
products (fluorochrome) 
Gene Target 
TRB reaction A 240-285 (6FAM) TRB Vβ - Jβ2 
240-285 (HEX) Vβ - Jβ1 
TRB reaction B 240-285 (6FAM) Vβ - Jβ2 
TRB reaction C 170-210 (6FAM) Dβ - Jβ2 
285-325 (HEX) Dβ - Jβ1 
TRG reaction A 175-195 (6FAM) TRG Vγ10 - Jγ 1.1/2.1 
230-255 (6FAM) Vγ1-8 - Jγ 1.1/2.1 
145-175 (HEX) Vγ10 - Jγ 1.3/2.3 
195-230 (HEX) Vγ1-8 - Jγ 1.3/2.3 
TRG reaction B 110-140 (6FAM) Vγ11 - Jγ 1.1/2.1 
195-220 (6FAM) Vγ9 - Jγ 1.1/2.1 
80-110 (HEX) Vγ11 - Jγ 1.3/2.3 
160-195 (HEX) Vγ9 - Jγ 1.3/2.3 
 Table 27 Expected size ranges of PCR products in T-cell receptor re-
arrangement assay 
 
2.15 RNA analysis 
2.15.1 Extraction of RNA 
RNA was extracted from PBMCs and cultured cells using the ReliaPrep RNA cell 
miniprep system (Promega) according to the manufacturers protocol, which includes 
DNase I treatment. Between 0.1 and 2 x106 cells were used in each extraction with 
the resulting RNA eluted into a minimum of 10µl of NFW. Typical yields of RNA were 
between 1 – 100 µg per sample. 
RNA was extracted from myocardial tissue using the ReliaPrep RNA tissue miniprep 
system (Promega) according to the manufacturers protocol including DNase I 
treatment. Between 5-10 mg of tissue were used in each extraction with the resulting 
RNA eluted into a minimum of 10µl of NFW. Typical yields of RNA were between 1 – 
10 µg per sample. 
2.15.2 Assessment of RNA quality  
RNA yield and the levels of contamination with proteins and salts were assessed by 
photo-absorbance spectrometry using a Nanodrop 2000 (Thermo). Samples with 
260:280 ratios >1.8 were considered to have minimal levels of proteins 
contamination and those with 260:230 ratios >1.8 considered to have minimal levels 
of salt contamination. Samples with either ratio below these levels were discarded. 
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2.15.3 Synthesis of cDNA from RNA 
cDNA was synthesised using the GoScript Reverse Transcription System 
(Promega) as per the manufacturers protocol. Each 10µl annealing reaction 
contained 100ng/µl RNA and 100ng/ul primer. cDNA prepared for assessment of 
transgenes was synthesised using random primers provided in the kit. cDNA 
prepared for the assessment of endogenous gene expression was synthesised using 
oligo(dt)15 primers provided in the kit. Annealing reactions were run on an Eppendorf 
Mastercycler gradient thermocycler. Additional regents were then added to each 
annealing reaction, the resulting 40µl reverse transcription reactions contained 
25ng/µl RNA, 25ng/µl primer, 4mM MgCl2, 0.5mM dNTPs and 8 U/µl GoScript 
reverse transcriptase (RT), Reverse transcription reactions were run on the same 
thermocycler as the annealing reaction. Details of thermocycler program are provided 
in Table 28. cDNA was stored at -20oC until used for PCR experiments. 
 
Reaction Name of stage Details of stage 
Annealing Annealing 70oC, 5 mins 
Holding 4oC, indefinite 
Reverse transcription Priming 25oC, 5 mins 
Reverse transcription 42oC, 1 hour 
RT inactivation 70oC, 15mins 
Holding 4oC, indefinite 
 Table 28 Thermocycler program for reverse transcription 
 
2.15.4 PCR to assess persistence of reprogramming vectors 
PCR reactions to determine if reprogramming vectors were detectable within 
cultured cells were prepared using the GoTaq G2 DNA PCR system (Promega) as 
per the manufacturers protocol. The sequences of the primers used are given in 
Table 30 and the locations they amplify within the Sendai RNA are illustrated in 
Figure 15. Each 10µl reaction volume reactions contained 0.25ng/µl cDNA, 1µM 
primers, 0.2mM dNTPs, 0.025 U/µl G2 Taq polymerase and 1.5mM MgCl2. Reactions 
were run on an Eppendorf Mastercycler gradient thermocycler. Details of 
thermocycler program are provided in Table 29. 
PCR products were separated by electrophoresis in 2% agarose gels containing 
0.01% Gel Red (Biotium) and imaged using a GelDoc-It 310 Imaging System (UVP). 
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Name of stage Details of stage 
Initial denaturing / Taq activation 95oC, 2mins 
Cycle Denaturing 95oC, 30s 
Annealing X oC , 1min * 
Extension 72oC, 2min 
Number of cycles 35 
Final extension 72oC, 10min 
Holding 4oC, indefinite 
 Table 29 Thermocycler program for amplification of genomic DNA prior to 
sequencing and of cDNA in non-quantitative PCR experiments 
* annealing temperatures varied between primer sets depending on the results of 
optimisation experiments. 
 
 
Target Fw 
/Rv 
Sequence Binding site Annealing 
temperature 
(oC) 
Size of 
product 
from target 
(bp) 
SeV Fw GGATCACTAGGTGATATCGAGC L 61 181 
Rv ACCAGACAAGAGTTTAAGAGATATGTATC Non-coding 
region 3’ to L 
SeV-
KLF4 
Fw CCTACACAAAGAGTTCCCAT Exon 4 of 
KLF4 
64 309 
Rv AATGTATCGAAGGTGCTCAA N 
SeV-
KOS 
Fw ATGCACCGCTACGACGTGAGCGC Exon 1 of 
SOX2 
64 528 
Rv ACCAGACAAGAGTTTAAGAGATATGTATC Non-coding 
region 3’ to L 
Sev-
MYC 
Fw TAACTGACTAGCAGGCTTGTCG Non-coding 
region 3’ to 
HN 
58 532 
Rv TCCACATACAGTCCTGGATGATGATG Exon 2 of 
MYC 
 Table 30 Primers used for the amplification of cDNA in RT-PCR experiments. 
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 Figure 15 Organisation of Sendai virus and vectors and predicted binding 
sites primer set used in their detection. 
The wild type Z strain Sendai virus is an enveloped single strand RNA virus 
consisting of 6 single exon genes separated by non-coding regions. The genes 
encode nucleocapsid protein (N), phosphoprotein (P), matric protein (M), fusion 
protein (F), Haemagglutinin-Neuraminidase  (HN) and large protein (L). The 
structure of the Cytotune 2.0 vectors is proprietary information but may be inferred 
from the binding sites of the primer sets recommended by the manufacturer to 
detect the vectors. The predicted binding sites of primer sets were identified using 
Primer-BLAST (Ye et al., 2012) to searching against all RNA and DNA reference 
sequences. 
 
2.15.5 qPCR 
qPCR reactions were prepared using GoTaq qPCR Master Mix (Promega) as per 
the manufacturers instructions. Each 10µl qPCR reaction contained 0.25ng/µl cDNA, 
1µM primers, 0.3µM carboxy-X-rhodamine (CXR) reference dye. The master mix 
also contained a heat activated Taq polymerase, the BRYT Green dsDNA indicator 
dye the concentrations of which are proprietary information. 
Reactions were run in 384 well plates (Applied Biosciences) on a QuantStudio 7 
Flex (Applied Biosciences) qPCR machine, using QuantStudio 6 and 7 Flex Real 
Time PCR system software v1.0. A melt curve was performed in all experiments. 
Details of the PCR and melt curve program as given in (Table 31). 
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Name of stage Details of stage  
Initial holding 50oC, 2mins 
Taq activation 95oC, 10mins 
Cycle Denaturing 95oC, 15s 
Annealing and extension 60 oC, 1min 
Number of cycles 40 
Melt Curve Denaturing 95oC, 15s 
Annealing and extension 60 oC, 1min 
Melt curve 0.05oC/s to 95oC 
 Table 31 Thermocycler program for qPCR reactions 
The rate of change between stages of the program was 1.6oC/s, with the exception 
of the melt curve 
 
The efficiencies of all primers were assessed from a standard curve generated from 
4 fold serial dilutions of cDNA pooled from PSCs, iPSC-CMs, HaCaT cells and right 
atrial appendage (RAA). Efficiency were calculated by QuantStudio 6 and 7 Flex 
Real Time PCR system software v1.0 from standard curves containing 3-5 data 
points. Satisfactory primers had an estimated efficiency of 90-100% estimated from 
standard curves with an R2 of >0.990. 
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Target Strand targeted by 
Primer 
Sequence Location of primer 
binding 
Efficiency / R2 / points on 4-
fold dilution standard curve 
Size of product 
from target (bp) 
ACTB Fw GCACAGAGCCTCGCCTT Exon 1 91% / 0.995 / 5 77 
Rev GTTGTCGACGACGAGCG Exon 2 
ENOX2 Fw *  - * 
Rev *  
ERCC6 Fw *  - * 
Rev *  
GAPDH Fw TGCACCACCAACTGCTTAGC Exon 7 112% / 0.998 / 4 87 
Rev GGCATGGACTGTGGTCATGAG Exon 7-8 junction 
PRDM4 Fw * Accession sequence: 
NM_012406 
Anchor nucleotide: 2346 
Intron spanning 
- Context length: 
174bp Rev * 
RPL7 Fw GGCTTCGATTAACATGCTGAGG Exon 4 - 177 
Rev CAGATGATGCCGTATTTACCAAGAG Exon 5-6 junction 
RNF20 Fw *  - * 
Rev *  
SCLY Fw *  - * 
Rev *  
SDHA Fw TGGGAACAAGAGGGCATCTG Exon 2 92% / 0.994 / 5 86 
Rev CCACCACTGCATCAAATTCATG Exon 3 
UBE4A Fw *  - * 
Rev *  
VIPAS39 Fw * Accession sequence: 
NM_022067 
Anchor nucleotide: 448 
Intron spanning 
- Context length: 
166bp Rev * 
 Table 32 Primers targeting reference genes used in RT-qPCR experiments 
  
 
 
  
 
82 
 
Target Strand targeted by 
Primer 
Sequence Location of primer 
binding 
Efficiency / R2 / points on 4-
fold dilution standard curve 
Size of product from 
target (bp) 
KLF4 Fw TTACCAAGAGCTCATGCCACC Exon 3-4 junction 98% / 0.999 / 3 222 
Rev GCGAATTTCCATCCACAGCC Exon 5 
MYC Fw CACCAGCAGCGACTCTGA Exon 2 105% / 0.996 / 5 138 
Rev CTGTGAGGAGGTTTGCTGTG Exon 3 
OCT4A Fw AGCTGGAGAAGGAGAAGCTG Exon 1 98% / 0.996 / 3 183 
Rev TGGTCGTTTGGCTGAATACCT Exon 3 
SOX2 Fw TTGTTCGATCCCAACTTTCC Exon 1 - 198 
Rev ACATGGATTCTCGGCAGACT Exon 1 
 Table 33 Primers targeting pluripotency associated genes used in RT-qPCR experiments 
 
 
Target Strand targeted by 
Primer 
Sequence Location of primer 
binding 
Efficiency / R2 / points on 4-
fold dilution standard curve 
Size of product from 
target (bp) 
ACTN2 Fw ACAGCATTGAGGAGATCCAGAGT Exon 14-15 junction 97% / 0.992 / 5 211 
Rev TGCTTCACCTTGTCCCACTTG Exon 15-16 junction 
MYH6 Fw TCTCCGACAACGCCTATCAGTAC Exon 5 94% / 0.997 / 3 140 
Rev GTCACCTATGGCTGCAATGCT Exon 7 
MYH7 Fw GGCAAGACAGTGACCGTGAAG Exon 3-4 junction 96% / 0.996 / 3 133 
Rev CGTAGCGATCCTTGAGGTTGTA Exon 4 
MYL2 Fw CCTTGGGCGAGTGAACGT Exon 3-5 junction 97% / 0.991 / 5 120 
Rev GGGTCCGCTCCCTTAAGTTT Exon 4-5 junction 
TNNI3 Fw CCAACTACCGCGCTTATGC Exon 3 90% / 0.997 / 3 120 
Rev CTCGCTCCAGCTCTTGCTTT Exon 5 
TNNT2 Fw ACTTGGAGGCAGAGAAGTTCG Exon 14 99% / 0.993 / 4 108 
Rev GGGTCTTGGAGACTTTCTGGTTATC Exon 15-16 junction 
 Table 34 Primers targeting genes encoding cardiac sarcomeric proteins used in RT-qPCR experiments  
 
  
 
 
  
 
83 
 
Target Strand 
targeted 
by Primer 
Sequence Location of primer binding Efficiency / R2 / points on 4-
fold dilution standard curve 
Size of product 
from target (bp) 
DSC1 a+b Fw GCTGTGTGTTGTCAAGCCATTG Exon 9-10 junction 98% / 0.993 / 4 110 
Rev TAGGAGTTTGTGAGCTCGCTG Exon 10 
DSC1 a Fw CTCGGCTTGGCGAAAAGGTG Exon 15-17 junction 
(specific to the “a” splice variant) 
95% / 0.996 / 5 156 
Rev GAAACTCCAGTCCCTCTTCTTCC Exon 17 
DSC1 b Fw ATATGCGTACACGGACTGGC Exon 15 93% / 0.997 / 5 74 
Rev TCAGAGTGTGTCCTCTAATGGATTC Exon 16 
(specific to the “b” splice variant) 
DSC2 a+b Fw GCATCCTGTTTACGCTGGTC Exon 14 - 180 
Rev AAACTCCCTGAGCAGAAGCG Exon 15 
DSC3 a+b Fw ACTTGGAAAATGGGCAATCCTTG Exon 13 106% / 0.981 / 5 186 
Rev TTGGCAGAGCACACTCTATCG Exon 14-15 junction 
DSG1 Fw CAACGACTGTTAGGTATGTAATGGG Exon 10 - 144 
Rev AGAGAATCGTTCCTTGGTATTTTCC Exon 10-11 junction 
DSG2 Fw ACCTGAAGACAAGGTGGTGC Exon 13-14 junction 98% / 0.999 / 3 166 
Rev CCACCTTCCATCCATCTCGG Exon 14 
DSG3 Fw TGTTGACCTGTGACTGTGGG Exon 13 102% / 0.998 / 3 138 
Rev TATTTGTGATTTCCTTGTCTTCAGG Exon 13-14 junction 
DSG4 Fw GATCAACAAATGCTACCTCGGC Exon 11-12 - 87 
Rev TGTCCTTCACCAGGATTGGG Exon 12 
DSP I+II Fw CAGGATGTACTATTCTCGGCG Exon 1 94% / 0.998 / 3 135 
Rev ATCAAGCAGTCGGAGCAGTT Exon 2 
JUP Fw CTCAACAAGAACAACCCCAAG Exon 5 98% / 0.991 / 5 141 
Rev ACTGTAGTTACGCATGATCTGC Exon 6 
PKP1 a+b Fw GACATGTGGTCCAGCAAGGAAC Exon 12 96% / 0/998 / 3 170 
Rev TCTCAGCTGGGTCATATCTTCCTG Exon 13-14 junction 
PKP2 a+b Fw GCACGCGACCTTCTAAACAC Exon 12 94% / 0.997 / 3 168 
Rev TGTCTTCTTAAACTGAGCCTTCTTG Exon 13-14 junction 
PKP3 a+b Fw CAAATGCGAGGACAAGAGCGT Exon 7-8 junction 95% / 0.997 / 3 75 
Rev ATCTCGTCGTAGAGGCGGTAG Exon 8 
 Table 35 Primers targeting genes encoding desmosomal plaque proteins used in RT-qPCR experiments 
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2.15.6 Selection of reference genes for RT-qPCR data 
The stability of reference gene expression varies between tissue and cell types 
(Vandesompele et al., 2002). The geNorm algorithm (accessed via QBase+) was 
used to select the combination of reference genes that had the greatest stability for 
the combination of tissue and cell types compared by RT-qPCR in this study from a 
pre-defined list of candidates. The first stage of the algorithm was to conduct a 
GeNorm pilot experiment to assess the gene expression in multiple samples from 
each of the tissue or cell types to be assessed. Fifteen 15 cDNA samples were 
assessed of which 3 were from PBMCs of different individuals, 3 from iPSC lines, 3 
from iPSC-CMs, one was a from a hESC line and 3 were from RAA samples. Eleven 
potential reference genes candidates were evaluated (see Table 32), seven of these 
genes were pre-selected by a commercial provider (Primer Design), the other four 
genes were those used in previous ARVC/D iPSC-CM studies and commonly used in 
our laboratory. The RT-qPCR reactions as a single experiment as described above.  
Ct values from this experiment were processed by the geNorm algorithm which is a 
component of the QBase+ software package. The geNorm algorithm uses the Ct 
values to calculate an M-value and coefficient of variance (CV) for each reference. 
M-values are an index of the variability of gene expression relative to other genes 
across the sample set. Genes with a high stability will have similar variations 
expression levels across the sample types and therefore lower M and CV values 
(Vandesompele et al., 2002). When tested in groups of samples from a similar cell 
type, reference genes with M values of <0.5 and a CV values of <25% are 
considered to be stably expressed (Hellemans et al., 2007). In groups of samples 
from a range of cell types stable reference genes are indicated by M values of <1.0 
and a CV values of <50% (Hellemans et al., 2007).  
The geNorm algorithm then assesses the mean M-value of the candidate genes and 
determines the gene which, if excluded, would reduce the mean M-value of the 
remaining group by the greatest amount. This process was repeated iteratively and 
the genes are ranked in the order that they were excluded. Then, starting with the 
two most stable reference genes, the improvement in stability resulting from inclusion 
of the third most stable gene was calculated and expressed by a GeNormV value. 
GeNormV values of >0.15 are considered to indicate that the additional gene should 
be used, this process was repeated iteratively until the additional of a further 
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reference gene was associated with a GeNormV value of ≤0.15 at which point the 
group of reference genes recommended by the algorithm was identified 
(Vandesompele et al., 2002). 
2.15.7 Processing qPCR data 
qPCR data were analysed using QuantStudio software (Life Technologies). Each 
primer set was assessed in three technical repeats for each cDNA sample. Technical 
repeats differing by >0.5 Ct were considered for exclusion as outliers. The mean Ct 
(mCt) value of technical repeats was calculated for each sample. A mean of mCt 
(RefCt) values of the two reference genes (VIPAS39 and PRDM4) was calculated for 
each sample. Target gene expression normalised to reference gene expression (ΔCt) 
was calculated as: 𝛥𝐶𝑡 = 𝑚𝐶𝑡 − 𝑅𝑒𝑓𝐶𝑡 
 In some cases this gene expression in cell line was expressed with respect to that 
in a control cell line or tissue in these cases the ΔΔCt value was calculates as 
follows: 𝛥𝛥𝐶𝑡 = 𝛥𝐶𝑡 𝑠𝑎𝑚𝑝𝑙𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 −  𝛥𝐶𝑡 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑠𝑎𝑚𝑝𝑙𝑒) 
Fold expression was then calculated as 2-ΔCt or 2-ΔΔCt as appropriate. 
 
The expression levels of pluripotency marker genes in hESCs in maintenance 
culture were considered to be indicative of those associated with the state of 
pluripotency in general. Therefore the expression of these genes in specific cell lines 
or types was expressed relative to the mean expression across the 3 passages of H9 
hESCs. 
The expression levels of cardiomyocyte marker genes in RAA was considered to be 
indicative of cardiomyocytes in general. Therefore the expression of these genes in 
specific cell lines or types was expressed relative to the mean expression across the 
3 samples  of RAA. 
Calibration to a reference cell type was not used in the assessment of desmosomal 
gene expression in order that these data could to provide an indication of the 
absolute levels of gene expression of the different genes in a particular cell or tissue 
type e.g. to assess whether the expression of one or more of the three desmocollin 
genes is dominant in a particular cell or tissue type. 
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2.16 Flow cytometry and FACS 
2.16.1 Assessment of pluripotency associated protein expression in 
expandable clones 
Cultures of adherent cells were prepared as follows, maintenance medium was 
removed, cultures were washed once with DPBS and then incubated at room 
temperature with Accutase for 5-10 minutes until cells could be detached from the 
culture surface and fragmented by gentle trituration. Accutase was inactivated by 
adding an equal volume of DPBS and the cell suspension filtered through a 40µM 
nylon mesh (BD) to remove any clumps. Samples were centrifuged at 400g, at room 
temperature for 4 minutes the supernatant aspirated. The pellets were resuspended 
by in DPBS and an equal volume of 4% formaldehyde added (giving a final 
concentration of 2% formaldehyde) and incubated for 15 minute at room temperature.  
Samples were centrifuged at 400g, 20oC for 4 minutes the supernatant aspirated. 
Cells were permeabilised by resuspension of the pellet with ice cold 90% methanol at 
-20oC for at least 4 hours. The methanol was diluted with DPBS and the samples 
centrifuged at 400g, 20oC for 4 minutes the supernatant aspirated.  
The cellular debris used in experimental set-up of the these experiments was 
generated by the incubation of unfixed iPSCs exposed to 0.1% triton X-100 before 
fixation as described above. 
Samples undergoing labelling were first blocked by resuspension in 10% FBS and 
incubation for 30 minutes.  Aliquots of 1x105 cells were incubated with antibodies to 
the proteins if interest in a volume of 100ul, in the dark, at room temperature for 45 
minutes. The antibodies and dilutions used are detailed in Table 36. 
. Pluripotency marker protein signals were assessed using a single colour 
experimental design for the control iPSC clones from subject 2 i.e. each sample was 
divided into multiple aliquots with each aliquot labelled for a different target protein. 
iPSC clones derived from ARVC/D subjects were assessed using a multi-colour 
experimental design i.e. an aliquot of sample was co-labelled with multiple antibodies. 
The same antibodies were used for all experiments. Samples were washed twice 
using a BD FACS lyse wash assistant machine prior to analysis. 
Samples were analysed using an LSR II (BD). The fluorochromes of the antibodies 
used were selected to avoid overlap in their absorption spectra where possible such 
that each was maximally exited by a different wavelength laser in the LSR-II. In 
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addition the filter-sets associated with each laser were selected to ensure that the 
fluorescence quantified was limited to a range of wavelengths in which the overlap in 
emission spectra of fluorochromes was minimal. The combination of laser and filter-
set used to measure fluorescence from a specific fluorochrome will be referred to as 
its channel. For multi-colour experiments preliminary experiments defined the colour 
compensation parameters to be used in these experiments and these parameters 
where kept constant across experiments at different time points.  
Events likely to be derived from cells were distinguished from those from debris by 
having forward scatter area (FSC-A) and side scatter area (SSC-A) values within 
specified ranges (Figure 16). The gate used to exclude debris was validated 
experimentally using samples of cellular debris (generated as described above). 
Events likely to be derived from single rather than clusters of cells were defined by a 
similar gate defining a range of FSC-A and forward scatter height (FSC-H) values 
clustered around the line described by x=y (Figure 16), this gate could not be 
validated experimentally. 
A target of 10,000 single cell events was set per sample. Samples in which <5,000 
single cell events could be collected were repeated. 
 
 Figure 16 Classification of flow cytometry events as cells and single cells. 
Panel A shows a contour plot of forward scatter – area (FSC-A) against side scatter 
- area (SSC-A) for all flow cytometry events. The criterion defining the subset of all 
events that was classified as “cell” events is described by the polygonal gate. This 
gate excludes small (a) and large (b) events that are likely to be debris. Panel B 
shows a contour plot of forward scatter – area (FSC-A) against forward scatter - 
height (FSC-H) for all the “cell” events defined in panel A. The criteria defining “cell” 
events as “single cell” events are described by the polygonal gate which 
approximates the line x=y. This gate excludes events with higher area to height 
ratios (a) that are likely to be clusters of cells. 
 
 
 
  
 
88 
Flow cytometry data were analysed with FACSDiva 8.0.1 software (BD). For each 
channel (pluripotency marker), single cell events from a labelled sample were 
classified as positive if the fluorescence value exceeded a specific threshold. This 
threshold was the 99th centile of fluorescence values of single cells events in an 
unlabelled aliquot of the same sample (Figure 17). 
The difference between the median fluorescence of labelled and unlabelled single 
cell events was also assessed (Figure 17). 
 
 
 Figure 17 Analysis of flow cytometry data 
Panel A illustrates the classification of labelled cells as positive for the expression of 
a target protein. The 99th centile fluorescence value of unlabelled single cell event 
was identified (a). All single cell events in the labelled sample with a fluorescence 
value greater than this threshold were classified as positive for the marker protein 
(b). Panel B illustrated the assessment of relative fluorescence. The median 
fluorescence of unlabelled single cell event (a) was subtracted from the median 
fluorescence of labelled single cell events (b).  
2.16.2 Assessment of iPSC-CM markers in contracting cultures 
After aspiration of culture medium contracting cultures were washed with DPBS and 
a single cell suspension was prepared by incubation with either 0.25% Trypsin/EDTA 
or Accutase (both from Gibco).  
Samples for experiments in which signal regulatory protein α (SIRPA) expression 
was assessed were incubated with Accutase for up to 45 minutes in standard 
conditions and triturated to produce a single cell suspension. Enzyme activity was 
stopped by the addition of a volume of DPBS equal to that of the Accutase.  
Samples in all other experiments were incubated with 0.25% Trypsin/EDTA (Gibco) 
for 10-20 minutes in standard conditions and triturated to produce a single cell 
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suspension. Enzyme activity was stopped by the addition of a volume of RPMI-20 
equal to that of the trypsin.  
Cell suspensions produced by either method were filtered through a 100µM nylon 
mesh, centrifuged at 400g for 4 minutes, room temperature, the supernatant 
aspirated.  
The pellet was resuspended in DPBS, the number of cells in the sample estimated 
by haemocytometer and aliquoted into two samples. One sample was used for 
analysis by flow cytometry and the second for the analysis of RNA (see 2.13.3). The 
flow cytometry aliquot was centrifuged at 400g for 4 minutes, room temperature, the 
supernatant aspirated.  
In experiments in which cell viability was assessed and the pellet resuspended in 
100µl of DPBS containing 1:100 Zombie aqua and incubated at room temperature in 
the dark, for 15 minutes. DPBS was added, samples were centrifuged at 400g for 4 
minutes, room temperature, the supernatant aspirated, the pellet was resuspended in 
DPBS and the sequence repeated to wash the cells. In all other experiments this 
stage was omitted. 
After centrifugation the pellet was loosened in 50µl of DPBS and resuspended in 
≥2ml of 4% formaldehyde. The suspension was incubated for 20 minutes at room 
temperature. Samples were centrifuged at 400g for 4 minutes, room temperature, the 
supernatant aspirated, then resuspended in 0.1% Triton X-100 in DPBS for 10 
minutes. Samples were centrifuged at 400g for 4 minutes, room temperature, the 
supernatant aspirated, then resuspended 10% FBS in DPBS and incubated for 30 
minutes at room temperature. The number of cell was assessed by haemocytometer 
during this time. Samples were centrifuged at 400g for 4 minutes, room temperature, 
the supernatant aspirated, and the pellet resuspended in flow buffer (2% FBS in 
DPBS) to give a concentration of 1x105 cells/ml. Aliquots of 1x105 cells were 
incubated with antibodies to the proteins if interest in a volume of 100ul, in the dark, 
at room temperature for 45 minutes. The antibodies used were: anti-cTnI-Alexa647 
(1:20), anti-cTnT-PE (1:20) anti-SIRPA-PE (1:100) and isotype controls from the 
same manufacturer and matched for protein concentration. Samples were washed 
once using a BD wash/lyse machine prior to analysis. 
The flow cytometry set-up and analysis of data were performed using the same 
protocol as described in 2.16.1.  
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2.16.3 FACS of cells from contracting cultures based on SIRPA expression 
and the assessment of cTnI expression in the resulting populations. 
After aspiration of culture medium contracting cultures were washed with DPBS and 
a single cell suspension was prepared by incubation with Accutase for up to 45 
minutes in standard conditions. A single cell suspension was produced by gentle 
trituration and an equal volume of DPBS added to the suspension to stop enzyme 
activity. The cell suspension was filtered through a 100µM nylon mesh, centrifuged at 
200g for 4 minutes, room temperature, the supernatant aspirated and the pellet 
resuspended in 10% FBS in DPBS. The number of cells was estimated by 
haemocytometer and the sample concentration adjusted to achieve 20x106 cells/ml. 
Aliquots of this suspension were incubated with antibodies for 20 minutes at room 
temperature in the dark. The antibodies used were anti-SIRPA-PE (1:100) and an 
isotype control from the same manufacturer and matched for protein concentration. 
Further details of the antibodies are given in Table 36. Samples were centrifuged at 
200g for 4 minutes, room temperature, the supernatant aspirated and the pellet 
resuspended in 2% FBS in DPBS. 
Samples were sorted using a FACSAria flow cytometer (BD), fitted with a 100µm 
nozzle in the flow cell. Cells were distinguished from debris, and single cell events 
distinguished from clusters of cells using the same as approach as describe in 2.16.1. 
Single cell events from the sample labelled with the SIRPA antibody were classified 
as being SIRPA positive if their fluorescence exceeded that of the 97th centile of cells 
from the same sample labelled with the corresponding isotype control (Table 36). 
Both the SIRPA positive and SIRPA negative fractions were collected for analysis. 
SIRPA positive, SIRPA negative and non-sorted cells were fixed, permeabilised, 
labelled with anti-cTnI-Alexa647, and analysed as described in 2.16.2. 
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 Name Manufacturer Product 
identification 
code 
Host 
species 
Immunogen Clonality Reported 
inter-species 
reactivity 
Isotype Conjugated 
fluorochrome 
Pluripotency markers Anti-OCT4-
488 
BD Pharmingen 611202 Mouse Synthetic peptide, aa 
252-372 of mouse Oct3 
∞ 
Monoclonal 
(40/Oct-3) 
Humans, 
mouse 
IgG1κ Alexa Fluor 488 
(Alexa488) 
Anti-TRA-1-
60-PE 
BD Pharmingen 560071 Mouse Human Embryonal 
Carcinoma Cell Line 
Monoclonal 
(TRA-1-60) 
Human IgMκ Phycoerythrin (PE) 
Anti-SSEA4-
PerCP-Cy5.5 
BD Pharmingen 561565 Mouse Human Teratocarcinoma 
Cell Line 
Monoclonal 
(MC813-70) 
Human, Mouse IgG3κ Peridinin-chlorophyll 
protein - cyanine 5.5 
(PerCP-Cy5.5) 
Anti-NANOG-
647 
Cell Signalling 
Technologies 
5448 Rabbit Synthetic peptide, n-
terminus of human 
NANOG 
Monoclonal 
(D73G4) 
Human IgG Alexa Fluor 647 
(Alexa647) 
Cardiac sarcomeric 
proteins 
Anti-TnI-647 BD Pharmingen 564409 Mouse Human tissue Monoclonal 
(C5) 
Human, mouse IgG2bκ Alexa Fluor 647 
(Alexa647) 
 Anti-TnT-PE BD Pharmingen 564767 Mouse Rabbit cardiac troponin T Monoclonal 
(13-11) 
Human, 
mouse, rabbit, 
pig,  
IgG1κ Phycoerythrin (PE) 
Cardiomyocyte 
surface markers 
Anti-SIRPA BD Pharmingen 563441 Mouse Human SIRPA 
extracellular domain 
recombinant protein 
Monoclonal 
(SE5A5) 
None IgG1κ Phycoerythrin (PE) 
Isotype controls Isotype 
control-488 
BD Phosflow 557782 Mouse None* Monoclonal 
(MOPC-21) 
None IgG1κ Alexa Fluor 488 
(Alexa488) 
Isotype 
control IgM -
PE 
BD Pharmingen 555584 Mouse Trinitrophenol (TNP) -
Keyhole Limpet 
Hemocyanin 
Monoclonal 
(G155-228) 
None IgMκ Phycoerythrin (PE) 
Isotype 
control IgG1-
PE 
BD Pharmingen 554680 Mouse None* Monoclonal 
(MOPC-21) 
None IgG1κ Phycoerythrin (PE) 
Isotype 
control-
mouse 647 
BD Phosflow 558713 Mouse dansyl (5-
[dimethylamino] 
naphthalene-1-sulfonyl) 
Monoclonal  
(27-35) 
None IgG2bκ Alexa Fluor 647 
(Alexa647) 
Isotype 
control-rabbit 
647 
Cell Signalling 
Technologies 
2985 Rabbit Unknown Monoclonal 
(DA1E) 
None IgG Alexa Fluor 647 
(Alexa647) 
Table 36 Antibodies used in flow cytometry experiments. 
*Mouse myeloma immunoglobulin identified as having low human reactivity by screening. 
∞Maximum homology in humans is with OCT4 (90%), Mouse Oct3 sequence compared with human reference proteome using protein 
blast tool.
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2.17 Phase contrast Microscopy 
Live cell imaging was performed using an Zeiss Axiovert200M microscope fitted with 
a Zeiss Axiocam HRc 1.4 Megapixel CCD camera and operated using Axiovision 
4.8.2 imaging software. 14bit, 1300x1030 pixel, monochrome images of iPSC colony 
morphology were acquired with a 10x objective. 
Video recordings of spontaneously contracting cultures were acquired with Zeiss 
1.25x Plan-Neofluar air objective and whilst the microscope stage was heated to 
37oC. 
2.18 Immunofluorescence microscopy  
2.18.1 Pluripotency associated proteins 
iPSC colonies in feeder-free culture were fixed with 4% formaldehyde for 15 minutes 
at room temperature. Samples to be labelled with an anti-OCT4 antibody were 
permeabilised with 0.1% Triton X-100 for 15 minutes. All samples were blocked with 
10% FBS in DPBS for 30 minutes. Samples were incubated overnight, with primary 
antibodies diluted in labelling solution (DPBS with 1% bovine serum albumin) at 4oC. 
The primary antibodies and dilutions used were: mouse anti-OCT4 (1:100) and 
mouse anti-TRA-1-60 (1:100). More details of the primary antibodies are given in 
Table 38. Samples were washed three times in DPBS, three minutes per wash and 
then incubated with a rabbit anti-mouse TRITC secondary antibody (1:200), in the 
dark for one hour at room temperature. More details of the secondary antibody are 
given in Table 39. 
Samples then incubated with DPBS containing DAPI 1µg/ml for 15 minutes before 2 
further washes with DPBS. DBPS was then added to all sample and they imaged 
immediately. 
Images were acquired with a Zeiss Axiovert200M inverted microscope fitted with an 
HBO100 mercury arc lamp, Zeiss filter set numbers 02, 13 and 15 (Table 40), a Zeiss 
Axiocam HRc 1.4 Megapixel CCD camera and operated using Axiovision 4.8.2 
imaging software. 14bit, 1300x1030 pixel, monochrome images of fluorescence 
signal were acquired with a Zeiss Plan-Apochromat 10x air objective. In some cases 
Z-stack images were acquired. Samples labelled with secondary antibodies only, 
were imaged with the same exposure times as the corresponding sample labelled 
with both primary and secondary antibodies. 
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2.18.2 Germ cell layer marker proteins 
Cultures of adherent differentiated cells were prepared for imaging using the 3 germ 
cell layer immunocytochemistry  (Life Technologies) as per the manufacturers 
instructions. Samples were fixed with “fixative solution” containing 4% formaldehyde 
for 15 minutes at 20oC. At this point some samples were stored at 4oC in DPBS for 
up to 2 weeks until further processing. Samples were permeabilised with 
“permeabilisation solution” containing 1% saponin for 15 minutes at 20oC, then 
blocked with “blocking solution” containing 3% bovine serum albumin for 30 minutes, 
at 20oC. Samples were single labelled with primary antibodies diluted in blocking 
solution by incubation overnight at 4oC. The following day samples were washed 
three times in DPBS, three minutes per wash, and then incubated with the 
appropriate secondary antibody diluted in blocking solution for 1 hour at room 
temperature. Samples were then washed 3 times with DPBS, 3 minutes per wash 
with the final wash containing NucBlue fixed cell stain (DAPI). DPBS was then added 
to all samples and they were imaged immediately. Details of the antibodies and the 
concentrations used are given in Table 37. 
Images were acquired using the same equipment and protocol as described in 
2.18.1. 
2.18.3 Cardiac sarcomeric, gap junction and desmosomal protein 
After the aspiration of culture medium dishes were washed with DPBS and 
incubated with 0.25% trypsin/EDTA for 15-30minutes and triturated with a serological 
pipette to aid the dissociation of clumps. A volume of RPMI-20 equal to that of the 
typsin was added to each well to stop the enzymatic activity. The cell suspension 
was filtered through a 100um nylon sieve and the filtrate centrifuged 400g 4mins 
20oC. After aspiration of the supernatant the pellet was re-suspend in RPMI 1640 
supplemented with 20% FBS (Life Technologies) and 10µm Y27632 (Chemicon). 
Concentrations of cells in suspension were estimated by haemocytometer. Cells 
were then plated onto 13mm diameter coverslips within 4 well plates (Nunc) that had 
been previously coated with 0.01% gelatin. Approximately 50 x103 cells were plated 
to each well and incubated for 48 hours in standard conditions. After the aspiration of 
culture medium dishes were washed with DPBS and fixed with 4% formaldehyde for 
30 minutes at room temperature. After a further wash with DPBS they were 
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permeabilised with 0.1% Triton X-100 for 15 minutes at room temperature, blocked 
with 5% donkey serum for 30 minutes at room temperature and then incubated 
overnight with primary antibodies at 4oC. The primary antibodies were: goat anti 
cTnT (1:400), mouse anti-PKP2 (1:100), mouse anti-DSP (1:200), mouse anti-JUP 
(1:100), mouse anti-DSC2 (1:100), mouse anti-DSG2 (1:100), mouse anti- 
sarcomeric alpha actinin (1:400). More details of the primary antibodies are given in 
Table 38. Samples were washed three times with DPBS and then incubated with 
secondary antibodies for one hour, in the dark, at room temperature. The secondary 
antibodies were: donkey anti-mouse alexa 488, donkey anti-goat alexa 488, donkey 
anti-goat alexa 555 and donkey anti-mouse alexa 647 (all used at 1:400). Samples 
then incubated with DPBS containing DAPI 1µg/ml for 15 minutes before 2 further 
washes with DPBS. Coverslips were inverted and mounted on glass slides with 
Vectashield and sealed with nail varnish. 
Images were acquired with a Zeiss Axioimager Z1 fitted with an Apotome 2.0, an 
HBO100 mercury arc lamp, Zeiss filter set numbers 49, 38HE, 20HE and 50 (Table 
41), a Zeiss Axiocam HRm 1.4 Megapixel CCD camera and operated using 
Axiovision 4.8.2 imaging software. 14bit, 1300x1030 pixel, monochrome images of 
fluorescence signal were acquired with a Zeiss Plan-Apochromat 63x oil immersion 
objective. Z-stacks of optical sections were acquired. Images used to compare 
fluorescence of a given labelling combination between samples were acquired with 
the same exposure time. Secondary only labelled sampled were image with the 
same exposure times as their primary labelled counterpart.  
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Target germ-cell layer Primary antibody Secondary antibody 
Neuro-ectoderm Rabbit anti-TUJ1, 1:500 Donkey anti-rabbit AF488, 1:250 
Mesoderm Mouse anti-SMA, IgG2a, 1:100 Goat anti-mouse IgG2a AF555, 1:250 
Endoderm Mouse anti-AFP, IgG1, 1:500 Goat anti-mouse IgG1 AF488, 1:250 
Table 37 Antibodies used in preparation of samples from immunofluorescence microscopy for cell from the three germ cell 
layers. 
All antibodies were included in the kit produced by Life Technologies. 
 
 Name Manufacturer Product 
identification 
code 
Host 
species 
Immunogen Clonality Reported inter-
species 
reactivity 
Isotype Secondary Abs used with 
this primary 
Pluripotency 
markers 
Anti-OCT3/4 BD Transduction 
laboratories 
611202 Mouse Recombinant protein, aa 
252-372 of mouse Oct3 ∞ 
Monoclonal 
(40/Oct-3) 
Humans, mouse IgG1κ TRITC rabbit anti-mouse 
Anti-TRA-1-60 BD Pharmingen 560071 Mouse Human Embryonal 
Carcinoma Cell Line 
Monoclonal 
(TRA-1-60) 
Human IgMκ TRITC rabbit anti-mouse 
Sarcomeric 
proteins 
Anti-αSA ThermoFisher 
(Thermo) 
MA122863 Mouse Purified rabbit skeletal α-
actinin 
Monoclonal 
(EA-53) 
Human, Mouse, 
extensive cross-
reactivity other 
species 
IgG1κ 647-donkey-anti-mouse 
Anti-TnT Abcam ab64623 Goat Human cardiac troponin T Polyclonal  Human IgG 488-donkey-anti-goat 
555-donkey-anti-goat 
Desmosomal 
proteins 
Anti-DSC2/3 ThermoFisher 
(Invitrogen) 
32-6200 Mouse Extracellular domain, 
human DSC2, N-terminus 
* 
Monoclonal 
(7G6) 
Human,  IgG1κ 488-donkey-anti-mouse 
Anti-DSG2 ThermoFisher 
(Invitrogen) 
32-6100 Mouse Human DSG2 Monoclonal 
(6D8) 
Human IgG1κ 488-donkey-anti-mouse 
Anti-PKP2 Abcam ab151402 Mouse Recombinant protein, aa 
1-350 of human PKP2, N-
terminus. 
Monoclonal 
(8H6) 
Human, Mouse IgG1κ 488-donkey-anti-mouse 
Anti-JUP Sigma P8087 Mouse Recombinant chicken JUP 
★ 
Monoclonal 
(15F11) 
Human, dog, cow IgG1κ 488-donkey-anti-mouse 
Anti-DSP Abcam ab16434 Mouse Full length cow 
desmoplakin 
Monoclonal 
(2Q400) 
Human, Mouse, 
Rat, Chicken, 
Cow 
IgG1κ 488-donkey-anti-mouse 
Table 38 Primary antibodies used in immunofluorescence microscopy experiments 
∞Maximum homology in humans is with OCT4 (90%), Mouse Oct3 sequence compared with human reference proteome using protein blast tool. 
* Cross reacts with identical sequences on DSC3 
★ Does not cross react with β-catenin
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Name Manufacturer Product 
identification 
code 
Host 
species 
Immunogen  Clonality Reported 
interspecies 
reactivity 
Isotype Conjugated fluorochrome 
TRITC rabbit anti-
mouse 
Sigma T2402 Rabbit Mouse IgG Polyclonal None IgG Tetramethylrhodamine 
isothiocyanate (TRITC) 
Donkey-anti-goat-
488 
ThermoFisher (Molecular 
probes) 
A-11055 Donkey Mouse IgG Polyclonal None IgG Alexa Fluor 488 (Alexa 488) 
Donkey-anti-goat-
555 
ThermoFisher (Molecular 
probes) 
A-21432 Donkey Mouse IgG Polyclonal None IgG Alexa Fluor 555 (Alexa 555) 
Donkey-anti-mouse-
647 
ThermoFisher (Molecular 
probes) 
A-31571 Donkey Mouse IgG Polyclonal None IgG Alexa Fluor 647 (Alexa 555) 
Donkey-anti-mouse-
488 
ThermoFisher (Molecular 
probes) 
A-21202 Donkey Mouse IgG Polyclonal None IgG Alexa Fluor 488 (Alexa 488) 
Table 39 Secondary antibodies used in immunofluorescence microscopy experiments 
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Zeiss filter 
set number 
Excitation 
filter 
wavelength 
(nm) 
Emission 
filter 
wavelength 
(nm) 
Fluorochrome 
(peak excitation wavelength 
(nm), peak emission 
wavelength (nm)) 
02 300-400 >420 DAPI  (358, 463) 
13 450-490 505-530 Alex488 (493, 520) 
15 540-552 >590 TRITC (555, 580) 
Alexa555 (555, 565) 
 Table 40 Axiovert200M Filters 
 
Zeiss filter 
set number 
Excitation 
filter 
wavelength 
(nm) 
Emission 
filter 
wavelength 
(nm) 
Fluorochrome 
(peak excitation wavelength 
(nm), peak emission 
wavelength (nm)) 
49 300-400 420-470 DAPI  (358, 463) 
38HE 450-490 500-550 Alex488 (493, 520) 
20HE 540-552 568-647 Alexa555 (555, 565) 
50 625-655 665-715 Alexa647 (653, 669) 
 Table 41 Axioimager Filters 
 
2.19 Imaging of calcium and voltage transients 
2.19.1 Preparation of cultures for imaging. 
On day 25-30 of differentiation contracting cultures were re-plated into culture 
dishes that were 35mm in diameter and contained a central 7mm diameter glass 
bottomed depression (MatTek). Before plating the cells the glass bottomed 
depression was coated in Matrigel using the same technique previously described for 
plastic cultureware. Dishes were coated immediately before use. Dishes were 
incubated for at least 30 minutes at room temperature before use. 
iPSC-CM monolayers were re-plated onto glass bottomed dishes (MatTek) as 
follows. MCMM was replaced with RPMI-20-RI and incubated for 2 hours. Dishes 
were washed with DPBS and incubated with 0.25% trypsin/EDTA for 15-30minutes 
and triturated with a serological pipette to aid the dissociation of clumps. A volume of 
RPMI-20 equal to that of the trypsin was added to each well to stop the enzymatic 
activity. The cell suspension was filtered through a 100um nylon sieve and the filtrate 
centrifuged 400g 4mins 20oC. The cell pellet was resuspended in RPMI-20-RI and 
the concentration of the cell suspension estimated with a haemocytometer. The 
volume of RPMI with which the cell pellet was resuspended was decided based on 
the culture area of iPSC-CMs trypsinised. The Matrigel coating solution was 
aspirated from the dishes and the depressed region of the dishes filled with a bleb of 
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cell suspension containing the desired number of cells. Dishes were incubated in 
standard conditions for 8 hours before replacing the solution with MCMM, 2ml of 
solution per well. Re-plated cells were cultured for 5-7 days with medium changes 
every 2-3 days.  
A fraction of the cell solution was not plated and prepared were prepared for flow 
cytometry assessment of cTnT expression as previously described.  
2.19.2 Loading cells with Fluo-4-AM and imaging of transients 
For each differentiation experiment 3 different dishes of re-plated cells were 
prepared for imaging. Every dish contained spontaneously contracting regions 
identified by phase contrast microscopy before loading with Fluo-4-AM.  
Cultures were incubated for 20 minutes in standard culture conditions with MCMM 
containing 4ug/ml Fluo-4-AM and that had been pre-warmed to 37oC. During imaging 
the culture medium was replaced with normal Tyrode’s solution (NTS) consisting of 
an aqueous solution of 140mM NaCl, 6mM KCl, 1mM MgCl2, 5mM HEPES, 2mM 
CaCl2, 10mM D-glucose, adjusted to a pH of 7.4. The labelling medium in each dish 
was changed for 2ml of NTS, that had been pre-warmed to 37oC, and the dishes 
were then incubated in the dark, on the microscope stage, heated to 37oC, in room 
air, for 20 minutes. 
Imaging was performed with a Nikon Ellipse TE2000-U fitted with a Redshirt-CMOS 
camera. Calcium imaging was performed with a 470nm LED and 475nm LP filter. All 
images were acquired using a Nikon x40 Plan Fluor oil emersion objective. Calcium 
transients were imaged at a 250 frames per second (fps) for between 5 and 15s 
seconds. 
If spontaneous transients were present they were recorded in 3 different locations. 
Field pacing using a pulse of 20V and 10ms duration was then delivered and the 
resultant transients recorded. The frequency of pacing was 1Hz except for the 
following circumstances. If the rate of spontaneous transients exceeded 1 Hz, then 
the lowest pacing rate that exceeded the spontaneous rate was used. If pacing at 
1Hz failed to result in a transient for every pacing pulse then the rate was lowered to 
achieve the fastest rate at which this was present. 
Images were acquired using Neuroplex v9.6.0 software. The same software was 
used to manually define an area within the images in which fluorescence was judged 
to vary through time and to calculate the mean fluorescence signal intensity of this 
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area in each frame of the recording. Graphical representations of these data were 
constructed using GraphPad Prism 7.  
2.20 TEM analysis 
2.20.1 Collection of samples from adherent cell cultures  
Culture medium was aspirated from tissue culture plates containing adherent 
cultures and washed with RPMI. Cultures were incubated with TEM dissociation 
solution (Dispase 2.4U/ml in RPMI), for 30-45minutes at 37oC, 5% CO2. Cultures 
either detached spontaneously from the culture surface or were released by gentle 
flushing using a P1000 pipette. Detached cultures were transferred to a 1.5ml 
microcentrifuge tube using a Pasteur pipette that had been modified to have a wide 
tip aperture to reduce shear stress during pipetting. The sample was allowed to settle 
by gravity over 5 minutes and the dissociation solution aspirated with a P1000 pipette. 
TEM fixative buffer (2% glutaraldehyde in 0.1M sodium cacodylate buffer) was added 
to each tube and the samples stored at 4oC until the next stage of processing. 
Samples were stored for a maximum of 1 month in these conditions. 
2.20.2 Collection of right atrial appendage samples 
Immediately after excision from the subject, cardiac tissue was manually dissected 
with a scalpel into fragments no larger that 3mm diameter and placed into TEM 
fixative buffer. Samples stored at 4oC until the next stage of processing. Samples 
were stored for a maximum of 1 month in these conditions. 
2.20.3 Sample processing 
TEM samples were processed in batches of 5-10 samples. Samples were washed 
in cacodylate buffer 3 times, for a minimum of 30 minutes per wash before being 
incubated overnight in cacodylate buffer. The following day the samples were 
washed twice in dH2O, for 15 minutes per wash, then incubated with the secondary 
fixative (1% osmium tetroxide in dH2O) for 1 hour. Samples were then washed twice 
with dH2O, for 15 minutes per wash. 
Dehydration using acetone was performed as follows. Samples were incubated with 
25% acetone for 30 minutes, 50% acetone for 30 minutes, 75% acetone for 30 
minutes and then twice with 100% acetone for 60 minutes each time. 
Impregnation with epoxy resin (Epoxy pre mix, TAAB, T028H) was performed as 
follows. Samples with incubated with 25% resin in acetone for 60 minutes, 50% resin 
in acetone for 60 minutes, 75% resin in acetone for 60 minutes, twice times in 100% 
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resin for 1 hour each time and finally in 100% resin for at least 3hrs. Samples were 
then incubated at 60oC for 24 hours to solidify the resin. 
Semi-thin sections of approximately 0.5µm were cut and stained with 1% toluidine 
blue in 1% borax to identify the location of samples within the resin. Ultrathin sections 
of approximately 70 nm were then cut using a diamond knife on a RMC MT-XL 
ultramicrotome. The sections were stretched with chloroform to eliminate 
compression and mounted on Pioloform-filmed copper grids. 
2.20.4 TEM Image acquisition 
Images were acquired by a single investigator who was blinded to the sample 
identity. Sections were examined using a Philips CM 100 Compustage (FEI) 
Transmission Electron Microscope operating at 100kV/. Digital images were collected 
using an Optronics 1824x1824 pixel CD camera with the AMT image capture 
software - AMT40 version 5.42 (Deben). 
The scaling factor necessary to calculate spatial data from TEM images was 
estimated using a shadow cast carbon diffraction grating replica with 2160 lines per 
millimetre. The grid was imaged at 19,000X magnification, three measurements of a 
ten line distance within the grid were made by a single observer in both of the two 
perpendicular axes within the grid (i.e. a total of six measurements) and the mean 
distance in pixels was equated to 4.6296296µm. The scaling factor was re-calculated 
once a month.  
Grids were first examined at approximately 500X magnification and the locations of 
levels within a grid recorded. Random locations within a level were then searched at 
13,500X magnification for putative desmosomes i.e. electron dense adhesion 
junctions associated with the plasma membranes. When viewing iPSC-CM and RAA 
samples only those locations in which striated myofibrils could be identified were 
searched for adhesion junctions.  
Image magnification is a determinant of image resolution and resolution affects the 
precision of spatial measurements made from the image. An increase in 
magnification will be accompanied by a reduction in dynamic range of pixel values 
within the image unless it is accompanied by and increase in electron beam density. 
Images with a high dynamic range will describe the regions of the desmosome with a 
greater range of pixel values, rendering them more easily distinguishable. There is an 
upper limit to the density of electron beam that may be generated by a microscope 
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and this determines the maximum magnification at which the dynamic range of an 
image can be maintained. 
In order to determine the optimal magnification at which to acquire images for 
morphometric analysis the same desmosome was imaged at a range of 
magnifications with the electron beam density adjusted to maximise the dynamic 
range of the image in each case (Figure 18). Identification of the intra and extra-
cellular surfaces of the plasma membrane was taken as a useful indicator of image 
quality. These structures are sensitive to being obscured by either pixelation or a loss 
of dynamic range. 
At magnifications up to 92,000x the plasma membrane appeared pixelated and 
difficult to localise. A loss of dynamic range was apparent at 340,000x. Image quality 
was optimal at magnifications between 130,000x and 245,000x. The maximum 
density of a microscope’s electron beam may vary due to operational factors e.g. 
microscope filament performance. Variations in the thickness of TEM sections may 
require increased electron beam density to obtain an adequate image at a given 
magnification. In order to minimise the potential of these factors to affect image 
quality it was decided that all images used for quantitative desmosomal analysis 
would be acquired at 130,000x. 
 
Figure 18 A TEM image of a section of desmosome at different magnifications  
The magnifications illustrated are 46,000x (Panel A), 64,000x (Panel B), 92,000x 
(Panel C), 130,000x (Panel D), 180,000x (Panel E), 245,000x (Panel F), 340,000x 
(Panel G). The locations intra and extracellular surfaces of the plasma membrane 
are indicated (arrow-heads). Scale bars represent 10nm. 
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Junctions viewed at 130,000X magnification were then assessed to determine 
whether they met the criteria for classification as a desmosome (Table 42) (Figure 
19) and thereby inclusion in the study.  
 
Term Definition 
Desmosome Two bi-laminated, electron dense plaques, oriented in 
parallel, localised to a plasma membrane and 
separated by a region of extra-cellular space. 
Cardiac desmosome A desmosome localised to the plasma membrane of a 
cell containing striated myofibrils. 
 Table 42 The criteria used to identify a desmosome and cardiac desmosome 
within a TEM image. 
 
 
Figure 19 Criteria used to define a desmosome and cardiac desmosome. 
 
Samples were tilted to a position between -50o and +50o from horizontal to the angle 
at which the investigator estimated the intermembranous gap and clarity of the 
junction plaques to be greatest.  Optimised images were then acquired for analysis. 
2.20.5 TEM image analysis 
TEM images were analysed using digital image analysis software (FIJI).  
Definitions of the desmosomal width parameters measured are described in Table 
43 and illustrated in Figure 20. 
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Desmosomal 
Parameter 
Definition 
Intermembrane width 1 
(IMW1) 
The length of a straight line, that is perpendicular the midline of 
the desmosome, which begins at the pixel judged to be closest 
to the centre of the linear structure representing the extra-
cellular surface of the plasma membrane, and ending at the 
pixel judged to be closest to the centre of the same structure on 
the opposite side of the intermembrane gap. 
Intermembrane width 1 
(IMW2) 
The length of a straight line, that is perpendicular the midline of 
the desmosome, which begins at the pixel judged to be closest 
to the centre of the linear structure representing the cytoplasmic 
surface of the plasma membrane, and ending at the pixel 
judged to be closest to the centre of the same structure on the 
opposite side of the intermembrane gap. 
Inter-ODP width (IOW) The length of a straight line, that is perpendicular the midline of 
the desmosome, which begins at the pixel judged to represent 
the cytoplasmic surface of the ODP, and ends at the pixel 
judged to represent the cytoplasmic surface of the ODP on the 
opposite plaque. 
Desmosomal length 
(DL) 
The length of a curved line that traces the midline of the 
intermembrane gap over the distance that is judged to be 
formed by two parallel ODPs. 
Desmosomal plaque 
length (PL) 
The length of a curved line that traces the mid point of an ODP 
over its length.  
 Table 43 Definitions of desmosomal width and length parameters 
  
  
Figure 20 A region of a desmosome illustrating the definitions of the three 
desmosomal width parameters. 
Examples of locations at which the three width parameters: intermembrane width 1 
(IMW1), intermembrane width 2 (IMW2) and inter-ODP width (IOW) may be 
measured are indicated. The midline is indicated by a dashed line and each 
desmosome width parameter measurement is perpendicular to this line at the point 
of their intersection. 
 
 
 
  104 
Images were assessed as having adequate quality for assessment if any region of a 
desmosome had two parallel regions of ODP and plasma membrane that were 
sufficiently distinct to measure at least one of the desmosomal width parameters. 
Images not meeting this criterion were excluded. Each parameter was measured at 
three different locations on each image. 
Definitions of desmosomal length parameters are given in Table 43 and illustrates in 
Figure 21. 
  
Figure 21 An example of the measurement of desmosomal length parameters.  
Segments in which there are symmetrical desmosomal plaques i.e. parallel plaques 
on both sides of the intermembrane gap, are indicated (S1 and S2). Segments in 
which the desmosome is asymmetrical i.e. a plaque on only one side of the 
intermembrane gap are also indicated (A1, A2 and A3). All length measurements 
are made along the midline of the intermembrane gap. The scale bar represents 
100nm. 
 
2.21 Statistical analysis 
Data from continuous variables are summarised as either mean (standard deviation) 
unless otherwise stated. For data sets with ≥8 values the similarity of distribution of 
sample data to a Gaussian distribution was assessed with the D’Agostino and 
Pearson omnibus K2 normality test. Comparisons of pairs of datasets were made 
using either a two tailed unpaired T-test or a two tailed Mann-Whitney U test as 
appropriate. Comparisons of groups of more than two datasets were made using 
either a one way ANOVA followed by a post hoc Tukey’s multiple comparisons test, 
or a Kruskal-Wallis test followed by a post hoc Dunn’s multiple comparisons test. P 
values <0.05 were considered statistically significant. Statistical analysis was 
performed using GraphPad Prism 7c Software Inc. (San Diego, CA, USA). 
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3 Chapter 3. Clinical Characteristics Of Study Participants 
3.1 Introduction 
This chapter will discuss the recruitment of subjects from which blood and 
myocardial samples were obtained. 
3.2 Aims 
The aim of this part of the project were: 
• To recruit three subjects with a clinical diagnosis of ARVC/D from which 
iPSCs would be generated to the study. 
• To confirm that these subjects met the 2010 task force criteria for having a 
definite diagnosis of ARVC/D through the collation of data from their clinical 
records. 
• To recruit control subjects without inherited cardiac disease or a family 
history of inherited cardiac disease to the study from which control iPSC 
lines would be generated. 
• To collect samples of myocardium from adult subjects without inherited 
cardiac disease or a family history of inherited cardiac disease to act as a 
positive control for assessments of cardiac gene expression and 
ultrastructure.  
3.3 Results 
Three subjects (0101, 0202 and 0203) with a clinical diagnosis of ARVC/D were 
recruited to the study. In all three cases data from their clinical records was such that 
they were categorised as having a definite diagnosis of ARVC/D according to the 
2010 task force criteria (Marcus et al., 2010). The major and minor criteria identified 
in these clinical data that resulted in the classification of ARVC/D as definite is 
summarised in Table 44. 
 A detailed description of these clinical data are given in subsequent sections. 
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 Subject 
0101 0202 0203 
Major Minor Major Minor Major Minor 
Category 
I Global or regional 
dysfunction and 
structural alterations 
(Echocardiography, 
CMRI) 
    ✔  
II Tissue characterization ✔      
III Repolarisation 
abnormalities 
(12-lead ECG) 
✔  ✔  ✔  
IV Depolarization / 
conduction abnormalities 
(12-lead ECG, SAECG) 
 ✔ ✔ ✔  ✔ 
V Arrhythmias 
(12-lead ECG) 
✔  ✔   ✔ 
VI Family history / Genetic 
testing 
✔ ✔ ✔  ✔  
Diagnosis of ARVC/D Definite Definite Definite 
Table 44 Diagnosis of ARVC/D in subjects recruited to the study as defined in 
the current task force criteria.  
The table indicates (✔) if a subject’s clinical features met one or more of the major 
or minor criteria for diagnosis for a given category.  
 
3.3.1 Subject 0101 
Subject 0101 was a male of 57 years of age at the point of recruitment. He 
presented with chest pains, palpitations and dyspnoea as an emergency to a hospital 
at age 46. He was found to have a broad complex tachycardia on admission that was 
considered to be ventricular tachycardia (VT) (Figure 22). He underwent coronary 
angiography which found no obstructive coronary disease. An echocardiogram 
showed a dilated right ventricle with severely impaired systolic function. He 
subsequently underwent the implantation of an implantable cardioverter defibrillator. 
During follow-up his 12-lead ECG developed features typical of ARVC/D (Figure 26). 
At age 56 he developed symptomatic right heart failure. Shortly after recruitment to 
this study (and after providing a blood sample for reprogramming) he underwent 
cardiac transplantation. Gross pathological and histological examination of the 
explanted heart was consistent with the diagnosis of ARVC/D (Figure 25). 
 Subject 0101 underwent sequencing of PKP2, DSG2, DSC2 and DSP as part of his 
clinical management to facilitate screening of his family for ARVC/D. Sequencing 
identified the mutation PKP2 c.2146-1G>C (Figure 24). The mutation disrupts the G 
of the invariant AG nucleotides of the splice acceptor site of intron 10. Splice site 
mutations may produce exon skipping, cryptic splicing or intron retention. Possible 
cryptic splice acceptor site have been reported in intron 12 or exon 13 (Svensson et 
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al., 2016). Exons 11 to 12 encode arm-repeats 6 to 7 and most of arm repeat 8. Exon 
11 also encodes part of the linker sequence preceding arm-repeat 6 which introduces 
a bend into PKP2. Aberrance splicing commonly results in the introduction of a 
premature stop codon leading to nonsense mediated decay of the mRNA and a 
reduction in gene expression. However if a viable transcript were generated then this 
variant may produce a truncated PKP2 molecule lacking multiple arm repeats. As 
discussed in the function of these arm repeats in PKP2 is uncertain since most 
interactions with DSP and desmosomal cadherins appears to be at the N-terminus 
domain. This mutation has been associated with ARVC/D in previously published 
cases however it has not been studies with animal or cellular models (Gerull et al., 
2004) (Syrris, 2006) (Dalal, 2006) (Watkins et al., 2009) (Asimaki et al., 2009) 
(Philips et al., 2014) (Svensson et al., 2016). Asimaki et al. reported a reduction in 
the immunofluorescence microscopy signal of both PKP2 and JUP at the intercalated 
discs of myocardial tissue for a subject with this variant (Asimaki et al., 2009). 
However there have been no studies verifying whether the variant results in a mutant 
protein and therefore whether this reduction in myocardial immunofluorescence 
signal represents an absolute reduction in PKP2 or intracellular redistribution.    
Several members of his family carry the same mutation but one of these relatives 
(his nephew) had the clinical features of ARVC/D. Other carriers were asymptomatic 
and had normal cardiac investigations including his father who was 94 years old at 
the time of the study. There was no history of ARVC/D or inherited cardiac disease in 
the maternal side of 0101’s pedigree, i.e no family history suggesting inheritance of a 
predisposition to ARVC/D from both parents. 
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 Figure 22 12-lead ECG recording of ventricular tachycardia recorded at age 
46 in subject 0101. 
The ventricular rate is approximately 160bpm, the QRS duration is >120ms, the 
QRS complexes have a left bundle branch block (LBBB) morphology (QS in V1 and 
an absence of q waves in I) and a superior axis (overall negative QRS in aVF). This 
arrhythmia would constitute a major criterion for ARVC/D within the current 
diagnostic guidelines. 
 
  
Figure 23 Pedigree chart for subject 0101. 
The chart was constructed using standardised nomenclature and symbols (Bennett 
et al., 2008). Only branches of the family with either clinically affected individuals or 
mutation carriers are shown. 
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Figure 24 Illustration of PKP2 c.2146-1G>C.  
The location of the mutation within the gene is illustrated (A). The mutation disrupts 
the G of the invariant AG nucleotides of the splice acceptor site of intron 10 (B). The 
mutation is predicted to result in aberrant splicing of exon 11 (Alamut v1.5). 
 
  
Figure 25 Histology of myocardium from explanted heart of 0101-C41 
Light microscopy images of myocardial tissue from the explanted heart of subject 
0101-C41. All panels show tissue prepared with a Martius, scarlet and blue (MSB) 
stain in which connective tissue is labelled blue and fibrin red stains red. Panels A 
and C shows samples from the anterior right ventricle in which part of the 
ventricular wall is seen to consist of only connective tissue and epicardial fat with no 
myocardium. In panel A the ventricular wall is thinned (*), in panel C the connective 
tissue makes up a layer of similar depth to the remaining myocardium (arrowhead). 
Panel B shows a sample from the anterior septum showing the presence of 
connective tissue within the myocardium. The epicardial surface of samples is 
indicated (ep).
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Figure 26 12-lead ECG recording from subject 0101 showing sinus bradycardia at a rate of 56bpm.  
The QRS duration is 104ms. The duration of the terminal phase of the S-wave in leads V2 and V3 (labelled C2 and C3 in the image) 
measures approximately 80ms (*) and there are inverted T-waves in leads V1 to V5 (hollow arrowheads). These findings constitute a 
minor criterion from the depolarisation abnormalities category (VI) and a major criterion from the repolarisation category (III) within the 
current diagnostic guidelines. Horizontal scale 40ms/mm. Vertical Scale 1mV/mm. 
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3.3.2 Subject 0202 
Subject 0202 was a male of 44 years of age at the point of recruitment. He 
presented with palpitations to a hospital at age 40. He was found to be in a broad 
complex tachycardia that was considered to be VT (Figure 27). He underwent 
coronary angiography which found no obstructive coronary artery disease. A cardiac 
MRI identified mild right ventricular dilation and systolic impairment but no regional 
wall motion abnormalities. An electrophysiology study induced VT of an identical 
morphology to the clinical VT and an implantable cardioverter-defibrillator was 
implanted. During follow up his 12-lead ECG developed features typical of ARVC/D 
including T-wave inversion in the pre-cordial leads (Figure 30). The T-wave inversion 
was not permanent and appeared to resolve in subsequent recordings (Figure 31). A 
signal averaged ECG provided additional evidence of depolarisation / conduction 
abnormalities (Figure 32). 
Subject 0202 underwent sequencing of PKP2, DSG2, DSC2 and DSP as part of his 
clinical management to facilitate screening of his family for ARVC/D. Sequencing 
identified the mutation DSG2 c.691-5T>A (Figure 28). In silico analysis predicted this 
to disrupt the polypyrimidine tract upstream of the splice acceptor site of intron 6 and 
thereby lead to skipping of exon 7 and the creation of an alternative acceptor splice 
site (Alamut v2.2). As part of the patient’s clinical assessment, RNA was extracted 
from a peripheral blood sample and the region between exons 6 to 8 was sequenced. 
This identified transcripts lacking exon 7 and an in-frame CAG insertion between 
exons 6 and 8 that was predicted to result in the insertion of a glutamine residue. On 
this basis the mutation was classified as pathogenic. Exon 7 encodes part of the 
second extra-cellular binding domain (ECB2). As described in 1.2.2 the ECBs 
mediate the trans and cis dimerisation of desmosomal cadherins. Therefore mutant 
proteins resulting from this variant (if integrated into the desmosomal plaques) would 
be predicted to disrupt the organisation of proteins within the desmosomal gap. This 
variant has not been reported previously in association with ARVC/D therefore there 
have been no studies of the myocardium of patients with this variant. Similarly there 
are no animal or cellular models of this variant. 
Several other members of his family were found to be carriers of the variant, but 
none of them had clinical features of ARVC/D Figure 29. 
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 Figure 27 12-lead ECG of ventricular tachycardia recorded from subject 0202. 
The ventricular rate is 210bpm. The QRS duration is >120ms, the QRS complexes 
have a LBBB morphology (rS or QS in V1 and an absence of q waves in I, V5 and 
V6), and a superior axis (indicated by the overall negative QRS in aVF). This 
arrhythmia would constitute a major criterion for ARVC/D within the current 
diagnostic guidelines. Horizontal scale 40ms/mm. Vertical Scale 1mV/mm. 
 
 
 Figure 28 Illustration of DSG2 c.691-5T>A. 
The location of the mutation within the gene is illustrated (A). The mutation disrupts 
the polypyrimidine tract upstream of the splice acceptor site of intron 6 (B). The 
mutation is predicted to result in aberrant splicing of exon 7 (Alamut v2.2). 
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Figure 29 Pedigree chart for subject 0202.  
The chart was constructed using standardised nomenclature and symbols (Bennett 
et al., 2008). Only branches of the family with either clinically affected individuals or 
mutation carriers are shown.
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Figure 30 12-lead ECG recording from subject 0202 showing sinus bradycardia at a rate of 55bpm.  
The QRS duration is 106ms. An Epsilon wave is present in leads V1 - V3 (solid arrowheads), the terminal phase of the S-wave in lead 
V2 is approximately 60ms in duration (asterisk) and there are inverted T-waves in leads V1 to V3 (hollow arrowheads). These findings 
constitute a major and a minor criterion from the depolarisation abnormalities category (VI) and a major criterion from the repolarisation 
category (III) within the current diagnostic guidelines. Horizontal scale 40ms/mm. Vertical Scale 1mV/mm. 
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Figure 31 12-lead ECG recording from subject 0202 showing sinus bradycardia at a rate of 59bpm.  
The QRS duration is 110ms. An Epsilon wave is still present in leads V1 - V3 (solid arrowheads), the terminal phase of the S-wave in 
lead V2 is remains approximately 60ms in duration (asterisk). The T-waves in leads V2 to V3 (hollow arrowheads) are now flattened 
rather than inverted and therefore do not constitute a criterion for the diagnosis of ARVC/D within the current diagnostic guidelines. 
Horizontal scale 40ms/mm. Vertical Scale 1mV/mm. 
 
 
  116 
  
Figure 32 Signal averaged ECG (SAECG) recording from 0202. 
The unfiltered QRS duration is 93ms excluding the presence of complete RBBB. 
The recording is of acceptable quality, averaging over 250 beats and with a noise 
level (b) of 0.29µV. The filtered QRS duration (c) is >114ms (153ms) and the 
duration of the terminal part of the QRS that is <40µV (d) is >38ms (79ms). The root 
mean square of the voltage in the terminal 40ms of the QRS complex (e) is <40µV 
(6µV). Each of these features constitutes a minor criterion in the depolarisation 
abnormalities category within the current diagnostic guidelines.  
 
3.3.3 Subject 0203 
Subject 0203 was a female of 70 years of age at the point of recruitment. She 
presented to hospital at age 67 with acute breathlessness and found be in a broad 
complex tachycardia that was considered to be VT (Figure 33). A cardiac MRI scan 
identified a severely dilated RV with focal thinning and dyskinesia consistent with 
ARVC/D. She underwent ICD implantation during this admission. During subsequent 
follow up her 12-lead ECG (Figure 36) showed features typical of ARVC/D. Structural 
and functional abnormalities of the right ventricle continued to be noted by 
echocardiography including a dyskinetic RV free wall and an RVOT diameter of 
44mm (or 23.4mm/m2 when indexed to body surface area). 
Subject 0203 underwent sequencing of PKP2, DSG2, DSC2 and DSP as part of her 
clinical management to facilitate screening of her family for ARVC/D. Sequencing 
identified the mutation DSP c.3195C>G which results in a premature stop codon at 
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amino acid position 1065 (p.Tyr1065X) (Figure 34). The variant lies within exon 23 
which encodes the central rod domain and is included in both isoforms of DSP (DSP 
I and DSP II). If translated it is predicted to result in a truncated protein lacking the C-
terminal plakin repeat domain that is responsible for binding to intermediate filaments. 
This mutation has not been previously reported in association with ARVC/D, but 
similar heterozygous nonsense mutations in this region have been (“ARVC database,” 
n.d.). There are no cellular or animal models of ARVC/D resulting from DSP 
truncated in the central rod domain. It could be speculated that since the resulting 
mutant protein would contain the N-terminal spectrin repeat domains, it would be 
capable of interacting with arm repeat proteins within the desmosomal plaque. In this 
circumstance it might be expected that changes in the morphology of the inner dense 
plaque region (where DSP interacts with intermediate filaments) are more likely than 
changes to the outer dense plaque morphology and desmosomal gap with and the 
redistribution of arm repeat proteins.  
Several other members of her family were found to be carriers of the variant. One of 
the subject’s sons was a carrier and suffered from VT, but no formal diagnosis of 
ARVC/D was made before he died from an unrelated condition. Other mutation 
carriers did not have clinical features of ARVC/D. 
 
 
Figure 33 12-lead ECG of a ventricular tachycardia recorded in subject 0203.  
The ventricular rate is 216bpm, the QRS duration is >120ms, the QRS complexes 
have a LBBB morphology (QS in V1 and an absence of q waves in I and V6) and an 
inferior axis (overall positive QRS morphology in aVF). This arrhythmia would 
constitute a minor criterion for ARVC/D within the current diagnostic guidelines. 
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Figure 34 Illustration of DSP c.3195C>G.  
The location of the mutation within the gene is illustrated (A). Exon 23 undergoes 
alternative splicing producing a transcript encoding the DSP I isoform, which 
contains the entire coding sequence (a) and a transcript encoding the DSP II 
isoform which contains the only first part of the exon (b). The mutation lies within 
the section of exon 23 that is included in both transcripts and results in a premature 
stop codon that, if translated, would result in a truncated protein lacking the 
carboxy-terminus that is responsible for binding to intermediate filaments. 
 
 
Figure 35 Pedigree chart for subject 0203.  
The chart was constructed using standardised nomenclature and symbols (Bennett 
et al., 2008). Only branches of the family with either clinically affected individuals or 
mutation carriers are shown.
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Figure 36 12-lead ECG from subject 0203 showing sinus rhythm. 
 The QRS duration is 96ms, excluding complete RBBB. The terminal phase of the S-wave in lead V1 and V2 is approximately 60ms in 
duration and the T-waves are inverted in leads V1 to V5 (hollow arrowhead). These findings constitute a minor criterion from the 
depolarisation abnormalities category (VI) and a major criterion from the repolarisation category (III) within the current diagnostic 
guidelines. Horizontal scale 40ms/mm. Vertical Scale 1mV/mm.
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3.3.4 Control subjects from which blood samples were collected 
A total of four control subjects were recruited to provide peripheral blood samples. 
All subjects had no history or family history of hereditary cardiac disease or sudden 
cardiac death. The sequencing of desmosomal genes was not performed in control 
subjects. Their baseline demographics are summarised in Table 45.  
The initial experimental design was to generate the same number of control iPSC 
lines as ARVC/D lines. However, due to resource constraints this was modified to the 
generate clones from a single control subject. At the point in time that this decision 
was made iPSC clones had been successfully generated from subject 2 but not from 
the other control subjects. It was decided to use iPSCs from subject 2 as controls for 
the ARVC/D lines to avoid using the additional resources necessary to generate 
control lines from the male controls. Samples from the three male control subjects 
were used in the comparison of gene expression in peripheral blood mononuclear 
cells (PBMCs) with other tissue types. 
Subject Sex Age at sample point 
of collection (years) 
2 Female 34 
6 Male 36 
7 Male 33 
8 Male 32 
 Table 45 Characteristics of control subjects from which blood samples were 
obtained. 
 
3.3.5 Control subjects from which right atrial appendage myocardium was 
collected 
Samples of right atrial appendage (RAA) myocardium were used in some analyses 
of cardiac and desmosomal gene expression and in transmission electron 
microscopy (TEM) experiments. These samples were collected as part of a different 
study and were kindly donated by Dr Andrew Owens. 
All subjects from which RAA tissue was collected were undergoing elective cardiac 
surgery involving cardiopulmonary bypass for valvular or ischaemic heart disease. 
Part of the right atrial appendage is routinely resected during this procedure. Tissue 
that would otherwise be discarded was collected for analysis. Subjects had no history 
or family history of ARVC/D or inherited cardiac disease. All subjects had normal 
right ventricular size and function documented as by cardiac imaging 
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(echocardiography or cardiac MRI) as part of their clinical care. Their baseline 
characteristics are summarised in Table 46. 
Subject Sex Age at sample point 
of collection (years) 
Indication for surgery 
RAA1 Male 72 Aortic valve disease 
RAA2 Female 85 Aortic valve disease 
RAA3 Female 67 Aortic valve disease and coronary artery 
disease 
RAA4 Female 66 Aortic valve disease 
 Table 46 Baseline characteristics of subjects from which right atrial 
appendage myocardium was collected. 
 
3.4 Discussion and conclusion 
Three subjects with a definite ARVC/D phenotype and desmosomal mutations 
classified as pathogenic were successfully recruited to give blood for the generation 
of iPSCs. None of the mutations carried by these subjects have been studied in 
cellular or animal models previously. Furthermore two of the ARVC/D mutations in 
this study are in genes for which (as the time of writing) iPSC-CM models have yet to 
be reported. The present study therefore has the potential to expand our 
understanding of the potential of iPSC-CMs to model ARVC/D.  
It is accepted that the use of iPSCs from a single female subject as a control for 
comparison to multiple ARVC/D iPSC lines, two of which are from male subjects is a 
limitation to the study design. Specifically it weakens the argument that any 
conclusions from a comparison of individual cell lines in this study indicate a more 
general pattern of difference between control and ARVC/D iPSCs. Further work will 
be needed with a larger number of control iPSC lines to establish the generalizability 
of this study’s conclusions. 
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4 Chapter 4. The Derivation And Characterisation Of Patient Specific 
IPSCs From The Peripheral Blood Of Subjects With And Without 
ARVC/D 
4.1 Introduction 
This chapter will describe the generation of induced pluripotent stem cells (iPSCs) 
from nucleated peripheral blood cells. The principles of generating iPSCs from 
peripheral blood cells are outlined in Chapter 1. The reprogramming protocols used 
in this study are described in Chapter 2.  
The first part of this chapter will describe the results of two different reprogramming 
protocols and the rationale for choosing one over the other in subsequent work.  
The second part of the chapter will describe the assessment of pluripotency in the 
clonal lines produced from both the initial and subsequent reprogramming 
experiments. 
The cell lines assessed in this chapter will be referred to as expandable clones. At 
the end of the chapter and thereafter cell lines which were classified as pluripotent 
will be referred to as iPSCs.  
4.2 Aims and hypotheses 
It was hypothesised that the transduction of PBMCs with reprogramming vectors 
followed by their maintenance in appropriate culture conditions would induce 
persistent changes in cellular behaviour, gene expression and protein expression 
consistent with pluripotency. These changes were expected to consist of the 
following characteristics.  
• Cells would change from being non-adherent and non-clustered, i.e. cultured 
as a suspension, to forming adherent expanding colonies.  
• Pluripotency marker gene and protein expression would be up-regulated with 
respect to PBMCs.  
• The expression of pluripotency marker genes and proteins would be at a 
level comparable to that of established pluripotent cell lines.  
• When allowed to differentiate there would be evidence from patterns of 
protein expression and tissue histology that the cells are capable of forming 
tissues from each of the three germ cell layers. 
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It was hypothesised that the change in characteristics from PBMCs to pluripotent 
cells would not be attributable to changes in genomic DNA acquired during 
reprogramming. 
 
4.3 Results 
4.3.1 The selection of PBMC reprogramming protocols for testing 
At the time this work was begun the reprogramming PBMCs to iPSCs had not (to 
the best of our knowledge) been attempted previously at Newcastle University. In the 
initial phase of this study it was decided to adapt two protocols from published work 
and test their efficacy in generating iPSCs from a control subject.  
When choosing the protocols to adapt we excluded those using vectors that 
integrated transgenes into the iPSC genome (e.g. lentivirus) in order to avoid the 
possibility of mutation and transgene re-activation that might undermine evidence of 
pluripotency in resultant cell lines. Within Newcastle University there was already 
experience of using a commercial, non-integrating, Sendai based reprogramming 
system (Cytotune 2.0, Thermo-Fisher) in reprogramming fibroblasts to iPSCs. 
Protocols using Sendai vectors were therefore considered in preference to other 
techniques. 
PBMC samples consist of a mixture of cell types (Table 1) and reprogramming 
protocols differ depending on the cell type at which they are directed. Protocol have 
been published describing iPSC generation from peripheral blood haematopoietic 
progenitor cells, erythroblasts and T-cells (see appendix Tables 60 to 62). At the time 
of writing the feasibility of reprogramming certain human PBMC types (e.g. 
monocytes) has yet to be established. The culture conditions used prior to 
transduction differ depending on the type of cell that is the target of reprogramming 
e.g. protocols to reprogram T-cells typically employed the cytokine IL2 and anti-CD3 
antibodies whereas protocols to reprogram CD34+ progenitor cells typically used a 
combination of SCF, FLT3L, IL6, IL3 and TPO  (see appendix Tables 49 to 51 for 
references and comparison of media compositions in different published protocols). 
Some of these protocols used mechanical selection of the target cell type before pre-
transduction culture e.g. FACS. Others relied on the pre-transduction culture 
conditions to favour the proliferation one type of PBMC over others.  
The two protocols chosen were each designed to target different PBMC types: T-
cells and non-T-cells. The non-T-cell protocol was adapted from two recommended 
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by the manufacturer of the reprogramming vector for the generation of iPSCs from a 
mixed PBMC sample (Life Technologies, 2012) (Life Technologies, 2013). The cell 
type at which this protocol is targeted was not specified by the manufacturer, but the 
composition of this medium is similar to those used for the reprogramming of CD34+ 
cells. The T-cell protocol tested was adapted from two publications describing the 
generation of T-cell derived iPSCs from a starting population of mixed PBMCs (Seki 
et al., 2011) (Brown et al., 2010). These adapted protocols were referred to as the 
non-T-cell and T-cell protocols respectively. 
4.3.2 Non-T-cell derived iPSC protocol testing 
PBMCs samples from three control subjects were cultured and transduced using the 
non-T-cell protocol. Co-culture of transduced PBMCs from the same subject with 
inactivated MEF feeders resulted in adherent colonies with ESC-like characteristics 
by phase contrast microscopy in all experiments (Figure 37). For each 
reprogramming experiment a sample of un-transduced cells were cultured in parallel 
to the transduced cells from the same subject. No colonies resulted from the culture 
of un-transduced PBMCs. Despite the formation of adherent colonies, expandable 
clones could only be established in one experiment and therefore one subject 
(subject 2) (Table 47). 
Subject Cell type Pre-transduction culture Number of 
cells 
transduced 
(x103) 
Number of 
colonies with 
and ES-like 
morphology 
from initial 
plating of 
transduced 
PBMCs 
Results of 
expansion 
culture 
Duration 
(days) 
PBMC population size 
after pre-transduction 
culture 
(percentage of starting 
population) 
1 Unselected 
/ mixed 
PBMCs 
5 50% 100 5 No 
expandable 
clones 
2 5 110% 100 11 3 expandable 
clones 
4 4 100% 200 1 No 
expandable 
clones 
Table 47 Results of initial reprogramming experiments aimed at generating 
non-T-cell derived iPSCs. 
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Figure 37 Example of a colony observed by phase contrast microscopy with 
“stem-cell-like” features arising from primary culture of transduced PBMC on 
an inactivated MEF feeder layer. 
Panel A shows the colony (c) as compact, circular and flat, surrounded by more 
sparsely distribute fusiform cells (f). Panel B shows the boxed area from panel A in 
detail. The cells within the colony are ≤10µM in diameter with a high nuclear to 
cytoplasmic ratio. Scale bars indicate 500µM and 50µM respectively. 
4.3.3 T-cell derived iPSC protocol testing 
PBMCs samples from three control subjects were cultured and transduced using the 
T-cell protocol. Transduced PBMCs from the first subject using the T-cell protocol 
failed to generate any adherent colonies. In order to maximise the number of T-cells 
exposed to reprogramming vectors the two subsequent experiments used a 
population of CD3+ cells purified from the initial blood sample by FACS. Adherent 
colonies with an ESC-like morphology developed in the initial MEF co-culture of 
transduced cells. No colonies developed in parallel cultures of un-transduced cells. 
Expandable clones could only be established in the experiment using cells from 
subject 2 (Table 48). No expandable clones could be established from subject 3. 
Subject Cell type Pre-transduction culture Number of 
cells 
transduced 
(x103) 
Number of 
colonies with 
and ES-like 
morphology 
from initial 
plating of 
transduced 
PBMCs 
Results of 
expansion 
culture 
Duration 
(days) 
PBMC population size 
after pre-transduction 
culture 
(percentage of starting 
population) 
1 Unselected 
/ mixed 
PBMCs 
4 160% 50 0 NA 
2 FACS 
sorted 
CD3+ cells 
11 910% 50 8 3 expandable 
clones 
3 8 330% 326 >100 No 
expandable 
clones 
Table 48 Results of initial reprogramming experiments aimed at generating T-
cell derived iPSCs. 
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4.3.4 Choice of protocol for iPSC lines derived from ARVC/D subjects 
The experimental assessments of the pluripotency of the clonal lines generated is 
described later in this chapter and confirmed that both protocols had generated 
iPSCs from subject 2. Further work demonstrated and that these iPSCs could 
differentiate to cardiomyocytes and generate desmosomes (see chapters 3, 4 and 5). 
It was therefore concluded that either the non-T-cell protocol or the T-cell protocol 
(when applied to FACS sorted CD3+ cells) could be considered for the generation of 
iPSCs from subjects with ARVC/D. The non-T-cell protocol was chosen for further 
work due to the additional cost and labour associated with FACS sorting CD3+ cells 
for the T-cell protocol. 
PBMCs from three subjects with ARVC/D (0101, 0202 and 0203) were transduced 
as part of the non-T-cell protocol. In all experiments adherent colonies with an ESC-
like morphology developed in cultures of transduced cells and no such colonies were 
observed in cultures of un-transduced cells. Multiple expandable clones were 
obtained from all experiments. 
4.3.5 Overview of iPSC characterisation 
An overview of the characterisation of all the iPSC clones generated is given in 
Table 49. Characterisation assessments can fall into two broad groups: (1) 
assessments of cellular identity and (2) assessments of pluripotency.   
The assessments of cellular identity had the following aims: 
• To determine whether the clones generated originated from the subject 
sampled and that the clones derived from ARVC/D subjects carried the 
ARVC/D associated pathogenic mutations reported during clinical testing.   
• To determine whether the clones originated from T-cells or non-T-cells. 
Assessments of pluripotency were of three types:  
• Those to identify characteristics which preclude pluripotency, such as the 
persistence of transgene expression and the presence of acquired 
pathogenic cytogenetic abnormalities. 
• Those that identify markers of pluripotency in un-differentiated cells, this 
includes cellular morphology and the expression of pluripotency associated 
genes and proteins. 
• Those that identify the tissues generated when a cell line is allowed to 
differentiate.  
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Not all clones underwent all forms of characterisation assessment. The rationale for 
selection of some clones over others for full characterisation is given in subsequent 
sections. 
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Table 49 Summary of iPSC characterisation 
✔  Indicates that an assessment of this clone was performed with this modality
Subject / 
Line 
Clone Sendai and 
transgene 
expression 
SNP microarray Mutation 
sequencing 
TRB and TRG 
rearrangement 
Colony 
morphology 
(phase contrast 
microscopy) 
Pluripotency 
associated 
gene 
expression 
(RT-qPCR) 
Pluripotency associated 
protein expression 
Spontaneous 
differentiation 
to 3 germ cell 
layers 
Teratoma 
assay 
CNV Genetic 
identity 
Flow 
cytometry 
 
Immuno-
fluorescence 
microscopy 
  
2 C2 ✔     ✔      
C3 ✔ ✔ ✔  ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
C7 ✔ ✔ ✔  ✔ ✔ ✔ ✔ ✔ ✔  
C1 ✔     ✔      
C4 ✔ ✔ ✔  ✔ ✔ ✔ ✔ ✔ ✔  
C6 ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
0101 C4 ✔     ✔  ✔ ✔ ✔  
C12 ✔     ✔  ✔ ✔ ✔  
C41 ✔ ✔ ✔ ✔  ✔ ✔ ✔ ✔ ✔  
0202 C7 ✔     ✔  ✔ ✔ ✔  
C10 ✔     ✔  ✔ ✔ ✔  
C13 ✔ ✔ ✔ ✔  ✔ ✔ ✔ ✔ ✔  
0203 C8 ✔     ✔  ✔ ✔ ✔  
C12 ✔     ✔  ✔ ✔ ✔  
C13 ✔ ✔ ✔ ✔  ✔ ✔ ✔ ✔ ✔  
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4.3.6 Genetic identity of clonal cell lines with respect to parent PBMCs 
Data from genomic DNA analysed by single nucleotide polymorphism (SNP) 
microarray was used to assess the genetic identity of clonal cell lines with respect to 
PBMCs. This was performed by the comparison of fluorescence values encoding 
SNP genotypes from clonal cell lines with those from PBMCs (Figure 38) (see 
methods for full description). All analyses indicated that clonal lines were derived 
from the PBMCs that were transduced (Table 50).   
 
Figure 38 Examples of comparison of SNP array fluorescence data.   
Panel A shows comparison of two samples with a similar genetic identity indicated 
by a clustering of points on the x=y axis and quantified by the correlation co-efficient 
(r) which approaches 1. Panel B shows comparison between two samples with 
dissimilar genetic identities and a correlation co-efficient approaching 0.5. 
Abbreviations: arbitrary units (au). 
 
Comparison Correlation co-efficient 
2-PBMC vs 2-C1(NT) 0.996 
2-PBMC vs 2-C4(NT) 0.997 
2-PBMC vs 2-C6(NT) 0.996 
2-PBMC vs 2-C3(T) 0.997 
2-PBMC vs 2-C3(T) 0.996 
2-PBMC vs 2-C7(T) 0.995 
0101-PBMC vs 0101-C41 0.993 
0202-PBMC vs 0202-C13 0.993 
0203-PBMC vs 0203-C8 0.992 
Negative control  
(2-PBMC vs 0202-PBMC) 
0.636 
Table 50 Correlation co-efficient values for generated by comparison of “red” 
fluorescence intensity values in iPSC lines with those of the PBMCs used in 
the reprogramming experiments from which they were generated. 
4.3.7 Mutation sequencing 
ARVC/D associated mutations had been identified in the ARVC/D subjects by 
clinical screening prior to enrolment. The presence of these mutations in the 
corresponding clonal lines was confirmed by Sanger sequencing. The sequencing of 
2-C6 confirmed that subject 2 did not carry any of these mutations and was therefore 
appropriate to use as a control for these lines (Figure 39). 
 
 
  130 
 
 
Figure 39 Chromatographs from Sanger sequencing experiments.  
Panels A-C demonstrate that in each ARVC/D iPSC clone carried the same 
ARVC/D associated mutation as the subject from which it was derived and that 
these mutations were absent in a control iPSC line (2-C6). 
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4.3.8 T-cell receptor gene re-arrangement 
T-cell receptors may consist of either α and β chains or γ and δ chains. Each T-cell 
expresses a single T-cell receptor type and is thereby classified as a αβT-cell or a 
γδT-cell. In the peripheral blood 85-99% of T-cell are of the α/β type (Eberl et al., 
2003). The α, β, γ and δ chains are encoded by the T-cell receptor α (TRA) T-cell 
receptor β (TRB), T-cell receptor δ (TRD) and T-cell receptor γ (TRG) genes 
respectively. These genes contain multiple exons that may encode the variable (V), 
diversity (D) and joining (J) regions of the chains. During the maturation of a T-cell 
these genes undergo rearrangement in which segments of genomic DNA are spliced 
out and three VDJ regions are made contiguous. The multiple possible combinations 
of VDJ exons and in splice sites within them produce the highly variable protein 
sequences encoding the antigen-binding site of the T-cell receptor.  
In developing T-cells the re-arrangement events leading to T-cell receptor 
expression follow an ordered sequence. Re-arrangement of TRB, TRD and TRG 
occur first and almost simultaneously. Re-arrangement of TRA is thought to occur 
after a T-cell has committed to the α/β lineage, and should therefore be absent in γ/δ 
T-cells (Mahe et al., 2017). 
The identity of T-cells can be inferred from the presence or absence of gene re-
arrangements. An absence of TRA or TRB re-arrangement is indicative of γ/δ T-cells 
and conversely the absence of TRG re-arrangement indicates α/β T-cells9. Both α/β  
and γδ T-cells may contain rearrangements in TRB and TRG. In this situation only 
one of the rearrangements will be productive in terms of a translatable protein. The 
multiplex PCR assay used in this study does not assess the productivity of 
rearrangements. However, unsuccessful TRB re-arrangements are reported to be 
rare and therefore cells with both TRG and TRB rearrangements are most likely to be 
αβT-cells (Joachims et al., 2006). 
All six clones from subject 2 were assessed for rearrangements in the T-cell 
receptor β gene (TRB) and the T-cell receptor γ gene (TRG). Rearrangements were 
detected in all three clones derived using the T-cell protocol (2-C2, 2-C3 and 2-C7). 
No rearrangements were identified in the clones derived using the non-T-cell protocol 
(2-C1, 2-C4 and 2-C6) (see appendix Table 69 and Figure 84 for full details of 
results). 
                                            
9 TRD is always absent in α/β T-cells, since it lies within TRA and is therefore spliced out during TRA rearrangement. 
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The SNP microarray identified a complete loss of SNPs in a region predicted to be 
400kb long on 14q11.2 in all three clones derived using the T-cell protocol (2-C2, 2-
C3 and 2-C7). This region includes the variable regions of TRA and the entirety of 
TRD (Appendix Figure 83). The finding indicates that TRA re-arrangement was 
present and that these cell lines originated from αβT-cells, since the could not be 
from γδT-cells if the TRD genes had be completely deleted. No such deletions were 
detected in any clones derived using the non-T-cell protocol (2-C1, 2-C4 and 2-C6).  
No copy number variations (CNVs) were detected in this region in the three ARVC/D 
clones assessed by SNP microarray (0101-C41, 0202-C13 and 0203-C8). It is 
therefore reasonable to conclude that these clones did not originate from αβT-cells. 
The probability that these cells originated from γδT-cells is low since γδT-cells are 
infrequent in the peripheral blood (~ 7% of all lymphocytes in peripheral blood and 
therefore <7% of PBMCs) and the pre-transduction culture conditions used in 
ARVC/D lines did not favour T-cell reprogramming (Mitogawa et al., 1992)10. Analysis 
of these clones by multiplex PCR would be necessary for confirmation. 
Overall the results of the T-cell receptor gene rearrangement assay and the micro 
array data support two hypotheses. Firstly that use of the T-cell reprogramming 
protocol with a population of CD3+ PBMCs is effective in generating iPSC lines from 
αβT-cells. Secondly that use of the non-T-cell reprogramming protocol in an un-
selected PBMC population is effective in generating iPSCs from non-T-cells and has 
a low (less than one in six) probability of generating iPSCs from T-cells. 
4.3.9 Genomic copy number variations 
All PBMC samples, the six clones from subject 2 and one clone each from the three 
ARVC/D subjects were screened for copy number variations (CNVs) using a single 
nucleotide polymorphism (SNP) microarray (see methods). Summaries of the quality 
control indices from the analysis of each sample, of all the CNVs detected and of the 
genes affected by the pathogenic CNVs are given in the appendix (Tables 65 to 66 
and Figures 79 to 82). 
No pathogenic CNVs, or CNVs of unknown significance were detected in any of the 
PBMC samples. Two of the non-T cell derived clones from subject 2 (2-C4 and 2-C1) 
were found to have acquired regions in which there was a gain in copy number 
suggestive of a duplication (appendix Figures 79 to 82, Table 66) (Table 51) (Figure 
                                            
10 The absence of CNVs in the regions of TRD, TRB or TRG in these clones does not exclude the possibility of there  
being re-arrangements in these genes since the microarray was not sufficiently sensitive to detect the rearrangements of TRB 
in 2-C3 and 2-C7, or of TRG in 2-C2 and 2-C7 detected by multiplex PCR. Similarly there is no information regarding its 
sensitivity in detecting re-arrangements in TRD. 
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40). For the single CNV identified in 2-C4 and one of the CNVs in 2-C1 there were 
clinical reports of subjects with duplications of the same region who manifested 
multiple congenital abnormalities (Sharma et al., 2014) (Schinzel et al., 1981) (Avila 
et al., 2013). This provides evidence that although these CNVs are associated with 
developmental abnormalities they do not compromise pluripotency since this would 
be expected to result in embryonic lethality. No inference of this type could be made 
with respect to the other two duplications identified in 2-C1.  
The gain in copy number at 20q11 found in 2-C4 has been reported in >20% of 
hESC lines and 18% of hiPSC lines (International Stem Cell Initiative et al., 2011) 
(Martins-Taylor et al., 2011). Its prevalence has been attributed to the presence of 
BCL2L1 in this region. BCL2L1 down regulates apoptosis and its upregulation by a 
gain in copy number is reported to increase cell survival (Avery et al., 2013). After the 
initial mutation it is hypothesised that this provides cells carrying the CNV with a 
selective advantage in maintenance culture resulting in them becoming the most 
abundant cell type within a culture (Lefort et al., 2008). 
The reported incidence of cytogenetic abnormalities varies depending on the 
method of analysis. When screened by karyotyping a prevalence of 12% has been 
reported (Taapken et al., 2011). By contrast studies using high resolution SNP arrays 
have detected at least one CNV the majority of iPSC lines with a increase incidence 
at higher passage numbers (Laurent et al., 2011). In this context the prevalence of 
CNVs detected in this study is relatively low. This may be explained by the lower 
resolution of array used in this study. In addition although the quality control indices 
for the array data were within acceptable limits they were not optimal, indicating 
some noise in the data (Appendix Table 66). Both of these factors could have 
reduced the sensitivity of the assay to detect small CNVs and those present at low 
levels of mosaicism. 
The use of multiple non-T-cell clones was to be important in the assessment of 
cardiac differentiation protocols in subsequent work, particularly in determining 
whether there was any difference in the differentiation potential of T-cell and non-T-
cell derived iPSCs. Since there were no other non-T-cell clones available it was 
decided to complete the characterisation of either 2-C1 or 2-C4 despite the CNVs. If 
the selected clone was found to be pluripotent is would be considered for use in 
cardiac differentiation experiments.  
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The CNVs in 2-C1 and 2-C4 did not included include any pluripotency marker genes, 
desmosomal genes or genes associated with intercellular adhesion in 
cardiomyocytes. Clinical reports of the 20q11 duplication found in 2-C4 described 
subjects as having a normal cardiac phenotype suggesting no effect on cardiac 
differentiation potential (Avila et al., 2013). By contrast cardiac malformations were 
reported in subjects with a 22q11 duplication similar to that found in 2-C1. On this 
basis 2-C4 was selected for further characterisation.  
Since only two non-T-cell derived clones from subject 2 were fully characterised (2-
C4 and 2-C6), statistical comparisons between T-cell derived and non-T-cell derived 
clones were not possible. Given this limitation and the resource intensive nature of 
iPSC characterisation it was decided that the value of characterisation of all three T-
cell clones was limited. Two T-cell derived iPSC clones (2-C3 and 2-C7) were 
selected at random for full characterisation. 
 
Sample 
Predicted location of CNV 
Size of CNV 
(bp) 
Copy 
number 
gain or 
loss  
Related clinical phenotype 
Cytogenetic GRCh37/h19 
2-C1 
4q34.3 - 
4q35.1 
 4:181,008,167-
183,628,586 2,620,420 Gain None 
7q36.1  7:150,327,024-151,893,675 1,566,652 Gain None 
22q11.1 - 
22q11.21 
22:16,079,545-
18,908,641 2,829,097 Gain 
Cat eye syndrome (Schinzel et 
al., 1981) 
(OMIM 115470) 
2-C4 20p11.1 - 20q11.21 
20:26,158,741-
31,042,348 4,883,608 Gain 
20q11 duplication syndrome 
(Avila et al., 2013) 
Table 51 Pathogenic CNVs acquired by iPSC clones during reprogramming.  
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Figure 40 Representative example of a CNV detected by analysis of SNP 
microarray.  
Panels B and D illustrate a pathogenic CNV predicted to be at 20p11.1-20q11.21 in 
the iPSC line 2-C4. Panels A and C illustrate the corresponding data from PBMCs 
from subject 2.   X-axis ticks indicate approximate positions within GRCh37/h19 e.g. 
“20-30” indicates the approximate position 30,000,000 in chromosome 20. Data 
from valid SNP calls are displayed as blue dots, no-calls are displayed as orange 
dots. The average Log R ratio is indicated by a green line, this is at zero in regions 
the BlueFuse Multi algorithm considers structurally normal. CNVs are indicated by a 
step change in this line, with the degree of deviation indicating the median Log R 
ratio across the CNV. The localised increase in log R ratio (B) and pattern of B-
allele frequency (BAF) values (D) in the same region suggest an increase in copy 
number of this region in 2-C4. The absence of these patterns in the PBMCs (A)(C) 
support the hypothesis that this CNV was acquired during generation of the clonal 
line. 
4.3.10 Sendai vector elimination 
All clones were tested for the persistence of Sendai vector RNA by RT-PCR (see 
methods). Any adherent colonies that remained in the initial MEF plate after picking 
clones for expansion were tested for the presence of Sendai vector by RT-PCR in 
samples. All samples were collected within 30 days of transduction. Evidence of 
Sendai vector was found in all samples (Figure 41). There was no evidence of 
Sendai vector in any clones at the passage numbers used for pluripotency 
assessments (Figure 41). These experiments provided evidence that the formation of 
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adherent expandable clones was associated with successful transduction with the 
reprogramming vectors.  
 
Figure 41 Screening for the persistence of Sendai reprogramming vectors in 
iPSC clones by RT-PCR. 
Cropped images of gels showing the regions in which PCR product of the expected 
size would be expected (ladder not shown). False positive results due to reagent 
contamination with cDNA are excluded by the absence of signal in the no template 
sample. GAPDH serves as a positive control for the presence of template cDNA 
within the other samples tested. The absence of signal in the H9 samples indicates 
that the primers do not amplify components of a pluripotent cell’s endogenous 
transcriptome. The signal from all three Sendai vectors (SeV) in the cells collected 
within 30 days of transduction indicate that transduction was successful. The 
absence of these signals in the iPSC clones indicates that the SeVs have been 
eliminated during the subsequent culture. 
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4.3.11 Colony and cell morphology 
When viewed with phase contrast microscopy all expandable clones had 
morphological features that were similar to those of the reference pluripotent cell 
lines (H9 hESCs) and dissimilar to non-pluripotent fibroblasts (Figure 42).  
 
Figure 42 Phase contrast microscopy images of expandable clones and 
reference cell lines.  
Expandable clones (panels A and B) and hESCs (panel C) formed similar flat, 
compact colonies, which expanded radially until becoming confluent and consisted 
of cells of approximately 10µM diameter with a high nuclear to cytoplasmic ratio 
(Figure 42). These were distinct from fibroblasts which formed sparse stellate cells 
with a large area of cytoplasmic (panel D). Scale bars illustrate 100µm. 
4.3.12 Pluripotency marker gene expression 
Up-regulated OCT4A (Nichols et al., 1998) (Matin et al., 2004), NANOG (Chambers 
et al., 2003) (Mitsui et al., 2003) (Loh et al., 2006) and SOX2 (Avilion et al., 2003) 
(Fong et al., 2008) expression have been established as critically important in the 
maintenance of pluripotency in vitro. Both the KLF and MYC families of transcription 
factors are up-regulated and essential to the maintenance of pluripotency in ESCs 
(Jiang et al., 2008) (Varlakhanova et al., 2010). KLF4 and MYC are included in these 
families but are not independently critical due to functional redundancy within these 
groups (Nakatake et al., 2006) (Jiang et al., 2008) (Varlakhanova et al., 2010) 
(Malynn et al., 2000) (Davis et al., 1993).  
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The expression of these genes was assessed by RT-qPCR in all clonal lines, an 
hESC line (H9) and in PBMC samples.  
No significant differences were detected between the hESC line (H9) and individual 
clones for any of the genes assessed (Figure 43) (Table 52). This is consistent with 
the hypothesis that the clones were pluripotent. Since only one hESC line was tested 
it cannot be determined whether there is any difference in expression between clonal 
lines generated by our methodology and hESCs in general. 
When comparing clonal lines to the non-pluripotent PBMCs there was evidence of 
higher levels of NANOG, OCT4A and SOX2 expression in the clonal lines (Figure 44) 
(Table 53). This is consistent also with the hypothesis that the clonal lines are 
pluripotent. 
KLF4 expression was higher in PBMCs relative to the clonal lines and no significant 
difference was detected in the level of MYC expression between the two cell types 
(Figure 44) (Table 53). These findings are consistent with previous reports describing 
the upregulation of KLF4 and MYC expression in the most abundant PBMCs cell 
types relative to pluripotent cells. A meta-analysis of publicly available gene 
expression array data found KLF4 expression was higher in monocytes and CD34+ 
progenitors cells than hESCs and found MYC expression to be similar between 
PBMCs and hESC lines (Mabbott et al., 2013). Similar patterns have been described 
in reports of the generation of iPSCs from PBMCs (Brown et al., 2010) (Loh et al., 
2009) (Seki et al., 2010) (Chou et al., 2011) (Kunisato et al., 2011). The relative 
expression of KLF4 and MYC in clonal lines and PBMCs identified in this study is 
consistent with the pluripotency of the clonal lines, but also illustrates that these 
genes have functions in addition to mediating pluripotency. 
PBMC expression data represent the average expression across a population of 
mixed cell types. Therefore these expression levels reflect those in the most 
abundant PBMC types. There may have been populations of PBMCs within that 
sample in which all these genes were up-regulated but which were too scare to 
influence the overall expression levels. Since each clone may be derived from any 
single cell within the PBMC sample these data cannot prove that the reprogramming 
process up-regulated these genes in a clone relative to its originating cell type. 
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Figure 43 Comparison of expression of pluripotency associated genes 
between clonal cell lines (iPSCs) and an hESC line (H9) by qPCR. 
Bar charts indicate the median and range of expression levels. The expression 
levels of these marker genes in hESCs in maintenance culture were considered to 
be indicative of those associated with pluripotency in general. Therefore expression 
in the clonal cell lines (iPSCs) and H9 hESCs is presented relative to the mean 
expression across the three passages of H9 hESCs assessed. For each clonal line 
gene expression was assessed in three samples each from a different passage. 
(Kruskal-Wallis) tests were used to look for significant (p>0.05) differences between 
clones. 
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Cell type Cell line OCT4A NANOG SOX2 KLF4 MYC 
hESC H9 14.9±0.2 20.0±0.1 17.8±0.1 25.5±0.4 21.9±0.1 
T-cell derived 
control iPSCs 
2-C3 15.7±0.3 21.4±0.3 17.6±0.2 25.9±0.8 22.3±0.7 
2-C7 15.5±0.2 21.0±0.2 18.1±0.3 27.2±0.5 23.1±0.3 
Non-T-cell derived 
control iPSCs 
2-C4 15.3±0.2 20.3±0.2 17.5±0.3 25.6±0.5 22.1±0.4 
2-C6 15.6±0.1 21.0±0.2 17.7±0.1 26.1±0.1 23.2±0.2 
ARVC/D iPSCs 0101-C41 15.5±0.4 20.9±0.4 17.8±0.0 25.4±0.5 23.0±0.0 
0202-C13 16.2±0.5 21.6±0.6 17.1±0.3 25.7±0.3 22.1±0.3 
0203-C8 15.3±0.0 20.2±0.1 17.9±0.0 26.1±0.3 22.0±0.1 
 
Table 52 Unadjusted Ct values from the assessment of pluripotency 
associated genes in clonal cell lines (iPSCs) and an hESC line (H9) by qPCR  
For each cell line the mean±SEM gene expression assessed in three samples each 
from a different passage are given. 
 
 
Figure 44 Expression of pluripotency associated genes in PBMCs and clonal 
lines (iPSCs) 
Bar charts indicate median values, whiskers indicate 75th centile values. The 
expression levels of these marker genes in hESCs in maintenance culture were 
considered to be indicative of those associated with pluripotency in general. 
Therefore expression in the clonal cell lines (iPSCs) and H9 hESCs is presented 
relative to the mean expression across three passages of H9 hESCs. PBMC data 
were derived from six samples from unrelated subjects including the three ARVC/D 
subjects. Clonal line data were derived from seven lines, the three clones from 
different ARVC/D subjects and four clones from the control subject 2 (2-C3, 2C7, 2-
C4 and 2-C6). Gene expression for each clone was the mean of the expression in 
samples from three different passages. For each gene, a Mann-Whitney U test was 
used to look for differences between cell types. Exact significance p values < 0.05 
are indicated by *. 
  
 
 
  141 
Cell type OCT4A SOX2 NANOG MYC KLF4 
PBMC 23.1±0.2 23.2±0.3 23.2±0.3 22.9±0.2 20.2±0.4 
iPSC 15.6±0.3 17.6±0.2 21.0±0.4 22.6±0.2 26.0±0.3 
 
Table 53 Unadjusted Ct values from the assessment of pluripotency 
associated genes in PBMCs and clonal lines (iPSCs) 
The mean±SEM un adjusted Ct values are presented. PBMC data were derived 
from six samples from unrelated subjects including the three ARVC/D subjects. 
Clonal line data were derived from seven lines, the three clones from different 
ARVC/D subjects and four clones from the control subject 2 (2-C3, 2C7, 2-C4 and 
2-C6). 
 
4.3.13 Pluripotency marker protein expression 
Evidence of the expression of NANOG and OCT4 provided by RT-qPCR analysis is 
described in the previous section. The detection the proteins encoded by these 
genes was sought by flow cytometry and immunofluorescence microscopy. 
In addition to the nuclear transcription factors, the expressions of two surface 
markers of pluripotency (SSEA4 and TRA-1-60) were sought by these modalities. 
Stage specific embryonic antigen 4 (SSEA4) is a carbohydrate epitope on a globo-
series ganglioside found in the plasma-membrane (Kannagi et al., 1983). TRA-1-60 
is the carbohydrate epitope for a monoclonal antibody of the same name located on 
podocalyxin (Schopperle and DeWolf, 2007). Both molecules are expressed at high 
levels in ESCs, have decreased expression during differentiation and are considered 
pluripotency markers (Henderson et al., 2002) (Draper et al., 2002). 
All expandable clones, an hESC line (H9) and fibroblasts (HDF) were assessed for 
the expression of NANOG, OCT4, TRA-1-60 and SSEA4 using flow cytometry. The 
average number of single cell events assessed per sample was 7993±1535 
(mean±SD).  
hESC samples were chosen as positive controls for the assay on the basis that they 
were a pluripotent cell line that would be expected to express the target proteins at 
high levels. For every pluripotency marker, the difference between the median 
fluorescence of labelled and unlabelled hESCs >1.5x103 au (Appendix Table 72).  
Fibroblasts were chosen as a negative control for the assay on the basis that they 
were a non-pluripotent cell line which would be expected to express the target 
proteins at low levels or not at all. For every pluripotency marker, the differences 
between the median fluorescence of labelled and unlabelled fibroblasts was <0.5x103 
au (Appendix Table 72).  
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In all clones and for every pluripotency marker, the difference between the median 
fluorescence of labelled and unlabelled samples was >2.0x103 (Appendix Table 72). 
This supports the hypothesis that the iPSC clones express the four pluripotency 
markers and do so at a high level similar to that seen in hESCs. 
In every iPSC clone assessed and for all four pluripotency makers, the proportion of 
single cell events classified as positive for the expression of a given protein was 
≥93% (Appendix Table 73). This suggests that the majority of cells the maintenance 
cultures were in an undifferentiated state. 
The use of unlabelled cells rather than those labelled with an isotype antibody to 
define the threshold for classifying events as positive or negative for a given protein 
is a methodological limitation in this work. Non-specific binding by a pluripotency 
marker antibody could increase the fluorescence of an event above the threshold 
despite the absence of the target protein.  
An estimate of the contribution of non-specific binding was made using isotype 
controls in a small number of samples (n=3). Because these samples were examined 
in a multicolour experiment, each isotype control sample was also labelled with the 
three pluripotency marker antibodies not under investigation. This is referred to as a 
fluorescence-minus-one (FMO) with an isotype control sample. The effect of using 
this FMO with an isotype control to classifying events as positive rather than 
unlabelled cells on the percentage of positive events was assessed. In the case of 
OCT4, TRA1-60 and SSEA4 the use of an FMO with an isotype control reduced the 
percentage of event classed as positive by <2%. The reduction in the percentage of 
NANOG positive events was variable ranging from 2-13% (Appendix Table 74). 
These data suggest that the percentage of clonal cells expressing pluripotency 
markers is likely to have been over estimated in experiments without an FMO isotype 
control. Despite this overestimate the majority of clonal cells would be expected to be 
classified as expressing the pluripotency marker protein. 
OCT4 and TRA-1-60 expression in iPSC lines was also assessed by 
immunofluorescence microscopy. The primary antibodies used in these experiments 
were identical to those used to assess these proteins in the flow cytometry 
experiments except for the lack of a conjugated fluorochrome. Signal was compared 
with an hESC line (H9) and human dermal fibroblasts (HDF) that acted as positive 
(pluripotent) and negative (non-pluripotent) controls respectively.  
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The highest intensity OCT4 signal in the hESCs (H9) positive control co-localised 
with DAPI (Appendix Figure 85). This suggests nuclear localisation and is consistent 
with its known function as a transcription factor.  
The TRA-1-60 signal in the hESCs (H9) appeared as a cluster of adjacent polygons 
with the highest intensity signal at their borders and a lower intensity, diffuse signal 
internally (Appendix Figure 85). This is consistent with descriptions of TRA-1-60 as 
being located on the extracellular surface of the plasma membrane. 
The fluorescence signals from the fibroblast (HDF) and secondary only negative 
controls were close to that of auto-fluorescence and showed no characteristic 
localisation (Appendix Figure 85).  
In all clonal lines assessed the OCT4 and TRA-1-60 signal resembled that of the 
hESCs (H9) positive controls rather than the HDF negative controls (Figure 45) 
(Appendix Figure 85). This supports the hypothesis that the clonal lines express 
pluripotency associated proteins. 
 
Figure 45 Immunofluorescence microscopy for OCT4 and TRA-1-60.  
The panels show signal obtained from 2-C7(T) p27 and are representative of the 
signal seen in all other pluripotent cell lines assessed. Panel A shows OCT4 signal 
and its co-localisation with DAPI (see inset), consistent with a nuclear distribution. 
Panel B shows TRA-1-60 signal which is diffuse but with linear higher intensity 
regions (see inset), consistent with localisation to the plasma membrane. Scale 
bars illustrate 50µM. 
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4.3.14 Assessments of differentiation potential 
The expression of pluripotency markers is not unique to pluripotent cells. The 
embryonal carcinoma cell line 2102Ep has been described as nullipotent despite 
expressing high levels of pluripotency markers (Josephson et al., 2007). hESCs 
cultured to high passage numbers have reduced differentiation potential despite high 
levels of expression of pluripotency markers (Park et al., 2008). Therefore although 
the expression of these markers is consistent with pluripotency, evidence of an 
expandable clone’s capacity to differentiate to all three germ layers must be obtained 
before it may be considered pluripotent. 
The differentiation potential of clonal lines were assessed using two methods. All 
clones were differentiated in vitro by embryoid body formation (Wobus et al., 1984). 
The resultant tissues were assessed for protein markers of the three germ cell layers 
by immunofluorescence microscopy. A limited number of clones were assessed 
using in vivo differentiation by the teratoma formation assay (Wobus et al., 1984) 
(Wesselschmidt, 2011). The resultant tissues were then assessed histologically for 
tissue architecture typical of tissues from the three germ cell layers.  
4.3.15 Assessment of expression of the proteins indicating differentiation to 
the three primitive germ cell layers after spontaneous embryoid body 
differentiation. 
Expandable clones were induced to differentiate by the formation of embryoid 
bodies and then cultured as adherent tissues in the presence of serum (see 
methods). Immunofluorescence microscopy of the resulting cultures was performed 
to identify expression of proteins specific to each of the three germ cell layers. The 
expression of β III tubulin (TUJ1) in neuron-like filamentous structures was 
considered a marker of neuro-ectoderm. The expression of smooth muscle actin 
(SMA) in a diffuse fibrillar pattern within polygonal and stellate structures was 
considered a marker of mesoderm. The expression of α-fetoprotein (AFP) in compact 
cuboidal cells was considered a marker of endoderm.  
A characteristic pattern of expression of all three proteins was found in all of the 
seven clones that underwent full characterisation and use in cardiac differentiation 
experiments i.e. 2-C3, 2-C7, 2-C4, 2-C6, 0101-C41, 0202-C13 and 0203-C8 (Figure 
46) (Table 54) (Appendix Figure 86). 
Evidence of differentiation to all three germ cell layers was not obtained for some 
clones. Specifically no evidence of differentiation of 0202-C7, 0202-C10 and 0203-
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C12 to neuro-ectoderm was obtained. There was also no evidence of the 
differentiation of 0203-C12 and 0203-C13 to endoderm.  
 
 
Figure 46 Immunofluorescence microscopy for germ-layer markers 
The panels show signal obtained from 2-C3(T) and are representative of the 
positive signals seen in all other pluripotent cell lines. Panel A shows beta III tubulin 
(TUJ1) signal in a linear branching pattern consistent with the localisation of the 
protein to branching filamentous processes associated with neural (neuro-
ectodermal) cells. Panel B shows a diffuse fibrillar (see inset) smooth muscle actin 
(SMA) signal suggesting stellate and polygonal cells typical of mesodermal smooth 
muscle cells. Panel C shows α-fetoprotein (AFP) signal in compact cells typical of 
endodermal hepatic progenitors. Scale bars indicate 100µm. 
 
Subject Clones Neuro-ectoderm (TUJ1) 
Mesoderm 
(SMA) 
Endoderm 
(AFP) 
2 
C1 ✔ ✔ ✔ 
C4 ✔ ✔ ✔ 
C6 ✔ ✔ ✔ 
C2 ✔ ✔ ✔ 
C3 ✔ ✔ ✔ 
C7 ✔ ✔ ✔ 
0101 
C4 ✔ ✔ ✔ 
C12 ✔ ✔ ✔ 
C41 ✔ ✔ ✔ 
0202 
C7 ✖ ✔ ✔ 
C10 ✖ ✔ ✔ 
C13 ✔ ✔ ✔ 
0203 
C8 ✔ ✔ ✔ 
C12 ✖ ✔ ✖ 
C13 ✔ ✔ ✖ 
Table 54 Summary of immunofluorescence microscopy for the three primitive 
germ cell layers 
iPSCs were allowed to differentiate in the presence of serum and were assessed for 
the expression of proteins indicative of each of the three germ cell layers by 
immunofluorescence microscopy. Target protein signal identified (✔). No evidence 
of target protein (✖). 
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4.3.16 Teratoma assay 
The differentiation potential of 2-C6 and 2-C3 were assessed by teratoma assay. 2-
C6 produced tumours with a typical teratoma histology. 2-C3 produced cystic 
tumours with some differentiated tissues but no typical teratoma histology. 
The generation of teratomas by 2-C6 is consistent with the line being pluripotent.. 
The protocol used in this work has been reported to yield teratomas in 80-100% of 
mice injected with hESC lines (Gropp et al., 2012) (Prokhorova et al., 2009) (Hentze 
et al., 2009). In this context the absence of teratoma in the tumours generate from 2-
C3 suggests that this line is not pluripotent. This is inconsistent with the results of in 
vitro differentiation experiments in which there was evidence that 2-C3 could 
differentiate to all three germ layers. 
There are several possible explanations for these apparently conflicting results. 
There is evidence that cultures of pluripotent cell lines have sub-populations with 
methodology specific differentiation capacities. It has been reported that for a single 
culture the subpopulations responsible for teratoma generation are distinct from 
those that generate the three germ layers by in vitro differentiation (Stewart et al., 
2010). It may be that 2-C3 contains a sub-population capable of in vitro differentiation 
but lacks a sub-population able to form teratomas. 
Alternatively teratoma tissue could have been present but undetected if it was 
localised and not sampled in the sections examined. It is possible that an error could 
have occurred in the handling of the 2-C3 sample leading to the injection of non-
pluripotent cells. Due to the high cost of the assay in labour and materials it was 
decided not to investigate these possibilities by repeating the assay for 2-C3. Instead 
it must be concluded that evidence for the pluripotency of 2-C3 is not as strong as for 
other clonal lines. 
4.4 Discussion 
In its strictest sense pluripotency is defined as the ability of a cell to give rise to any 
cell within a mature organism (Daley et al., 2009). A less demanding and more widely 
used definition requires only the capacity to differentiate to cell types from each of the 
three germ layers. Cells classified as pluripotent by the second definition may lack 
the capacity to differentiate to the cell types found in mature organisms and may be 
restricted in their potential cell fates.  
The most stringent experimental tests of pluripotency for a cultured cell line are the 
tetraploid complementation assay and to a lesser degree, chimera formation (Nagy et 
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al., 1990) (Boland et al., 2009) (Kang et al., 2009). Human cell lines cannot be tested 
in these ways due to both legal and practical constraints. This essentially precludes 
the classification of human cell lines as pluripotent according to the strictest definition 
of the term.  
Experimental evidence of pluripotency according the second definition may be 
obtained by the identification of cells from the three germ layers in tissue generated 
by the differentiation of cells in vitro or as part of a teratoma assay (Singh et al., 
2016).  
Only two clonal lines were assessed by teratoma assay in this study due to the time 
and resource intensive nature of the test. The assay provided evidence of 
pluripotency in only one of these clones, the non-T-cell derived 2-C6. This provided 
evidence that the non-T-cell protocol was capable of generating iPSCs meeting the 
most stringent criteria available for the assessment of human cell lines.  
In vitro differentiation followed by immunofluorescence microscopy to identify 
expression of a single protein markers per germ layer was the principle method of 
assessing differentiation capacity in this study. All the clonal lines selected for cardiac 
differentiation showed evidence of pluripotency using this assay. The combination of 
these results with the expression of pluripotency markers in an undifferentiated state 
was the basis upon which they were classified as pluripotent and therefore iPSCs. 
Pluripotent cells exhibit considerable heterogeneity in their differentiation potential. 
Cell lines may exhibit a greater or lesser resistance to leave the pluripotent state and 
have a tendency to differentiate towards some cell fates over others (Osafune et al., 
2008) (Park et al., 2008) (Hu et al., 2010). The mechanisms regulating this 
phenomenon are not well understood. 
The assessment and manipulation of heterogeneity in differentiation potential is 
important to the study of embryonic development and for studies using pluripotent 
cells as a substrate for tissue generation i.e. for disease modelling or regenerative 
medicine. One approach to this issue has been to examine global gene expression 
patterns of pluripotent cells in maintenance culture. The Pluri-test assay uses this 
approach and quantifies the predicted pluripotency of a cell line relative to a 
pluripotent reference as a pluripotency score and a novelty score indicating the 
degree of pluripotency associated gene expression and the degree of divergence in 
the pattern of expression from reference pluripotent lines respectively (Müller et al., 
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2011). Pluripotent lines are defined as having a high pluripotency score and a low 
novelty score. 
An alternative approach is the quantitative assessment of tissues generated when 
PSCs differentiate. Attempts to quantify the abundance of tissue and cell type by 
microscopy are labour intensive and difficult to scale to the high throughput 
applications. Multi-gene assays allow a quantitative assessment of a large number of 
germ layer markers from a relatively small amount of tissue, within a relatively short 
time frame and are easily scalable. The TeratoScore and hPSC ScoreCard are 
examples of this type of assay (Avior et al., 2015) (Tsankov et al., 2015). The 
TeratoScore summarises gene expression within tumours produced by the teratoma 
assay protocol, into a single value that reflects the probability that a histological 
analysis would find all three germ layers to be present within that tissue. The hPSC 
ScoreCard assesses the products of in vitro differentiation experiments produces 
values reflecting the abundance of each of the three germ layers relative to 
undifferentiated tissues.  
All of these gene expression based techniques would have enhanced the 
characterisation of iPSCs generated in this study. The PluriTest assay would allow 
the comparison of gene expression in the iPSC lines with the 223 hESC and 41 iPSC 
lines making up the pluripotent reference for the assay as opposed to the single 
hESC line used in the RT-qPCR analyses in this study. The TeratoScore could have 
helped to determine whether the absence of teratoma histology in 2-C3 derived 
tumours reflected a lack of the tissue in the tumour or an error in sampling and 
analysis of the tissue. The hPSC ScoreCard would have provided more robust 
evidence of differentiation to the 3 germ cell layers than the single markers assessed 
by immunofluorescence microscopy. It may also have allowed the screening of 
clones for those with the greatest tendency to mesodermal differentiation and 
therefore a higher probability of efficient cardiac differentiation. 
4.5 Conclusions 
This study has demonstrated the generation of clonal cell lines from the PBMCs of a 
control subject and three subjects with ARVC/D. These clonal line have been shown 
to meet the criteria established by the study to be defined as pluripotent and 
therefore as iPSCs.  
Both of the reprogramming protocols tested by this study have been demonstrated 
to be effective in generating iPSCs. The T-cell reprogramming protocol was shown to 
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be effective in generating iPSC lines from αβT-cells when applied to CD3+ PBMCs. 
Use of the non-T-cell reprogramming protocol was shown to be effective in 
generating iPSCs from an un-selected PBMC population and there is evidence that it 
is successful in promoting the reprogramming of non-T-cells in preference to T-cells. 
Further assessments of these clones by techniques such as the PluriTest, hPSC 
ScoreCard and TeratoScore would be valuable in further characterising their 
pluripotency and should be considered in the assessment of any further cell lines 
generated using the protocols described in this study. 
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5 Chapter 5. The Derivation Of Cardiomyocytes From Blood Derived 
iPSCs And Their Characterisation. 
5.1 Introduction 
This chapter will discuss the generation of cardiomyocytes from iPSCs. The 
principles of generating iPSC derived cardiomyocytes (iPSC-CMs) are outlined in 
Chapter 1 and details of the differentiation protocols are given in Chapter 2.  
The first part of this chapter will describe the testing of two types of cardiac 
differentiation protocols. The first type of protocol involved embryoid body formation 
(EB) and the differentiation of iPSCs in suspension culture. The second type of 
protocol differentiated iPSCs as an adherent monolayer. All the protocols tested were 
based on those described in previous reports (Kattman et al., 2011) (Lian et al., 
2013a). The two EB protocols tested in this study were based on the methodology 
described by Kattman el al, but differed in several respects (Kattman et al., 2011). 
Kattman et al. used iPSCs co-cultured with mouse embryonic fibroblasts (MEFs) 
from which EBs were formed by enzymatic digestion of adherent colonies into multi-
cellular fragments. Both the EB protocols in the present study used iPSCs cultured 
with mTeSR1 and Matrigel. One of the EB protocols used in this study used the 
same approach to EB formation as Kattman et al., the other involved the formation of 
EBs by forced aggregation of a single cell suspension. The monolayer protocol used 
in this work was unchanged from the methodology described by Lian et al. (Lian et al., 
2013a). The goal of the work described in the first part of this chapter was to 
determine if these protocols could generate contracting cultures and to select one 
protocol for subsequent experiments. 
The second part of the chapter will describe the characterisation of contracting 
cultures from multiple iPSC lines using the protocol selected in the first part of the 
chapter. The goal of these experiments was to determine if these cultures contained 
functional iPSC-CMs as defined by patterns of gene and protein expression, 
ultrastructural features and electrophysiological characteristics that are analogous to 
in vivo cardiomyocytes. 
The third part of the chapter will describe attempts to generate contracting cultures 
that contain ≥75% iPSC-CMs and to obtain RNA samples that are suitable for 
analysis by RT-qPCR from samples of this type11. Two protocols for generating 
                                            
11 The hypotheses regarding desmosomal gene expression investigated in subsequent chapters were specific to iPSC-CMs 
therefore a consistent and high proportion of iPSC-CMs was necessary in samples to be used for these analyses. The target of 
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samples of this type were tested, both of which have been reported previously 
(Dubois et al., 2011) (Tohyama et al., 2013). The first protocol used fluorescence 
activated cell sorting (FACS) to select iPSC-CMs from a cell suspension on the basis 
of the expression of the cell surface protein, signal regulatory protein α (SIRPA) 
(Dubois et al., 2011). The second protocol involved the exposure of contracting 
cultures to medium containing no glucose with the intention of inducing the death of 
non-cardiomyocytes and leaving viable iPSC-CMs (Tohyama et al., 2013). The goal 
of the work described in this part of the chapter was to select one of these protocols 
and to generate samples suitable for later analysis from multiple cell lines. 
5.2 Aims and hypotheses 
It was hypothesised that iPSC-CM could be generated from iPSCs using a protocol  
based on previously published methodologies. Successful differentiation was 
expected to result in: 
• Spontaneously contracting cultures in which intracellular calcium transients 
could be detected in association with these contractions. 
• The downregulation of pluripotency associated gene expression in 
contracting cultures relative to iPSCs. 
• The upregulation of genes encoding cardiac sarcomeric proteins in 
contracting culture relative to iPSCs. 
• The expression of cardiac sarcomeric proteins in contracting cultures and the 
organisation of these proteins into striated myofibrils that have ultrastructural 
features similar to those observed in myocardial tissue. 
It was also hypothesised that the cell populations containing ≥75% iPSC-CMs could 
be obtained consistently using a combination of this protocol and a protocol for the 
purification of iPSC-CMs from contracting cultures.   
5.3 Results 
The first differentiation experiments performed were to test the EB cardiac 
differentiation protocol. This work was conducted before PBMC derived iPSCs had 
been fully characterised. An hESC line (H9) and an iPSC line (SBNeo1-C3) that was 
generated outside this study were used in these experiments.  
                                                                                                                                        
≥75% cardiomyocytes was chosen as it was predicted to be achievable in the majority of experiments using a combination of  
differentiation and purification protocols.  
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5.3.1 Embryoid body differentiation 
Two of the EB protocols (referred to as EB protocol A and EB protocol B) were 
tested. These protocols differed in the technique used for form EBs.  
EB protocol A involved the enzymatic digestion of iPSC cultures to form fragments 
of approximately 500µm diameter. Fragments were then cultured in suspension 
culture for seven days to encourage EB formation. Duplicate experiments, each 
using approximately 2x106 cells were conducted with SBNeo1-C3. The majority of 
EBs generated with these experiments disintegrated into debris during the initial 
seven days of suspension culture and those that survived did not generate adherent 
cultures (Figure 47 A).  
EB protocol B involved the enzymatic digestion of iPSC cultures to produce a single 
cell suspension from which EBs were formed by forced aggregation in a micro-well 
plate (Aggrewell 400Ex, Stem cell technologies). EBs were cultured in suspension in 
the same manner as in EB protocol A. Duplicate experiments, each using 1.4x106 
cells, aggregated in 4,700 microwells to produce EBs of approximately 300 cells 
each, were conducted with SBNeo1-C3 and H9. Once again the SBNeo3-C3 iPSC 
derived EBs fragmented and did not survive suspension culture (Figure 47 B). H9 
hESC EB survived suspension culture in both experiments and successfully adhered 
to gelatin coated plates (Figure 47 C). In one of these two experiments spontaneous 
contractions were identified. 
5.3.2 Monolayer differentiation 
The monolayer protocol was tested in both SBNeo1-C3 and H9. Each line was 
tested in five independent experiments with each experiment using cells from a 
different passage. Each experiment was conducted in one or two 12 well plates that 
were estimated to contain 12-24x106 iPSCs at the start of differentiation. Contracting 
cultures were observed in multiple wells in one (20%) of the five experiments using 
SBNeo1-C3 and in two (40%) of the five experiments using H9. 
5.3.3 The selection of a protocol for further work 
The monolayer protocol was selected for subsequent experiments since it resulted 
in contracting cultures from both cell lines tested, whereas the EB protocols had only 
yielded contracting cultures from H9 hESCs. 
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Figure 47 Phase contrast microscopy images of EBs in suspension culture during cardiac differentiation protocol 
Panels in row A are representative of the appearance of EBs during differentiation of SBNeo1-C3. Fragments generated by enzymatic 
digestion of adherent cultures are shown on the day 0 image. The formation of EBs that decrease in size over the duration of 
suspension culture and the accompanying cellular debris resulting from the degeneration of EB are shown in the images from days 1 
and 5. Panels in row B and C are representative of the appearance of EBs during the Aggrewell differentiation protocol.  EBs of similar 
size were seen on days 0 and 3. On day 5 larger EBs were observed in the H9 experiment, which subsequently yielded adherent 
contracting cultures by day 15. Scale bars illustrate 500µm. 
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5.3.4 Characterisation of contracting cultures generated by monolayer 
differentiation 
 The extent to which contracting cultures were characterised varied between cell 
lines (Table 55).  
 Table 55 Summary of the characterisation of contracting cultures performed 
in different cell lines. 
Cell lines assessed by a specific modality are indicated (✔), the results of these 
assessments are described in subsequent sections. 
5.3.5 Spontaneous contractions 
Spontaneous contractions were identified and recorded by bright-field microscopy. 
Regions of spontaneously contracting cells were detected within 15 days of the start 
of differentiation in cultures from all cell lines.  
The frequency with which individual experiments resulted in spontaneously 
contracting cultures is an indication of the efficacy of the protocol. Over the entire 
duration of the study, and across all cell lines, 97 monolayer differentiation 
experiments were initiated. Spontaneously contracting cultures were generated by 61 
(63%) of these experiments. The proportion of experiments using 0101-C41 that 
yielded contracting cultures was significantly lower than other cell lines (Fishers exact 
test p<0.05). The mean proportion of experiments yielding contracting cultures for 
per cell line was 67% (SD 6) (Figure 48). 
 Spontaneous contraction Sarcomeric and 
pluripotency 
related gene 
expression 
Sarcomeric protein expression Sarcomeric 
ultrastructure 
Subject / 
Line 
Clone Phase 
contrast 
microscopy 
Calcium 
transient 
imaging 
RT-qPCR Flow 
cytometry 
Immuno-
fluorescence 
microscopy 
TEM  
2 C3 ✔  ✔ ✔ ✔ ✔ 
C7 ✔  ✔ ✔ ✔ ✔ 
C4 ✔  ✔ ✔ ✔ ✔ 
C6 ✔ ✔ ✔ ✔ ✔ ✔ 
0101 C41 ✔   ✔ ✔ ✔ 
0202 C12 ✔  ✔ ✔ ✔ ✔ 
0203 C8 ✔ ✔ ✔ ✔ ✔ ✔ 
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Figure 48 Proportion of experiments yielding contracting cultures, per cell 
line and in total. 
The number of experiments performed with each line is indicated by the figure 
within each bar. The mean proportion of experiments yielding contracting cultures 
across all cell lines is indicated by the dotted line. Pairwise comparisons using 
Fishers exact test found the proportion of experiments in which contracting cultures 
were observed were significantly lower in 0101-C41 than for 0202-C13 and 0203-
C8 (p<0.05). All other differences were non-significant. 
 
5.3.6 Calcium transient imaging 
Two cell lines were assessed for the presence of spontaneous calcium transients by 
fluorescence microscopy (2-C6 and 0203-C8). Each line was assessed in two 
independent differentiation experiments. Cells from each differentiation experiment 
were re-plated into multiple glass bottomed culture dishes and three dishes 
containing spontaneously contracting cells were imaged from each experiment. 
Spontaneous calcium transients were identified in iPSC-CMs from both lines (Figure 
49). Spontaneous transients were recorded in four (67%) of the six dishes across 
both the experiments that used 2-C6. Spontaneous transients were recorded in two 
(33%) of the six dishes containing differentiated 0203-C8, with both dishes originating 
from the same differentiation experiment. Field pacing was applied to all dishes and 
resulted in induced calcium transients in all cases.  
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Figure 49 Calcium transients recorded from differentiated cultures. 
Representative data from contracting cultures derived from 2-C6 (Panels A and C) 
and 0203-C8 (Panels B and D) are shown. Panels A and B illustrate spontaneous 
transients recorded from each cell line. Panels C and D illustrate calcium transients 
triggered by field pacing at 1Hz. 
5.3.7 Sarcomeric and pluripotency related gene expression 
The expression of pluripotency marker genes (NANOG, OCT4) and genes encoding 
sarcomeric proteins (ACTN2, TNNT2, TNNI3, MYH6, MYH7) were assessed by RT-
qPCR. For each iPSC clone the mean expression was estimated from three different 
passages. For differentiated cells the mean expression was estimated from three 
different differentiation experiments.  
NANOG, OCT4 and TNNT2 expression levels were assessed in all clones that 
underwent cardiac differentiation except 0101-C4112. The median expression of 
NANOG in iPSCs was 4.9 times that of the contracting cultures and the median 
expression of OCT4A in iPSCs was 209 times that of the contracting cultures (Figure 
50, panel A) (Table 56). The median expression of TNNT2 was 265 fold greater in 
the contracting cultures than in the iPSCs (Figure 50, panel B) (Table 56). These 
                                            
12 Due to the low number of differentiations using 0101-C41 that yielded contracting cultures a limited quantity of RNA was 
available for RT-qPCR. It was decided that these samples would be used for assessments of desmosomal rather than 
sarcomeric gene expression. 
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differences were statistically significant (exact p values from 2 tailed Mann-Whitney U 
(MWU) test were <0.05). 
The expression of the other sarcomeric genes was only assessed in the four clones 
from subject 2. The median expressions of ACTN2, TNNI3, MYH6, MYH7 in 
contracting cultures were 318, 40, 7700 and 8100 times that of the expression in 
iPSCs (Figure 50, Panel B) (Table 56). These differences were statistically significant 
(exact p values from 2 tailed MWU test were <0.05). 
 
  
Figure 50 RT-qPCR data illustrating the expression of genes encoding 
pluripotency markers and sarcomeric proteins in iPSCs and contracting 
cultures generated from these lines by directed cardiac differentiation. 
Pluripotency gene expression is presented in panel A, sarcomeric gene expression 
is presented in panel B. The expression levels of pluripotency marker genes in 
hESCs in maintenance culture were considered to be indicative of those associated 
with pluripotency in general. The qPCR experiment summarised in panel A was 
performed to provide evidence of a loss of pluripotency during differentiation 
therefore expression iPSCs and iPSC-CMs is presented relative to the mean 
expression of these genes across the three passages of H9 hESCs. The expression 
levels of sarcomeric genes in RAA tissue is considered to be reflective of those 
found in cardiomyocytes in general. The qPCR experiment summarised in panel B 
was performed to provide evidence of differentiation of iPSCs towards a 
cardiomyocyte phenotype therefore expression iPSCs and iPSC-CMs is presented 
relative to the mean expression of these genes from RAA samples from three 
different subjects. Figures represent the median and 75th centile for each population. 
The number of clones assessed was considered too small for statistical estimates 
of data normality to be reliable. Assessments of the differences between iPSCs and 
the differentiated cells using a 2 tailed Mann-Whitney U test that produced exact p 
values <0.05 are indicated (*). 
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Gene Cell type 
iPSC iPSC-CM 
NANOG 21.1±0.4 22.9±0.3 
OCT4A 15.7±0.3 23.3±0.2 
ACTN2 25.8±0.1 17.8±0.1 
TNNT2 26.6±0.3 15.4±0.1 
TNNI3 28.2±0.0 23.4±0.3 
MYH6 31.1±0.1 18.7±0.3 
MYH7 31.2±0.1 18.7±0.3 
 
Table 56 Unadjusted Ct values from the assessment of expression of genes 
encoding pluripotency markers and sarcomeric proteins in iPSCs and iPSC-
CMs. 
5.3.8 Expression of sarcomeric proteins 
The expression of cardiac troponin I (cTnI) by differentiated cells in spontaneously 
contracting cultures was assessed by flow cytometry. TnI positive cells were detected 
in all contracting cultures. The mean proportion of cells that were classified as 
positive for cTnI across all experiments was 37% (SD 26, n=32, median 41%, Q1-Q3 
11-56%, range 1 to 86%). There was no significant difference in the proportion of 
cTnI positive cells between different clones (Figure 51). 
  
Figure 51 Proportion of cells in contracting cultures expressing cTnI as 
determined by flow cytometry. 
Bars indicate median values. The results of individual experiments are indicated by 
data points. 
 
Cells labelled with antibodies to alpha actinin (αAct2) and the cardiac troponin T 
(cTnT) were identified by immunofluorescence microscopy in all contracting cultures. 
In all cases the signals from these proteins were spatially distinct and combined to 
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formed linear structures traversed by alternating bands of cTnT and αAct2 signal 
(Figure 52).  
  
Figure 52 Immunofluorescence microscopy for sarcomeric proteins in cells 
differentiated from iPSCs. 
Maximum intensity projections from Z-stacks of immunofluorescence microscopy 
images of cTnT and αAct2 signals from cells differentiated from 2-C6 iPSCs. The 
pattern of signals is representative of those seen in all contracting cultures. No 
signal was observed in cells labelled with secondary antibodies only (data not 
shown). The scale bar indicates 10µm.  
5.3.9 Ultrastructural features of iPSC-CMs 
The ultrastructural features of cardiac sarcomeres are described and defined in 
Chapter 1. Samples of adult human right atrial appendage (RAA) acted as a positive 
control for the TEM assessment. Striated myofibrils with M lines and H zones were 
identified in RAA samples (Figure 53 A). A bands and I were not clearly seen in the 
RAA samples.  
Contracting cultures generated from iPSCs were examined at 30 days from the start 
of differentiation (see methods). Striated myofibrils were identified in all samples from 
contracting cultures. M lines were not identified in any sarcomeres assessed. H 
zones and I bands were present in some sarcomeres (Figure 53 B). 
Some cultured cells contained contractile apparatus in which the fibres were not 
oriented in parallel, some of these structures contained both Z-lines and structures 
similar to the dense bodies described in smooth muscle (Figure 53 C). 
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Figure 53 Sarcomeric ultrastructure in RAA cardiomyocytes and cells 
produced by directed differentiation 
Representative TEM images of sarcomeres in RAA (Panel A) and cells generated 
by directed differentiation from 2-C6 and 2-C7 (Panels B and C respectively). The 
Z-lines defining sarcomeres are indicated (z). M lines (m) were identifiable in the 
sarcomeres of RAA cardiomyocytes (A) but not in differentiated cells (B). I bands (i), 
A bands (a) and H zones (h) were identified in the sarcomeres of cultured cells (B) 
but not in RAA cardiomyocytes (A). Some cultured cells (C) contained fibres that 
were not organised in parallel running between Z-lines and dense bodies similar to 
smooth muscle (*). Scale bars indicate 500nm 
5.3.10 Purification of iPSC-CMs by FACS based on SIRPA expression 
Despite optimisation of the differentiation protocol to maximise efficiency only 4/32 
(13%) of un-purified monolayer differentiation experiments assessed by flow 
cytometry contained cultures containing ≥75% cTnI positive cells.  
Protocols for the purification of iPSC-CM were investigated to obtain samples of the 
purity necessary for assessment of iPSC-CM desmosomal gene expression. The first 
protocol tested was based on the expression of SIRPA, a cell surface molecule 
reported to be a marker of PSC derived cardiomyocytes (Dubois et al., 2011). 
The co-expression of cTnI and SIRPA by cells from contracting cultures was 
assessed in samples from two independent differentiation experiments. The samples 
from these experiments contained 55% and 72% cTnI positive cells overall. Of those 
cells classed as positive for SIRPA, 77% and 98% co-expressed cTnI, suggesting 
that collection of SIRPA positive cells would produce samples of the required quality 
(Figure 54).  
Samples from a further three independent differentiation experiments were then 
sorted by FACS on the basis of SIRPA expression and the proportion of cells 
expressing cTnI subsequently analysed. In two samples the SIRPA positive fractions 
contained ≥75% cTnI positive cells and one sample (2-C6-WB2) failed to reach this 
standard (Figure 55). 2-C6-WB2 contained 13% cTnI positive cells prior to sorting, 
this is lower than that contained in the other two samples (41% and 82%). 
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Attempts were made to extract RNA from the two SIRPA positive samples 
containing ≥75% cTnI positive cells. Samples were analysed using the Nanodrop 
spectrophotometer (see methods). The yields from these samples were 0.22µg/x106 
cells and 0.44µg/x106 cells, which are less than a twentieth of the expected yields 
from cultured cells described by the manufacturer of the kit used for RNA extraction 
(Promega, 2012). An addition result of the low yield was that the 260/230 ratios for 
these samples were 0.24 and 1.23, suggesting a high concentration of salts and 
making the samples unsuitable for analysis in this study. 
 
 
  
Figure 54 Co-expression of cTnI and SIRPA in cells from contracting cultures 
Contour plots of single cell events co-labelled with antibodies to cTnT and SIRPA 
showing the fluorescence intensities of corresponding fluorophores when excited 
during flow cytometry. Panels A and B show data from the analysis of cells from two 
independent experiments (2-C4-WB2 and 2-C7-WB5). The protocol for defining the 
position of gates is described in Methods. The proportion of all single cell events 
falling in each quadrant is illustrated. 
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Figure 55 Bar chart showing the proportion of cells expressing cTnI in 
samples before and after SIRPA based FACS, as assessed by flow cytometry 
The method of identifying single cell events and classifying events as positive for a 
marker are described in the methods section. The target of ≥75% cTnI positive cells 
is illustrated by the dotted line. Each bar represents the results of a single 
experiment. 
 
5.3.11 Purification of iPSC-CMs by metabolic selection 
Metabolic purification by the exposure of contracting cultures to medium lacking 
glucose was initially tested in contracting cultures from a single differentiation 
experiment (2-C4-WB4) (Figure 56). The experiment was conducted using 
contracting cultures in a single 12 well plate, with the proportion of cTnI positive cells 
in each well being assessed by flow cytometry. Pre-purification iPSC-CM content 
was estimated from a single well. The other wells were cultured with either 
purification medium for 7 days from day 12 followed by return to normal 
cardiomyocytes maintenance medium (MCMM) (n=4) or in MCMM throughout (n=7). 
The proportion of cells expressing cTnT were analysed on day 21 by flow cytometry. 
The median (Q1-Q2) percentages of cTnT positive cells in the purified and un-
purified wells were 71% (61-82) and 50% (47-70), with no significant difference 
between the two groups, assessed by the Mann-Whitney U test (Figure 56). 
RNA of the quality required for further analysis was successfully extracted from 
samples exposed to metabolic purification. 
The proportion of cells and iPSC-CMs within purified cultures that were viable after 
purification was also investigated in this experiment. After preparation of the single 
cell suspension, but before fixation, samples were incubated with Zombie aqua dye 
(BioLegend), which will only stain cells with a compromised plasma membrane. Once 
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exposed to a fixative Zombie dyes do not redistribute to label other cells and 
therefore it was inferred that Zombie positive cells were dead before fixation. The 
median (Q1-Q2) proportion of single cells (i.e. including non-cardiomyocytes) that 
were dead before fixation was 7.6% (2.4-12.0) in the metabolic purification samples 
and 1.9% (1.7-3.4) in the control samples. The proportions of iPSC-CMs (i.e. troponin 
positive cells) that were dead before fixation were 4.6% (2.3-7.4) in the metabolic 
purification samples and 2.1% (1.7-3.8) in the control samples. There was no 
significant difference in proportion of dead cells between purified and non-purified 
samples in either parameter. 
 
Figure 56 The effect of exposure of contracting cultures to metabolic 
purification medium on the proportion of iPSC-CMs in culture, as quantified 
by flow cytometry. 
Each point represents the result of a flow cytometry analysis from cells contained 
within a single well of a 12 well plate. Samples were compared using a 2-tailed 
Mann-Whitney U test, exact p values p>0.05 were considered non-significant (ns). 
 
5.3.12 The selection of a purification method and its application in further 
work 
The data from initial testing did not demonstrate the efficacy of metabolic purification. 
Samples of cells containing ≥75% iPSC-CMs were collected from cultures exposed 
to this protocol and RNA was successfully extracted from these cells. Therefore the 
metabolic purification protocol was used in subsequent attempts to obtain high purity 
iPSC-CM samples.  
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The metabolic purification protocol was modified such that purification medium was 
introduced at an earlier point in differentiation (day 9) and for a shorter period (5 
days). This modified protocol was used in differentiation and purification experiments 
with five different cell lines. Of the 19 experiments yielding spontaneously contracting 
cultures that were assessed by flow cytometry, samples consisting of ≥75% iPSC-
CMs were obtained from 18 experiments (95%) (Figure 57). All cultures in these 
experiments were exposed to purification medium i.e. there were no control cultures 
that had MCMM throughout.   
At least three RNA samples suitable for use in desmosomal gene expression 
analysis were obtained for each of 0202-C13, 0203-C8, 2-C6 and AD3-C1 but not for 
0101-C41. Despite 19 independent differentiation experiments using 0101-C41, 
including eight which used the metabolic purification protocol, samples containing 
≥75% iPSC-CMs could only be produced in one experiment. 
 
 
 
Figure 57 Comparison of the proportion of iPSC-CMs in samples from 
experiments with and without metabolic purification. 
Bars indicate the median proportion of cTnI positive cells across multiple 
experiments. Whiskers indicate the range. The data from experiments in which 
metabolic purification was not performed are the same as presented in Figure 51. 
Experiments conducted with and without purification were compared with a 2-tailed 
MWU test, exact p values <0.05 are indicated (*). 
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5.4 Discussion  
5.4.1 The testing of two cardiac differentiation protocols 
The monolayer differentiation protocol was selected in preference to the EB 
protocols on the basis that it generated contracting cultures from the iPSC line tested 
(SBNeo1-C3). 
EB protocol A was used to generate iPSC-CMs from multiple cell lines in a 
subsequent study in our lab thereby validating the protocol (Yang et al., 2017). The 
generation of iPSC-CMs using EB protocol B has not been reported. The generation 
of iPSC-CMs from iPSCs cultured on Matrigel with MEF conditioned medium using 
the Aggrewell plate system has been reported (Pesl et al., 2014). 
The reasons for the failure of the EB protocols to generate contracting cultures in 
this study are unclear but the following hypotheses could be investigated. (1) Failure 
of the EB protocol was due to chance. Since not all experiments generated 
contracting cultures the probability of this outcome is related to the number of 
experimental repeats performed and the number of EBs undergoing differentiation. 
The EB protocols in this study were tested in only two experimental repeats per cell 
line and with a relatively small starting population of EBs. (2) Failure of the EB 
protocol reflects an incompatibility between it and the SBNeo1-C3 cultures. The 
potential of SBNeo1-C3 to produce iPSC-CMs was confirmed using the monolayer 
differentiation protocol. The efficiency of differentiation of this line may vary between 
protocols. Yang et al. did not use SBNeo1-C3 in their study and to date there have 
been no reports iPSC-CMs being generate from this line using this protocol (Yang et 
al., 2017). (3) Failure of EB protocol B are due to differences between it and the 
protocol used by Pesl el al, namely that iPSCs were cultured in in MEF conditioned 
medium (rather than mTeSR1) before EB formation (Pesl et al., 2014).  
Further experiments and protocol optimisation would be necessary to investigate 
these hypotheses further. 
5.4.2 Characterisation of contracting cultures 
The upregulation of cardio-specific genes (TNNT2, TNNI3) and the expression of 
their proteins (detected by immunofluorescence microscopy and flow cytometry) 
provided evidence that a proportion of iPSCs differentiated to a cardiomyocyte 
lineage. Subsequent analyses provided evidence that the cells expressing these 
genes and proteins also had the functional characteristics of cardiomyocytes.  
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Immunofluorescence microscopy provided evidence that the cTnT expressed was 
organised into striated myofibrils in association with αAct2. The cTnT and αAct2 
signals were spatially distinct, consistent with the localisation of αAct2 to the Z-discs 
and cTnT to the sarcomeres. 
Myofibrils are composed of a large number of proteins, the expression of genes 
encoding three of these (MYH6, MYH7 and ACTN2) was assessed this this study 
and were expressed at higher levels in contracting cultures than in iPSCs. Myofibril 
contraction is a calcium dependent process and therefore the presence of 
spontaneous contractions would be consistent with the presence and functionality of 
the apparatus necessary to mediate rapid cycling changes in intracellular calcium 
concentration. The presence of these calcium transients was confirmed by 
fluorescence microscopy. The ability of field pacing to trigger these calcium 
transients is also consistent with the presence of the voltage gated trans-membrane 
ion channels that mediate the cardiac action potential. The synchronisation of 
contractions within cultures is consistent with presence of intercellular junctions 
forming an electrical syncytium by which action potentials are transmitted though 
cultures. 
Skeletal myocytes also contain striated myofibrils and express MYH6, MYH7 and 
ACTN2. The generation of iPSC derived skeletal myocytes (iPSC-SkM) within 35 
days of the start of differentiation has been reported using a protocol that has 
similarities to the cardiac differentiation protocol used in this study (Shelton et al., 
2016). Both protocols involve the direction of iPSCs to mesodermal specification by 
the upregulation of Wnt signalling using with the GSK3 inhibitor CHIR99021 (Lian et 
al., 2013a) (Shelton et al., 2014). Thereafter the protocols differ in that the cardiac 
differentiation protocol involves a subsequent inhibition of Wnt signalling and an 
absence of insulin in the culture medium to promote cardiomyocyte specification from 
cardiac mesoderm, whereas this is not a component of skeletal muscle protocols 
(Kattman et al., 2011) (Lian et al., 2013a) (Willems et al., 2011) (Lian et al., 2013b) 
(Shelton et al., 2016). The expression of cardiac lineage markers Nkx2-5 and MYH6 
was reported in cultures of iPSC-SkMs derived using the CHIR based protocol 
(Shelton et al., 2014). This supports the idea that these cell types may co-exist in 
cultures of differentiated iPSCs generated by protocols with these similar 
characteristics.  
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The assessment of sarcomeric protein expression by immunofluorescence 
microscopy provided an opportunity to screen for the presence of skeletal myocytes 
within differentiated cultures. αAct2 is expressed at the Z-discs of both skeletal and 
cardiac myocytes whereas cTnT is cardio-specific. No cells were observed that 
contained striated αAct2 signal in the absence of cTnT. Although this cannot exclude 
the presence of iPSC-SkMs it suggest that, if they are present, it is at a low 
frequency. The presence of skeletal myocytes in differentiated cultures could be 
investigated in further work by screening for a larger range of protein markers that 
distinguish skeletal from cardiac myocytes markers such as Pax7, aortic smooth 
muscle actin and myosin light chain kinase 2 . 
In adult cardiomyocytes studied by TEM, striated myofibrils have the following 
typical features. They consist of bundles of fibres traversed at regular intervals by 
electron-dense Z-lines. The region between two adjacent Z lines on the same 
myofibril is referred to as a sarcomere. A range of proteins are localised to the 
sarcomeres including actin, myosins, troponins and titin. The organisation of proteins 
within the sarcomere gives rise to regions of greater and lesser protein density which 
appear as regions of differing electron density in TEM images. Regions in which actin 
and myosins overlap are more electron dense than non-overlapping regions and 
define features referred to as A bands, I bands and H-zones. The identification of 
these A and I bands in the cells of iPSC derived contracting cultures in this study is 
further evidence of the expression of the multiple sarcomeric proteins and their 
organisation into myofibrils. The reasons for the lack of identifiable I band and A 
bands in the RAA samples studies by TEM are unclear. It was hypothesised that this 
was because the samples were fixed whilst the sarcomeres were in a contracted 
state. 
The identification of striated myofibrils allows myocytes to be distinguished from 
other cell types within TEM samples. There are no ultrastructural features by which 
cardiac myofibrils can be distinguished from those found in skeletal muscle. 
Therefore, strictly speaking, the identification of striated myofibrils by TEM is 
consistent with, rather than proof of cardiac differentiation. The immunofluorescence 
data discussed above did not support the idea that iPSC-SkMs were present in 
contracting cultures and therefore supported the assumption that cells containing 
striated myofibrils by TEM were iPSC-CMs. 
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5.4.3 Purification 
A goal of this study is to compare the levels of expression of genes encoding 
desmosomal proteins in iPSC-CMs with and without ARVC/D associated mutations. 
The presence of non-cardiomyocytes within samples of differentiated cells collected 
for analyses such as RT-qPCR and western blotting have the potential to influence 
the level of gene expression detected within those samples. For example the 
presence of a high proportion of non-cardiomyocytes in which a low level of 
desmosomal gene expression is normal would result in the average expression level 
in that sample to be lower than if it contained only cardiomyocytes. Without 
controlling for this variable it cannot be determined whether differences in gene 
expression between cell lines are due to differences in their expression in iPSC-CMs 
or due to the influence of non-cardiomyocyte populations within the samples. The 
potential for non-cardiomyocytes to influence the result can be minimised by 
obtaining samples with a uniformly high percentage of iPSC-CMs. A target of ≥75% 
of cells expressing cTnI was chosen for samples to be used in assessments of 
desmosomal gene expression.  
Strategies to achieve high purity samples can be divided into those directed at 
optimising the efficiency of differentiation and those directed at purifying iPSC-CMs 
from a mixed population.  
The monolayer differentiation protocol used in this study was adapted from that 
published by Lian et al. who reported the production of cultures containing 80-98% 
iPSC-CMs across multiple cell lines (Lian et al., 2013a). The protocol modifications 
recommended by the authors to optimise differentiation efficiency were pursued in all 
cell lines. Despite these attempts, cultures with a consistent high proportion of iPSC-
CMs could not be generated consistently. 
The decrease in OCT4A and NANOG expression in contracting cultures relative to 
iPSCs suggests that the reduced efficiency was not due to a failure of the protocol to 
induce the differentiation of iPSCs. The cell types constituting the non-cardiomyocyte 
fraction of contracting cultures were not characterised in greater detail in this study. 
Two strategies for purifying iPSC-CMs from mixed populations were investigated. 
The first strategy assessed was the purification of live cells by FACS according to 
expression of the surface protein SIRPA (Dubois et al., 2011). The second strategy 
was purification by culture in the absence of glucose thereby causing the death of 
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non-cardiomyocytes which have less resistance to this type of metabolic stress than 
iPSC-CMs (Tohyama et al., 2013). 
The ability of SIRPA based selection to purify iPSC-CMs from a sample is based on 
the principle that a high proportion of SIRPA positive cells are iPSC-CMs. The finding 
that 77-98% of SIRPA positive cells expressed cTnI in this study are broadly in 
agreement with those of Dubois et al. for whom 67-90% of SIRPA positive cells 
expressed cTnT (Dubois et al., 2011). 
We found the sensitivity of SIRPA based selection to be lower than that reported by 
Dubois et al. In our sample 42-55% of SIRPA negative cells expressed cardiac 
troponin compared with 5-16% in the experiments reported by Dubois (Dubois et al., 
2011). Differences in study protocols may account for this apparent discrepancy. 
Dubois et al. employed the EB based cardiac differentiation protocol described by 
Kattman et al. . This may result in iPSC-CMs with higher levels of SIRPA expression 
than the monolayer protocol used in this study. The most mature cultures sorted by 
Dubois et al. were 20 days into differentiation compared with the 30 day old cultures 
used in this study the proportion of cells. This may indicate that the proportion of 
iPSC-CMs expressing SIRPA decreases over time. Finally, Dubois et al. identified 
iPSC-CMs on the basis of cTnT expression, whereas in this study antibodies to cTnI 
were used. Different antibody specificities may account for these different results. 
Overall selection on the basis of SIRPA identified 49-54% of cTnI positive cells in 
culture in our study suggesting that a large proportion of iPSC-CMs cannot be 
purified using the protocol employed in this study. Alternative strategies for FACS 
based purification other than SIRPA have been proposed. The combination of CD90 
(THY1), CD31 (PECAM1), CD140B (PDGFRB) and CD49A (ITGA1) has been 
reported to identify the majority of non-cardiomyocytes in differentiated cultures at 
day 20 (Dubois et al., 2011). Purification based on negative selection using these 
markers may allow the collection of a greater proportion of the iPSC-CM population 
than with SIRPA.   
Results of the attempt to purify 2-C6-WB2 (in which only 13% of the initial sample 
were cardiomyocytes) by FACS also merit further discussion. Dubois et al. reported 
that samples containing approximately 10% iPSC-CMs could be purified to contain 
60-70% iPSC-CMs (Dubois et al., 2011). Samples containing 40% hESC-CMs could 
be purified to 90±4% iPSC-CMs (Dubois et al., 2011). It was hypothesised that 
SIRPA sorting may be unable to adequately purify samples containing a low 
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percentage of iPSC-CMs and this may account for the failure to purify 2-C6-WB2. It 
was also notable that the proportion of cTnI positive cells was higher in the SIRPA 
negative fractions of 2-C6-WB2 than in the unsorted sample. It was therefore 
hypothesised that the process of FACS itself acts to remove non-cardiomyocytes. 
Further experiments would be necessary to investigate both these hypotheses. 
The low yield of RNA from sorted SIRPA positive cells coupled with the high salt to 
nucleic acid ratio in these samples made them unsuitable for use in RT-qPCR 
experiments. It was hypothesised that the process of FACS resulted in cell injury that 
reduced the RNA yield in these samples. Further experiments would be necessary to 
investigate this hypothesis and optimise the FACS protocol to allow RNA samples of 
the required quantity and quality to be obtained from sorted iPSC-CMs. 
Taken together it was concluded that the feasibility of obtaining RNA samples for 
FACS purified samples containing ≥75% iPSC-CM has not been established in this 
study. 
The purification of iPSC-CMs by modifying culture conditions to cause the death of 
non-cardiomyocytes was first described by Tohyama et al. (Tohyama et al., 2013). 
The technique is based on the observation that cardiomyocytes can survive culture 
with medium that does not contain glucose whereas non-cardiomyocytes die rapidly 
in these condition (Tohyama et al., 2013). Purification by glucose free culture has 
been reported to be able to generate cultures in which >95% of cells are reported to 
be iPSC-CMs from initial cultures with as little as 8% of this cell type present 
(Tohyama et al., 2013) (Burridge et al., 2014).  
Tests of the purification protocol in this study found that within a single experiment 
(2-C4-WB4) only produced cultures containing ≥75% iPSC-CMs in 50% of wells 
tested. A modified version of the protocol generated cultures containing ≥75% iPSC-
CMs in all experiments across three cell lines but only in 50% of experiments 
involving 0101-C41. When considering the effect of purification on individual cell lines, 
the proportion of iPSC-CMs was significantly greater in the experiments where the 
purification protocol was used, than in earlier experiments when it was not, in three of 
the four cell lines assessed. This would be consistent with the purification protocol 
being effective. There were no control cultures that were not exposed to the 
purification medium in these experiments. Therefore, the possibility that these results 
occurred due to the efficiency of differentiation and not the effect of purification 
cannot be excluded. 
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If it is accepted that metabolic purification did increase the proportion of iPSC-CMs 
in some cultures then reasons for the success of the modified purification protocol 
and failure of the protocol tested with 2-C4-WB4 may be considered. The protocols 
differed from the initial purification protocol in two respects: (1) the purification began 
at an earlier stage of differentiation (day 9 vs day 12) and (2) the duration of 
exposure to the purification medium was less (5 vs 7 days) 13. Both purification start 
points (day 9 and day 12) are close to that reported by Burridge et al. (day 10) whose 
protocol produced cultures containing >90% iPSC-CMs. There is no evidence from 
published reports to support the idea that the earlier start point resulted in improved 
efficiency. Tohyama et al. reported that the duration of purification influenced the 
resulting proportion of iPSC-CMs in a culture (Tohyama et al., 2013). They reported 
that a culture starting with 4% iPSC-CMs was enriched to 33% iPSC-CMs after 4 
days of purification and to >90% after 6 days. This suggests that high purity samples 
obtained in the later experiments were generated in spite of, rather than as a result of, 
shortening the purification duration from 7 to 5 days. 
The proportion of dead cells (identified by the Zombie dye) contained within the 
2C4-WB4 cultures after exposure to the purification medium was relatively low 
(median 8%) and not significantly different from control cultures. This suggests that if 
cells died during purification, they were released into the culture medium rather than 
remaining within cultures. The proportion of dead iPSC-CMs was also low in the 
purified sample (median 5%) and consequently, in subsequent experiments, where 
Zombie was not used, it was assumed that the proportion of single cell events 
expressing a cardiac troponin was indicative of the proportion of viable iPSC-CMs 
from which RNA could be extracted.  
5.5 Conclusions 
Directed cardiac differentiation of iPSCs in adherent feeder-free culture conditions is 
feasible using the monolayer differentiation protocol. The feasibility iPSC 
differentiation by the EB differentiation protocols tested was not established in this 
study. 
The resultant contracting cultures contained iPSC-CMs expressing a typical array of 
sarcomeric proteins that are arranged into myofibrils with many of the ultrastructural 
characteristics of adult cardiomyocytes. The iPSC-CMs in these cultures have the 
                                            
13 These modifications followed discussions with Dr Nicola Hellen, Imperial College London, who used a similar protocol. 
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functional characteristics of cardiomyocytes including spontaneous and voltage 
inducible contractions associated with calcium transients.  
RNA samples from samples containing ≥75% live iPSC-CMs may be obtained in 
experiments in which cultures have been exposed to the metabolic purification 
protocol. The data from this study are consistent with the efficacy of this purification 
protocol. The feasibility of iPSC-CM purification by FACS for SIRPA using the 
protocol testing in this study was not established. 
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6 Chapter 6. Desmosomes, Desmosomal Genes And Desmosomal 
Proteins In hESCs, iPSCs, iPSC-CMs And Myocardium 
6.1 Introduction 
This chapter will discuss the identification of desmosomes in pluripotent cell cultures 
and iPSC-CMs. It will also discuss the patterns of expression of desmosomal genes 
and the localisation of desmosomal plaque proteins in these tissues. A summary of 
normal desmosomal morphology and the localisation of desmosomal proteins has 
been described in chapter 1, along with a discussion of the changes to these 
parameters in ARVC/D myocardium and iPSC-CM models of ARVC/D.  
6.2 Aims and hypotheses 
It was hypothesised that: 
• hESCs and iPSCs contain inter-cellular adhesions that have the 
characteristic ultrastructural features of desmosomes. 
• hESCs and iPSCs express a range of desmosomal plaque proteins and the 
cellular distribution of these proteins is consistent with their incorporation in 
the focal intercellular adhesion junctions.  
• iPSCs, iPSC-CMs and RAA myocardium have different patterns of 
desmosomal gene expression. 
• The ARVC/D mutations investigated in this study will result in a reduction in 
the abundance of transcripts from the affected genes. 
• ARVC/D iPSC-CMs exhibit a redistribution of desmosomal plaque proteins to 
the cytoplasm or nucleus that is identifiable by immunofluorescence 
microscopy. 
6.3 Results 
6.3.1 The identification of desmosomes in iPSCs, iPSC-CMs, RAA and hESCs 
Desmosomes were identified in iPSCs, iPSC-CMs and RAA myocardium  (Figure 
58) and in hESCs (Figure 59). Desmosomes in all tissue types had a typical 
appearance. Bi-laminar structures defining the intercellular gap were attributed to the 
plasma membrane. Electron-dense ODPs were observed on the cytoplasmic side of 
this laminated structure, often separated by a region of reduced electron density. The 
cytoplasmic side of the ODPs abutted with less dense IDPs which were, in-turn 
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associated with intermediate filaments within the cytoplasm (Figure 58 D to F). In 
some desmosomes a dense midline was also visible (Figure 58 D and F).  
Desmosomes were identified in two different iPSC lines and H9 hESCs, but were 
very sparse and only seen at the edges of these samples (Figure 59). The cytoplasm 
adjacent to the IDPs in these PSC desmosomes had a less granular appearance that 
in IPSC-CMs and RAA suggesting less abundant intermediate filaments. In RAA, 
desmosomes were exclusively co-localised with adherens junctions and myofibrils to 
the regions of highly convoluted plasma membrane between adjacent cells i.e 
forming the expected area composita of the intercalated discs (ICDs) (Figure 58 C). 
Desmosomes were found in regions similar to ICDs in iPSC-CMs (Figure 58 B), but 
were also seen in isolation. 
  
Figure 58 TEM images of desmosomes in iPSCs, iPSC-CMs and RAA 
Panels A and D show areas images from samples of 2-C6 iPSCs collected from 
feeder-free maintenance culture. Panels A to C are low magnification images in 
which the locations of desmosomes are indicated by arrowheads. In panels B and C 
the locations of striated myofibrils are indicated (M). Panels D to F are high 
magnification images of desmosomes illustrating the typical laminated appearance 
of their plaques. The region of the plasma membrane (pm), ODP (o), IDP (i) and 
intermediate filaments (f) that converge on the plaque are indicated. A dense 
midline (d) is also visible in D and F. Scale bars in images A to C indicate 1µm, and 
in images D to F indicate 50nm. 
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Figure 59 Desmosomes in iPSCs and hESCs 
Scale bars in section A indicate 1µm. Scale bars in section B indicate 50nm. 
  
 
6.3.2 Frequency of desmosomes within TEM images 
Regions of a sample containing 2-C6 iPSC-CMs were selected at random and 
imaged at 13,500X (each image covering 59nm2 of sample). 64% of the images 
contained no desmosomes. Additionally only a subset those images containing 
desmosomes were of sufficient quality for morphometric analysis, this proportion was 
not quantified. Approximately 6 hours of TEM imaging time were needed to obtain 
the 30 fully optimised high magnification images necessary for morphometric 
evaluation, for each cell line assessed. A similar finding was observed in the RAA 
sample (no desmosomes were seen in 77% of images). Although theoretically this 
technique could have been used to assess the abundance of desmosomes within 
samples this approach was not performed due to the resource constraints. 
6.3.3 IDP morphology 
In the majority of desmosomes imaged in both iPSC-CMs and cardiomyocytes the 
edge of the IDP on the cytoplasmic side of the plaque did not appear as a continuous 
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boundary running parallel to the ODP. In some desmosomes the IDP appeared as a 
region of heterogeneous electron density that became gradually less dense with 
increasing distance from the plaque until it merged with the region of the intermediate 
filaments. In other desmosomes a distinct boundary was present, but it followed a 
broken or tortuous path that was not a consistent distance from, or parallel to, the 
ODP (Figure 60).  
 
Figure 60 Assessment of the IDP-intermediate filament junction in 
desmosomes from iPSC-CMs and RAA.  
Representative regions of desmosomes from control iPSC-CMs (2-C6) (Panel A) 
and RAA myocardium (Panel B). Structure representing the IDP and the IDP-IF 
junction were sought in the indicated region between the dashed lines (*). Scale 
bars indicate 20nm.  
6.3.4 Desmosomal gene expression, experimental design and sample details. 
The expression of genes encoding desmosomal proteins was assessed in PBMCs, 
iPSCs, iPSC-CMs and RAA tissue. Samples from HaCaT cells and RAA were used 
as positive controls for the primers. Primer sets were validated in for all genes except 
that for DSG1. This primer set generated the product of the expected size from 
HaCaT samples by RT-PCR, but in RT-qPCR experiments the expression levels 
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were very low, with the mean Ct being 32 (SD 1.2). Desmosomal gene expression 
was normalised to a combination of reference genes selected to be most stable 
across the four cell types from preliminary experiments analysed using the geNorm 
algorithm. The mean Ct for reference genes in these experiments was 24 (SD 0.8). A 
more detailed description of the results of these experiments is given in the appendix. 
Expression in PBMCs was assessed in samples from seven subjects including the 
three from which ARVC/D lines were derived. IPSC samples consisted of RNA from 
eight iPSC lines (2-C3, 2-C7, 2-C4, 2-C6, AD3-C1, 0101-C41, 0202-C13 and 0203-
C8). Each line was assessed with RNA from three different passages. iPSC-CM 
samples consisted of RNA from the four lines in which samples containing ≥75% 
cTnI positive cells could be obtained (2-C6, AD3-C1, 0202-C13 and 0203-C8). Each 
line assessed with RNA from three independent cardiac differentiation experiments. 
Expression in RAA was assessed in four samples from different individuals.  
6.3.5 Comparison of desmosomal gene expression in PBMCs, iPSCs, iPSC-
CMs and RAA 
In the analysis of these data, expression data from AD3-C1 iPSCs (a fibroblast 
derived cell line) were excluded to allow the comparison of PBMCs with blood 
derived iPSCs.  
DSC1 expression was very low or effectively absent in iPSCs and iPSC-CMs (mean 
expression <10% of the mean expression of reference genes) but expressed at a 
high level in RAA (mean 6.0, SEM 2.1) (mean unadjusted Ct 22.6, SEM 2.6) (Figure 
61) (Table 57). The expression of DSC1 by RAA and its absence in iPSC-CMs and 
HaCaT cells was confirmed by assessment with two additional primer sets to DSC1a 
and DSC1b (Figure 62) (Table 58). These experiments suggested that both isoforms 
of the protein may be present in the myocardium. 
DSC2 was expressed in iPSCs, iPSC-CMs and RAA (Figure 61) (Table 57). The 
expression in PBMCs was approximately 10 fold lower than in the desmosome 
bearing tissues. The differences in mean expression between tissue types were 
statistically significant (one way ANOVA p<0.001). The mean expression of DSC2 in 
iPSCs (1.80, SEM 0.20) (unadjusted Ct 23.2, SEM 0.2) was higher than in PBMCs 
(0.18, SEM 0.12) (unadjusted Ct 25.6, SEM 0.8) (Tukey’s test p<0.0001) and iPSC-
CMs (1.05, SEM 0.15) (unadjusted Ct 23.9, SEM 0.2) (Tukey’s test p=0.01). 
DSC3 was also expressed in iPSCs, iPSC-CMs and RAA, but not in PBMCs (Figure 
61) (Table 57).  The differences in mean expression between tissue types were 
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statistically significant (one way ANOVA p<0.001). Mean expression in iPSCs (0.66, 
SEM 0.05) (unadjusted Ct 24.6, SEM 0.2) and iPSC-CMs (1.2, SEM 0.5) (unadjusted 
Ct 24.4, SEM 0.5) were similar (Tukey’s test p>0.05), but the mean expression in 
RAA (0.17, SEM 0.11) (unadjusted Ct 28.3, SEM 0.8) was lower than iPSC-CMs 
(Tukey’s test p=0.03). 
DSG2 was the most abundantly expressed of the four desmogleins in all three 
desmosome bearing tissues (Figure 61) (Table 57). The mean expression of DSG2 
in iPSC-CMs (1.20, SEM 0.09) (unadjusted Ct 23.5, SEM 0.2) was similar to that of 
RAA (1.5, SEM 0.39) (unadjusted Ct 24.5, SEM 0.6) (Tukey’s test p>0.05), but lower 
than the mean of iPSCs (3.93, SEM 0.28) (unadjusted Ct 22.1, SEM 0.2)  (Tukey’s 
test p<0.0001). The expression of DSG1, DSG3 and DSG4 was low or absent in all 
desmosome bearing tissues (all mean expression levels <10% of reference genes).  
PKP2 was the most abundantly expressed plakophilin in all three desmosome 
bearing tissues, and was also expressed at low levels in PBMCs (Figure 61) (Table 
57). The differences in mean expression between tissue types were statistically 
significant (one way ANOVA p<0.001). The mean expression in iPSC-CMs (76.2, 
SEM 1.3) (unadjusted Ct 17.5, SEM 0.1) was higher than the mean expression in 
both iPSCs (4.0, SEM 0.3) (unadjusted Ct 22.0, SEM 0.2) and RAA (42.1, SEM 4.5) 
(unadjusted Ct 19.6, SEM 0.4) (Tukey’s test p<0.0001 for both). The difference 
between the mean expression of PKP2 in PBMCs (0.11, SEM 0.03) (unadjusted Ct 
28.1, SEM 0.3) and iPSCs did not reach statistically significance in the post hoc 
analysis. 
 JUP was expressed in the three desmosome bearing cell types and in PBMCs 
(Figure 61) (Table 57).  The differences in mean expression between tissue types 
were statistically significant (one way ANOVA p<0.001). The mean expression in 
iPSC-CMs (9.52, SEM 0.56) (unadjusted Ct 20.7, SEM 0.3) was similar to that of 
RAA (8.88, SEM 1.45) (unadjusted Ct 21.9, SEM 0.4)  (Tukey’s test p>0.05), and 
greater than that of iPSCs (5.14, SEM 0.45) (unadjusted Ct 22.0, SEM 0.3)  (Tukey’s 
test p=0.0004). The mean expression in PBMCs (0.64, SEM 0.08) (unadjusted Ct 
25.5, SEM 0.5) was less than that of the iPSCs (Tukey’s test p<0.0001).  
DSP expression was noted in iPSCs (mean 1.80, SEM 0.19) (unadjusted Ct 23.2, 
SEM 0.2), iPSC-CMs (mean 3.87, SEM 0.59) (unadjusted Ct 21.8, SEM 0.2) and 
RAA (mean 3.64, SEM 1.16) (unadjusted Ct 23.3, SEM 0.7), but not in PBMCs 
(Figure 61) (Table 57). Although the differences in mean expression between tissue 
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types were statistically significant (one way ANOVA p<0.001), post hoc analysis did 
not identify significant pairwise differences. 
 
 
Figure 61 Comparison of the expression of desmosomal genes in PBMCs 
iPSCs, iPSC-CMs and RAA 
The expression of genes of interest relative to mean reference gene expression is 
presented. (Continued over) 
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Bars illustrate the mean expression for each cell/tissue type. Data are presented 
without calibration to a reference cell type in order that the figure provides an 
indication of the relative expression of different genes within a given cell type (e.g. it 
illustrates the relative expression of DSC2 and DSC3 in PBMCs) in addition to the 
comparison of a gene between cell types. Whiskers illustrate the SEM. The data 
were generated from seven PBMC samples, seven PBMC derived iPSC lines (each 
tested in three different passages), four iPSC-CM lines (each tested with samples 
from at least three different differentiation experiments in which >75% of the cells 
expressed cTnI by flow cytometry) and four RAA samples. Genes with mean 
expression levels <0.1 were considered effectively absent and these data are not 
displayed. Raw Ct values associated with these data are presented in Table 57. 
Means were compared by one way ANOVA and post hoc pairwise comparisons 
make by Tukey’s test. P values <0.05 are indicated (*) 
 
Gene PBMC iPSC iPSC-CM RAA 
DSC1 27.8±0.8 >30 >30 22.6±0.6 
DSC2 25.6±0.8 23.2±0.2 23.9±0.2 25.0±0.6 
DSC3 >30 24.6±0.2 24.4±0.5 28.3±0.8 
DSG1 >30 >30 >30 28.6±0.8 
DSG2 >30 22.1±0.2 23.5±0.2 24.5±0.6 
DSG3 27.0±0.4 29.9±0.2 28.9±0.5 >30 
DSG4 29.1±0.6 >30 29.9±0.3 >30 
PKP1 >30 >30 >30 >30 
PKP2 28.1±0.3 22.0±0.2 17.5±0.1 19.6±0.4 
PKP3 >30 25.6±0.4 >30 >30 
JUP 25.5±0.5 22.0±0.3 20.7±0.3 21.9±0.4 
DSP >30 23.2±0.2 21.8±0.2 23.3±0.7 
Table 57 Unadjusted Ct values from the assessment of expression of 
desmosomal gene in PBMCs, iPSCs, iPSC-CMs and RAA samples. 
The values presented are the means samples ± SEM. 
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Figure 62. Expression of DSC1 and its isoforms in HaCaT, iPSC-CMs and RAA 
The expression of genes of interest relative to mean reference gene expression is 
presented. Bars illustrate the mean expression for each cell/tissue type. Whiskers 
illustrate the SEM. Data are presented without calibration to a reference cell type in 
order that the figure provides an indication of the relative expression of the isoforms 
in the same cell type. Genes with mean expression levels <0.1 were considered 
effectively absent and these data are not displayed. The data were generated from 
four iPSC-CM lines (each tested with samples from at least three different 
differentiation experiments in which >75% of the cells expressed cTnI by flow 
cytometry), three passages of HaCaT cells and four RAA samples. 
 
Gene Cell type 
iPSC-CM HaCaT RAA 
DSC1 a+b >30 28.5±0.4 22.6±0.6 
DSC1a >30 29.8±0.3 22.8±0.4 
DSC1b >30 29.8±0.5 22.6±0.4 
Table 58 Unadjusted Ct values from the assessment of DSC1 isoform 
expression in iPSC-CMs, HaCaT cell and RAA. 
The values presented are the means samples ± SEM. 
 
6.3.6 Comparison of desmosomal gene expression between individual cell 
lines in PSCs and iPSC-CMs 
Differences in genes expression between the nine pluripotent cell lines assessed 
were noted for DSC2, DSC3, DSG2 and PKP2 in the (one way ANOVA, p<0.05) 
(Figure 63) (Table 58).   
Amongst the four iPSC-CM lines a significant difference between cell lines was only 
noted for DSP (one way ANOVA, p<0.05) (Figure 64) (Table 60).  
Post hoc analysis of iPSCs suggested that the expression of DSC3, DSG2 and 
PKP2 was greater in AD3-C1 than other lines in multiple pairwise comparisons 
(Tukey’s test p<0.05) (Figure 63). This trend was not reproduced in iPSC-CMs 
(Figure 64). Similarly although DSC2 expression was greater in 0202-C13 than other 
 
 
  182 
iPSCs but there was no difference in expression of DSC2 by 0202-C13 iPSC-CMs 
compared to other iPSC-CMs (Figure 64). 
Post hoc analysis suggested that the mean expression of DSP in 0203-C8 iPSC-
CMs (2.4, SEM 0.1) (unadjusted Ct 22.3, SEM 0.2) was significantly less that 0202-
C13 (5.2, SEM 0.1) (unadjusted Ct 21.1, SEM 0.3) (Tukey’s test p=0.001) (Figure 64) 
(Table 60), other pairwise comparisons were non-significant. The pattern of 
expression of DSP in iPSCs also suggested a trend towards lower DSP expression in 
0203-C8 compared with other cell lines but this did not reach statistical significance.  
 
Figure 63 Expression of major desmosomal genes in PSCs 
Bars indicate mean expression levels across three different passages. Expression 
levels of desmosomal genes are expressed relative to mean reference gene 
expression in the sample sample. Whiskers indicate SEM. Differences between cell 
lines were investigated with a one way ANOVA test, α=0.05. Post hoc pairwise 
comparisons were made using Tukey’s test, samples with one or more comparisons 
with a p<0.05 are indicated (*). 
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iPSC Genes 
DSC2 DSC3 DSG2 PKP2 JUP DSP 
H9 22.9±0.2 23.6±0.2 21.6±0.2 21.8±0.1 21.4±0.5 22.5±0.2 
AD3-C1 22.1±0.1 23.3±0.0 20.6±0.2 20.2±0.2 20.7±0.1 22.7±0.1 
2-C3 23.6±0.9 25.5±0.8 22.7±1.1 22.3±1.0 22.5±1.3 23.4±1.0 
2-C7 23.8±0.6 25.0±0.6 22.7±0.7 22.5±0.3 23.5±1.8 23.7±0.9 
2-C4 23.2±0.6 24.9±0.8 22.0±0.7 22.6±0.6 21.9±1.0 23.1±0.6 
2-C6 23.2±0.1 24.2±0.1 22.1±0.1 21.7±0.0 21.6±0.2 23.1±0.1 
0101-C41 23.4±0.2 25.0±0.2 22.1±0.2 22.2±0.3 21.3±0.1 23.2±0.1 
0202-C13 21.8±0.0 23.7±0.1 20.9±0.0 21.3±0.0 20.6±0.1 22.2±0.1 
0203-C8 23.1±0.3 24.1±0.3 21.8±0.3 21.7±0.3 22.4±1.1 23.9±0.3 
 
Table 59 Unadjusted Ct values from the assessment of the expression of 
desmosomal genes in pluripotent cell lines. 
The values presented are the means samples ± SEM. 
 
 
Figure 64 Expression of major desmosomal genes in iPSC-CMs 
Bars indicate mean expression levels for each cell line across samples from three 
independent differentiation experiments, with the exception of 2-C6 which was 
across 5 experiments. Whiskers indicate SEM. Differences between cell lines were 
investigated with the one-way ANOVA, post hoc pairwise comparisons were made 
with Tukey’s test p values <0.05 are indicated (*). 
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iPSC-CM Genes 
DSC2 DSC3 DSG2 PKP2 JUP DSP 
AD3-C1 23.7±0.6 24.3±0.7 23.9±0.5 17.6±0.3 20.7±0.2 21.7±0.2 
2-C6 23.9±0.2 24.4±0.7 23.8±0.2 17.8±0.3 21.6±1.0 22.2±0.3 
0202-C13 23.3±0.5 26.0±0.2 23.0±0.4 17.3±0.2 20.2±0.3 21.1±0.3 
0203-C8 24.2±0.2 23.0±0.9 23.5±0.2 17.3±0.3 20.2±0.3 22.3±0.2 
 
Table 60 Unadjusted Ct values from the assessment of desmosomal gene 
expression in iPSC-CMs. 
The values presented are the means samples ± SEM. 
 
6.3.7 Cellular localisation of desmosomal proteins in iPSCs 
Immunofluorescence microscopy was used to assess the cellular localisation of DSP, 
JUP, PKP2, DSG2 and DSC2. The antibody to DSC2 was also known to cross react 
with DSC3. HaCaT cells were used as a positive control for these studies. This cell 
line has been reported to form desmosomes and express a wide range of 
desmosomal plaque proteins in previous publications (Kimura et al., 2007) (Nie et al., 
2011). The presence of desmosomes in HaCaT cell cultures by TEM analysis was 
also confirmed in the study (data not shown). 
In the HaCaT cell line an abundant punctate signal forming linear patterns distinct 
from the DAPI signal was seen with all antibodies (Figure 65). In addition to the linear 
patterns a more diffuse signal punctate was seen in some cells. Desmosomal protein 
signal was not observed to co-localise with DAPI. 
Desmosomal protein localisation was assessed in five pluripotent cell lines: 2-C6 
iPSCs and H9 hESCs (Figure 65) and the three ARVC/D iPSCs (Figure 66). Each 
line was assessed in a single passage.  
The DSC2/3, DSG2 and DSP signal in all iPSCs (control and ARVC/D) formed a 
clear puncti-linear pattern that often enclosed nuclei. The DSG2 signal in 0203-C8 
iPSCs appeared less abundant such that it formed a more scattered punctate signal 
rather than lines suggesting a boundary between cells. Manual analysis of individual 
slices of Z-stack images found that the DSC2/3, DSG2 and DSP signals did not co-
localise with the DAPI signal of the nucleus. 
Punctate signals were also observed with labelling of PKP2 and JUP signal in iPSCs 
but not in H9 hESCs in which it appeared diffuse and cytoplasmic. In some areas the 
punctate JUP signal was organised into linear patterns, but for both JUP and PKP2 
the signal was mostly not organised into a pattern.  Punctate PKP2 signal that co-
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localised with nuclear DAPI signal was seen in all iPSC lines (control and ARVC/D) 
and in the HaCaT cells (Figure 65) (Figure 66). 
6.3.8 Cellular localisation of desmosomal proteins in iPSC-CMs 
iPSC-CMs were studied from 2-C6, 0101-C41, 0202-C13 and 0203-C8. For each cell 
line, samples from three independent differentiation experiments were studied, with 
all five desmosomal antibodies assessed in each experiment. Signal associated with 
iPSC-CMs was identified by co-labelling with an antibody to cTnT. 
Signal for all desmosomal proteins was seen in all cell lines (Figure 67). All the 
antibodies produced a punctate signal. This signal was frequently organised into 
puncti-linear patterns or regions of continuous linear signal consistent with the 
presence of adjacent intercellular adhesion junctions at the plasma membrane.  
In some cells the punctate signal was not clearly organised into linear patterns. This 
was particularly noticeable in the assessment of DSG2 signal in 0202-C13 and 0203-
C8. The DSG2 signal in 0203-C8 also appeared less abundant that in the control cell 
line (Figure 67), echoing the pattern seen in undifferentiated iPSCs. Occasional 
punctate JUP and PKP2 signal that co-localised with the nucleus was noted in both 
the control and ARVC/D iPSC-CMs (Figure 68). 
The signal intensity for all antibodies was highly variable both within samples and 
between experimental repeats. Samples from both control and ARVC/D clones 
contained clusters of iPSC-CMs in which no desmosomal signal was apparent and 
other regions in which there was a strong signal. 
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Figure 65 Immunofluorescence microscopy images of desmosomal protein signal in immortalised keratinocytes (HaCaT) and 
pluripotent cell lines. 
Scale bars indicate 10µm. 
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Figure 66 Immunofluorescence microscopy images of desmosomal protein signal in ARVC/D iPSCs. 
Scale bars indicate 10µm. 
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Figure 67 Representative immunofluorescence microscopy image of desmosomal protein localisation in iPSC-CMs 
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 (continued) 
 
Scale bars indicate 10µm 
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Figure 68 Nuclear localisation of punctate JUP and PKP2 signal in iPSC-CMs 
Single slice images from Z-stack suggesting co-localisation of punctate JUP and PKP2 signal with nuclear DAPI signal (arrow heads). 
Scale bars indicate 10µm
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6.4 Discussion 
6.4.1 Desmosomal ultrastructure and quantitative assessments of 
morphology  
The data in this chapter demonstrate that the study methodology was capable of 
generating images of desmosomes of sufficient quality for quantitative analyses of 
desmosomal morphology. The bi-laminar appearance attributed to the plasma 
membrane and the ODP separated from this by the less electron dense region are 
similar to those reported in the studies discussed in chapter 1 (Kelly, 1966) (North et 
al., 1999). These structures were a sufficiently consistent feature of the desmosome 
images that they were considered suitable to define the parameters used for 
morphometric analysis.  
The IDP is thought to consist of rod domains and plakin repeat domains (PRD) of 
DSP along with points of interaction with intermediate filaments (IF) (Holthöfer et al., 
2007). The initial plan for this study was to use this junction to define a parameter 
referred to as the inter-IDP width (IIW). IIW was to be the distance between the IDP-
IF junctions of adjacent plaques of a desmosome, thereby encompassing both the 
ODP and intermembranous gap. This parameter was chosen because it was 
comparable to a parameter measured by Caspi et al. called total desmosomal width, 
which was reported to be significantly increased in ARVC/D iPSC-CMs compared 
with controls (Caspi et al., 2013). In this study the junction of the IDP and the 
intermediate filaments was not consistent in being either identifiable or a consistent 
distance from the edge of the ODP. Consequently was decided that the IIW could not 
be measured. Difficulty in defining the IDP-IF junction as a line that is parallel to the 
ODP has been reported in previous publications that have attempted to quantify 
desmosomal widths (Al-Amoudi et al., 2011). There are several possible 
explanations for this finding. Since definition of the IDP-IF junction requires a step 
change in the protein density between the IDP and IFs it could be obscured by the 
density associated with converging IFs. Alternatively it may suggest that the 
organisation of DSP within the plaque is such that the IF binding PRD is not located 
at a single distance from the ODP edge.   
6.4.2 Desmosomes in iPSCs and hESCs 
The data from this study suggest that pluripotent cells in vitro (iPSCs and hESCs) 
express desmosomal genes at levels that are comparable to that found in 
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desmosome bearing tissues (myocardium) and are greater than in non-desmosome 
bearing tissues (PBMCs). TEM analysis confirmed the presence of desmosomes in 
cultures of both iPSCs and hESCs. The puncti-linear signal seen by 
immunofluorescence microscopy in these cultures is consistent with both the 
expression of desmosomal proteins and with their localisation to focal inter-cellular 
adhesion junctions.  
Previous reports have suggested that desmosomes are absent from the inner cell 
mass (ICM) (the archetypal pluripotent cell type) in vivo  (Ducibella et al., 1975). In 
these studies of mouse embryos desmosomes were detected by TEM in the late 
morulae stage. Following compaction and blastulation they are localised to the 
trophectoderm. Desmosomes appear to be absent from the inner cell mass (ICM) 
until it begins to differentiate into epithelia of the primitive germ cell layers (Jackson 
et al., 1981). The expression of some desmosomal genes (DSC3, DSG2, JUP, DSP) 
have been reported to be expressed throughout embryonic development (Den et al., 
2006). Homozygous knock-out mouse models of DSC3, DSG2 JUP, PKP2 or DSP 
have been found to result in embryonic lethality. In DSC3 and DSG2 knock-out 
models this occurs before or around the time of implantation and is thought to 
represent abnormalities in the trophectoderm (Den et al., 2006) (Eshkind et al., 2002). 
In DSP knock-out embryos, implantation occurs as normal but abnormalities in tissue 
architecture develop in the blastocoel (Gallicano et al., 1998). PKP2 and JUP knock-
out does not appear to affect early embryonic development but does result in death 
in mid-gestation from cardiovascular abnormalities (Bierkamp et al., 1996) 
(Grossmann et al., 2004). Taken together these studies do not suggest that 
desmosomal proteins are important to the function of pluripotent cells of the ICM in 
vivo. 
Despite their absence in the ICM, desmosomes have been reported in cultures of 
ESCs in vitro (Sathananthan et al., 2002). In addition the expression of a range of 
desmosomal genes has been reported in cultures of pluripotent cell lines in a meta-
analysis of publically available RNA expression data (Mabbott et al., 2013). Other 
investigators have described intercellular junctions between ESCs that lack the 
laminated plaque and connections to the cytoskeleton that are typical of 
desmosomes but contain at least one desmosomal plaque protein (DSG2) (Eshkind 
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et al., 2002)n. This study was specifically focused on identifying structures with the 
typical ultrastructural features of desmosomes in PSCs. The frequency of junctions 
without this morphology, such as the immature junctions described by Eshkind et al. 
was not systematically assessed.  
Collectively, previous reports and the data from this study support the idea that the 
expression of desmosomal genes and the organisation of their proteins into 
intercellular junctions is a characteristic of PSCs in vitro. 
The function of these proteins in PSCs remains unclear. It has been reported that 
the knock-out of JUP in ESCs had no effect on the maintenance of pluripotency (Sun 
et al., 2017). Similar knock-out experiments in PSCs for the other desmosomal genes 
have not been reported and may be a useful focus for future work. 
Since desmosomes are most commonly found in differentiated epithelia, it could be 
argued that the identification of desmosomes at the edges of PSC colonies indicates 
a loss of pluripotency in these regions. It is a limitation of the study methodology that 
co-labelling of pluripotency markers and desmosomal proteins was not performed in 
order to investigate this possibility. There is evidence that the organisation of the 
cytoskeleton (and associated adhesions junctions) in cells at the peripheries of ESC 
colonies represents a mechanism for the maintenance of pluripotency. Bundles of 
actin and myosin filaments have been identified in peripheral cells forming a band 
circumscribing the colony centre (Närvä et al., 2017) (Rosowski et al., 2015). It has 
been suggested these fibres generate mechanical forces within PSC via focal 
adhesions of the cells to the culture substrate and that these forces act to maintain 
pluripotency within the colony and regulate colony expansion. If mechanical forces do 
have a role in maintaining pluripotency and regulating colony growth it is also 
possible that intercellular adhesion has a role in this process. In this context the 
ability of ESCs to form intercellular adhesion junctions (such as desmosomes) in 
peripheral cells of colonies may have a role in maintaining pluripotency in vitro. The 
intermediate filament protein vimentin has been reported to be expressed in ESCs at 
a level comparable to that of fibroblasts, although its organisation in cells in colonies 
has not been characterised (Boraas et al., 2016). The hypothesis that intercellular 
adhesion mediated by desmosomes (or junctions containing desmosomal proteins) 
                                            
n The cells in which Eshkind et al. reported these immature junctions did not express the DSP protein which is known to both 
regulate desmosome formation and mediate interactions with intermediate filaments. Therefore it may be that the immature 
junctions in this report are secondary to an abnormality in the cell line studied and are not representative of ESCs in general. 
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has a role in maintaining pluripotency regulating colony growth and could be a focus 
for future work.  
6.4.3 The effect of ARVC/D associated mutations on desmosomal gene 
expression 
The ARVC/D cell lines in this study carried mutations in PKP2, DSG2 and DSP.  
The PKP2 mutation carried by 0101-C41 was predicted to result in aberrant splicing 
of exon 11, a region that is included in transcripts encoding PKP2b and the dominant 
shorter cardiac isoform PKP2ao (Gandjbakhch et al., 2011). The primer set used to 
assess PKP2 expression was designed such that it would amplified transcripts 
containing exon 12 and a correctly spliced exon 13-14 junction. This primer set 
therefore assessed the total quantity of transcripts encoding both PKP2a and PKP2b 
including any in which exon 11 might be missing due to mutation induced exon 
skipping. Since it was not possible to generate samples containing >75% iPSC-CMs 
from 0101-C41 the analysis of PKP2 expression in this line was limited to iPSCs. In 
this analysis PKP2 transcripts were not significantly less abundant than in other iPSC 
lines. This would be consistent with the formation of an alternatively spliced mutant 
transcript that is not degraded by mechanisms such as nonsense mediated decay 
and may be translated to a mutant protein. Further work is needed to investigate 
these possibilities. RT-PCR combined with sequencing of the region encoded by 
exons 10 to 12 region would be useful to assess its effect on exon 11. If a significant 
level of mutant transcripts could be demonstrated to be present further studies to 
look for the expression of mutant proteins could be pursued. 
The DSG2 mutation carried by 0202-C13 was demonstrated by clinical testing to 
result in transcripts missing exon 7 and the insertion of CAG between exons 6 and 8. 
The primer set used to assess DSG2 expression was designed to amplify a region 
between the exon 13-14 junction and part of exon 14 and would therefore detect both 
normal and abnormal length transcripts. No significant difference was observed in the 
abundance of DSG2 transcripts between 0202-C13 and other cell lines in both iPSCs 
and iPSC-CMs. RT-PCR and sequencing of the DSG2 transcripts resulting from this 
mutation had been assessed as part of the subject’s clinical assessment. The work in 
this study suggests that the abnormal transcript produced is not degraded and may 
result in synthesis of a mutant protein. 
                                            
o Created by alternative splicing that excludes exon 6. 
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The DSP mutation carried by 0203-C8 was predicted to result in transcripts 
containing a premature stop codon in exon 23 that would be predicted to affect both 
DSP I and II. The primer set used to assess DSP was designed to amplify a region 
between exon 1 and 2 and therefore both normal and abnormal transcripts. A trend 
towards reduced DSP expression was observed in iPSCs and iPSC-CMs but DSP 
expression was only significantly different between cell lines in iPSC-CMs and 
expression was only lower in 0203-C8 in the pairwise post hoc comparison with 
0202-C13. The trend to reduced DSP expression in 0203-C8 could be better 
characterised with samples from a greater number of experimental repeats and by 
comparison of the expression of a group of PBMC derived control lines from multiple 
individuals.  
Both Ma et al. and Caspi et al. studied ARVC/D iPSC-CMs bearing PKP2 mutations 
and reported an associated reduction in PKP2 expression. In addition Ma et al. 
reported a reduction in JUP expression, the mechanism for which was not elucidated. 
Neither study quantified the proportion of cells in the samples used for the RT-qPCR 
analysis. As a result of this, and the fact that non-cardiomyocytes also express 
desmosomal genes any conclusions regarding desmosomal gene expression in 
iPSC-CMs that might be drawn from their data are weak.p  In the present study the 
proportion of cardiomyocytes in samples used for RNA was quantified and was ≥75% 
in all sample used in the analyses of desmosomal genes. In this respect the 
conclusions of this study, that the expression of desmosomal genes in iPSC-CMs 
were not affected by an ARVC/D mutation studied, may be considered to have 
greater validity than those of previous reports.  
It could be argued that the use of unrelated iPSC lines as a standard against which 
changes in expression in mutation bearing lines were compared limited the power of 
this experiment to detect such changes. Considerable inter-line variations in gene 
expression was noted e.g. the expression of DSG2 and PKP2 in AD3-C1 was 
significantly greater than other control cell lines. It is conceivable that the effect of the 
mutation in 0101-C41 was to reduce the expression of PKP2 from a level similar to 
that of AD3-C1 to the level observed in this study. Alternative controls could be 
generated by the correction of ARVC/D mutations using gene editing. 
                                            
p Ma et al. attempted to control for a variable proportion of cardiomyocytes in the samples by normalising desmosomal gene 
expression to sarcomeric gene expression (MYH7 and ACTN2). This is based the assumption that sarcomeric gene expression 
is proportional to the proportion of iPSC-CMs in a sample. It is therefore possible that the difference in JUP and PKP2 
expression reported by Ma et al. resulted from the control samples containing fewer iPSC-CMs than the ARVC/D samples (and 
therefore lower MYH7 expression) combined with containing a non-cardiomyocyte population that expresses desmosomal 
genes.  
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6.4.4 Desmosomal gene expression in iPSC-CMs relative to iPSCs and RAA 
This study has identified differences between iPSCs, iPSC-CMs and RAA 
myocardium in the expression of desmosomal genes. 
The difference in DSC1 expression between iPSC-CMs, where it was effectively 
absent, and RAA, in which mean expression was 6.0 fold reference gene expression 
(SEM 2.1) is striking. The expression of DSC1 and its protein by myocardium in vivo 
had been reported by the Human Protein Atlas and the genotype-tissue expression 
(GTEx) project (Uhlén et al., 2015) (GTEx Consortium, 2013). Data from the GTEx 
project is of particular interest since it assessed gene expression in atrial appendage 
samples and left ventricular samples by mRNA sequencing assays. The median level 
of DSC1 expression was below the project’s detection threshold of 1 transcript per 
million (TPM) in the left ventricular samples but was detectable in the RAA samples 
(median expression 9.1 TPM). Since myocardium consists of a mixture of cell types 
including cardiomyocytes, fibroblasts and endothelial cells, it is possible that these 
differences in expression reflect differences in the cellular composition of ventricular 
and atrial myocardium. Immunohistochemistry data from the HPA indicates that the 
DSC1 protein is localised to the intercalated discs of cardiomyocytes (“HPA DSC1 
heart immuno,” 2018). This raises the possibility that there are regional variations in 
DSC1 expression by cardiomyocytes within the heart. In this context the absence of 
DSC1 expression iPSC-CMs is difficult to interpret. Further work could be directed at 
investigating the hypothesis that DSC1 is a chamber specific cardiomyocyte marker. 
The gene expression data in this study also suggested that despite differentiation 
from pluripotency to a cardiomyocyte cell type the expression of DSC3 in iPSC-CMs 
remains similar to that seen in iPSCs and greater than seen in RAA samples. The 
mean expression of DSC3 was lower than DSC2 in iPSCs 0.66 (SEM 0.05) vs 1.80 
(SEM 0.20) (2 tailed T-test, p=0.0001). These data conflict with that of the Primary 
Cell Atlas which suggested that DSC3 expression was low or absent in hESCs and 
iPSCs (Mabbott et al., 2013). The low levels of DSC3 in RAA are consistent with data 
from the HPA which found no evidence of either gene or protein expression in 
myocardium (“HPA heart DSC3,” 2018). Further work is needed to confirm the 
expression of DSC3 in iPSCs and iPSC-CMs. Sequencing of RT-PCR amplicons 
from DSC3 targeted primer sets could be used to provide additional evidence of gene 
expression. Immunofluorescence and immunoblotting studies with DSC3 specific 
antibodies would provide additional evidence of the presence and localisation of the 
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protein in these cells. If the expression of DSC3 and its protein were confirmed in 
iPSCs and iPSC-CMs it would suggest that, despite differentiation, iPSC-CM retain 
some aspects of the cadherin expression pattern seen in iPSCs. This point is broadly 
supported by previously reports that the transcriptomic and proteomic profile of 
hESC-CMs is similar to but distinct from both fetal and adult cardiomyocytes (Cao et 
al., 2008) (Xu et al., 2009) (Poon et al., 2015).  
6.4.5 Desmosomal protein localisation in control an ARVC/D iPSCs and  
iPSC-CMs 
The cellular distribution of desmosomal proteins in undifferentiated ARVC/D iPSCs 
has not been described in previous reports. Previous reports of cellular 
manifestations of ARVC/D in tissues other than myocardium (see Chapter 1) provide 
a precedent for the study of ARVC/D in un-differentiated iPSCs.  
No difference was identified between control and ARVC/D iPSCs in terms of protein 
localisation. In this study the DSC2, DSG2 and DSP signal in ARVC/D iPSCs had the 
same puncti-linear pattern in the control iPSC line (2-C6). The JUP and PKP2 signal 
in ARVC/D iPSCs also showed the same pattern as control lines, with the exception 
of occasional nuclear punctate signals that were not observed in control samples. In 
iPSC-CMs these punctate nuclear signals were observed in control and ARVC/D 
samples. Kim et al. found a similar JUP signal in ARVC/D iPSC-CMs but not in 
controls and concluded that this was evidence of the redistribution of JUP from the 
plasma membrane to the nucleus (Kim et al., 2013). As discussed in chapter 1 JUP 
and PKP2 have roles in intracellular signalling pathways (such as Wnt and Hippo 
signalling) which have the potential to produce the cellular pathophysiology 
characteristic of ARVC/D.  
The modulation of Wnt signalling by changes in desmosomal protein expression 
was demonstrated by Garcia-Gras et al. (Garcia-Gras, 2006). They reported that the 
suppression of DSP  (by siRNA in HL-1 cells and in a cardiac restricted DSP knock-
out mouse model) resulted in a shift of plakoglobin from the cytoplasm to the nucleus 
and a suppression of Wnt signalling. Evidence supporting this was mainly in the form 
of immune-blotting of cytosolic and nuclear fractions. The nuclear JUP 
immunofluorescence pattern of HL-1 cells manifesting these changes was diffuse 
and homogenous rather than a punctate signal. This would be consistent with the 
activity of non-membrane bound JUP which regulates TCF/LEF1 transcription factors 
and would not therefore be expected to be concentrated at a specific location. 
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Taken together the evidence that the punctate signal reported by Kim et al. and 
observed in this study represents nuclear redistribution of plakoglobin in weak, and it 
is suggested that such signals should be regarded as artefact. 
There have been two reports of a reduction in the intensity of JUP and PKP2 
immunofluorescence signal in ARVC/D iPSC-CMs carrying PKP2 mutations. Ma et al. 
reported that the average intensity of PKP2 and JUP immunofluorescence signal in 
images of ARVC/D iPSC-CMs carrying a PKP2 mutation was lower than in a control 
iPSC-CM (Ma et al., 2012). Caspi et al. reported a similar finding but normalised this 
average signal intensity to the area of cTnT signal with which it was associated 
(Caspi et al., 2013). The approach of Caspi et al. complicates the interpretation of 
their results since they could result from the ARVC/D iPSC-CMs being larger and 
flatter rather than containing less PKP2. In addition, neither Ma et al. or Caspi et al. 
described whether the investigators were blinded to the sample identity whilst 
acquiring the images in their studies, raising the possibility that the lower JUP and 
PKP2 signal they reported in ARVC/D iPSC-CMs was due to observer bias. Neither 
report stated the number of experimental repeats from which their images were 
obtained, raising the possibility that the differences they reported were due to 
experimental variation. 
In the present study substantial variation was noted within individual samples in the 
intensity of desmosomal signal. For the purposes of assessing desmosomal protein 
distribution cells with the strongest signal were imaged. Quantification of signal 
intensity in this study would have required a strategy for selecting multiple regions of 
the sample at random followed by high magnification Z-stack imaging, and repeating 
this strategy across multiple samples. None of the ARVC/D samples consistently 
appeared to have less signal intensity or abundance that the control across multiple 
experiments. Given the wide range of signal intensities observed in all samples the 
probability that such an approach would detect a statistically significant quantitative 
difference between cell lines was felt to be too small to justify the resources needed 
to make this assessment. 
6.5 Limitations 
Several aspects of the study methodology limit the conclusions that may be drawn 
from this work. Co-localisation of immunofluorescence signals for desmosomal 
antibodies would have provided a stronger argument that the proteins present were 
combining to constitute the desmosomes seen by TEM. This was not possible with 
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the antibodies used in the work present here since they were all mouse monoclonal 
antibodies of the IgG1k isotype. Monoclonal antibodies were chosen for this work to 
provide optimal specificity of the signal. Future work could aim to demonstrate co-
localisation using a different selection of anti-desmosomal antibodies. 
In addition to the specific limitations already discussed a more general issue with 
this study is the number and quality of control lines.  All PBMC derived control lines in 
this study came from a single subject that did not provide a match of both age and 
sex for any of the ARVC/D subjects. Although an additional control line was used 
(AD3-C1) this had a different cellular origin (fibroblast) to the disease lines, and this 
may also have an effect on its behaviour. In addition only a single clone from each of 
the ARVC/D subject was assessed raising the possibility that clonal variation may 
have masked more subtle ARVC/D changes.  
 
6.6 Conclusions 
The work presented in this chapter is consistent with the hypothesis that the 
generation iPSCs from PBMCs is associated with an upregulation of six desmosomal 
genes: DSC2, DSC3, DSG2, PKP2 and JUP. The data presented in this chapter also 
supports the idea that the expression of desmosomal proteins and their incorporation 
into adhesion junctions (some of which have the typical appearance of desmosomes) 
is a feature of pluripotent cells in culture in general. It is hypothesised that these 
intercellular adhesion junctions have a function in regulating colony morphology and 
pluripotency as part of a more general system of cytoskeletal organisation at the 
edges of colonies of PSCs in vitro.  
The differentiation of iPSCs to iPSC-CMs involves further changes in the pattern of 
desmosomal gene expression, specifically a decrease in the expression levels of the 
two main desmosomal cadherins (DSC2 and DSG2) and an increase in the 
expression of the main plakophilin (PKP2) and of JUP.  Despite these changes, the 
same puncti-linear immunofluorescence pattern of these proteins is seen in both cells 
types. Further work is needed to assess the co-localisation of these proteins and thus 
the composition of adhesion junctions identified by TEM. 
No changes in the abundance of desmosomal gene transcripts were detected in 
ARVC/D iPSCs and iPSC-CM relative to controls in genes affected by ARVC/D 
associated mutations. Suggesting that mutant transcripts were not degraded by 
mechanisms such as nonsense mediated decay. It is unclear whether this is 
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representative of the effects of these mutations in vivo or whether biological and 
experimental variability in the iPSC and iPSC-CM models used in this study were 
sufficiently large to obscure the effects of the mutation. Further work is needed to 
investigate this possibility and whether these mutations result in the synthesis of 
abnormal proteins. 
There was no evidence of a redistribution of desmosomal proteins (specifically JUP) 
from the plasma membrane to the nucleus in ARVC/D iPSC-CMs. Furthermore is 
argued that evidence for this being observed in any previously reported iPSC-CM 
model of ARVC/D was weak.  
The intensity of immunofluorescence signal for all desmosomal proteins was highly 
variable in this study and therefore the quantification of desmosomal proteins by 
immunofluorescence was not attempted. Although previous reports have described 
using this technique for quantification of desmosomal proteins a critical appraisal of 
their methodology suggests that their reports of a reduction in signal intensity of 
desmosomal protein should be treated with caution. Other methods of quantification 
of these proteins such as by immunoblotting may be more robust that quantified 
cellular immunofluorescence. This approach was not possible in the present study 
due to the difficulty in consistently generating cultures containing a high proportion of 
iPSC-CMs. Optimisation of the differentiation protocol and further innovations in 
iPSC-CM generation and purification may allow this type of analysis in future work. 
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7 Chapter 7. A Comparison Of Desmosomal Ultrastructure In Control 
And ARVC/D iPSC-CMs. 
7.1 Introduction  
This chapter will discuss the ultrastructural morphology of desmosomes in control 
and ARVC/D iPSC-CMs. An outline of desmosomal ultrastructure and reports that 
the morphology of desmosomes differs between control and ARVC/D 
cardiomyocytes are given in Chapter 1. A description of the methodology of sample 
collection, processing, imaging and analysis are given Chapter 2. 
7.2 Aims and hypotheses 
The main aim of this work is to determine whether desmosomes of iPSC-CMs 
carrying an ARVC/D associated mutation were different to those of control iPSC lines.  
It was hypothesised that: 
• Morphologically abnormal or hazy desmosomes would be present in 
ARVC/D lines but not in controls. 
• Asymmetrical desmosomes are more frequent in ARVC/D lines compared 
with controls and the total length of asymmetrical segments per desmosome 
is longer in ARVC/D lines compared with controls. 
• The average length of desmosomes is greater in ARVC/D lines compared 
with controls 
• The intermembranous gap and inter-ODP widths would be increased in 
ARVC/D lines compared with controls. 
   202 
7.3 Results 
7.3.1 Sampling and data structure 
 All quantitative analyses of iPSC-CMs in this chapter are based on the same 
sample of 151 desmosome images from control cell lines and 93 desmosome images 
from ARVC/D iPSC-CMs. The control desmosome images were from four control cell 
lines (2-C3, 2-C7, 2-C4 and 2-C6) and the ARVC/D desmosomes images were from 
three ARVC/D cell lines (0101-C41, 0202-C13 and 0203-C8). Desmosome images 
for each cell line were from three differentiation experiments with each experiment 
using cells of a different passage, with the exception of 2-C6 which was assessed in 
six experiments. At least 10 desmosomes were assessed from each experiment. 
Averaged values for each cell line were used for comparisons of ARVC/D with 
control iPSC-CMs. These averaged values were calculated as follows. An average of 
the parameter across the 10 (or more) desmosomes in each experimental repeat 
was calculated. If the data in all experiments were normally distributed (Shapiro-Wilk 
test p>0.05) this average used was the mean, otherwise the median was used. The 
mean of these experimental averages was then calculated across the three (or more) 
experimental repeats for each cell line.  
A total of 32 desmosome images from three RAA samples, with at least 10 
desmosomes per sample, were also assessed and averaged depending on the 
normality of data distribution as described above. 
7.3.2 Hazy desmosomes 
Adhesion junctionsa with a hazy appearance were seen in RAA samples, 
immortalised keratinocytes (HaCaT cells), control iPSC-CMs and ARVC/D iPSC-CMs. 
In some cases the tilting of samples within the electron beam during imaging 
changed the appearance of these hazy junctions such that laminated plaques were 
observed indicating that these junctions were desmosomes (Figure 69). 
  
                                            
a This will be used as a general term to encompass desmosomes, adherens junction and adhesion junctions of an 
indeterminate type. 
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Figure 69 The effect of tilting a sample within the electron beam upon the 
appearance of desmosomes images by TEM.  
Representative example of the effect observed with desmosomes from all tissues. 
Panels A to C and D to F show images of two desmosomes from different samples 
of RAA. The electron beam was oriented perpendicular to the TEM level in images 
B and E. The sample was tilted by 40o anti-clockwise from this starting position to 
obtain images A and D and by 40o clockwise from this starting position to obtain 
images C and F. Regions of the image in which typical laminated plaques are seen 
identifying the structure as a desmosome (solid arrowheads) and those in which it 
appears hazy (hollow arrowheads) and are indicated in each panel. Scale bars 
represent 50nm. 
 
7.3.3 Desmosomal asymmetry 
Asymmetrical desmosomes were identified within samples from control iPSC-CMs, 
ARVC/D iPSC-CMs, RAA cardiomyocytes and immortalized keratinocytes (HaCaT) 
(Figure 70). Short regions of discontinuity in desmosomal plaques were observed. It 
was also noted that curved desmosomes typically have plaques of slightly different 
lengths. No definition of desmosomal asymmetry has been published in previous 
literature. For the purposes of assessing the frequency of asymmetrical desmosomes 
and their characteristics desmosomes were classified as asymmetrical if the total 
length of its asymmetrical segments was >20nm. The frequency of greater degrees 
of asymmetry was also assessed using cut-off values of a total asymmetrical length 
>50nm and >100nm. 
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The distribution of total length of asymmetrical segments across all 244 desmosome 
images had a strong positive skew (skewness 3.4). This pattern was similar in both 
the control desmosomes and ARVC/D desmosomes (Figure 71 A). If only the 112 
asymmetrical desmosomes are considered, the median (Q1-Q3) proportion of total 
length taken up by asymmetrical segments was 34% (24-49) for control iPSC-CMs 
and 28% (22-48) for ARVC/D iPSC-CMs (Figure 71 B). 
After averaging the mean proportion of desmosomes classified as asymmetrical was 
44% (SD 7) for control desmosomes and 48% (SD 5) of ARVC/D desmosomes (two 
tailed T-test, p>0.05). The mean proportion of desmosomes with asymmetrical 
segments >50nm was 26% (SD 6) for control desmosomes and 28% (SD 4) of 
ARVC/D desmosomes (two tailed T-test, p>0.05). The mean proportion of 
desmosomes with asymmetrical segments >100nm was 12% (SD 4) for control 
desmosomes and 10% (SD 4) of ARVC/D desmosomes (two tailed T-test, p>0.05). 
Differences at the level of individual lines were also assessed. There was no 
significant difference between any of the control or ARVC/D cell lines in the degree of 
asymmetry (Figure 72 A-B) or the frequency of asymmetrical desmosomes using any 
of the three cut off values (>20nm, >50nm or >100nm (Figure 72 C-E) (one way 
ANOVA, p>0.05). 
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Figure 70 Examples of asymmetrical desmosomes 
Representative desmosomes from differentiated iPSCs (2-C6) (Panels A and B), 
immortalised keratinocytes (HaCaT) (Panel C), and myocardium (RAA) (Panel D). 
Regions in which a desmosomal plaque is only present on one side of the 
intermembrane gap are indicated by a dashed line. Scale bars represent 100nm. 
 
 
Figure 71 Total length of asymmetrical segments of desmosomes in control 
and ARVC/D iPSC-CMs 
The histogram in panel A summarises the length of asymmetrical segments in all 
151 desmosomes assessed across the four control lines (2-C3, 2-C7, 2-C4 and 2-
C6) and the 93 desmosomes across the three ARVC/D lines (0101-C41, 0202-C13, 
0203-C8). Each bin contains values that are within 20nm of the bin centre value. 
The histogram in panel B summarises length of asymmetrical segments as a 
proportion of the total desmosomal length in those desmosome classified as 
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asymmetrical i.e. with a total of >20nm length of asymmetrical segments. Data from 
67 control desmosomes and 45 ARVC/D desmosomes across multiple cell lines is 
summarised. 
 
 
Figure 72 The length and frequency of asymmetrical desmosomes in iPSC-
CMs from control and ARVC/D lines.  
Bars in all panels represent the mean of the data points in panels A and B represent 
the means of the 10 desmosomes measured in experimental repeats. Data points in 
panels C to E represent the proportions of desmosomes meeting the asymmetry 
criterion in single experimental repeats. Cell lines were compared using one way 
ANOVA tests, no significant differences were identified in any parameter, p>0.05. 
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7.3.4 Desmosomal length 
Analysis of individual desmosomal length measurements (i.e. not average across 
experiments and cell lines) confirmed a positively skewed uni-modal distribution in 
both control and ARVC/D lines (Figure 73). The median (Q1-Q3) length was 156nm 
(123-233) for control iPSC-CMs (skewness 2.3) and 155nm (117-223) for ARVC/D 
iPSC-CMs (skewness 1.5). After averaging, the mean desmosomal lengths were 
124nm (SD 14) for control iPSC-CMs and 118nm (SD 17) for ARVC/D iPSC-CMs 
(two tailed T-test, p>0.05). 
In order to detect whether a greater range of desmosomal sizes were present in 
ARVC/D iPSC-CMs compared with control iPSC-CMs the spread of lengths within 
individual experiments (i.e. without averaging according to cell line) was assessed. 
The mean interquartile range of lengths per experiment was 93nm (SD 29) in control 
iPSC-CMs and 110nm (SD 7) in ARVC/D iPSC-CMs (two tailed T-test, p>0.05). 
Differences between individual cell lines were also investigated. No differences were 
observed between four control lines or the three ARVC/D lines in terms of total 
desmosomal length or the interquartile range of the lengths per experiment (one way 
ANOVA, exact p>0.05) (Figure 74). 
A total of 32 desmosomes in three samples of RAA myocardium were also studied. 
When length measurements for individual desmosomes were considered the median 
(Q1-Q3) total length was 205nm (118-300). After averaging within samples the mean 
total length was 224nm (SD 74), this was not significantly different from the values 
obtained for the control iPSC-CMs (two tailed T-test, p>0.05). 
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Figure 73 Histogram of individual desmosomal length measurements. 
The histogram summarises the total length in all 151 desmosomes assessed across 
the four control lines (2-C3, 2-C7, 2-C4 and 2-C6) and the 93 desmosomes across 
the three ARVC/D lines (0101-C41, 0202-C13, 0203-C8). Each bin contains values 
that are within 25nm of the bin centre value. 
 
 
Figure 74 Total desmosomal length and interquartile range of total lengths in 
control and ARVC/D iPSC-CMs 
Bars in all panels represent the median of the data. Data points represent the 
means of the 10 desmosomes measured in experimental repeats. Cell lines were 
compared using the one way ANOVA, no significant differences were identified in 
either parameter, p>0.05. 
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7.3.5 Desmosomal width 
Of the 244 iPSC-CM desmosomes images assessed, IMW1 measurements were 
possible in 243 images (99.6%), IMW2 measurements were possible in 224 images 
(91.8%) and IOW measurements were possible in 241 images (98.8%).  
When width measurements for individual desmosomes are considered (i.e. without 
averaging) the mean values for IMW1 was 12.4 nm (SD 1.6) for control iPSC-CMs 
and 12.6nm (SD 1.6) for ARVC/D iPSC-CMs, for IMW2 the mean was 22.0nm (SD 
2.3) for control iPSC-CMs and 21.3nm (SD 2.3) for ARVC/D iPSC-CMs, and for IOW 
the mean was 49.5nm (SD 4.1) for control iPSC-CMs and 50.9nm (SD 4.1) for 
ARVC/D iPSC-CMs. 
After averaging within experiments, across repeats and cell lines the mean IMW1 
was 12.39nm (SD 0.25) in the control lines and 12.66 (SD 0.07) in the ARVC/D lines, 
the mean IMW2 was 21.83nm (SD 0.42) in the control lines and 21.32 (SD 0.03) in 
the ARVC/D lines and the mean IOW was 49.33nm (SD 1.61) in the control lines and 
50.96 (SD 1.03) in the ARVC/D lines. None of the differences in means between 
control and ARVC/D lines were statistically significant (two tailed T-test, p>0.05). 
Differences between individual cell lines were also investigated (Figure 75). There 
was no significant difference detected between four clones from the same control 
iPSC line in terms of three of the desmosomal width parameters i.e. IMW1, IMW2 
and IOW (one way ANOVA, p>0.05). 
The widths of desmosomes in the RAA myocardium samples were also studied. 
When width measurements for individual desmosomes are considered (i.e. without 
averaging between samples) the mean IMW1 was 13.4nm (SD 1.3), the mean IMW2 
was 21.5nm (SD 1.6) and mean IOW was 52.1nm (SD 2.7). After averaging between 
samples the mean IMW1 was 13.3nm (SD 0.7), the mean IMW2 was 21.53nm (SD 
0.7) and mean IOW was 52.0nm (SD 1.1). There was no significant difference 
between these values and those of the control iPSC-CMs (two tailed T-test, p>0.05). 
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Figure 75 Desmosomal width in control and ARVC/D lines 
Bars in all panels illustrate the mean of the data. Data points represent the means 
of the 10 desmosomes measured in experimental repeats. Cell lines were 
compared using the one way ANOVA test, no significant differences were identified 
in any of the three parameters, p>0.05. 
 
7.4 Discussion 
This study found no significant difference between control and ARVC/D iPSC-CMs 
in any of the measures of desmosomal morphology that have been described as 
abnormal in ARVC/D in previous reports.  
The choice of parameters to be investigated in this study was based on two 
previous reports of ultrastructural abnormalities in ARVC/D. The only study of 
ARVC/D iPSC-CMs in which desmosomal morphology was quantified was by Caspi 
et al. (Caspi et al., 2013). There have been multiple reports of the ultrastructure of 
desmosomes in the myocardium from subjects with ARVC/D, but only the study by 
Basso et al. performed systematic quantitative analysis comparing cohorts of 
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ARVC/D cases and controls (Basso, 2006). The following sections will discuss the 
findings of this study with respect to these previous reports, with particular focus on 
differences in methodology between this study and these reports.  
7.4.1 Hazy desmosomes 
Hazy desmosomes were observed in all the samples in this study (including control 
iPSC-CMs, adult cardiomyocytes and immortalized keratinocytes). For some of these 
hazy desmosomes, tilting the sample within the electron beam during imaging 
changed their appearance to that of a typical (non-hazy) desmosome with the 
characteristic laminated plaques.  
This phenomenon may be explained by consideration of the spatial orientation of 
desmosomes within a TEM level. Desmosomes are thought to consist of two disc-like 
plaques oriented in parallel and separated by an intermembranous gap (Figure 76 A 
and B). When captured within a TEM level (Figure 76 C and F) such a structure will 
only produce an image that is typical of desmosome (two parallel oriented linear 
structures separated by a gap) when the electron beam used to image the sample is 
oriented along the same plane as the intermembranous gap (Figure 76 D and H).  
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Figure 76 Schematic representing a simplified desmosome; its possible 
orientations within a TEM level; and the effect of tilting a level within the 
electron beam of a TEM on the resultant image.  
Panels A and B show a simplified representation of a desmosome consisting of two 
cylindrical outer dense plaques whose circular surfaces are separated by and 
oriented parallel to the plane of an intermembrane gap. Panel A shows illustrates 
this arrangement in three dimensions. Panel B illustrates the structure when viewed 
along the same plane as the intermembrane gap. The dimensions are provided to 
give an approximate indication of scale, the normal range of values for ODP width 
and desmosomal plaque length are discussed in the text. Panels C and F illustrates 
the part of a desmosome that may be contained within a given TEM level 
depending on its orientation in relation to the level. Panel C illustrates the region 
contained within a desmosome whose intermembrane plane is oriented 
perpendicular to the plane of the TEM level. Panel F illustrates the region contained 
within a desmosome whose intermembrane plane is oriented at 50o to the plane of 
the TEM level. Panels D and G illustrate how these different orientations will affect 
the resultant TEM image if the level is studied with the electron beam perpendicular 
to the TEM level. Panels E and H illustrate the effect of tilting the TEM level within 
the electron beam upon the resultant TEM image. 
   213 
This study has demonstrated that a proportion of hazy desmosomes are the result 
of sectioning and imaging artefact. The appearance of a proportion of hazy 
desmosomes could not be normalised by tilting. The suggestion that such 
desmosomes may genuinely have a structural abnormality is speculative.  
The idea that hazy desmosomes result from ARVC/D could be investigated by 
determining the frequency with which they are found in ARVC/D samples compared 
with controls. This could be considered in future work. 
Caspi et al. reported that abnormal and “hazy” desmosomes were found in ARVC/D 
iPSC-CMs and not in control iPSC-CMs (Caspi et al., 2013). The identity of many of 
the structures presented by Caspi et al. as examples of abnormal desmosomes 
(Figure 77) is questionable. One such structure (Figure 77, panel D) does not appear 
to be associated with a plasma membrane and has a very high electron density with 
no obvious linear plaques, on these grounds it could be argued that it is more likely to 
be staining artefact than a desmosome. Other structures presented as desmosomes 
(Figure 77, panels E and F) are membrane associated collections of electron dense 
materials but without any apparent laminated plaques. Desmosomes are defined 
morphologically by this laminated electron dense structure. In order for a structure to 
be an abnormal desmosome it must have some features to identify it as a 
desmosome as opposed to any other type of adhesion junction. The argument in 
favour of these structures being desmosomes is therefore weak. 
Some of the abnormal structures desmosomes presented by Caspi et al. do have a 
resemblance to desmosomes (Figure 77, panels A and B). These structures have an 
appearance that is very similar to the desmosomes from this study that had a normal 
appearance after tilting (Figure 69). No mention is made of tilting samples to correct 
artefactual haziness in Caspi’s methodology. 
Overall the evidence present by Caspi that desmosomal morphology was abnormal 
in ARVC/D iPSC-CMs is weak. Despite these criticisms it remains unclear why hazy 
desmosomes were not noted in the control iPSC-CMs in their study. Caspi et al. 
stated that the investigator performing the analysis was blinded to the sample identity 
and therefore observer bias should not be the cause. The differentiation protocol 
used in this study was different to that of Caspi et al. a. If it is assumed that hazy 
desmosomes genuinely represent abnormal junctions it may be that the 
differentiation protocol used in this study induced structural abnormalities in the 
                                            
a Caspi et al. used iPSCs maintained in MEF co-culture and a non-directed EB based cardiac differentiation protocol. 
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desmosomes of all cell lines (including control iPSC-CMs) whereas Caspi’s protocol 
did not.  
An additional argument in favour of hazy desmosomes being artefact is that they 
have not been reported as a feature of ARVC/D in vivo, particularly by Basso et al.   
In summary the data from this study suggests that hazy desmosomes are not 
specific to ARVC/D and there is a strong argument that they represent artefact rather 
than abnormal desmosomal ultrastructure. 
 
Figure 77 Images provided in Caspi et al. of hazy and abnormal desmosomes. 
Images contain the original annotations of Caspi et al. who labelled structures 
considered to be desmosomes (D). Panels A and B show structures with parallel 
electron dense plaques typical of desmosomes. The hazy appearance of the 
intercellular gaps and plaques are similar to those shown in Figure 69 and Figure 
76 and are considered to be an artefact of sample orientation within the electron 
beam. Panel C illustrates an asymmetrical but not hazy desmosome (*). Panel E, 
panel F and the region in panel C indicated by and arrowhead contain ill defined 
electron dense regions in proximity to the intermembranous gap. Whilst it is 
possible that these represent inter-cellular adhesion junctions, in the absence of a 
distinct electron dense plaque it is speculative to refer to them as desmosomes. 
The structure labelled in panel D is not associated with a plasma membrane and its 
high electron density is suggestive of artefact. Scale bars in panels C and D 
indicate 200nm, scale bars are unavailable for the other panels.   
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7.4.2 Asymmetrical desmosomes 
The identification of asymmetrical desmosomes in all iPSC-CMs tested suggests 
that their presence or absence is not a useful indicator of an ARVC/D associated 
mutations in a cell line. This is in contrast to the findings of Caspi et al. who reported 
that asymmetrical desmosomes were only present in ARVC/D iPSC-CMs (Caspi et 
al., 2013).  
This might be explained if the differences in differentiation protocol (as described 
above) induced desmosomal asymmetry in control iPSC-CMs in this study. Also 
Caspi et al. examined iPSC-CMs after 40 days of differentiation, whereas in this 
study samples were examined after 30 days. It is possible that the presence of 
asymmetrical desmosomes in the control iPSC-CMs reflects their relative immaturity.  
The possibility that ARVC/D lines had a greater tendency to contain asymmetrical 
desmosomes than control iPSC-CMs was considered in this study through 
assessments of the frequency of different degrees of asymmetry and the total length 
of asymmetrical segments. This analysis found no difference between ARVC/D and 
controls. 
The identification of asymmetrical desmosomes in non ARVC/D myocardium and 
immortalised keratinocytes suggests that this is not a feature that is unique to iPSC-
CMs. Reports of myocardial tissue from subjects with ARVC/D (including Basso et al. 
(Basso, 2006)) did not describe asymmetrical desmosomes as a feature of the 
disease.  
In summary the data from this study taken in the context of previous reports suggest 
that desmosomal asymmetry is a common feature of desmosomes in iPSC-CMs and 
that asymmetry is not more frequent of more in iPSC-CMs containing ARVC/D 
associated mutations. 
7.4.3 Desmosomal length 
No differences in length parameters were identified between control and ARVC/D 
iPSC-CMs. Desmosomal length parameters were not reported in Caspi’s study. 
Basso et al. reported that the desmosomes in ARVC/D myocardial tissue had a mean 
length of 310nm (SD 80) compared with a mean length of 160nm (SD 80) in controls 
(p<0.001) (Basso, 2006). They also reported that overall desmosomes constituted a 
greater proportion of the total length of the intercalated discs in ARVC/D myocardium 
than in controls. Other reports of ARVC/D myocardium did not describe an increase 
in desmosomal length (Pilichou, 2006) (Lahtinen et al., 2008). In this study the mean 
total length of desmosomes was (224nm, SD 74) in RAA and (193nm, SD 120) in 
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control iPSC-CMs, these values are similar to those reported by Basso et al.. There 
was no significant difference between the length of ARVC/D iPSC-CM desmosomes 
(177nm, SD 93) and control iPSC-CMs. This may indicate that the processes 
resulting in longer desmosomes in ARVC/D develop in response to 
electromechanical and neurohumoral stimuli that are present in vivo but absent in the 
in vitro system used in this study.  
Several reports of ARVC/D myocardium have described chains of multiple 
desmosomes or desmosome like junctions that are not localised to the intercalated 
discs (Pilichou, 2006) (Lahtinen et al., 2008) (Basso, 2006). In this study the absence 
of a bimodal distribution in desmosomal lengths in ARVC/D iPSC-CMs and the lack 
of a difference in the interquartile range of desmosomal lengths between ARVC/D 
and control iPSC-CMs suggests that ARVC/D iPSC-CMs did not contain a 
combination of larger and smaller than normal desmosomes, as had been described 
in myocardial tissue.  
7.4.4 Desmosomal gap width 
In this study the regions of desmosomal plaque that define the inter-
cellular/intermembranous gap had a complex laminated appearance. This 
appearance has been reported by previous authors and is due to protein dense 
regions either side of the central (electron-lucent) lipid bilayer of the plasma 
membrane (Kelly, 1966) (North et al., 1999). On this basis, IMW1 was considered to 
measure the distance between the outer (extracellular) surfaces of the plasma 
membranes of adjacent cells and IMW2 was thought to measure the distance 
between the intracellular surfaces. 
The similarity of the mean IMW1 and mean IMW2 values for RAA and control iPSC-
CM supports the idea that this aspect of desmosomal morphology is preserved 
between tissue types. 
 In this study no significant difference was observed in IMW1 and IMW2 between 
control and ARVC/D iPSC-CMs. This result is in contrast to the findings of Caspi et al. 
who reported that the mean desmosomal gap width of control iPSC-CMs was 24nm 
(SEM 1) compared with 32nm (SEM 2) in ARVC/D iPSC-CMs (p<0.05) (Caspi et al., 
2013). Basso et al. reported that the mean desmosomal gap width was 22nm (SD 3) 
in control myocardium and 29nm (SD 9) in ARVC/D myocardium (p=0.004) (Basso, 
2006).  
Many of the points discussed in 7.4.2 are equally relevant in explaining the conflict 
between the results of this study and that of Caspi et al. with respect to desmosomal 
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gap width. The EB differentiation protocol use by Caspi et al. may have had a greater 
potential to precipitate desmosomal structural changes than the monolayer protocol 
and the later time-point of analysis may have allowed more time for this to be 
manifest. Similarly the development of increased desmosomal gap width in the 
myocardial tissues studies by Basso et al. may be precipitated by factors that are 
absent in the in vitro model used in this study. 
Another explanation for the difference in results compared with both Caspi et al. and 
Basso et al. could be that the development of an increased desmosomal gap width in 
an iPSC-CMs model is a dependent on the specific mutation present. The mutations 
present in ARVC/D iPSC-CMs in this study were different to those studied by both 
Caspi et al. and Basso et al. a (Caspi et al., 2013) (Basso, 2006). 
Both Caspi et al. and Basso et al. reported using investigators that were blinded to 
the sample identity during desmosomal analysis therefore it must be assumed that 
observer bias is not responsible for the differences they described between cells with 
ARVC/D mutations and controls. 
Caspi et al. did not describe the number of independent differentiation experiments 
from which their TEM samples originated. The possibility that the data for this cell line 
came from a single experiment and possibly from a single TEM section cannot be 
excluded. In this situation the apparent difference in desmosomal width between 
control and ARVC/D may be due to variation resulting from the differentiation 
protocol and/or the collection and processing of samples rather than a property of the 
cell lines. In this study the greatest difference in mean desmosomal widths for 
experimental repeats was 2.7nm for IMW1 and 5.2nm for IMW2. This is less than the 
8nm difference in desmosomal gap they reported between the ARVC/D and control 
line. This makes the argument that their results may be due to a lack of experimental 
repeats weaker, but does not refute it since the degree of inter-experimental 
variability was not quantified in their study and may therefore be greater than in this 
study. 
7.4.5 Desmosomal plaque width 
In this study the distance between the cytoplasmic edges of the ODPs (IOW) was 
measured as an indirect assessment of the width of the ODPs. Caspi et al. reported 
that a parameter referred to as total desmosomal width (TDW) was 171nm (SEM 12) 
in ARVC/D iPSC-CMs and 101nm (SEM 5) in control iPSC-CMs. The illustration 
                                            
a The mutation studied by Caspi et al. produced a premature stop codon in exon 3 of PKP2. The PKP2 mutation carried by 
0101-C41 is predicted to result in aberrant splicing of exon 11. 
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provided by Caspi et al. to define this parameter suggests that it describes the sum of 
the desmosomal gap width, the width of the ODPs and the width of electron dense 
material in the region of the IDP and its junction with the intermediate filaments (IFs) 
(Figure 78). Caspi et al. did not describe which of these desmosomal components 
had an increased width leading to this result. Since the difference in mean 
desmosomal gap they reported was only 8nm it may be inferred that some increase 
in the width of the plaque components was present, but Caspi et al. offer no 
suggestion as to whether this is due to a change in ODP structure, IDP structure or a 
more prominent appearance of the IFs at the IDP boundary. IOW was measured in 
this study to provide a more detailed assessment of the width of desmosomal plaque 
components than TDW. In this study the appearance of the IDP was found to be 
highly variable and the point of transition between the IDP and intermediate filaments 
indistinct such that a clear line of transition from IDP to cytoplasm running parallel to 
the ODPs was rarely seen. The gradual reduction in electron density at the junction 
of the IDP and intermediate filaments meant that the apparent width of the IDP was 
very sensitive to changes in brightness and contrast of the image. Consequently it 
was decided that accurate and reproducible measurements of the IDP width were not 
possible in this study and no equivalent to TDW was measured.  
The mean IOW in control iPSC-CMs was 49nm in this study. This is consistent with 
previous reports describing the width of the ODPs in other tissues (North et al., 1999) 
(Karrer, 1960) (Kelly, 1966). The lack of difference between mean IOW in ARVC/D 
and control iPSC-CMs suggests that the structure of the ODP was not affected by the 
ARVC/D mutations present in the cell lines. 
Taken together these data suggest that the ODP width of iPSC-CMs was not 
affected by the ARVC/D mutations tested in this study. It is also suggested that the 
parameter TDW as measured by Caspi et al. is highly un-informative with respect to 
understanding the ultrastructural effects of ARVC/D mutations.  
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Figure 78 Image from Caspi et al. illustrating the desmosomal width 
parameters measured in that study. 
Image A shows a desmosome from a control iPSC-CM. Image B shows ARVC/D 
iPSC-CMs. Desmosomal gap width (DG) and total desmosomal width (TD) 
measurements are indicated. Scale bars illustrate 200nm. 
 
7.4.6 Limitations 
The limitations resulting from having control iPSCs from only a single subject have 
been discussed in Chapter 3. The highly conserved desmosomal width parameters in 
all iPSC-CM lines suggest that assessment of additional control lines would be 
unlikely to reveal a difference between ARVC/D and control lines. 
The methodology of this study only allowed the morphometric assessment of 
junctions that could be positively identified as desmosomes by the presence of 
laminated plaques. It could be argued that this introduced a selection bias whereby 
abnormal desmosomes in which the plaque structure was disorganised and lacked 
this laminated structure were systematically excluded from the analysis. In this way 
the disease phenotype may not have been captured by the study methodology. The 
problem with this criticism is that the presence of laminated plaques are the only 
consistent feature allowing desmosomes to be distinguished from features such as 
small adherens junctions or junctions that appear disorganised due to sectioning 
artefact. 
7.5 Conclusions 
The data from this study found no difference in the ultrastructural appearance of 
desmosomes between control iPSC-CMs and those from subjects with ARVC/D.  
Critical appraisal of the only previous report describing desmosomal ultrastructural 
abnormalities in iPSC-CMs has identified numerous methodological issues which 
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weaken its conclusions. The methodology of this study was intended to be 
transparent, objective and robust providing a high degree of confidence in the 
veracity of these conclusions.  
Further work is needed to determine whether the changes in desmosomal 
ultrastructure previously reported in ARVC/D iPSC-CMs: (1) are mutation specific, (2) 
only occur in the context of specific culture conditions (3) are an artefact of the 
experimental design and methodology used to analyse desmosomal ultrastructure. 
The approach to quantitative assessment of iPSC-CM desmosomal ultrastructure 
described in this study may be useful for the design any future studies in this area. 
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8 Chapter 8. Conclusion And Future Perspectives  
The main aim of this work was to determine whether iPSC-CMs carrying ARVC/D 
associated desmosomal mutations that have not previously been studied by in vitro 
modelling recapitulate features of ARVC/D. This study specifically focused on 
abnormalities of desmosomal ultrastructure and the reduced abundance and/or 
redistribution of desmosomal proteins since both have been proposed as 
components of a common pathway of pathogenesis for the disease. 
8.1 Major findings 
Expandable cell lines were successfully derived from the PBMCs of three subjects 
with clinical diagnosis of ARVC/D that each carried different ARVC/D associated 
desmosomal mutations and from the PBMCs of a single control subject. Seven of the 
expandable cell lines (four control lines and three ARVC/D lines) were fully 
characterised. These cell lines met the study criteria for pluripotency and were 
therefore classified as iPSCs. 
Spontaneously contracting cultures were generated from all seven iPSC lines using 
a monolayer differentiation protocol which involved the transient manipulation of Wnt 
signalling by small molecule inhibitors. Differentiated cultures contained cells with the 
characteristics of functional cardiomyocytes including the presence of cardiac 
isoforms of sarcomeric proteins organised into striated myofibrils, confirming the 
generation of iPSC-CMs. 
Pluripotent cells were found to express desmosomal genes at a level comparable to 
that of desmosome bearing tissues. Desmosomal proteins were expressed in a 
pattern consistent with their participation in intercellular adhesion. These cultures 
also contained junctions that were morphologically typical of desmosomes when 
assessed by TEM. 
The differentiation of iPSCs to iPSC-CMs was associated with a relative reduction in 
the expression of the genes encoding desmosomal cadherins and an increase in  
expression of genes encoding arm-repeat proteins. The cellular distribution of 
desmosomal protein signal my immunofluorescence changed from being exclusively 
punctate to one in which the signal was distributed in a continuous linear pattern. It 
was argued that this was consistent with the formation of area composite that have 
been described in cardiac ICDs. 
No differences were detected in the abundance of transcripts of desmosomal genes 
when comparing ARVC/D iPSC-CMs (and iPSCs) with controls. This included genes 
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affect by ARVC/D associated variants that might have been affected by nonsense-
mediated decay. 
There was no evidence of the cellular redistribution of desmosomal proteins, 
particularly plakoglobin and plakophilin 2 from the plasma membrane to the 
cytoplasm or nucleus in ARVC/D or control iPSC-CMs. 
There was also no difference between ARVC/D and control iPSC-CMs in terms of 
the ultrastructural parameters: intermembrane gap width, plaque width, length and 
asymmetry. 
Several of the features reported in previous publications as evidence of an ARVC/D 
phenotype in iPSC-CMs were seen in both control and ARVC/D lines. These features 
include hazy and asymmetrical desmosomes assessed by TEM and the presence of 
punctate high intensity immunofluorescence signal localised to the nucleus of cells. It 
is argued that many of these features should be considered to be either artefact or a 
normal feature of the iPSC-CMs, and the evidence that these same features 
represented an ARVC/D phenotype in other studies is weak. 
8.2 Limitations 
As discussed in chapter 3 the use of PBMC derived iPSC and iPSC-CM control 
lines from a single subject for comparison with ARVC/D lines limits the 
generalizability of this study’s conclusions. Although no significant differences in 
desmosomal morphology were noted between the control line clones and ARVC/D 
lines it remains possible that the control lines from this subject are unrepresentative 
of control iPSC-CMs in general. As such the possibility that there are differences 
between iPSC-CMs from a population of ARVC/D subjects and iPSC-CMs from a 
population of controls cannot be excluded. 
An important limitation to this study was the inability to quantify desmosomal protein 
abundance in iPSC-CMs. This was the result of difficulty in generating samples in 
which >70% of cells were iPSC-CMs. A sufficient number of such samples were 
generated for gene expression analysis but not for western blotting and resources 
and time were not available to conduct further differentiation experiments to generate 
such samples. Quantitative immunofluorescence was not attempted as an alternative 
since the range of fluorescence intensities within all samples was so large that it was 
judged to be futile. 
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8.3 Suggestions for future work 
As discussed in chapter 6, the role of desmosomal proteins and adhesion junctions 
containing them in pluripotent cells could be the subject of further investigation. The 
following questions could be addressed: 
• Are desmosomal proteins co-localised to the same junctions? 
• Are there regional differences in the abundance of desmosomal proteins in 
colonies of pluripotent cells? 
• Do cells with adhesion junctions and punctate desmosomal protein signal at 
the peripheries of colonies differ in terms of pluripotency markers to those 
without these features at the centre of colonies? 
• Are the adhesion junctions associated with organised intermediate filaments? 
• Do desmosomal proteins and the junctions in which they participate have a 
role in the maintenance of pluripotency and regulation of colony expansion in 
vitro? 
Further investigation of ARVC/D using iPSC-CMs could address the follow 
questions: 
• Are mutant ARVC/D transcripts and proteins expressed in iPSCs and iPSC-
CMs in this study? This could be assessed by a combination of RNA 
sequencing and immunoblotting of cell lysate. 
• Is there evidence of altered Wnt or Hippo signalling in ARVC/D lines 
compared to controls? The mutations studied in this work may be such that 
the mutant proteins do not affect the assembly of desmosomes but are 
pathological by virtue of their effect on intracellular signalling pathways. 
• Were the differences in differentiation protocols between this study and 
previous reports of ARVC/D iPSC-CMs responsible for the absence of a 
detected disease phenotype in this work? This could be investigated by 
generating iPSC-CMs using this study’s protocol from one or more of the 
iPSCs lines described in previous publications. 
• How is iPSC-CM desmosomal ultrastructure and protein expression 
influenced by the duration and conditions of maturation? Could modified 
maturation conditions precipitate a disease phenotype? 
This final question is of particular relevance since ARVC/D is an adult onset disease 
and physical training has been associated with the precipitation and exacerbation the 
disease phenotype (James et al., 2013) (Saberniak et al., 2014). The absence of a 
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disease phenotype in iPSC-CMs in this study could be a reflection of their relative 
immaturity and aspects of their exposure to the forces of contractile activity.  
The idea that the appearance of a disease phenotype in ARVC/D models is 
dependent on exposure to mechanical forces and/or contractile activity is supported 
by several studies. Cruz et al. reported that a mouse model of an ARVC/D 
associated PKP2 mutation only manifested a disease phenotype after exercise 
training (Cruz et al., 2015). Similarly, Hariharan et al. reported that neonatal rat 
ventricular myocytes (NRVMs) expressing mutant JUP or PKP2 only displayed a 
disease phenotypea after exposure the shear stress (Hariharan et al., 2014). 
Hariharan et al. applied shear stress by oscillation of culture medium of cultures 
within a flow chamber. The same approach could be applied to iPSC-CMs in future 
work. An alternative to fluid shear stress are the mechanical forces to which iPSC-
CMs are already exposed through their intrinsic contractility. Factors that have been 
reported to be important in regulating the contractility of iPSC-CMs include: (1) 
duration in culture, (2) mechanical properties of their culture substrate, (3) frequency 
of contractions and (4) loading conditions. A study of iPSC-CMs reported a significant 
increase in force generation during the first 30 days of maturation (Wheelwright et al., 
2018).  The same study also reported that force generation of was enhanced by 
culture on a substrate with a low elastic modulus (Wheelwright et al., 2018). Cardiac 
tissue constructs with a low elastic modulus may be generated by combining iPSC-
CMs with hydrogels of extracellular matrix proteins and in some cases fibroblasts to 
mimic the mixture of cell populations seen in myocardium (Nunes et al., 2013) 
(Breckwoldt et al., 2017) (Tiburcy et al., 2017) (Ronaldson-Bouchard et al., 2018). 
The maturation of iPSC-CMs in these constructs reported to be enhanced compared 
with adherent monolayers, particularly when these constructs are exposed to static 
loading and the stimulation of frequent contractions through electrical pacing 
(Jackman et al., 2016) (Ronaldson-Bouchard et al., 2018) (Nunes et al., 2013). iPSC-
CMs in these culture have been reported to show a reversal of the negative force-
frequency relationship typically observed in iPSC-CMs to the positive relationship 
seen in adult myocardium (Germanguz et al., 2011) (Ruan et al., 2016). This is 
accompanied by a greater alignment of sarcomeres and changes in calcium handling 
apparatus. There is also evidence that intercellular adhesion is affected by these 
culture conditions. Nunes et al. reported an increase in the number of desmosomes 
                                            
a The disease phenotype was a failure of junctional plakoglobin immunofluorescence signal intensity to increase following 
shear stress. 
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in tissue constructs continuously paced at higher frequencies (Nunes et al., 2013). 
The characteristics of desmosomal gene and protein expression have yet to be 
reported in these paced tissue constructs. In summary there is evidence supporting 
the idea that cardiac tissue constructs may be superior to monolayer iPSC-CM 
cultures in modelling ARVC/D by (1) promoting a cardiac phenotype that is closer to 
that of the adult cardiomyocytes in which the disease is manifest in vivo and (2) by 
enhancing the exposure of iPSC-CMs to the mechanical forces that have been 
associated with manifestation of a disease phenotype in other cellular and animal 
models of the disease. 
iPSC-CMs have the potential to provide valuable insights into the pathogenesis of 
ARVC/D within cardiomyocytes. This is of particular importance since the most 
clinically important features of ARVC/D are cardiac. However many of the questions 
relating to the pathogenesis of ARVC/D variant could be addressed using less 
resource intensive cellular modelling techniques. These may be grouped into: (1) 
techniques involving the generation of expandable cell line directly from ARVC/D 
subjects bearing variants of interest i.e. patient specific cell lines and (2) techniques 
involving the expression of ARVC/D variants in established cell lines by genetic 
modification. 
Expandable keratinocyte lines have been generated from skin biopsy samples of 
subjects with ARVC/D carrying pathogenic DSP, DSG2 and PKP2 variants (T B 
Rasmussen et al., 2013) (Torsten B Rasmussen et al., 2013) (Rasmussen et al., 
2014). These keratinocytes cell lines were used to demonstrate changes in gene 
transcription, protein quantity and protein localisation resulting from the ARVC/D 
associated variants. In cases where myocardial tissue was also available the 
investigators were able to demonstrate that the findings in keratinocytes mirrored the 
patterns seen in the patient myocardium. Cells from the non-keratinised stratified 
squamous epithelium of the buccal mucosa have also been investigated as for 
patient specific patterns of desmosomal protein expression resulting from ARVC/D 
variants (Asimaki et al., 2016). Immunofluorescence microscopy of these cells has 
been reported to show the expression of desmosomal proteins and changes in the 
cellular distribution of plakoglobin similar to those reported in myocardium (Asimaki et 
al., 2016). To date expandable cell lines have not been generated from this cell type 
and further work is needed to establish the value of this cell source for modelling 
ARVC/D. 
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The expression of ARVC/D mutant transcripts has been induced in a variety of 
desmosome bearing cell lines (e.g. HEK, COS-1, neonatal rat ventricular myocytes 
and HL-1 see Table 20 for references) by either site directed mutagenesis of DNA or 
transduction with mRNA encoding the mutant variant. The culture of these cell types 
is generally less resource intensive than iPSCs and iPSC-CM differentiation, making 
it easier to conduct on a larger scale, allowing a greater number of experimental 
repeats and ensuring that there is enough culture material for testing with a wide 
range of modalities. Avoiding attempts at transforming cells from only type to another 
(e.g. by cardiac differentiation) also makes it easier to obtain samples of a single cell 
type for analysis and avoids transitions in culture conditions which may introduced 
experimental variation and bias. 
Preliminary work studying ARVC/D associated variants with a non-iPSC-CM model 
could have been valuable in this study. If such work had demonstrated that the 
ARVC/D variants under investigation produced a disease phenotype in a non-iPSC-
CM model it would make the lack of phenotype in iPSC-CMs more likely to be due to 
problems with iPSC-CM maturity and culture conditions. 
8.4 Significance of the findings 
ARVC/D is a relatively common inherited cardiac disease for which there is no 
proven disease modifying therapy. The development of such therapies requires an 
understanding of the mechanisms by which a wide range of mutations result in a 
similar clinical phenotype. Patient specific iPSC-CMs have the potential to be a 
valuable tool in developing this knowledge. However, iPSC-CMs have a greater 
similarity to fetal cardiomyocytes and ARVC/D typically manifests in adulthood. It is 
therefore important to verify that this immaturity does not limit or modify the 
phenotype of iPSC-CM based models of ARVC/D. Prior to this study the only 
mutations in PKP2 had been modelled with iPSC-CMs and were reported to show 
features consistent with the clinical disease. The finding of this study suggests that 
iPSC-CM models of at least one PKP2 mutation and of mutations in DSP and DSG2 
may either require specific culture conditions to manifest features of ARVC/D in 
iPSC-CMs, or may not do so at all. Future work should take advantages of non-iPSC-
CM cellular models of ARVC/D to assess the mechanisms of pathogenicity of 
ARVC/D associated variants. The use of iPSC-CMs to investigate pathogenic 
mechanisms in cardiomyocytes should take account of the advances in 
understanding of the maturation of iPSC-CMs and innovations in in vitro culture 
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environments to maximise the potential that a clinically relevant disease phenotype 
will develop.  
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Appendix 
Summary of pre-transduction culture media from reports of the reprogramming of PBMCs to iPSCs. 
 
References Medium  Cytokines Culture 
duration 
Notes 
(Merling et al., 2013) X-VIVO 10 (Lonza) 
Human serum albumin 1% 
SCF 50ng/ml 
FLT3L 50ng/ml  
TPO 50ng/ml 
IL3 5ng/ml or 50ng/ml 2-4 days Reprogramming started once 50,000 
cells available. 
(Ye et al., 2009) Not described SCF 100ng/ml 
FLT3L 100ng/ml 
TPO 20ng/ml 
 2-4 days  
(Mack et al., 2011) Stemspan SFEM (StemCell 
Technologies) 
SCF 300ng/ml 
FLT3L 300ng/ml 
TPO 300ng/ml 
IL6 100ng/ml 
IL3 10ng/ml 
3-13 days  
Table 61. Pre-transduction culture conditions used for the reprogramming of CD34+ populations isolated from PBMCs 
  
   
276 
 
Reference Selection prior to 
culture 
Medium Cytokines used expand/activate target 
population 
Duration of pre-
transduction 
culture 
Notes 
(Vizcardo et al., 
2013) 
CD3+ cells selected 
using antibody coated 
magnetic beads  
RPMI 1640 
FBS 10% 
L-glutamine 2mM 
Sodium pyruvate 1mM 
Sodium bicarbonate 2mg/ml 
Non-essential amino acid 0.2mM 
2-Mercaptoethanol 
Streptomycin 100mg/ml 
Penicillin 100U/ml 
Anti CD3/CD28 Dynabeads (Life 
Technologies) 
1 day - 
CD3+ cells selected 
using antibody coated 
magnetic beads  
then 
CD3+CD4-CD8+ cells 
selected by FACS 
(Seki et al., 
2010) 
CD3+ cells selected by 
FACS 
GT-T502 (Kohjin Bio) IL2 175 JRU/ml*  
Plate bound anti CD3 
6 days IL2 is a component of 
GT502 
No 
(Seki et al., 
2012) 
No GT-T502 (Kohjin Bio) IL2 175 JRU/ml 
Plate bound anti CD3 
5 days IL2 is a component of 
GT502 
Brown  
2010 48 
No AIM-V (Life Technologies) 
Penicillin* 
Streptomycin* 
Glutamine* 
IL2 300 IU/ml 
Soluble anti CD3 10ng/ml 
3 days Doses of these 
components were not 
specified 
(Loh et al., 
2010) 
No Stemline dendritic cell medium SCF* 
GM-CSF* 
2 days Doses of these 
components were not 
specified IMDM 
FBS 15% 
SCF 100ng/ml 
FLT3L 100ng/ml 
IL3 20ng/ml 
 
Table 62 Pre-transduction culture medium compositions used in publications describing the generation of T-cell derived 
iPSCs 
* Concentrations not specified in methods 
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Reference Medium Cytokines / antibodies / drugs  Duration of 
pre-
transduction 
culture 
Notes 
(Loh et al., 2010) Stemline dendritic cell medium  SCF* 
GM-CSF* 
 2 days Doses of these 
components were 
not specified IMDM 
FBS 15% 
 SCF 100ng/ml 
FLT3L 100ng/ml 
IL3 20ng/ml 
 
(Mack et al., 2011) Stemspan SFEM (StemCell 
Technologies) 
ExCyte Medium supplement 
(Millipore) 
Glutamax* 
 SCF 250ng/ml 
IL3 20ng/ml 
EPO 2U/ml 
IGF-1 40ng/ml 
Dexamethasone 1µM 
 Not described  
(Chou et al., 2011) 
 
IMDM/Ham’s F12, 1:1 
Lipid concentrate* 
L-ascorbic acid 0.28mM 
Glutamine 2mM 
Insulin* 
Transferrin* 
Selenium* 
Bovine serum albumin 
5mg/ml 
SCF 50ng/ml 
IL3 10ng/ml 
EPO 2U/ml 
IGF-1 40ng/ml 
Dexamethasone 1µM 
 8-9 days * Concentrations 
not specified in 
methods 
(Dowey et al., 2012) IMDM/Ham’s F12, 1:1 
Lipid concentrate 1% 
L-ascorbic acid 2-phosphate 
0.17mM 
L-Glutamine 2mM 
1-Thioglycerol 200µM  
Ethanolamide 33 nM 
Insulin 1.7µM 
Transferrin 0.069 µM 
Holo-transferrin 1.25 µM 
Sodium selenite 39 nM 
Bovine serum albumin 
5mg/ml 
SCF 50ng/ml 
IL3 10ng/ml 
EPO 2U/ml 
IGF-1 40ng/ml 
Dexamethasone 1µM 
 14 days  
(Churko et al., 2013) IMDM/Ham’s F12, 1:1 
Lipid concentrate 1% 
L-ascorbic acid 2-phosphate 
0.17mM 
Glutamine 2mM 
1-Thioglycerol 450µM 
Insulin 1.7µM 
Transferrin 1.25 µM 
Sodium selenite 81nM 
Bovine serum albumin 
5mg/ml 
 
SCF 50ng/ml 
IL3 10ng/ml 
EPO 2U/ml 
IGF-1 40ng/ml 
Dexamethasone 1µM 
 6-8 days  
(Lin Ye et al., 2013) IMDM/Ham’s F12, 1:1 
Lipid concentrate 1% 
L-ascorbic acid 0.28mM 
Glutamine 2mM 
Insulin 1.7µM 
Transferrin 0.069 µM 
Sodium selenite 29 nM 
Bovine serum albumin 
5mg/ml 
SCF 50ng/ml 
IL3 10ng/ml 
EPO 2U/ml 
IGF-1 40ng/ml 
Dexamethasone 1µM 
 5-8 days Medium changes 
on days 3 and 6 
Table 63 Pre-transduction culture medium composition used in publications describing the generation of iPSCs from mixed 
PBMC samples 
(Continued) 
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(Kunisato et al., 
2011) 
DMEM 
FBS 10% 
SCF 100ng/ml 
TPO 100ng/ml 
IL3 100ng/ml 
IL6/IL6 receptor fusion protein 
20ng/ml 
 2 days  
SCF 100ng/ml 
TPO 100ng/ml 
IL3 100ng/ml 
IL6/IL6 receptor fusion protein 
20ng/ml 
GM-CSF 100ng/ml 
M-CSF 50ng/ml 
FLT3L 100ng/ml 
SCF 100ng/ml 
TPO 100ng/ml 
IL3 100ng/ml 
IL6/IL6 receptor fusion protein 
20ng/ml 
Anti-CD3 antibody 
Anti-CD28 antibody 
Anti-CD40 antibody 
Lipopolysaccharide 
(Su et al., 2013) IMDM 
FBS 10% 
 SCF 100ng/ml 
TPO 100ng/ml 
IL3 10ng/ml 
G-CSF 100ng/ml  
FLT3-l 100ng/ml 
StemRegenin1  1µM 
6-8 days  
(I.-P. Chen et al., 
2013) 
DMEM 
FBS 10% 
 SCF 20ng/ml 
TPO 20ng/ml 
IL3 20ng/ml 
IL6 20ng/ml 
IL6 receptor α 20ng/ml  
GM-CSF 20ng/ml 
M-CSF 50ng/ml 
FLT3L 20ng/ml 
5 days  
(Staerk et al., 2010) αMEM 
FBS 10% 
 IL7 10ng/ml  5 days  
IL6 10ng/ml 
IL3 10ng/ml 
G-CSF 10ng/ml 
GM-CSF 10ng/ml 
(Life Technologies, 
2012) 
StemPro-34 
L-Glutamine 2mM 
 SCF 100ng/ml 
FLT3L 100ng/ml 
TPO 20ng/ml  
IL6 10ng/ml 
4 days  
(Life Technologies, 
2013) 
StemPro-34 
L-Glutamine 2mM 
 SCF 100ng/ml 
FLT3L 100ng/ml 
IL3 20ng/ml 
IL6 20ng/ml 
4 days  
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Summary of directed cardiac differentiation protocols  
Publica
tion 
hPSC maintenance  Pre-differentiation culture  EB formation Differentiation Cardiomyocyte 
maintenance 
Medium 
Sub-
strate 
Medium Sub-
strate 
Medium Protocol  Base medium Cytokines / small molecules / additives  
Day 0 Day 1 Day 2 Day 
3 
Day 4 Day 
5 
Day 
6 
Day 
7 
Yang 
2008 
(Yang et 
al., 
2008)et 
MEF DMEM/F12 
KSR 20% 
NEAA 0.1mM 
Glutamine 2mM 
BME 0.1mM 
50 U/ml penicillin 
50 u/ml 
streptomycin 
bFGF 20ng/ml 
Matrigel DMEM/F12 
KSR 20% 
NEAA 0.1mM 
Glutamine 2mM 
BME 0.1mM 
50 U/ml penicillin 
50 u/ml streptomycin 
bFGF 20ng/ml 
Cultured for 
24 to 48 
hours to 
deplete 
MEFs 
Formation of clusters of 10-20 
cells with: 
Collagenase B 1mg/ml for 20min 
Then 
Trypsin-EDTA (0.05%) for 2min 
StemPro34 
Glutamine 2mM 
Monothioglycerol 
0.4mM 
Ascorbic acid 50 
µg/ml 
BMP4  
0.5ng/ml 
Activin A    3ng/ml 
BMP4      10ng/ml 
bFGF         5ng/ml 
VEGF     10ng/ml 
DKK-1  150ng/ml 
StemPro34 
Glutamine 2mM 
Monothioglycerol 
0.4mM 
Ascorbic acid 50 
µg/ml 
VEGF 10ng/ml 
DKK-1  150ng/ml 
bFGF 5ng/ml 
Kattman 
2011  
MEF DMEM/F12 
KSR 20% 
NEAA 0.1mM 
Glutamine 2mM 
BME 0.1mM 
50 U/ml penicillin 
50 u/ml 
streptomycin 
bFGF 20ng/ml 
Matrigel DMEM/F12 
KSR 20% 
NEAA 0.1mM 
Glutamine 2mM 
BME 0.1mM 
50 U/ml penicillin 
50 u/ml streptomycin 
bFGF 20ng/ml 
Cultured for 
24 to 48 
hours to 
deplete 
MEFs 
Formation of clusters of 10-20 
cells with: 
Collagenase B 1mg/ml for 20min 
Then 
Trypsin-EDTA (0.05%) for 2min 
StemPro34 
Glutamine 2mM 
Monothioglycerol 
0.4mM 
Ascorbic acid 50 
µg/ml 
BMP4  0.5 – 5 
ng/ml 
Activin A  0-
6ng/ml 
BMP4     2-
10ng/ml  
bFGF          
5ng/ml 
VEGF           
10ng/ml 
DKK-1          
150ng/ml 
SB                  
5.4µM 
+/- DM   0.25-0.6 
µM 
VEGF    
10ng/ml 
DKK-1  
150ng/ml 
 
 StemPro34 
Glutamine 2mM 
Monothioglycerol 
0.4mM 
Ascorbic acid 50 
µg/ml 
VEGF 10ng/ml 
bFGF 5ng/ml 
Burridge 
2011  
As for pre-differentiation 
culture 
Geltrex MEF conditioned 
DMEM/F12 
KSR 15% 
NEAA 0.1mM 
L-Glutamine 1mM 
BME 0.1mM 
bFGF 4 ng/ml 
 
With a further bFGF 
4ng/ml added after 
MEF conditioning  
Passaging 
with TrypLE 
select every 
3 days in 
T25 flasks, 
plated at 
2.5x106 
cells/flask 
Cell suspension with TrypLE 
select. 
Forced aggregation of in 96 well 
V bottom plates, 5000 cells per 
well in day 0 differentiation 
medium.  
RPMI 1640 
Monothioglycerol 
0.4mM 
 
BMP4 25ng/ml 
bFGF 5ng/ml  
Insulin 10µg/ml 
RckInh 1µM  
PVA 4mg/ml 
CD Lipids 1% 
5% O2 
FBS 20% 
or 
L-ascorbic acid 280 
µM 
HAS 5mg/ml 
CD Lipids 1% 
 
 RPMI 1640 
Monothioglycerol 
0.4mM 
CD Lipids 1% 
Insulin 10µg/ml 
Burridge 
2007  
As for pre-differentiation 
culture 
Matrigel MEF conditioned 
DMEM/F12 
KSR 15% 
NEAA 0.1mM 
L-Glutamine 1mM 
BME 0.1mM 
bFGF 4 ng/ml 
 
With a further bFGF 
4ng/ml added after 
MEF conditioning 
Passaging 
with TrypLE 
select 
Cell suspension with TrypLE 
select. 
Forced aggregation of in 96 well 
V bottom plates, 10,000 cells per 
well in day 0 differentiation 
medium. 
IMDM/F12 
CD Lipids 1% 
Monothioglycerol 
0.45mM 
Insulin 7µg/ml 
Transferrin 
15µg/ml 
PVA 1mg/ml 
 
Activin A 10ng/ml 
bFGF 12ng/ml 
 DMEM 
FBS 20% 
Elliot  
2011  
As for  pre-differentiation 
culture 
MEF NA Passaging 
with TrypLE 
select 
Cell suspension with TrypLE 
select. 
Forced aggregation of in 96 well 
V bottom, 3,000 cells per well 
In day 0 differentiation medium. 
Low insulin-APEL 
(1µg/ml) 
BMP4 20-40ng/ml 
Activin A  20ng/ml 
VEGF 30ng/ml 
SCF 40ng/ml 
Wnt3A 50-80ng/ml 
  Low insulin BEL 
Table 64 Protocols for directed embryoid body differentiation of hPSCs to cardiomyocytes 
(Continued over) 
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KSR = knock-out serum replacement, DMEM = Dulbecco’s modified eagle medium, F12 = Ham’s F12 nutrient mix, NEAA = non-
essential amino acids, bFGF = basic fibroblast growth factor, BMP4 = bone morphogenetic protein 4, VEGF = vascular endothelial 
growth factor, SB = SB-431542, BME = β-mercaptoethanol, DM = dorsomorphin MEF = inactivated mouse embryonic fibroblasts, DKK-
1 = Dickkopf related protein 1, RckInh = Y-27632, HAS = human serum albumin, CD lipids = chemically defined lipids, SCF = stem cell 
factor
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Table 65 Protocols for directed monolayer differentiation of hPSCs to cardiomyocytes 
(Continued over) 
Publication hPSC maintenance  Pre-differentiation culture  Differentiation Cardiomyocyte 
maintenance 
Medium 
Substrate Medium Substrate Medium Cytokines / small 
molecules / media 
additives 
Protocol Base medium Cytokines / small molecules / additives 
Day 0 Day 
1 
Day 2 Day 
3 
Day 4 Day 5 
Laflamme 
2007  
Matrigel MEF conditioned 
KO DMEM 
KSR 20% 
NEAA 0.1mM 
L-Glutamine 1mM 
BME 0.1mM 
bFGF 4 ng/ml 
 
With a further bFGF 
4ng/ml added after 
MEF conditioning 
Matrigel, 
growth factor 
reduced 
MEF 
conditioned 
KO DMEM 
KSR 20% 
NEAA 0.1mM 
L-Glutamine 
1mM 
BME 0.1mM 
bFGF 4 ng/ml 
 
With a further 
bFGF 8ng/ml 
added after 
MEF 
conditioning 
None Passaged with EDTA 
0.5mM or collagenase IV 
200U/ml to Matrigel. 
Cultured till confluent. 
RPMI 1640 
B27 with insulin 2% 
Activin A 
100ng/ml 
 
BMP4 10ng/ml  RPMI 1640 
B27 2% 
Zhang 
 2012  
MEF DMEM/F12 
KSR 20% 
NEAA 0.1mM 
L-Glutamine 1mM 
BME 0.1mM 
bFGF 4 – 100ng/ml 
Matrigel, 
growth factor 
reduced 
mTeSR1 Y27632 10μM on day of 
single cell suspension. 
 
Matrigel, growth factor 
reduced 0.03 – 
0.06mg/ml  
Passaged from MEFs to 
Matrigel and cultured for 
5-6 days. 
Further passage with 
EDTA to produce a single 
cell suspension. 
Matrigel added when 80-
90% confluence. Further 
culture for 1-2 days until 
100% confluence 
RPMI 1640 
B27 without insulin 
2% 
Activin A 
100ng/ml 
Matrigel 
BMP4 5-10ng/ml 
bFGF 5-10ng/ml 
 RPMI 1640 
B27 with insulin 
2% 
Ye 2013 MEF DMEM/F12 85% 
KSR 15% 
bFGF 8ng/ml 
Pen/Strep 0.5% 
NEAA 0.1mM 
L-Glutamine 1mM 
BME 55µM 
Matrigel, 
growth factor 
reduced 
mTeSR1 None Passaged from MEFs to 
Matrigel, Plated as single 
cells and cultured for 4 
days or until confluent 
RPMI 1640 
B27 without insulin 
2% 
Activin A 50ng/ml 
BMP4 25ng/ml 
VEGF 5 or 10mg/ml  RPMI 1640 
B27 with insulin 
2% 
Hudson 
2012 
MEF NA 
cells passages 
enzymatically with 
TrypLE select 
Matrigel mTeSR1 None Passaged from MEFs to 
Matrigel, Plated as single 
cells and cultured for 4 
days or until confluent 
RPMI 1640 
B27 with insulin 2% 
Activin A 6ng/ml 
BMP4 20ng/ml 
IMP4   5 µM 
Or 
IWR1   10µM 
(continued until day 15) 
RPMI 1640 
B27 with insulin 
2% 
(from day 15) 
Lian 2013  
Protocol B  
Matrigel, 
hESC 
certified 
mTeSR1 Matrigel, 
hESC 
certified 
mTeSR1 RckInh 5μM on day of 
single cell suspension. 
Single cells plated and 
cultured for 4 days or until 
confluent 
RPMI 1640 
B27 without insulin 
2% 
CHIR99021 
12µM 
None IWP2   5µM None RPMI 1640 
B27 with insulin 
2% 
Lian 2013  
Protocol C  
Matrigel, 
hESC 
certified 
mTeSR1 Matrigel, 
hESC 
certified 
mTeSR1 RckInh 5	μM on day of 
single cell suspension. 
 
CHIR99021 1μM from 
day after plating until day 
0. 
Single cells plated and 
cultured for 4 days or until 
confluent 
RPMI 1640 
B27 without insulin 
2% 
Activin A 
100ng/ml 
bFGF 10ng/ml 
BMP4 5ng/ml 
bFGF 5ng/ml 
None RPMI 1640 
B27 with insulin 
2% 
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KSR = knock-out serum replacement, DMEM = Dulbecco’s modified eagle medium, F12 = Ham’s F12 nutrient mix, NEAA = non-
essential amino acids, bFGF = basic fibroblast growth factor, BMP4 = bone morphogenetic protein 4, VEGF = vascular endothelial 
growth factor, SB = SB-431542, BME = β-mercaptoethanol, DM = dorsomorphin MEF = inactivated mouse embryonic fibroblasts, DKK-
1 = Dickkopf related protein 1, RckInh = Y-27632, HAS = human serum albumin, CD lipids = chemically defined lipids, SCF = stem cell 
factor
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SNP array quality control indices 
Sample Median Log R Deviation Median Call Rate 
2-PBMC 0.19 0.98 
2-C7 0.22 0.97 
2-C6 0.22 0.98 
2-C4 0.19 0.98 
2-C3 0.21 0.97 
2-C2 0.19 0.97 
2-C1 0.18 0.98 
0101 PBMC 0.22 0.98 
0101-C41 0.21 0.97 
0202 PBMC 0.22 0.98 
0202-C13 0.21 0.97 
0203 PBMC 0.23 0.98 
0203-C8 0.21 0.97 
 
Table 66 SNP microarray quality control indices for PBMC and iPSC lines 
The array manufacturer considers median log R deviations <0.20 and median 
call rates >0.98 to indicate high quality data.  
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Copy number variations in iPSCs 
Classification of CNV Sample 
Predicted location of CNV 
Size of CNV (bp) Mean Log R ratio of CNV Additional comments Cytogenetic GRCh37/h19 
Pathogenic 
Present before and after reprogramming  None 
Acquired during reprogramming 
2-C1 
4q34.3 - 4q35.1  4:181,008,167-183,628,586 2,620,420 0.22 BAF pattern present, no obvious anti/proapoptotic genes 
7q36.1  7:150,327,024-151,893,675 1,566,652 0.16 BAF pattern present, KCNH2, PRKAG2,  
22q11.1 - 22q11.21 22:16,079,545-18,908,641 2,829,097 0.15 BCL2L and BID both of which are pro-apoptotic 
2-C4 20p11.1 - 20q11.21 20:26,158,741-31,042,348 4,883,608 0.09 adjacent to centromere mainly in 20q BCL2-L1 
Unknown pathogenicity 
Present before and after reprogramming  None 
Acquired during reprogramming None 
Benign 
Present before and after reprogramming 
0203 PBMC 10q11.22 10:47,596,804-47,694,722 97,919 0.17  
2 PBMC 16p13.3 16: 6,299,235- 6,387,348 88,113 -0.27  
2 PBMC 21q21.1 21:23,624,026-23,759,395 135,370 -0.41  
0101 PBMC 14q11.2 14:20213937-20386397 172461 -0.21  
Acquired during reprogramming None 
T-cell receptor genes CNVs of T-cell receptor genes 
2-C2 
14q11.2 
 
14:22,590,996-23,015,874 424,879 -3.31 
This CNV includes TRD and the variable region of TRA. 
 
2-C3 14:22,351,008-22,957,900 606,893  -2.96 
2-C7 14:22,260,045-22,984,586 724,542  -3.88 
0203 PBMC 14:22,536,874-22,983,223 446,350 -0.39 
0202 PBMC 14:22,562,099-22,993,720 431,621 -0.23 
2-C3 7p14.1  7:38,298,285-38,418,891 120,607  -1.14 This CNV includes part of TRG 
C2 7q34  7:142,122,115-142,418,236 296,122  -0.33 This CNV includes part of TRB 
 
Table 67 Summary of CNVs detected by SNP microarray in all samples tested 
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Figure 79 Characterisation of CNV predicted to be at 20p11.1-20q11.21 in the 
iPSC line 2-C4. 
X-axis ticks indicate approximate positions within GRCh37/h19 e.g. “20-30” 
indicates the approximate position 30,000,000 in chromosome 20. Data from valid 
SNP calls are displayed as blue dots, no-calls are displayed as orange dots. The 
average Log R ratio is indicated by a green line, this is at zero in regions the 
BlueFuse Multi algorithm considers structurally normal. CNVs are indicated by a 
step change in this line, with the degree of deviation indicating the median Log R 
ratio across the CNV. The localised increase in log R ratio (B) and pattern of BAF 
values (D) in the same region suggest an increase in copy number of this region in 
2-C4. This pattern is absent in 2-PBMCs (B and D). 
 
 
Figure 80 Characterisation of CNV predicted to be at 4q34.3 - 4q35.1 in the 
iPSC line 2-C1. 
The localised increase in log R ratio (B) and pattern of BAF values (D) suggest an 
increase in copy number in 4q34.3 - 4q35 in 2-C1. This pattern is absent in 2-
PBMCs (B and D). 
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Figure 81 Characterisation of CNV predicted to be at 7q36.1 in the iPSC line 2-
C1. 
The localised increase in log R ratio (B) and pattern of BAF values (D) in 7q36.1 of 
2-C2 suggest an increase in copy number of this region. This pattern is absent in 2-
PBMCs (B and D). 
 
 
 
Figure 82 Characterisation of CNV predicted to be at 22q11.1 - 22q11.21 in the 
iPSC line 2-C1. 
 
The localised increase in log R ratio (B) and pattern of BAF values (D) in 22q11.1 - 
22q11.21 in 2-C1suggest an increase in copy number of this region. This pattern is 
absent in 2-PBMCs (B and D). 
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Figure 83 Characterisation of CNVs predicted to be at 14q11.2 in the multiple iPSC lines. 
A localised reduction in Log R ratio and large number of failed SNP calls at 14q11.2 in three iPSC clones derived from 2-PBMCs 
suggests a loss of all copies of this region of the genome in these clones (region a in panels C – H). In two of these clones (2-C3 and 2-
C7) there is an adjacent region with a reduced log R ratio and a BAF pattern consistent with a loss in copy number (region b in panels E 
- H). This CNV was not detected in the PBMCs from which the clones were derived or from three other clones derived from this 
individual.   
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Clone Location Direction 
of change 
HGNC genes affected OMIM genes affected OMIM associated diseases Reference to description of clinical phenotype 
associated with the CNV identified 
2-C1(NT) 4q34 Gain LINC00290 
MIR1305 
RN7SKP13 
RN7SKP67 
RNU2-34P 
TENM3 
ODZ3 (*610083)  MCOPCB9 (#615145) No published reports of the clinical phenotype of 
duplication of this region 
7q36 Gain ABCB8 
ABCF2 
AGAP3 
AOC1 
ASB10 
ASIC3 
ATG9B 
CDK5 
CHPF2 
CRYGN  
GBX1 
ETF1P2 
FASTK 
GALNT11 
GALNTL5 
GIMAP1 
GIMAP2 
GIMAP5 
GIMAP6 
IQCA1P1 
NOS3 
NUB1 
PRKAG2 
PRKAG2-AS1 
RHEB 
RN7SL76P  
KCNH2 
KMT2C 
MIR3907 
MIR671  
RNU6-604P 
SLC4A2 
SMARCD3 
TMEM176A 
TMEM176B 
TMUB1 
WDR86 
WDR86-AS1 
YBX1P4 
ABCB8 (*605464)  
ABCF2 (*612510) 
ABP1 (*104610)  
ACCN3 (*611741) 
ASB10 (*615054)  
ATG9B (*612205) 
CDK5 (*123831) 
CHPF2 (*608037)  
CRYGN (*609603) 
FASTK (*606965) 
GALNT11 (*615130) 
GALNTL5 (*615133) 
GBX1 (*603354) 
GIMAP1 (*608084) 
GIMAP2 (*608085)  
GIMAP5 (*608086)  
HCA112 (*610334) 
KCNH2 (*152427)  
LR8 (*610385) 
MIR671 (*615245) 
MLL3 (*606833) 
NOS3 (+163729) 
NUB1 (*607981) 
PRKAG2 (*602743)  
RHEB (*601293) 
SLC4A2 (*109280) 
Familial hypertrophic cardiomyopathy type 6 
(#600858) 
LQT2 (#613688)  
NOS3 (+163729) 
Phosphorylase kinase deficiency - glycogen 
storage disease of heart (#261740) 
SQT1 (#609620) 
Wolff-Parkinson-White syndrome (#194200) 
 
No published reports of the clinical phenotype of 
duplication of this region 
22q11 Gain ABCD1P4 
ACTR3BP6 
ANKRD62P1 
ANKRD62P1 
ARHGAP42P3 
ARL2BPP10 
ATP6V1E1 
BCL2L13 
BCRP7 
BID 
BNIP3P2 
CCT8L2 
CECR1 
CECR2 
CECR3 
CECR5 
CECR5-AS1 
CECR6  
CECR7 
CECR9 
CHEK2P4 
CLCP1  
DGCR6 
DNAJA1P6 
DUXAP8 
FABP5P11 
FAM32B 
GAB4 
GGT3P 
GPM6BP3 
GRAMD4P2 
HSFY1P1 
IGKV1OR22-1 
IGKV1OR22-5 
IGKV2OR22-3 
IGKV2OR22-4 
IGKV3OR22-2 
IL17RA 
KCNMB3P1 
LINC00528 
MED15P7 
MICAL3 
MIR3198-1 
MIR648 
MTND1P17 
NBEAP3 
NEK2P2 
NF1P6 
OR11H1 
PABPC1P9 
PARP4P3 
PEX26 
POTEH 
POTEH-AS1 
PRODH 
RHEBP3 
RN7SL843P 
RNU6-816P 
SLC25A15P5 
SLC25A18 
SLC9B1P4 
TPTEP1 
TUBA8 
USP18 
VWFP1 
XKR3 
YME1L1P1 
ZNF402P 
ZNF72P 
ATP6V1E (+108746) 
BID (*601997) 
CECR1 (*607575) 
CECR2 (*607576) 
DGCR6 (*601279) 
IL17RA (*605461) 
MICAL3 (*608882)  
PEX26 (*608666)  
POTEH (*608913) 
PRODH (*606810) 
SLC25A18 (*609303) 
TUBA8 (*605742) 
USP18 (*607057) 
XKR3 (*611674) 
 CANDF5 (#613953) 
Cat eye syndrome (115470) 
Chromosome 22q11.2 deletion syndrome (611867) 
HPI (#239500) 
PBD7A (#614872) 
PBD7B (#614873) 
Polymicrogyria with optic nerve hypoplasia 
(#613180) 
SCZD (#181500)  
SCZD4 (#600850)  
Cat eye syndrome (115470) (Schinzel et al., 1981) 
(Sharma et al., 2014) 
2-C4(NT) 20p11 Gain ASXL1 
BCL2L1 
C20orf112 
CCM2L 
COX4I2 
DEFB115 
DEFB116 
DEFB117 
DEFB118 
DEFB119 
DEFB121 
DEFB122  
DEFB123 
DEFB124 
DKKL1P1  
DUSP15 
FOXS1 
FRG1B 
HAUS6P2 
HCK 
HM13 
HM13-AS1 
HM13-IT1 
ID1  
KIF3B 
LINC00028 
MIR1825 
MIR3193 
MIR663A 
MLLT10P1 
MYLK2 
PDRG1 
PLAGL2 
POFUT1 
REM1 
RNA5SP480 
RNA5SP481 
RNA5SP482 
RNU1-94P 
RNU6-384P 
RPL31P3 
RSL24D1P6 
TM9SF4 
TPX2 
TSPY26P 
TTLL9 
XKR7 
DEFB118 (*607650) 
REM1 (*610388) 
HM13 (*607106) 
ID1 (*600349) 
COX4I2 (*607976) 
BCL2L1 (*600039) 
C20ORF1 (*605917) 
MYLK2 (*606566) 
FOXS1 (*602939) 
PDRG1 (*610789) 
HCK (*142370) 
PLAGL2 (*604866) 
POFUT1 (*607491) 
KIF3B (*603754) 
ASXL1 (*612990) 
 
 Exocrine pancreatic insufficiency, dyserythropoietic 
anemia, and calvarial hyperostosis (#612714) 
Familial hypertrophic cardiomyopathy type 1 
(#192600) 
Bohring-opitz syndrome (#605039) 
Myelodysplastic syndrome (#614286) 
20q11.2 duplication syndrome (Avila et al., 2013) 
Table 68 Summary of genes affected by those CNVs classified as pathogenic 
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T-cell receptor gene rearrangements 
Signals from the 6FAM and HEX fluorophores which label the PCR products of this 
assay are referred to as blue and green respectively 
 
Clone Evidence of T-
cell receptor 
gene re-
arrangement 
Name of PCR reaction yielding a product 
2-C1 No No product 
2-C4 No No product 
2-C6 No No product 
2-C2 Yes 
TRB and TRG 
TCRB Tube B: 266bp and 278bp 6FAM labelled products 
indicating Vβ - Jβ2 re-arrangement in TRB 
TCRG Tube A: 164bp and 217 HEX labelled products 
indicating Vγ10 - Jγ 1.3/2.3 and Vγ1-8 - Jγ 1.3/2.3 re-
arrangement in TRG 
2-C3 Yes 
TRB and TRG 
TCRB Tube A: 255bp 6FAM labelled product indicating Vβ - 
Jβ2 re-arrangement in TRB 
TCRG Tube A 217bp HEX labelled product indicating Vγ10 - 
Jγ 1.3/2.3 re-arrangement in TRG 
TCRG Tube B 180bp HEX labelled product indicating Vγ9 - 
Jγ 1.3/2.3 re-arrangement in TRG 
2-C7 Yes 
TRB and TRG 
TCRB Tube A 255bp 6FAM labelled product indicating Vβ - 
Jβ2 re-arrangement in TRB 
TCRG Tube A 164bp and 217bp HEX labelled product 
indicating Vγ10 - Jγ 1.3/2.3 and Vγ1-8 - Jγ 1.3/2.3 re-
arrangements in TRG 
 
Table 69 Results of T-cell receptor rearrangement assay 
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Figure 84. Data plots of the T-cell receptor rearrangement assays which yielded positive results. 
 Plots of data from TRB and TRG rearrangement PCR assay for 2-C2 (A and B), 2-C3 (C, D and E) and 2-C7 (F and G). Each graph 
represents data from one multiplex reaction. Products labelled with 6FAM and HEX fluorophores are shown as blue and green peaks 
respectively. The expected size ranges used to identify peaks as valid positive results are illustrated. Abbreviations: arbitrary units (au), 
base pairs (bp).
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Selection of reference genes for RT-qPCR experiments 
Reference genes were selected using the geNorm algorithm accessed via 
QBase+ as described in the methods chapter. The M-values and coefficients of 
variance of the 11 candidate reference genes as calculated by the geNorm 
algorithm are listed in Table 70. These results identified seven candidate genes 
indicated by M values of <1.0 and a CV values of <50% (Hellemans et al., 
2007). 
Results of the ranking of the reference genes using the serial exclusion 
method are shown in Table 71. The geNorm algorithm recommends that at 
least two reference genes should be used in all cases. In this analysis these 
genes PRDM4 and VIPAS39. The GeNormV value associated with adding 
UBE4A to VIPAS39 and PRDM4 was 0.093. This value is <0.15 indicating that 
there was little value in this addition and therefore the mean Ct of VIPAS39 and 
PRDM4 were used as a reference value for RT-qPCR analysese across all cell 
and tissue types in this study (Vandesompele et al., 2002). 
 
Gene M-value Coefficient of 
variance (%) 
ACTB 1.371 84.3 
GAPDH 1.356 51.0 
SCLY 1.198 71.1 
ERCC6 1.143 49.7 
SDHA 0.966 48.6 
ENOX2 0.962 44.7 
RPL7 0.956 43.5 
RNF20 0.795 26.1 
UBE4A 0.769 23.0 
PRDM4 0.753 21.1 
VIPAS39 0.732 16.1 
Mean (all genes) 1.000 43.6 
Table 70 Reference genes ranked by M value  
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Stability Gene 
Least stable  ACTB 
 GAPDH 
SCLY 
ERCC6 
RPL7 
ENOX2 
SDHA 
RNF20 
UBE4A 
Most stable PRDM4 
VIPAS39 
Table 71 Reference genes ranked by the GeNorm algorithm. 
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Flow cytometry for pluripotency markers 
Marker Fold difference in median fluorescence of labelled single cell events 
relative to unlabelled single cell events, mean±SD, x103 au 
Single labelled experiments Multi-colour experiments 
H9, n=1 iPSCs, n=6 HDF, n=1 H9, n=1 iPSC, n=9 
NANOG 3.0 3.2±0.6 0.42 3.1 4.5±1.3 
OCT4 4.8 4.7±0.9 0.08 3.9 4.6±1.4 
TRA-1-
60 
6.2 23.7±5.0 0.03 1.7 2.3±0.5 
SSEA4 25.8 20.8±6.0 0.30 33.0 18.5±7.1 
 
Table 72 Expression of pluripotency associated proteins assessed by 
flow cytometry, fluorescence of labelled sample relative to unlabelled 
sample. 
Arbitrary units = au 
 
 
Marker Percentage of labelled single cell events classified as positive for the 
marker*, median(Q1,Q3) % 
Single labelled experiments Multi-colour experiments 
hESC, n=1 iPSCs, n=6 hESC n=1 iPSC n=9 
NANOG 98.2 97.3 (96.1-97.5) 99.2 98.5 (97.3-98.7) 
OCT4 98.9 96.7 (94.4-98.5) 99.6 98.0 (97.5-98.7) 
TRA-1-
60 
96.1 98.2 (97.6-99.4) 99.7 99.3 (98.4-99.4) 
SSEA4 100.0 99.8 (99.4-99.9) 99.9 99.6 (99.4-99.8) 
 
Table 73 Expression of pluripotency associated proteins by iPSCs 
assessed by flow cytometry, proportion of labelled sample classified as 
positive. 
* defined as a fluorescence value greater than the 99th centile fluorescence 
value of the single cell events in the paired unlabelled sample. 
 
 
Marker Reduction in percentage of single cell events in labelled sample 
classified as positive, mean (min-max), %, n=3 
NANOG 7.3 (1.6-12.9) 
OCT4 0.4 (0.1-0.6) 
TRA-1-60 0.8 (0.1-1.7) 
SSEA4 0.1 (0.0-0.1) 
  
Table 74 Reduction in percentage of single cell events in labelled sample 
classified as positive when FMO isotype control sample was used to 
define threshold rather than the unlabelled sample
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Immunofluorescence microscopy for pluripotency associated proteins 
 
Figure 85 Immunofluorescent microscopy for pluripotency markers. 
(continued over) 
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(continued over) 
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(continued) 
The images show OCT4 signal co-localised with DAPI and a more diffuse 
TRA-1-60 signal consistent with a cell surface protein in iPSC clones and 
derived from: Subject 2 (A – B), Subject 0101 (C – D), Subject 0201 (E – F), 
Subject 0202 (G – H), Subject 0203 (I – J). The pattern of signal was identical 
to that observed in H9 hESCs (K – L) which acted as a positive control. No 
evidence of either marker was identified in HDFs (M – N) and no signal was 
detected in the absence of the primary antibodies (O). Scale bars: 100µm. 
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Expression of proteins indicating differentiation to the three primitive germ cell layers 
 
Figure 86 Immunofluorescence microscopy assessment of TUJ1, SMA and AFP expression in cultures generated from iPSCs 
that underwent differentiation in the presence of serum. 
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(continued over) 
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(continued over) 
 
 
Immunofluorescence microscopy images of differentiated hiPSCs from subject 2 (A - C), 0101 (D - F), 0201 (G - I), 0202 (J-K) and 0203 
(L - M) labelled for TUJ1 (left hand panels), SMA (middle panels) and AFP (right hand panels) indicative of differentiation to 
neuroectoderm, mesoderm and endoderm respectively. Undifferentiated hiPSCs (N – P) and differentiated hiPSCs labelled with 
secondary antibodies only (Q – S) were negative controls. Scale bars: 100µm. 
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The testing of primer sets using in RT-qPCR experiments to assess 
desmosomal gene expression 
The primer sets used for these assessments were tested using sample from HaCaT 
cells. RNA array data from the Human Protein Atlas suggested that most of the 
desmosomal genes targeted in this study would be expressed at relatively high levels 
in HaCaT cells. The exceptions were DSG4 which was expected to have an 
intermediate expression level and DSC1 and DSG1 which were present at very low 
levels or were absent (Uhlén et al., 2015) (“HPA heart DSC1,” 2018) (“HPA HaCaT 
DSC2,” 2018) (“HPA HaCaT DSC3,” 2018) (“HPA HaCaT DSG1,” 2018)(“HPA 
HaCaT DSG2,” 2018)(“HPA HaCaT DSG3,” 2018)(“HPA HaCaT DSG4,” 2018) 
(“HPA HaCaT PKP1,” 2018)(“HPA HaCaT PKP2,” 2018)(“HPA HaCaT PKP3,” 
2018)(“HPA HaCaT JUP,” 2018)(“HPA HaCaT DSP,” 2018).  
All primer sets were tested with HaCaT samples by RT-PCR and gel electrophoresis. 
In all cases a single product in the predicted size range was identified (including for 
the primer sets targeting DSG1 and DSC1 transcripts). Gene expression was then 
assessed by RT-qPCR and confirmed the expected pattern of gene expression 
reported by the Human Protein Atlas (Figure 87). All reactions generate a melt curve 
with a single peak. The results of standard curve experiments use to predict reaction 
efficiencies have already been described in the methods chapter. Gene expression 
was normalised to the mean expression of the reference genes selected by the 
Genorm pilot experiment to be optimal for comparing samples from PBMCs, iPSCs, 
hESCs, iPSC-CMs and RAA. 
The HPA reported that heart tissue expressed DSC1 and therefore RAA samples 
were used to confirm the efficacy of the DSC1 primer set (“HPA heart DSC1,” 2018). 
No alternative positive control was obtained to test the DSG1 primer set. 
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Figure 87 Expression of desmosomal genes in HaCaT cells 
Bars indicate mean expression. Whiskers indicate the SEM. Each gene was 
assessed in samples from three different passages of HaCaT cells. Genes 
expressed at a level more than ten fold less than the reference genes were 
considered to be absent and are not shown. 
  
 
